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InTRoDUCTIon AnD oVeRVIeW of 
THe THeSIS
Few topics have received as much attention 
in the recent cardiovascular literature as 
risk stratification1. The assessment of risk 
has been a key element in efforts to define 
factors for coronary artery disease (CAD), to 
identify novel markers for cardiac events, 
to identify and assess potential targets of 
therapy, to enhance the decision making and 
implementing therapies for both primary 
and secondary prevention of CAD. Extensive 
efforts are needed to quantify an individual’s 
risk of an event according to each component 
of vulnerability (from coronary plaque to a 
comprehensive clinical profile assessment).
Advances in the field of cardiovascular 
imaging have made possible invasive and 
non-invasive assessment of the coronary 
atherosclerotic burden. Since the begin-
ning of interventional cardiology, coronary 
angiography has been the reference tool for 
the quantification of coronary artery disease 
burden in both clinical practice and scientific 
investigation. With growing knowledge about 
the pathophysiology of atherothrombosis it 
became of interest to visualise in vivo differ-
ent processes taking place at the level of the 
coronary plaque for the purpose of improving 
cardiovascular outcomes.2,3 Intracoronary 
imaging techniques overcome the lumeno-
graphic limitations of angiography by enabling 
a pathology-like cross-sectional view of the 
vessel wall and implanted devices. These 
invasive imaging methods have succeed to 
demonstrate good correlations with plaque 
vulnerability, patients’ clinical profile and 
cardiovascular events4-6. Moreover, in recent 
years, coronary CT angiography (CCTA) has 
become a widely adopted technique, not only 
due to its high diagnostic accuracy, but also 
to the fact that CCTA provides a non-invasive 
evaluation of the total (obstructive and non-
obstructive) coronary atherosclerotic burden, 
being also able to assess patient’s risk of 
cardiovascular events7.
However, the coronary atherosclerotic dis-
ease burden is not the only factor that affect 
patients’ prognosis. In patients with complex 
coronary artery disease, other factors beyond 
plaque (ex. : thrombogenic blood and electri-
cal instability of myocardium) are components 
of the final outcome. Therefore, it is needed a 
comprehensive risk-stratification tool capable 
of predicting cardiovascular events improving 
the decision-making proccess.
In addition, the cardiovascular science com-
munity has pursued the quest to modify the 
natural history of coronary atherosclerosis. Re-
cently, the implantation of coronary bioresorb-
able scaffolds have emerged as a promising 
strategy for plaque sealing and modification 
of natural history of CAD. These devices have 
the unique ability to provide a temporary scaf-
fold that is necessary to maintain the patency 
of the vessel after intervention, before they 
gradually dissolve, liberating the vessel from 
its cage, and permitting the restoration of 
vascular physiology and integrity. Neointimal 
tissue develops following either Absorb BVS 
implantation and shields lipid tissues and per-
miting late lumen enlargement 8, 9. This thesis 
will provide an insight into the development of 
these methods and their clinical application.
The first chapter reviews the imaging (inva-
sive and non-invasive) methods for quantifying 
patient risk at a coronary level. For successfully 
utilising these methods in research and clinics, 
it is necessary to understand their strengths 
and limitations.
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Chapter 2 describes the rational of combin-
ing anatomic and clinical factors in the risk 
assessment of coronary artery disease. Clinical 
characteristics are able to differentiate the 
manifestation of coronary artery disease as 
assessed by angiography and intravascular 
methods and affect patient symptoms and 
prognosis.
In chapter 3, we describe the risk stratifica-
tion of patients with complex coronary artery 
disease. We compare the improvement of the 
predictive performance of the combination of 
anatomical and clinical factors (SYNTAX score 
II) versus coronary anatomy in isolation (SYN-
TAX score). We evaluate in details the ability of 
these models in decision making for coronary 
revascularization, its cost-effectiveness, prog-
nostic implications and future perspectives.
Chapter 4 depicts post-revascularization 
risk assessment. We quantify the proportion 
of coronary artery disease burden treated by 
PCI and evaluate its impact on outcomes using 
a new prognostic instrument - the Synergy 
Between PCI with Taxus and Cardiac Surgery 
(SYNTAX) Revascularization Index (SRI). In 
addition, we describe the importance and chal-
lenges in modifying risk factors for secondary 
prevention after coronary revascularization.
In chapter 5, we describe the potential 
benefits of bioresorbable scaffolds (BRS) in 
percutaneous coronary revascularization. 
Bioresorbable vascular scaffolds (BRS) are 
a novel approach to the interventional 
treatment of coronary artery disease (CAD), 
providing short-term vascular scaffolding 
combined with drug-delivery capability. These 
devices present important differences with 
respect to metallic stents when imaged. We 
express in the details the methods for short 
and long-term assessment of bioresorbable 
scaffolds. Finally, we discuss the potential 
impact of BRS in the natural history of coronary 
atherosclerosis.
Introduction
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How Can The Vulnerable Plaque Be Identified?
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AbSTRACT
The precise identification of a vulnerable plaque may have substantial clinical impact since the 
absolute majority of cases of sudden death are related to acute coronary syndromes. Recent 
advances in imaging techniques have allowed the development of numerous invasive and 
noninvasive tools for the investigation of coronary atherosclerosis. Contemporary natural history 
of atherosclerosis studies added information on changes in the morphological and compositional 
plaque characteristics. The objective of understanding these temporal changes is to being able 
to predict plaques prone to have future events changing the way we approach its treatment and 
strengthening the concept of plaque passivation. This review article summarizes the current 
definitions on vulnerable plaque, describes the recent advances in the study of atherosclerosis, 
cites the current evidence, highlights our limitations in understanding the evolution of the plaque 
and in predicting plaque destabilization.
Chapter 1.1
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InTRoDUCTIon
Despite the recent medical advances, accord-
ing to the last report from the World Health 
Organization, 7.3 million people die of 
ischaemic heart disease every year1. Included 
in this population, there is a large number of 
individuals who are apparently healthy and 
die suddenly without prior symptoms. In this 
regard, plaque rupture is the most common 
type of plaque complication, accounting for 
70% of fatal acute myocardial infarctions and/
or sudden coronary deaths2. These reasons 
have been fueling a great scientific effort to 
understand, diagnose and treat properly the 
plaque that is prone to rupture. Therefore, 
there are currently several diagnostic imag-
ing techniques aiming to specifically evaluate 
indicators of plaque vulnerability. These tech-
niques can provide information on the vessel, 
lumen and wall size, tissue composition, and 
the status of inflammation (table 1). This article 
aims to review the current histopathological 
definitions and state-of-the-art of imaging 
techniques.
DefInITIonS
Cardiologists describe the plaque responsible 
for coronary occlusion and death as a culprit 
plaque. However, clinicians need a similar 
term for prospective evaluation, to describe 
such plaques before an event occurs, so called 
vulnerable plaque.
There are two major types of vulnerable 
plaques, rupture-prone and erosion-prone 
3-5. The prototype of a rupture-prone plaque 
contains a large and soft lipid-rich necrotic 
core (>30% of plaque) covered by a thin 
Table 1. Ability of the available imaging modalities to detect plaque features associated with increased 
vulnerability
Plaque characteristics 
associated with 
increased vulnerability
Thin fibrous
cap
necrotic
core
Assessment of
plaque burden
Positive
remodeling
neoangio-
genesis
Active
inflammation
IVUS/IVUS-RF ++ ++ +++ +++ - -
OCT +++ +++ ++ + ++ +
Angioscopy - ++ - - - -
IV-MRI spectroscopy* - ++ - - - -
NIRS - +++ - - - -
IV-MRI* - + + + - -
Photoacoustic imaging* - ++ - - - -
TRFS* + ++ - - - -
CTCA - + ++ ++ - -
Thermography - - - - - +
NIRF* - - - - + +++
PET* - - - - - ++
Abbreviations: IVUS= intravascular ultrasound; RF=radiofrequency; OCT=optical coherency tomography, IV-MRI, Intra-
vascular MRI; NIRS, near-infrared spectroscopic; TRFS, time-resolved fluorescence imaging; CTCA, Computed Tomogra-
phy Coronary Angiography; NIRF= Near-infrared fluorescence, PET, Positron emission tomography . The ability of the 
presented modalities to detect plaque characteristics associated with increased instability is graded as: unable (−), 
low (+), moderate (++), and high (+++). The modalities marked with an asterisk are in their initial development, and 
therefore, the data provided for these techniques derive from small scale in vivo or histology-based in vitro studies.
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(thickness usually  <  65 mm) and inflamed 
fibrous cap. Associated features include 
large plaque size, expansive remodelling 
mitigating luminal obstruction (mild stenosis 
by angiography), neovascularization plaque 
haemorrhage, adventitial inflammation, and 
a “spotty“ pattern of calcifications 4, 6.
The erosion-prone vulnerable plaque 
type are heterogeneous and defined only by 
their fate (thrombosis, mostly mural).7 The 
surface endothelium is missing, but whether 
it vanished before or after thrombosis remains 
unknown. No single morphological features 
have been identified but, in general, eroded 
plaques with thrombosis are scarcely calcified, 
rarely associated with expansive remodelling, 
and only sparsely inflamed7. Thus, it remains 
a challenge to distinguish erosion-prone 
plaques from stable plaques by imaging8.
InVASIVe IMAGInG of VUlneRAble 
PlAqUeS
Intravascular ultrasound (IVUS).Intravascular 
ultrasound (IVUS) was the first invasive modal-
ity that allowed imaging of the lumen and ves-
sel wall, quantification of plaque burden, and 
characterization of its composition. Positive 
vessel remodeling can readily be evaluated 
with IVUS 9-11. Visual assessment of plaque 
echogenicity provides semiquantitative tis-
sue characterization12. Calcification can be 
identified with a sensitivity and specificity of 
approximately 90% 13. Large eccentric plaques 
containing an echolucent zone by IVUS were 
associated with the development of ACS in 
a prospective study 14. Another feature that 
can be obtained by IVUS is attenuated plaque, 
defined as plaques with >30o ultrasonic attenu-
ation of deeper arterial structures despite the 
absence of bright calcium. In an assessment 
of 131 native lesions, attenuated plaques 
have confluent necrotic core in 93.5% when 
matched by VH-IVUS and 90.3% of lipid core 
on the block chemogram 15. Microbubble 
contrast-enhanced IVUS can measure activ-
ity and inflammation within atherosclerotic 
plaques by imaging vasa vasorum density, 
which is considered as a marker for plaque 
vulnerability16. The main limitation of IVUS is 
its 100–150 µm axial resolution, whereas the 
fibrous cap of a TCFA is thinner than 65 µm 
and, therefore, cannot be visualized by IVUS.
Intravascular ultrasound radiofrequency 
analysis (RF-IVUS). RF-IVUS involves spectral 
analysis of the IVUS gray-scale data and evalu-
ates different spectral parameters. Different 
plaque components are assigned different 
color codes: calcified (white), fibrous (green), 
fibrolipidic (greenish–yellow) and necrotic 
core (red) 17.
The PROSPECT trial has been the largest 
natural history of atherosclerosis study and 
used RF-IVUS to detect anatomical and compo-
sitional features associated with an increased 
risk for a plaque to evolve to a culprit lesion18. 
Six hundred ninety-seven patients treated 
for an acute coronary syndrome underwent 
RF-IVUS post intervention at the 3 epicardial 
coronary arteries. At 3-year follow-up, 104 
new symptomatic lesions became manifest 
in the nontreated segments. Multivariable 
analysis demonstrated that the presence of 
TCFA, a minimum lumen area ≤4 mm2, and a 
plaque burden ≥70% were associated with 
future events. Similar results were reported 
by the VH-IVUS in Vulnerable Atherosclerosis 
Study study that had a similar design 19. The 
PROSPECT trial not only showed the potential 
predictive value of intravascular imaging but 
also highlighted its limited prognostic accu-
Chapter 1.1
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racy as only 4% of the detected TCFA evolved 
to culprit lesions. This should be attributed 
to the fact that the included patients were 
on optimal treatment and to the inherited 
limitations of IVUS imaging 20.
Optical coherence tomography. Optical 
coherence tomography (OCT) is an optical 
analogue of ultrasound; however, it uses light 
instead of sound to create an image. It can 
provide a resolution of 10–20µm in vivo. This 
resolution permits visualization of details, 
which cannot be imaged by other intravascular 
techniques such as evaluation of the thickness 
of the fibrous cap, detection of macrophages, 
and neovascularization and identification 
of plaque erosion21. A limitation of OCT is 
its poor penetration, which often does not 
allow complete visualization of the vessel 
wall and assessment of vessel remodeling. In 
addition, OCT signal cannot penetrate lipid 
tissue, and thus, it is unable to quantify the 
lipid component.
Invasive techniques for the detection of 
inflammation. Thermography was the first 
invasive imaging technique developed to 
identify vessel wall inflammation and relies 
on the measurement of plaque heat. High 
temperatures indicate increased inflamma-
tory activity and, sometimes, vulnerability 
of the plaque. Initial reports demonstrated 
the efficacy of thermography in detecting 
high-risk plaques, but recent studies have 
raised concerns about its effectiveness in 
patent coronaries suggesting that blood flow 
obstruction is necessary to obtain accurate 
estimations, fact that has limited its current 
applications 22,23, 24.
Near-infrared fluorescence (NIRF) imaging is a 
novel technique introduced to detect vascular 
activity. It involves injection of agents that 
bind molecules related to plaque’s inflamma-
tion and have the ability to fluoresce after be-
ing irradiated with near-infrared light emitted 
by a specially designed catheter. Experimental 
studies demonstrated the feasibility and the 
potential of this technology 25. Recently, a 
hybrid NIRF-OCT catheter (diameter 2.4F) has 
been designed that allows simultaneous mo-
lecular functional imaging (provided by NIRF) 
and visualization of vessel pathology (given 
by OCT) 26. The feasibility of this approach 
has been tested ex vivo and in vivo in animal 
models and the first results appear promising. 
However, the safety of this technique has to be 
proven before being implemented in humans.
Near-Infrared Spectroscopy (NIRS). NIRS is 
based on the principle that different organic 
molecules absorb and scatter NIRS light to 
different degrees and wavelengths. Spectral 
analysis of the obtained signal provides a 
color-coded display, called a chemogram, 
which provides the probability that lipid core 
is present in the superficial plaque (studied 
depth approximately: 1 mm). Several studies 
have examined the reliability of this tech-
nique using histology as the gold standard 
and demonstrated a high overall accuracy 
in detecting lipid-rich plaques while others 
demonstrated its feasibility in the clinical 
setting27, 28. In NIRS sub-study of the European 
Collaborative Project on Inflammation and 
Vascular Wall Remodeling in Atherosclerosis 
(NCT01789411) lipid plaque burden is being 
weighting as a predictor of cardiac events.
nonInVASIVe IMAGInG MoDAlITIeS
Computed Tomography Coronary Angiog-
raphy (CTCA). CTCA seems that it provides 
useful prognostic information29,  assess the 
progression of coronary atherosclerosis30, 
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provides a promising noninvasive method for 
identifying  ischemia-causing  stenosis31 and 
gives information about anatomical complex-
ity 32. However, CTCA has limited capability in 
differentiating lipid-rich from fibrotic plaques 
and has low resolution, which does not permit 
visualization of plaque characteristics associ-
ated with increased vulnerability33. However, 
in this field, an ambitious prospective study 
commenced - the BioImage trial - that aims 
to include >6,000 asymptomatic subjects who 
will undergo noninvasive imaging (including 
CTCA if they have a high-risk cardiovascular 
profile) to identify new imaging-based predic-
tors of future cardiovascular events.
Magnetic resonance imaging (MRI). Mag-
netic resonance imaging appears to be able 
to detect the composition of the plaque and 
has been used to study the atherosclerotic 
process in the aorta and the carotids, but it 
has a limited value in assessing coronary 
pathology, as it requires prolonged acquisi-
tion time and has poor spatial resolution34. 
Further improvements in external coils as well 
as the development of contrast agents that will 
allow more accurate plaque characterization 
are required so as this modality to be useful 
in this setting.
Noninvasive imaging of vessel wall inflam-
mation. Nuclear imaging constitutes the lead-
ing noninvasive modality for the evaluation of 
vascular activity. Recent reports demonstrated 
the feasibility of the combined CTCA-18F-FDG 
imaging for the identification of inflamed 
plaques on the coronary tree 35, 36. The concept 
of fusing 2 noninvasive modalities that provide 
anatomical (derived from CTCA) and biologi-
cal (given by PET) information constitutes a 
breakthrough in the study of atherosclerosis as 
it will allow detailed imaging of plaque pathol-
ogy in larger populations and it is expected 
to provide additional information about the 
distribution of plaque inflammation and its 
association with different plaque components. 
Apart from 18F-FDG, several other tracers have 
been developed to assess vascular activity, 
such as the 99mTc-AA5, which binds phos-
phatidylserine produced by apoptotic cells; 
the 99mTc matrix metalloproteinase inhibitor 
that binds active metalloproteinases; and the 
IK17 tracer, which is labeled with I125 and is 
able to detect the presence of oxidized low 
density lipoprotein, without however being 
used in clinical setting yet 37-39.
fUTURe TRenDS AnD ConClUSIonS
Intravascular magnetic imaging40, photo-
acoustic imaging, Raman spectroscopy, and 
time-resolved fluorescence spectroscopy are 
emerging techniques that still under evalua-
tion and are expected to provide additional 
information about plaque. In parallel, an effort 
is being made to overcome the limitations of 
the prominent intravascular imaging modali-
ties either by developing new methodologies 
that would allow better processing of the 
acquired data (eg, focused acoustic computed 
tomography, micro-OCT, polarized OCT) or by 
creating hybrid catheters that would permit 
multimodality intravascular imaging 41, 42. A 
hybrid catheter that combines an IVUS and 
a NIRS probe (TVC, MC 7 system; InfraRedx, 
Burlington, MA) is currently available and be-
ing used in research arena43. Catheters that 
permit fusion of IVUS with OCT, photoacoustic 
imaging, or time resolved fluorescence spec-
troscopy are also under evaluation44. Initial 
experimental studies have shown promising 
results45-47. However, the large dimensions of 
the available catheters, the concerns regarding 
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the safety of the new techniques, and the low 
image acquisition rate as well as the moderate 
image quality that they provide have not allow 
their implementation in humans yet. These 
advances are expected to result in a better un-
derstanding of the composition and evolution 
of the atherosclerotic plaque in an attempt to 
anticipate and prevent acute coronary
figure 1. (A) IVUS gray scale plaque rupture represented by a large empty cavity from 11 to 2 o’clock. 
(B) Plaque to lumen with high content of necrotic core (red), adjacent to lumen, by intravascular ul-
trasound radiofrequency analysis. (C) The opctical coherence tomography image shows a thin-capped 
fibroatheroma and a (D) ruptured plaque with thrombus at that site (white arrow). (E,F) The output of 
the near-infrared spectroscopic (NIRS) catheter is illustrated (E, chemogram; F, block chemogram). The 
yellow-red color-coded map illustrates the probability of the presence of a lipid core (yellow corre-
sponds to high probability and red to low probability). (G) Output of a recently developed intravascular 
magnetic resonance probe (I-IV); the images were obtained in vitro from an atherosclerotic iliac artery. 
The dark areas at 9 (II, III) and 12 o’clock (IV) indicate the presence of calcific tissue. (H,I) Data Acquired 
by a Combined IVUS and NIRS Catheter showing IVUS cross-sections with the corresponding chemo-
gram obtained in a stented and a nonstented segment, respectively. The probability of the presence of 
a lipid-rich plaque is low in the stented segment (H) but high in the frame portrayed in (I), between 1 
and 7 o’clock. ep = echolucent plaque; ss = stent struts. # Area with insufficient NIRS signal.
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figure 2. Implications of CTCA in the study of atherosclerosis. (A) Accessment of progression/regres-
sion: Example of vessel analyzed at baseline (I) and 3-year follow-up (II). In both panels, 5 lines indicate 
the location in the vessel of the cross-sections shown at the bottom of the fi gure (from proximal to dis-
tal). In this lesion, the plaque burden (PB, %) decreases consistently from baseline to follow-up in the 
5 cross-sections analyzed. (B) Reconstruction of coronary tree from CTCA. (C) These data were used to 
model the distal circumfl ex, simulate blood fl ow, and evaluate the shear stress distribution (portrayed 
in a color-coded map).(D) Superimposition of the reconstructed model onto the coronary tree provided 
by CTCA. (E) Fusion of CTCA and positron emission computed tomography. Increased 18F-FDG uptake 
was noted in the aorta, left main stem, and left anterior descending artery (arrows) of a patient admit-
ted with an acute coronary syndrome. (F) On the other hand, minor infl ammation was detected in the 
aorta and coronary tree of a patient with stable angina. (G) Ability of CTCA to detect the composition of 
the plaque. The arrows indicate the location of the IVUS and CTCA cross-sectional images. Panels (I’-I”’) 
portray IVUS, IVUS radiofrequency backscatter analysis, and CTCA cross-sections for the distal calci-
fi ed plaque, whereas the panels (II’-II”’), the corresponding cross-sections for the proximal plaque. The 
luminal morphology and the distribution of the plaque are similar in the CTCA and IVUS images. CTCA 
appears to allow accurate diff erentiation between calcifi ed from noncalcifi ed plaques.
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AbSTRACT
Aims:
The objectives of the present study are to describe the algorithm for VH® IVUS using the 45 MHz 
rotational IVUS catheter and the associated ex vivo validation in comparison to the gold-standard 
histology.
Methods and Results:
The first phase of the present study was to construct the 45 MHz VH IVUS algorithm by using 
a total of 55 human coronary artery specimens [111 independent coronary lesions and 510 
homogenous regions of interest (ROIs)], obtained at autopsy. Regions were selected from histol-
ogy and matched with their corresponding IVUS data to build the plaque classification system 
using spectral analysis and statistical random forests. In the second phase, the ex vivo validation 
of the VH IVUS algorithm assessed a total of 1060 ROIs (120 lesions from 60 coronary arteries) 
in comparison with histology. In an independent manner, two interventional cardiologists also 
classified a randomly selected subset of the ROIs for assessment of inter- and intra-observer 
reproducibility of VH IVUS image interpretation.
When including all ROIs the predictive accuracies were 90.8% for fibrous tissue, 85.8% for 
fibro fatty tissue, 88.3% for necrotic core and 88.0% for dense calcium. The exclusion of ROIs 
in the acoustically attenuated areas improved the predictive accuracies, ranging from 91.9 to 
96.8%. The independent analysis of randomly selected 253 ROIs showed substantial agreement 
for inter-observer (k=0.66) and intra-observer (k=0.88) reproducibility.
Conclusion:
Tissue classification by 45 MHz VH IVUS technology, when not influenced by calcium-induced 
acoustic attenuation, provided combined tissue accuracy >88% to identify tissue types as 
compared with the gold-standard histologic assessment, with high inter- and intra-observer 
reproducibility.
Keywords: Atherosclerosis; coronary disease; spectral analysis; plaque; VH IVUS; IVUS
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InTRoDUCTIon
One of the biggest challenges the cardiologist 
has currently is to identify lesions precursor 
of acute coronary events, which sometimes 
manifest as sudden death. In patients under 
optimal medical treatment, it has been shown 
that the occurrence of death and acute coro-
nary syndromes may be associated with the 
total number of segments with significant 
disease rather than the ischemic burden 1. 
This suggests that plaque disruption might 
be the main cause of major cardiac outcomes 
rather than the ischemia induced by obstruc-
tive plaques. Therefore, assessment of plaque 
composition - identifying high risk plaques 
- and the effectiveness of a treatment to alter 
plaque composition are fields of significant 
clinical relevance.
In recent years, cardiovascular imaging 
research has sought potential strategies for 
detecting high-risk plaques. A number of 
intravascular ultrasound (IVUS) backscatter 
analysis techniques are promising and multiple 
approaches have been developed to produce 
colour-coded tissue maps, such as spectral 
analysis 2, 3, spectral analysis combined with 
statistical learning 4-6, and radiofrequency (RF) 
elastography analysis 7.
 IVUS RF backscatter analyses technologies, 
such as VH® IVUS (Volcano Corporation, San 
Diego, California, USA), are aimed at identifica-
tion of patients at risk, plaque monitoring and 
eventually to guide targeted therapy. High risk 
plaque interpretation via VH IVUS analysis, has 
been shown to be correlated with high risk 
clinical features as defined by the Framingham 
Risk Score8 and to have the ability to predict 
cardiac events9-11. Previously published in vivo 
and ex vivo studies4, 5, 12-14 on VH IVUS accuracy 
have reported on plaque characterization with 
the 20 MHz VH IVUS algorithm using the digital 
20MHz IVUS catheter (Eagle Eye® Catheter, 
Volcano Corporation, San Diego, California, 
USA), but this algorithm is restricted in de-
tecting thin-caps associated with vulnerable 
fibroatheromas5. IVUS of higher frequency has 
higher axial resolution, which could provide 
improved visualization of a thin-cap, albeit 
with loss of ultrasound penetration-depth.
Herewith we report a new higher frequency 
IVUS backscatter analysis algorithm for a 45 
MHz rotational IVUS catheter and the associ-
ated ex vivo validation in comparison to the 
gold-standard histology.
MeTHoDS
Subjects
Similar to the development of the 20 MHz VH 
IVUS algorithm 5, data were collected from 55 
coronary artery specimens obtained at autopsy 
with IRB approval from the Cleveland Clinic, 
Cleveland, Ohio. The study sample was limited 
to those without prior cardiac percutaneous 
interventions or surgical revascularization. Ad-
ditionally, data was not acquired from alcohol 
and drug abuse cases or those with known 
blood-borne pathogen diseases (HIV, hepatitis, 
etc.). All vessels were excised within 24 hours 
of death and data were collected within 24 
hours of vessel procurement.
Data Acquisition. Each vessel was pressure 
perfused using phosphate buffered saline 
(PBS) solution at systolic pressure (approxi-
mately 120 mmHg) and submerged within PBS 
to minimize any PBS-air interface reflections 
in the ultrasound data. Ans5™ IVUS imaging 
system (Volcano Corporation, San Diego, 
California) capable of saving the in-phase 
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and quadrature (IQ) backscattered signals, and 
the Revolution® 45 MHz rotational catheter 
(Volcano Corporation, San Diego, California) 
were used for data collection and for visu-
ally locating ROI. Sections-of-interest were 
identified on the gray-scale IVUS images as 
having ≥30% plaque burden and IQ data were 
collected at the 8 mm field-of-view setting. A 
suture was attached to the surrounding tissue 
of the vessel to mark the location. Adjacent le-
sions were separated by at least 1 cm to permit 
histology processing. In addition to placing the 
catheter at these specific sites, an automated 
IVUS pullback data collection was performed 
over the length of the artery specimen from 
the distal to the proximal site. The automated 
pullback rate was set to 0.5 mm/sec with a 
60 beats per minute simulated heart rate, 
to allow the ECG-gated IQ data acquisition. 
This triggers the imaging system to save an 
IVUS backscatter data-set once per simulated 
heartbeat, approximately 0.5 mm apart.
Following imaging and IVUS data collection, 
the artery specimens were pressure fixed us-
ing 10% buffered formalin at systolic pressure 
for at least four hours. The vessels were then 
sectioned into 1 cm lengths so that the sutures 
representing the location of the imaged le-
sions were centered within each section. The 
sections of artery specimens were then sent 
for histology processing, which included a 
decalcification stage, if needed. Following 
paraffin embedding, pairs of histology slides 
were prepared at multiple locations (100 µm 
apart) proximal, at, and distal to the suture 
location. Each pair of histology slides were 
stained using hematoxylin and eosin (H&E) 
and the Movat pentachrome stains, respec-
tively.
Image Correlation. Following data acqui-
sition, matches between corresponding 
histology slides and gray-scale IVUS images 
were determined by observing plaque burden 
and orientation and the surrounding tissue 
structures, such as side branch location, veins, 
location of the myocardium and pericardium, 
etc. The matching process with histology has 
been described previously 5. The slides were 
reviewed by an expert to identify regions-of-
interest (ROI) within the plaque that represent 
homogenous areas for each of the four tissue 
types, as described in previous work: FT - fi-
brous, FF - fibro-fatty, NC - necrotic core, and 
DC - dense calcium. Slides were reviewed both 
proximal and distal to the matched slide, to 
insure that the ROIs were consistent over a 
length along the vessel comparable to the 
out-of-plane resolution of the 45 MHz IVUS 
catheter. It was critical to have homogenous 
regions with respect to the ultrasound resolu-
tion both within the imaging plane and beyond 
the imaging plane, to successfully train the 
statistical classifier.
The ROIs obtained from the histology review 
were then translated onto regions within the 
matched gray-scale IVUS image by a second 
expert (different than the expert used for 
the histology review). Sectors of an annulus 
were drawn on the reconstructed gray scale 
image using customized software run with 
MATLAB® (Mathworks, Natick, Massachusetts). 
The software calculates the ultrasound back-
scatter signal location in the de-convolved IQ 
data for each ROI. Each of these homogenous 
ROIs comprised of 64 digitized IVUS samples 
in depth and 10 IVUS scan lines in width out 
of the total 256 scan lines that are used to 
construct one gray-scale IVUS image.
45 MHz VH IVUS Algorithm. A total of 111 
independent lesions and 510 homogenous 
ROIs were selected to train the 45 MHz VH 
IVUS algorithm. The homogenous ROIs com-
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prised 153 fibrous, 61 fibro-fatty, 112 necrotic 
core, and 184 dense calcium regions. The IQ 
signals representing each ROI were converted 
back to RF data and the signals were processed 
to remove system effects comparable to 
previously described efforts15. In addition, an 
adjustment factor was applied to the data to 
compensate for acoustic attenuation due to 
blood in the in vivo environment. This was 
to compensate for the higher attenuation of 
IVUS at 45 MHz in vivo, in an environment with 
blood as compared to the attenuaThe power 
spectra were then computed and spectral 
parameters were obtained. These included 
mid-band fit, intercept, slope, integrated 
backscatter, maximum power, frequency at 
maximum power, minimum power, and fre-
quency at minimum power. These spectral 
parameters were calculated from the normal-
ized power spectra for each homogenous ROI. 
The spectral parameters and corresponding 
homogenous tissue type categorization from 
histology formed the data set for further 
statistical classification using a Random For-
est 16, 17 as an ensemble classification method. 
The statistical random forests technique is an 
extension of tree classification schemes and 
is known for improved predictive power for a 
diagnostic test with multiple outcomes. Fifty 
classification trees were used in the 45 MHz VH 
IVUS algorithm with randomly chosen spectral 
parameters and a sub-sample of data to build 
each tree. The VH IVUS classification is a result 
of a voting scheme from all 50 trees in the 
forest, resulting in a robust and statistically 
stable algorithm. The ‘randomForest’ package 
was used within the R software environment 
18 to implement this approach.
45 MHz VH IVUS Image Construction. The 
45 MHz VH IVUS algorithm was applied to 
multiple backscatter data sets after user-
defined plaque lumen and medial-adventitial 
boundaries were obtained. Each lesion dataset 
was analyzed using a finite sized data-window 
that was 0.0736 radians in the lateral, or cir-
cumferential direction (approximately 147 µm 
at 2 mm depth) and approximately 250 µm in 
depth. This window of analysis was translated 
along each scan line one digitized sample at a 
time to construct a VH colourized tissue map 
out of the 256 scan lines that represent each 
IVUS backscattered image dataset.
45 MHz VH IVUS Algorithm Ex Vivo Accuracy 
Assessment. The data utilized for creating the 
45 MHz VH algorithm is based on relatively 
‘homogenous’ regions representing the four 
VH IVUS plaque types compared to the major-
ity of plaque composition. In contrast, most 
plaques are not as homogenous as these ROIs. 
Thus, to validate the accuracy of the VH IVUS 
algorithm, a systematic approach was used to 
blindly and randomly choose heterogeneous 
regions and compare the results from histology 
to the results from the reconstructed VH IVUS 
images; similar to the approach described for 
the 20 MHz VH IVUS ex vivo validation 5. VH 
tissue maps were constructed from 45 MHz 
IVUS data collected from a total of 120 lesions 
from 60 coronary artery specimens. Majority 
of these data were also used in training the 
VH algorithm, although an independent and 
different cohort of ROIs was used for training 
than the cohort of ROIs used for the accuracy 
assessment.
A team of four investigators analysed the data 
in a manner that minimizes potential bias. 
The first step was performed by two of the 
investigators and involved selecting random 
ROIs within the histology slides. A square grid 
pattern was printed on clear plastic overhead 
projection sheets. These were positioned over 
scaled printouts of the matched histology 
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Movat pentachrome stained slide images so 
that each square was 1/3 mm x 1/3 mm, or 
approximately a 333 µm sized square. The two 
investigators then traced the boundary of the 
plaque on the overhead projection sheet for 
each section. Next, they numbered every other 
square that was contained within the plaque 
boundary following a checkerboard pattern. 
This overhead (without the underlying histol-
ogy image) was provided to the third investiga-
tor who translated the numbered squares to 
corresponding positions on the matched and 
scaled VH image printouts. This step is neces-
sary since the paraffin embedding process in 
histology preparation, results in warping of 
the tissue. A third investigator interpreted and 
recorded the dominant VH IVUS tissue type 
within each of these heterogeneous ROIs. This 
third investigator was blinded to the histology 
data. The traced overhead projection sheets 
were then provided to a fourth investigator 
who interpreted the dominant feature of the 
histology slide for each of the numbered ROIs 
and was blinded to the matched VH IVUS 
image. A total of 1060 regions were thus 
analysed (see Figure 1).
In addition to this analysis the third inves-
tigator also identified ROIs that were located 
behind densely calcified ROIs in the radial di-
rection of the ultrasound backscatter. Calcium 
is known to attenuate or inhibit ultrasound 
and hence cast a ‘shadow’ on tissue located at 
deeper locations radially with respect to the 
IVUS transducer. This phenomenon is more 
common with the rotational IVUS modality 
where the IVUS catheter is constructed of a 
single unfocused ultrasound transducer. The 
singularity of the transducer lends it more 
prone to shadowed regions due to calcifica-
tions, because the single unfocused trans-
ducer responsible for imaging has backscatter 
blocked from the calcium in the path of the 
ultrasound. In contrast, the previous work with 
the 20 MHz solid-state IVUS modality 5was 
less prone to the calcium-induced shadowing 
due to the synthetic aperture image formation 
from a multi-element transducer array. Thus, 
in the present study, the accuracy results were 
determined by both, including and excluding 
regions that were potentially shadowed by the 
heavily calcified areas.
In an independent manner, two interven-
tional cardiologists (CMC and HMG) analysed 
253 randomly selected heterogeneous ROIs 
(30 random lesions). The comparison was 
performed blinded to the histologic findings 
to assess the inter- and intra-observer repro-
ducibility of VH IVUS image interpretation. At 
figure 1. Region-of-interest (ROI) selection for 
ex vivo accuracy assessment. Four investigators 
were engaged in the separate tasks of (A) draw-
ing histology image outlines on transparent pa-
per with a grid of 1/3x1/3 mm regions and high-
lighting alternating regions; (B) finding matching 
regions on corresponding VH IVUS images and in-
terpreting the VH IVUS outcome in each ROI; and 
finally (C) interpreting the pathology outcome in 
all ROIs. The investigators were blinded to each 
other’s results.
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first, the VH IVUS tissue type classification was 
performed in consensus between the two phy-
sicians to compare with the validation analysis 
done by the four investigators. Later, after a 
period of one month, the same 253 ROIs were 
re-analysed by the same two interventional 
cardiologists, to assess the intra-observer 
reproducibility.
Data Analysis. The statistical computation 
that was applied is based on a test for a single 
state. Thus for each computation, the results 
were interpreted as being in one of two states: 
chosen tissue type or not of the chosen tis-
sue type. Since this manuscript addresses 
four plaque tissue types, one of the types is 
chosen (Type X) and the three remaining tissue 
types are combined as ‘not of type X’. Then the 
common definitions for sensitivity, specificity, 
and accuracy can be applied. Finally the Kappa 
statistic was computed for determining the 
inter- and intra-observer reproducibility of the 
45 MHz VH IVUS images.
ReSUlTS
45 MHz VH IVUS Algorithm Ex Vivo Accuracy 
Assessment. VH IVUS tissue maps were con-
structed from 45 MHz IVUS data collected from 
a total of 120 lesions from 60 coronary artery 
figure 2. VH IVUS predictive accuracy for tissue types including all regions-of-interest (ROIs; n=1060). 
(A) Agreement between VH IVUS and histology and truth-table for the accuracy measurements. (B) VH 
IVUS predictive accuracy, sensitivity and specificity by tissue types as compared with histology. DC = 
dense calcium; FT = fibrous tissue; FF = fibro fatty; NC = necrotic core.
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specimens (51 hearts, 42 male, 9 female; 14 
black, 37 white; average age 57.0 ±12.7 years). 
The ex vivo accuracy was determined for all 
1060 ROIs and again after excluding the 290 
ROIs shadowed by calcium. Figure 2 describes 
the truth-table for inclusion of all ROIs and the 
corresponding accuracy statistics of sensitiv-
ity, specificity, and predictive accuracy. When 
including all ROIs the predictive accuracy 
ranged from a low of 85.8% for fibro-fatty to 
a high of 90.8% for fibrous tissue type, with an 
overall accuracy of 76.7% for all tissue types 
combined. The sensitivities were all greater 
than 81% except for dense calcium which is 
relatively low at 55.8%. The lowest specificity 
was for fibro-fatty at 84.9% with the other 
three tissue types at 90% or higher.
The truth-table resulting from the removal of 
the ROIs positioned behind calcium with the 
corresponding accuracy statistics is presented 
in Figure 3. The predictive accuracy ranged 
from a low of 93.0% for fibrous to a high of 
96.8% for fibro-fatty tissue, with an overall ac-
curacy of 88.6% for all tissue types combined. 
The sensitivities fall in the 82% to 93% range, 
while the specificity values remain high with 
all values greater than 90%.
Observer Reproducibility for VH IVUS Image 
Interpretation. Table  1 describes the inter-
observer reproducibility analysis of VH IVUS 
figure 3. VH IVUS predictive accuracy for tissue types excluding all calcium-shadowed ROIs (n=770). (A) 
Agreement between VH IVUS and histology and truth-table for the accuracy measurements. (B) VH IVUS 
predictive accuracy, sensitivity and specificity by tissue types as compared with histology. DC = dense 
calcium; FT = fibrous tissue; FF = fibro fatty; NC= necrotic core.
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image interpretations, without exclusion of 
shadowed ROIs (n=253). There was substantial 
agreement19 (k=0.66) between the assessment 
performed by the four investigators and the 
assessment performed by the independent 
interventional cardiologists. Table  2 sum-
marizes the intra-observer reproducibility 
analysis without exclusion of shadowed ROI, 
where there was higher agreement (k=0.88).
DISCUSSIon
The main findings of the present manuscript 
can be summarized as follows: first, a statisti-
cally robust algorithm was designed to yield 
analysis of 45 MHz IVUS backscatter, result-
ing in colour-coded tissue maps of the data; 
second, the VH IVUS algorithm with the 45MHz 
catheter had predictive accuracy >85.8% for 
each tissue type as compared with histology; 
third, the predictive accuracy for each tissue 
type improved to >91.9% when calcium shad-
owed areas were not taken into consideration; 
forth, tissue types classification and resulting 
interpretation of VH IVUS images showed high 
intra- and inter-observer reproducibility.
The present work is the first histologic 
validation of VH IVUS using a 45MHz rotational 
IVUS catheter. Adapting the VH IVUS algorithm 
to the 45 MHz catheter is nontrivial since the 
physical properties of the target plaque tissue 
types are quite distinct from the same tissue at 
the lower 20 MHz bandwidth, that was previ-
ously reported One key difference is that the 
attenuation at 45 MHz is considerably greater 
than at 20 MHz for both blood and tissue 20, 21 
.Another consideration is the fact that the 20 
MHz catheter has a multi-element transducer 
array with synthetic aperture image formation, 
while the 45 MHz catheter has a single me-
chanically rotated unfocused transducer. It has 
Table 1. Inter-observer reproducibility of VH IVUS interpretation without exclusion of shadowed ROIs 
(n=253). IC=interventional cardiologist
Developer
IC
DC ff fT nC Totals
DC 17 0 1 7 25 (9.9%)
ff 1 50 9 3 63 (24.9%)
fT 0 11 93 8 112 (44.3%)
nC 1 2 15 35 53 (20.9%)
 Totals 19 (7.5%) 63 (24.9%) 118 (46.6%) 53 (20.9%) 253
Table 2. Intra-observer reproducibility of VH IVUS interpretation without exclusion of shadowed ROIs 
(n=253). IC=interventional cardiologist
 
IC 2nd Analysis
IC 1st Analysis
DC ff fT nC Totals
DC 17 0 0 2 19 (7.5%)
ff 0 61 3 0 64 (25.3%)
fT 0 2 112 9 123 (48.6%)
nC 2 0 3 42 47 (18.6%)
 Totals 19 (7.5%) 63 (24.9%) 118 (46.6%) 53 (20.9%) 253
Chapter 1.2 
42
been shown that these factors influence the 
ultrasound’s depth of field and characteristic 
resolution 22. Figure 4 illustrates an example 
of IVUS grey-scale images obtained at 20 
MHz and 45 MHz from the same location in 
an ex vivo coronary artery sample, with the 
corresponding VH IVUS images and histologic 
findings. It is evident, that the 20 MHz image 
has greater IVUS depth of penetration and the 
45 MHz image has greater axial resolution 
(i.e., in the direction of the ultrasound beam) 
while it lacks in the depth of penetration 
due to higher attenuation (see Figure 4). In 
this 45 MHz IVUS study, the greater effect of 
calcium-induced shadowing and loss of signal 
with depth can be observed in the increased 
amount of fibro-fatty tissue appearing behind 
dense calcifications as demonstrated in the 45 
MHz VH IVUS image in Figure 4. This is due to 
the fact that spectral properties of backscat-
ter from atherosclerotic fibro-fatty tissue can 
overlap with properties of backscatter from at-
tenuated ultrasound, resulting in an incorrect 
classification of tissue type. This phenomenon 
also explains the low sensitivity observed for 
dense calcium and the low specificity ob-
served for fibro-fatty tissue in the ROI-cohort 
without exclusion of calcium-shadowed ROIs. 
Hence, for clinical studies utilizing the 45 MHz 
VH IVUS algorithm, regions with dominant 
shadowing can be excluded from analysis. 
This greatly increases the sensitivity of dense 
calcium and to a lesser extent the sensitivity 
of necrotic core tissue type while increasing 
the specificity of the fibro-fatty tissue type.
figure 4. Examples of (A) 20 MHz and (B) 45 MHz IVUS images with corresponding VH IVUS images, col-
lected ex vivo in a human coronary lesion (C). The 20 MHz IVUS image has lower axial resolution, but 
lesser attenuation in signal behind an area of dense calcification, and is displayed with a 10 mm field-
of-view. Whereas, the 45 MHz IVUS image has higher axial resolution, but higher attenuation of signal 
behind the dense calcification (evident from the increased fibro-fatty tissue in the VH IVUS image), and 
is displayed with an 8 mm field-of-view. This plaque phenotype is classified as a calcified fibroatheroma 
as it has a visible fibrous cap covering a more than 10% confluent dense calcium and necrotic core.
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The results lend themselves to direct com-
parison with previously reported measure-
ments for the 20 MHz VH IVUS algorithm 5. 
The previous manuscript reported predictive 
accuracy in the range of 93.5% to 96.7% 
which is comparable to the 45 MHz VH IVUS 
results when excluding ROIs located behind 
heavy calcifications (93-95.5%) and ranged 
from approximately 85% to 90% when 
including all ROIs.
It may be argued that, with similar catheter 
accuracy for tissue types, the change for the 
45 MHz IVUS catheter is inconsequential. 
However, the similar accuracy between the 
20 and the 45 MHz is in terms of correct colour 
code interpretation related to histology, and 
not to any dimensional assessment. The higher 
axial resolution of the 45 MHz IVUS has poten-
tial to improve the coronary atherosclerosis 
research and raises several questions to be 
answered in the future. The higher resolution 
may improve the discernment of the in vivo 
plaque phenotype, identifying with more 
precision, for instance, if a necrotic core is in 
contact with the lumen or not. In addition, the 
better resolution may enhance the ability to 
quantify tissue type changes with application 
in natural history of atherosclerosis trials, 
bioresorbable coronary scaffold degradation, 
pharma interventions, etc.
The reported inter-observer reproduc-
ibility analysis showed consistent agreement 
between the four investigators and the two 
independent interventional cardiologists and 
may translate to clinical utility for this tool. Ad-
ditionally, the intra-observer reproducibility 
demonstrated stable response in a relatively 
large sample of ROIs.
Limitations. Although the 45MHz catheter 
has improved axial resolution, the detection 
of a thin fibrous cap, which defines plaque 
vulnerability (less than 65 µm in thickness)23 
is still below the axial resolution of current 
IVUS and this may lead to false positive 
identification of some vulnerable atheromas. 
However, with similar accuracy and yet lower 
resolution, the spectral analysis approach of 
ultrasound backscatter used with the 20 MHz 
IVUS catheter has shown prognostic relevance 
9-11.
ConClUSIon
Tissue classification by 45 MHz VH IVUS 
technology, when not influenced by sig-
nificant calcium-induced acoustic attenuation, 
provided combined tissue accuracy >88% to 
identify tissue types as compared with the 
gold-standard histologic assessment, with 
high inter- and intra-observer reproducibility.
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AbSTRACT
In recent years, coronary CT angiography(CCTA) has become a widely adopted technique, not 
only due to its high diagnostic accuracy, but also to the fact that CCTA provides a comprehensive 
evaluation of the total (obstructive and non-obstructive) coronary atherosclerotic burden. 
More recently, this technique has become mature, with a large body of evidence addressing 
its prognostic validation. In addition, CT angiography has moved from the field of ‘imagers’ 
and clinicians and entered the interventional cardiology arena, aiding in the planning of both 
coronary and structural heart interventions, being transcatheter aortic valve implantation one of 
its most successful examples. It is therefore of utmost importance that interventional cardiologists 
become familiar with image interpretation and up-to-date regarding several CTA features, taking 
advantage of this information in planning the procedure, ultimately leading to improvement in 
patient outcomes. On the other hand, the increasing use of CCTA as a gatekeeper for invasive 
coronary angiography is expected to lead to an increase in the ratio of interventional to diagnostic 
procedures and significant changes in the daily cath-lab routine. In a foreseeable future, cath-labs 
will probably offer an invasive procedure only to patients expected to undergo an intervention, 
perhaps becoming in this change true interventional-labs.
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InTRoDUCTIon
Advances in the field of computed tomography 
(CT) have made possible the non-invasive 
evaluation of coronary artery disease (CAD) 
and in recent years coronary CT angiogra-
phy (CCTA) has become a widely adopted 
technique. This was due not only to its high 
diagnostic accuracy, but also to the fact that 
CCTA provides a comprehensive evaluation 
of both obstructive and non-obstructive CAD 
and, more recently, its prognostic information 
has been validated.
The initial studies of CCTA addressed mainly 
its diagnostic accuracy. This was done both by 
comparison with the gold standard invasive 
coronary angiography (ICA) and with intra-
vascular ultrasound (IVUS). As the technique 
became more robust and widely adopted in 
clinical practice, data were gathered regarding 
cardiovascular outcomes and this opened a 
second phase of studies addressing its prog-
nostic value.
The latest technological advances have sig-
nificantly improved CCTA temporal resolution 
and volume coverage, leading to a decrease in 
radiation and contrast dose, and improvements 
in image quality, that will further reinforce 
the role of CCTA for the evaluation of patients 
with possible CAD and potentially for making 
clinical decisions based on these findings (e.g. 
CT-based coronary atherosclerotic burden 
scores and functional assessment of coronary 
lesions).
CoRRelATIon WITH ICA: CARDIAC CT 
DIAGnoSTIC ACCURACY
Many studies have been published evaluating 
the diagnostic accuracy of CCTA, by comparing 
with the gold standard ICA. These were initially 
done with four-detector row,1–4 followed by 
16-detector row scanners,5 – 9 but by that time 
significant limitations existed related to the 
dose of contrast, long breath-hold times, 
and high percentage of segments excluded 
fromanalysis due to insufficient image quality. 
In a meta-analysis of 27 studies comparing 
CCTA (with scanners of at least 16-detector 
row) with ICA, the per-patient sensitivity was 
very high (96%), but the specificity was only 
modest (74%), leading to a positive predictive 
value (PPV) of 68%.10
The 64-detector row scanners are now 
considered to be the minimum requirement 
for CCTA.11 In a more recent meta-analysis, 
including only studies with 64-detector row 
scanners, the reported per-patient sensitivity 
was 99%, specificity 89%; PPV was 93% and 
negative predictive value (NPV) was 100%.12 
Nevertheless, even with 64-detector row scan-
ners, some multicentre trials, have reported 
low specificity and PPV when evaluating 
consecutive non-selected patients. In the as-
sessment by coronary computed tomographic 
angiography of individuals undergoing inva-
sive coronary angiography (ACCURACY) trial, 
a prospective multicentre evaluating stable 
patients without known CAD who underwent 
CCTA before clinically indicated ICA, CCTA had 
a diagnostic sensitivity, specificity, PPV, and 
NPV of 94, 83, 48, and 99%, respectively. 13 
The low specificity and PPV reported in this 
trial could be related to the fact that patients 
were consecutively included irrespective of 
the baseline coronary calcium score, body 
mass index, or heart rate, variables that are 
well known to influence image quality.
In another multicentre study, Meijboom et 
al. 14 evaluated the diagnostic performance of 
CCTA in a population including both stable and 
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acute chest pain patients without known CAD 
referred for ICA. No patients or segments were 
excluded because of impaired image quality 
attributable to either coronary motion or cal-
cifications and the prevalence of obstructive 
CAD was 68%, factors that could explain the 
low per-patient specificity of 64% for CCTA 
found in this study, leading to a PPV of 86%. 
Once again, the per-patient sensitivity was 
99% and the NPV was 97%.
With the development of dual source scan-
ners, there was a significant increase in tem-
poral resolution, leading to a less dependence 
on heart rate control.15 The introduction of new 
acquisition protocols with prospective ECG–
triggering16 lead to a significant reduction in 
radiation dose, which was further reduced to ,1 
mSv doses with high-pitch spiral acquisitions, 
without compromising diagnostic accuracy17,18 
(Figure 1).
Likewise, 320-detector row scanners also lead 
to significant improvements, reducing the 
radiation dose and amount of contrast while 
maintaining high diagnostic accuracy.19,20
Addressing another important technical is-
sue in CCTA, the improved spatial resolution of 
the high-definition scanners are also expected 
to lead to significant improvements, especially 
in the evaluation of calcified lesions, in-stent 
restenosis, lesions stenosis, and plaque com-
position, without increasing radiation dose.21,22
The possibility of extracting both anatomical 
and functional information from CT data sets 
could ultimately lead to significant improve-
figure 1: CCTA with prospective triggering with an estimated radiation dose of 1.1mSv (79DLP, conver-
sion factor of 0.014), in a patient with normal coronary arteries.
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ments in specificity and PPV, especially in the 
setting of lesions with intermediate stenosis. 
This concept has been recently reinforced 
by the DISCOVER-FLOW,23 DeFACTO,24 and 
NXT25 studies that demonstrated a significant 
improvement in CCTA diagnostic performance 
when combined with non-invasive fractional 
flow reserve (FFRCT). This novel method de-
rives the physiological significance of CAD by 
applying the principles of computational fluid 
dynamics, taking in consideration not only 
CAD severity, but also left ventricular mass.
Summing up the different multicentre trials 
and meta-analysis addressing this issue, it 
has become clear now that this non-invasive 
imaging technique has a very high sensitivity 
for detecting patients with significant CAD, 
leading to a very high (virtually 100%) NPV, 
which makes CCTA a perfect gatekeeper for 
invasive angiography.
The selection of patients for ICA is tradition-
ally based on noninvasive stress testing aimed 
at identifying patients with obstructive CAD 
who could benefit from revascularization. Nev-
ertheless, many patients undergoing ICAhave 
normal coronary arteries or nonobstructive 
lesions, which decrease its diagnostic yield. In 
a large contemporary registry, with data from 
almost 400 000 patients referred for ICA, ob-
structive CAD was found in only 37.6% of the 
patients, reflecting the low diagnostic yield 
in routine clinical practice.26 This way, better 
strategies for the identification of patients in 
need for ICA are needed and in this regard CT 
angiography (CTA), by having a high NPV, can 
be a useful gatekeeper.
In a recent analysis of the largeCONFIRM 
registry, the rates of ICA and revasculariza-
tion after a CCTA with no CAD (2.5 and 0.3%, 
respectively) or mild CAD (8.3 and 2.5%, 
respectively) were very low. On the other 
hand, in this registry, obstructive CAD (≥50%
stenosis) by CCTA was associated with a 
high percentage of revascularization, ranging 
from 28% for 1 vessel to 66.8% for 3 vessel 
CAD, supporting the concept of CCTA as a 
gatekeeper for ICA.27
Presently, some patients are referred for ICA 
for pure diagnostic purposes, like the evalu-
ation of possible CAD in patients scheduled 
to undergo non-coronary cardiac surgery, to 
evaluate the need of concomitant myocar-
dial revascularization. In those patients, CCTA 
seems to be a valid alternative28,29 and is con-
sidered to be appropriate when the pre-test 
probability of CAD is not high11,30 (Figure 2).
CCTA might also become an alternative 
to ICAfor a routine evaluation of coronary 
arteries following heart transplantation,31 
although this can be difficult in the setting 
of more advanced diffuse disease of chronic 
transplant arteriopathy, in face of the current 
limitations of CCTA spatial resolution.
Patients with new-onset or newly diag-
nosed heart failure and no prior CAD are 
recommended to undergo the evaluation of 
possible CAD and are frequently referred for 
ICA.11,32,33 In this setting, CCTA might be a valid 
alternative to exclude CAD as the underlying 
aetiology for dilated cardiomyopathy, with 
the advantage of providing in the same scan 
information on cardiac vein anatomy that 
might be potentially relevant in candidates for 
cardiac resynchronization therapy.34,35 Owing 
to its non-invasive nature and the ability to 
evaluate the coronary wall, CCTA has also been 
considered as a valuable imaging modality for 
coronary dissections and intramural haema-
tomas, especially in the follow-up of patients 
managed conservatively.36
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The use of CCTA in these purely diagnostic 
indications, coupled with a better selection 
of patients for ICA using CCTA as a gatekeeper, 
are expected to lead to an increase in the ratio 
of interventional to diagnostic procedures in 
the catheterizations laboratories.
In conclusion, when evaluating the diag-
nostic accuracy of CCTA, some factors have 
to be considered, that could influence the 
performance of the exam, and could explain 
the differences between different studies:
· type of scanner technology (64-detector 
row scanners are now considered to be 
the typical minimum standard).
• population studied, regarding expected 
prevalence of obstructive CAD (can be 
calculated with pre-test CAD probabil-
ity scores—CCTA is indicated in low-to-
intermediate CAD probability).
· inclusion of non-evaluable segments in 
the analysis (considering non-evaluable 
segments as positive improves sensitivity 
but reduces specificity).
• inclusion of patients with a high body mass 
index, high calcium score or high heart 
rates, factors known to negatively affect 
image quality.
figure 2: CCTA for the exclusion of obstructive CAD prior to valvular surgery, in a patient with a fibro-
elastoma of the aortic valve. Multiplanar (A, C, D, and E) and volume-rendering technique (B) recon-
structions showing the mass attached to the aortic cusps and predominantly calcified non-obstructive 
coronary lesions in the RCA and LCx. This 66-year-old female patient underwent surgery without the 
need for invasive coronary angiography.
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eVAlUATIon of PATIenTS WITH 
PReVIoUS ReVASCUlARIZATIon
The evaluation of patients with previous 
revascularization procedures can be challeng-
ing for CCTA and these patients are usually 
recommended to undergo stress imaging.37
In the evaluation of patients after PCI, 
there are two sets of difficulties faced by 
CCTA. Metallic artefacts caused by the struts 
(influenced by the type of alloy and strut 
thickness), impairing the assessment of stents 
with a diameter ,3 mm and/or stents with 
thick struts (≥140 um).38,39 In a meta-analysis 
of studies with 64-rows scanners including 
1398 stents, the sensitivity and specificity for 
the detection of in-stent restenosiswas only 
79 and 81%, respectively. 40 The increasing 
adoption of bioresorbable scaffolds in clinical 
practice might lead to an improvement in the 
diagnostic accuracy of
CCTA for stent evaluation, since the metallic 
artefacts are only limited to the radio-opaque 
markers at scaffold margins.41
Besides the aforementioned difficulties 
imposed to the evaluation of the stented 
lesions, these patients frequently have other 
lesions in the coronary tree, some of them of 
intermediate degree of stenosis, that could 
impair specificity on a patient-based level, 
figure 3: CCTAevaluation of a patient with previous PCI. (A) Chronic total occlusion of the proximal cir-
cumflex; (B) implantation of a Xience 2.5/23 mm stent; (C) final kissing-balloon; (D) CCTA with volume-
rendering technique reconstruction; (E) multiplanar reconstruction with a detail of the ostial scaffold-
ing to the first obtuse marginal; (F) mixed plaque in proximal LAD with intermediate stenosis.
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since specificity and/or PPV of CCTA has been 
shown to be lower in cohorts with higher 
disease prevalence13,14,24 (Figure 3). This last 
limitation is also true regarding the evalu-
ation of the native vessels in patients with 
prior coronary artery bypass grafts, because 
of the extent of CAD, often associated with 
severe calcifications and small vessel calibre, 
leading to a decrease in CCTA accuracy in this 
setting.42,43
In contrast, CCTA has a high accuracy for the 
evaluation of graft patency, due to the larger 
diameter, less motion and less frequently 
calcified, when compared with the native 
arteries (Figure 4). In addition, disease in grafts 
more often presents as occlusion rather than 
stenosis, which are easy to depict in CCTA. In 
a meta-analysis including studies with both 
16- and 64-rows scanners, the sensitivity and 
specificity for the detection of significant 
(≥50%) graft stenosis was 96 and 97%,44 
documenting a high overall performance for 
noninvasive graft assessment.
PlAqUe CHARACTeRIZATIon AnD 
CoRRelATIon WITH oTHeR IMAGInG 
MoDAlITIeS: PUSHInG THe lIMITS of 
SPATIAl ReSolUTIon
Since many myocardial infarctions present 
in previously asymptomatic patients and not 
infrequently the first manifestation of CAD 
is sudden cardiac death, the main challenge 
figure 4: Evaluation of bypass grafts by CCTA. Volume-rendering technique reconstructions showing 
saphenous vein grafts (SVG) to the posterior-descending (PD) and obtuse marginal (OM) branches and 
a left internal mammary artery to the left anterior descending artery (LIMA-LAD).
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that we face today is to identify patients at 
risk before those events occur. In this regard, 
clinical evaluation alone might be insufficient, 
since only a minority of patients experiencing 
and acute myocardial infarction would have 
been identified as high risk by the available 
risk factors based scores, prior to the event.45
Coronary plaque characterization, namely 
the identifications of features of vulnerability, 
has been the focus of extensive research by 
different coronary imaging modalities such 
as IVUS, IVUS-virtual histology (IVUS-VH), and 
optical coherence tomography (OCT). These 
imaging modalities, although providing the 
highest possible spatial resolution, have their 
applicability limited by their invasive nature, 
and are usually employed in patients already 
referred for invasive angiography because 
of suspected CAD or with acute coronary 
syndromes (ACS). Many of these patients will 
be (independent of the result of the imaging 
modality) under secondary prevention of CAD, 
which changes natural history and reduces the 
risk of subsequent cardiovascular events.46,47
In the multicentre PROSPECT study,47 a large 
plaque burden, a small lumen area and the 
presence of a thin cap fibroatheromas (TCFA) 
assessed by IVUS-VH in non-culprit lesions, 
were independent predictors of future major 
adverse cardiac events. In this study, lesions 
that led to major adverse cardiac event had a 
high plaque burden by IVUS, but were mild by 
baseline angiography, with a mean diameter 
stenosis of only 32%.
On the other hand, ischaemia based imag-
ing modalities have also some limitation in 
figure 5: Identification of non-obstructive CAD as a unique feature of CCTA as a non-invasive CAD imag-
ing modality.
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this regard, especially related to the fact that 
nonobstructive lesions are not associated 
with ischaemia, but can also be the culprit of 
coronary events47 – 50 (Figure 5).
Several studies have reported on the cor-
relation between CCTA plaque features with 
invasive coronary imaging modalities like 
IVUS, IVUS-VH, and OCT. In a meta-analysis 
published in 2011,CCTA had a good diagnostic 
accuracy to detect coronary plaques compared 
with the gold standard IVUS, with an area 
under the curve for the receiver operating 
characteristics analysis of 0.94, a sensitivity 
of 90%, and a specificity of 92%, with small 
differences in the assessment of plaque area 
and volume, percent area stenosis, and a slight 
overestimation of lumen area.51
Several CCTA plaque characteristics have 
now been shown to be more prevalent in 
culprit lesions in the setting of ACSs. In a 
study done by Hoffman et al.52, a significantly 
larger plaque area and positive remodelling 
were found in culprit lesions of ACS patients, 
compared with patients with stable CAD. 
Positive remodelling has been considered 
for many years a surrogate marker of plaque 
vulnerability, and many of these lesions have 
a high plaque burden, that is, underestimated 
by luminal angiograms because they undergo 
expansive or positive outward enlargement 
and are frequently non-stenotic49 (Figure 6). In 
another small study, Motoyama et al.53 found 
that culprit lesions of patients with ACS had 
more frequently positive remodelling, low 
figure 6: CCTA depicting a non-calcified plaque in the proximal left anterior descending artery without 
significant stenosis (A). In invasive angiography (B), this lesion was not apparent but was confirmed 
with IVUS (C).
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density plaque [<30 Hounsfield units (HU)] 
and spotty calcifications.
Extending on these results, the same authors 
conducted a large prospective trial including 
1059 patients who underwent CCTA, and 
demonstrated that positive remodelling and 
low-attenuation plaques were associated with 
the subsequent development of ACSs.48 In this 
study, the percentage of patients with these 
two features that subsequently developed and 
ACS was 22.2%, compared with only 3.7% for 
patients with only one feature and 0.5% for 
patients with neither positive remodelling nor 
low-attenuation plaques.
In a study by Kashiwagi et al.,54 evaluating 
105 patients with CAD, CCTA findings have 
been also validated against OCT. In this study, 
TCFAs had higher remodelling indexes, lower 
CT attenuation values and more often ‘ring-
like’ enhancement by CCTA (44% in the TCFA 
group vs. 4% for the non-TCFA group).
In a recent study, Papadopoulou et al.55 
evaluated the distribution and composition 
of coronary plaques at bifurcations with both 
CCTA and IVUS-VH. They found that plaques 
with a high-risk phenotype as assessed by 
IVUS-VH were more commonly found in seg-
ments proximal to the bifurcation, rather than 
in the bifurcation or distal to the bifurcation. 
Interestingly, by evaluating the geometry of 
the bifurcation, a feature easily assessed with 
CCTA, they found that a wide angle was more 
often associated with high-risk plaques.
As a group, these studies provide evidence 
on how CCTA can noninvasively provide 
information on several plaque characteris-
tics—like plaque volume, remodelling, plaque 
composition, distribution, and geometry of the 
coronary tree—that can be associated with the 
development of future coronary events.
lIMITATIonS of CCTA foR PlAqUe 
CHARACTeRIZATIon
Despite significant improvements in image 
quality, spatial resolution has not seen signifi-
cant improvements and remains presently one 
of the major technical limitations of CCTA. The 
spatial resolution of currently available scan-
ners (in the range of 400–600 µm) prevents 
the detailed assessment of several features 
associated with vulnerable plaques, as is the 
case of the evaluation of a thin fibrous cap.51 
This spatial resolution is significantly worse 
than that of IVUS (200–250 µm) or OCT (10–15 
µm)56 and this has to be taken in consideration 
and should temper our expectations regarding 
the potential of CCTA for plaque assessment in 
face of the limitations already faced by other 
invasive imaging modalities regarding the 
identification of the vulnerable plaque.
Another limitation faced by CCTA plaque 
characterization is related to the fact that 
coronary plaque attenuation values are sig-
nificantly modified by differences in lumen 
contrast densities, as has been demonstrated 
both ex vivo and in vivo.57,58 This is important 
because lumen attenuation can be influenced 
by different contrast and scanning protocols 
and therefore makes it difficult to establish 
thresholds for the definition of low-atten-
uation plaque as a surrogate of vulnerable 
plaque that can be widely adopted.
One last important limitation in this regard 
is related to the reproducibility of CCTA plaque 
measurements, as many previous studies have 
reported significant inter-observer variability 
in the assessment of several CCTA plaque 
characteristics.59,60 This is dependent on image 
quality, vessel size and degree of calcification, 
features that are dependent again on spatial 
resolution. In the future, improvements in 
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spatial resolution and the development of 
robust dedicated automated quantification 
software could contribute to overcome these 
difficulties.
PRoGnoSTIC VAlUe: CARDIAC CT 
ReACHInG ADUlTHooD
As the technique became more robust and 
more data become available, CCTA proved 
also to be a strong prognostic tool for the 
evaluation of patients with suspected CAD.61 – 66 
Pundziute et al.61 in 100 patients with known 
or suspected CAD, showed that there were no 
major cardiac events on the subset of patients 
without CAD, contrasting with the 30% event 
rate of patients with CCTA documented 
CAD upto 16 months. More importantly, the 
cumulative event rate of patients with non-
obstructive CAD was higher and different from 
the excellent prognosis of patients without 
plaques on CCTA. This earlier study had some 
limitations, both related to the small sample 
size and the fact that some of the included 
cardiovascular events (revascularization and 
unstable angina requiring hospitalization) are 
not ‘hard’ endpoints and could be influenced 
by the CCTA result.
Min et al.62 evaluated the prognostic value of 
identifying CAD with CCTA in a single-centre 
cohort of 1127 patients with stable chest 
symptoms. A negative CCTA was associ-
ated with an excellent prognosis and some 
CCTA-derived CAD indexes were developed 
and prognostically validated. Some of those 
indexes were expected to convey prognostic 
information, as these observations extend on 
what was previously documented for ICA, as 
was the case of number of diseased vessels, 
degree of stenosis and more proximal location. 
More importantly was the fact that they were 
able to demonstrate the prognostic value of 
more CCTA-specific indexes derived from the 
comprehensive information of both obstruc-
tive and non-obstructive plaque: the segment 
involvement score (SIS), obtained as the total 
number of segments with plaque (1 point for 
each segment with plaque, irrespective of the 
degree of luminal stenosis) and the segment 
stenosis score (SSS), obtained by grading the 
stenosis severity of each segment with plaque 
(segments graded from 0 to 3 according to 
the degree of stenosis). For both SIS and SSS, 
a value of 5 was identified as the best cut-off 
to predict all-cause mortality.
In 2011, two meta-analyses were pub-
lished63,64 evaluating the prognostic value of 
CCTA and (not surprisingly) had the same two 
main conclusions: (i) that the presence and 
extent of CAD on CCTA are strong and inde-
pendent predictors of future with an excellent 
prognosis. Of note, in both meta-analysis, it 
was possible to distinguish between the excel-
lent prognosis of patients in the absence of 
CAD from that of patients with non-obstructive 
CAD, as documented by CCTA.
In the CCTA registry CONFIRM (Coronary 
Computed Tomography Angiography Evalu-
ation for Clinical Outcomes: an International 
Multicentre Registry),65 which included >20 
000 patients, the absence of CAD was associ-
ated with an excellent prognosis (annualized 
death rate of 0.28%). At 2.3 years follow-up, 
both obstructive and non-obstructive CAD 
conferred an increased mortality risk with 
hazard ratios of 2.6 and 1.6, respectively.
In another report of the CONFIRM database, 
it was demonstrated that CCTA measures of 
CAD severity yield independent and incremen-
tal prognostic value to that of left ventricle 
ejection fraction (LVEF) and routine clinical 
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predictors.66 In this report, all-cause mortality 
occurred in 0.65% of patients without CAD, in 
1.99% of patients with non-obstructive CAD, 
2.90% of patients with non-high-risk CAD, and 
4.95% with high-risk CAD.
In what concerns the incremental prognostic 
value of CCTA over other CAD imaging mo-
dalities, Werkhoven et al.67 have evaluated the 
potential synergistic effect of a functional test 
(single-positron emission CT-SPECT) and CCTA 
(as an anatomical test). They found CCTA to be 
an independent predictor of cardiovascular 
events and its prognostic information was 
incremental to that of SPECT, in line with 
previous studies that showed an incremental 
value over exerciseECGtesting.68 Nevertheless, 
although the potential synergistic role of both 
anatomical and functional imaging modalities 
can be appealing, for both diagnostic and 
prognostic purposes, this concept might be 
difficult to prove as a cost-effective strategy 
and probably not desirable to perform both 
exams in the same patient. In addition, some 
studies evaluating the relative prognostic 
value of CCTA and exercise ECG testing sug-
gested that CCTA may be used as a first line 
exam, since a normal CCTA is always associated 
with a good prognosis, independent of the 
results of exercise ECG, and a non-negligible 
percentage of patients with a normal exercise 
ECG are found to have significant stenosis 
on CCTA, a finding associated with worse 
outcomes.69,70
This way, more research is needed to further 
evaluate the role and relative position of the 
different imaging modalities in the algorithm 
for the evaluation of patients presenting with 
possible CAD. One proposed approach is to se-
lect the type of exam according to the patient 
CAD probability, favouring functional exams in 
the intermediate probability and CCTA for the 
lower probability patient, as recommended by 
the National Institutes of Clinical Excellence 
(NICE) Clinical guidelines on ‘chest pain of 
recent onset’.71 The prognostic evaluation of 
CCTA data (as is the case for other CAD imaging 
modalities) is dependent on the baseline risk 
of the population included and the outcomes 
evaluated. Studies including a higher percent-
age of patients with intermediate-to-high CAD 
probability and/or risk, or even with known 
CAD, can more easily document the prognostic 
power of CCTA. This is also the case for studies 
evaluating the impact on total cardiovascular 
events (instead of only ‘hard’ CV events). This 
is especially true regarding the inclusion of 
revascularizations after CCTA, as the result 
of this anatomical test could influence and 
increase subsequent procedures. For this 
reason, many studies addressing this issue 
have now excluded earlier revascularizations 
from the outcome analyses.63,72
In another recently published study, 
Andreini et al. evaluated the long-term (.4 
years follow-up) prognostic value of CCTA in a 
cohort of 1304 patients with suspected CAD.72 
Although the authors excluded patients with 
known CAD, the mean pre-test probability of 
CAD in the study population was high (42.5%, 
with one quarter of the patients having a 
high CAD probability) and they also included 
patients with possible ACSs. This led to a 
higher than expected hard event rate for a 
stable CAD population (event-free survival 
of 54% for patients with obstructive CAD). 
Therefore, the design of studies to address the 
prognostic value of CCTA can be influenced 
by these two important aspects: inclusion of 
many high risk/high-CAD probability patients 
and of revascularization as a cardiovascular
event can lead to an overestimation of the 
prognostic power of CCTA.
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When comparing the prognostic information 
conveyed by CCTA with that of other non-
invasive imaging modalities such as SPECT 
or stress echo, it is remarkable that the 
excellent prognosis of a normal CCTA—no 
plaque—0.17.% annual event rate in a CCTA 
metaanalysis64 is even lower than what was 
previously demonstrated for patients with 
normal perfusion on SPECT (0.6% annual 
event rate) or normal wall motion on stress 
echo (1.0% annual event rate) in previous 
meta-analysis.73,74
This difference could be explained by the 
fact that CCTA identifies non-obstructive 
CAD(usually negative of stress-based exams) 
and in this way provides a more comprehen-
sive evaluation of the total coronary athero-
sclerotic burden that has a stronger prognostic 
meaning (Figure 7).
Scores that reflect the comprehensive infor-
mation provided by CCTA have already been 
developed and they can be useful tools to 
quantify the coronary atherosclerotic burden. 
One of these is the CT-SYNTAX score, a CCTA 
adaptation of its angiographic counterpart,
known to reflect the severity of CAD which 
has prognostic implications and is a useful tool 
for decision-making on myocardial revascular-
figure 7: Non-obstructive (but probably not non-significant!) coronary lesions identified with CCTA. 
Upper panel with a volume-rendering technique and lower panel with multiplanar reconstructions. (A) 
Mixed plaque in the proximal LAD with 25–50% stenosis in a 54-year-old female with dyslipidaemia 
and smoking habits; (B) mixed plaque in the proximalLADwith,25% stenosis in a 31-year-old male with 
a family history of premature CAD; (C) mixed plaque in the left main with ,25% stenosis in a 51-year-old 
male with hypertension and dyslipidaemia. None of these patients had a
high (≥5%) 10-year risk of cardiovascular death, as estimated by the HeartScore.
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ization. The score calculated with CCTA data 
acquired with last generation scanners has 
been shown to correlate well with the invasive 
SYNTAX and to have a high reproducibility.75 
This way it is also expected to be a useful prog-
nostic toll for risk stratification of patients with 
obstructive CAD. In addition, this information 
can be made available in advance, which could 
help in the planning of the revascularization 
procedure.
Another CCTA score that was recently 
described is the CT-Leaman score, in which 
all the atherosclerotic lesions are taken in 
consideration (both obstructive and non-
obstructive) in a comprehensive score that 
has three sets of weighting factors: lesion 
localization (taking in consideration the 
anatomical dominance), degree of stenosis 
(obstructive and non-obstructive), and type 
of plaque (calcified, non-calcified, and mixed 
plaques).76 This score
can become a useful tool to quantify a 
total coronary atherosclerotic burden and 
is expected to convey the strong prognostic 
information of CCTA. This could even be more 
useful in patients with non-obstructive le-
sions, whose prognosis has been shown to be 
worse than that of patients without coronary 
plaques,65,72 and is a very prevalent subset,77,78 
for whom risk stratification will be of utmost 
importance.
CTA AS A Tool In THe PlAnnInG of 
InTeRVenTIonAl PRoCeDUReS
CTA can also be used as a tool for the appropri-
ate selection and planning of interventional 
procedures, and has been routinely used in 
this setting in chronic total occlusions (CTOs), 
transcatheter aortic valve implantation (TAVI), 
and potentially many other coronary and 
structural heart procedures. Regarding CTOs, 
which still remain a challenging subset of 
lesions for percutaneous revascularization, 
appropriate selection of the cases is of utmost 
importance, since PCI in this setting is not only 
associated with higher contrast and radiation 
dosages, but also with a non-negligible rate 
of procedural complications. In this regard, 
several CTA features have been associated 
with success of PCI for CTOs like the length 
of the occluded segment, the amount of cal-
cification, the presence of a blunt stump and 
bending and tortuosity of the proximal vessel 
and/or occluded segment.79,80 The evaluation 
of myocardial perfusion by CT is also becom-
ing a reality81,82 and patients with CTOs might 
be an important subset to benefit from this 
combined anatomic and viability assessment 
for decision-making regarding intervention.83
CTA plays also an important role in the 
evaluation of the candidate for implanta-
tion of a catheter-based aortic valve. CTA 
provides information in correct sizing of the 
prosthesis since it is acknowledged that 3D 
imaging techniques, with a greater extent of 
evidence for CTA, yield larger aortic annulus 
dimensions than echocardiography.84,85 The 
improved accuracy of aortic annular sizing 
by CT can influence patient outcomes. In a 
study of 133 patients who underwent CTA 
before TAVI/TAVR, it was reported that, in 
comparison with TEE based sizing, the use of 
CTA-based aortic annulus dimensions led to a 
significantly lower rate of ‘worse-than-mild’ 
paravalvular regurgitation after TAVI (7.5 vs. 
21.9%).86
Besides aortic annulus size, distance of the 
coronary ostium to the aortic valve plane, 
aortic cusp length, width of the aortic sinus, 
width of the sinotubular junction, and width 
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of the ascending aorta are important measures 
for TAVI planning.85 Unlike surgery for aortic 
valve replacement, in TAVI the cusps are not 
resected but instead they are crushed by the 
endoprosthesis. This way, the distance of the 
coronary ostia to the aortic valve plane and 
aortic cusp length is important to evaluate 
the potential risk of coronary occlusion, a rare 
but menacing complication.87 The width of the 
aortic sinus, the sinotubular junction, and the 
ascending aorta are also important measure-
ments for the self-expandable TAVI, since it 
extends beyond the sinotubular junction into 
the ascending aorta. The evaluation of CAD in 
these patients might be challenging especially 
in the presence of advanced coronary calcifica-
tion, although some authors have reported a 
good accuracy in this setting.88
CTA also provides information on the suit-
ability of access site, taking in consideration the 
minimum vessel lumen required for each TAVI 
system (Table 1). Small vessel diameter, severe 
atherosclerotic disease, bulky calcification, 
and tortuosity are the main determinants of 
vascular complications in TAVI procedures.89,90
Not only the iliac and femoral artery, but 
also the entire aorta should be examined by 
CTA, since it can identify tortuosity, dissec-
tions or thrombus, all increasing the risk of 
procedure-related complications, which can 
be anticipated with CTA (Figure 8). In addition, 
the assessment of left ventricle and chest 
wall may influence the feasibility, safety, and 
effectiveness of the procedure. CTA data sets 
should be evaluated for the presence of LV 
thrombi as a source of embolic complications. 
The disposition of the LV apex relative to the 
chest wall and alignment of the LV-axis with 
LV outflow tract orientation may be useful 
information for transapical procedures. The 
optimal viewing projections for TAVI implanta-
tion can also be virtually simulated by CTA, 
with potential reductions in contrast dose and 
procedure time.
Percutaneous valvular interventions are 
not limited to TAVI, and mitral interventions 
are becoming a reality. CTA can be useful in 
this setting, especially for coronary sinus 
annuloplasty techniques, since CTA can 
provide information on the relation between 
the coronary sinus and the left circumflex 
and also between the coronary sinus and the 
level of the annulus and these anatomical 
relations have been linked to the success and 
safety of the procedure.91 The role of CTA for 
mitral interventions aimed at the leaflets, like 
edge-to-edge repair technologies, has yet to 
be defined, and presently echocardiography 
plays a central role in the selection and guid-
ance of these procedures.
Table 1 Manufacturer-suggested anatomic evaluation for TAVI
Aortic
annulus.
diameter,mm
Ascending
aorta.
diameter,mm
Sinus of
Valsalva.
width,mm
Sinus of
Valsalva.
height,mm
Distance
aortic 
annulus.
to left main
ostium,mm
Minimal
liofemoral
diameters,
mm
CoreValve Evolut Bioprosthesis 23 mm 18–20 ≤34 ≥25 ≥15 – 6
CoreValve Bioprosthesis 26 mm 20–23 ≤40 ≥27 ≥15 – 6
CoreValve Bioprosthesis 29 mm 23–27 ≤43 ≥29 ≥15 – 6
CoreValve Bioprosthesis 31 mm 26–29 ≤43 ≥29 ≥15 – 6
Edwards SAPIEN XT 23 18–21 – – – ≥10 6
Edwards SAPIEN XT 26 22–24 – – – ≥10 6.5
Edwards SAPIEN XT 29 25–28 – – – ≥10 7
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Other structural heart interventions can ben-
efit from the detailed anatomical evaluation 
prior to the procedure, like the evaluation of 
the left atrial appendage in patients candidate 
for closure devices.92 In addition, left atrial 
appendage morphology has been correlated 
with the risk of stroke in patients with atrial 
fibrillation, suggesting CTA as a potential tool 
for risk stratification regarding anticoagulation 
management in these patients.93
The detailed morphological characterization 
of coronary anatomy and plaque distribution 
provided byCCTAmight also be useful in the 
evaluation of bifurcation lesions, and can 
have some implications regarding selection 
of the PCI bifurcation technique.94,95 In a recent 
study, plaque distribution and morphology 
assessed by CCTA was associated with side 
branch compromise after left main PCI.96 The 
development of some complications during 
PCI has also been linked to CCTA plaque 
characteristics. In one study, the presence of 
low-attenuation plaque and napkin ring-like 
appearance of culprit lesions on CCTA were 
associated with the development of slow-flow 
or no-reflow phenomenon during PCI.97
Another condition easily identified with 
CCTA is myocardial bridging, and this explains 
the higher prevalence in CCTA reports, in line 
with classic autopsy series and much higher 
than in ICA studies.98 In most of the cases this 
is a benign finding, although it has been as-
sociated with the development of myocardial 
ischaemia and found to be more prevalent in 
patients with apical ballooning syndrome.99 
Additionally, bridging of the left anterior de-
scending imposes a higher technical difficulty 
for bypass surgery and has been associated 
with higher rates of complications, including 
perforation of the right ventricle,
Figure 8: CTA evaluation for TAVI. (A) and (B) Aortic annulus measurements; (C) Aortic cusps lengths; (D) 
and (E) Aortic sinus heights for left coronary cusp (LCC) and right coronary cusp (RCC); (F) CTA simulation 
of an optimal viewing projection for valve implantation; (G) Three dimensional reconstruction of the 
abdominal aorta showing severe iliofemoral tortuosity; (H) aortic root angulation measurement; (I ) and 
(J ) right and left femoral mensuration.
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and therefore its preoperative identification 
can potentially help planning the revascular-
ization procedure.98
In summary,
(1) CCTA is becoming an alternative for ICAin 
many purely diagnostic procedures that 
are becoming less often referred to the 
cathlab.
(2) The performance of CCTA as a gatekeeper 
for ICA is expected to lead to an increase 
in the ratio of interventional to diagnostic 
procedures.
(3) CCTA can potentially be useful in planning 
PCI especially more complex interventions 
like CTOs and bifurcations.
(4) CTA is routinely used in the selection 
process of percutaneous valvular interven-
tions as is the case of TAVI, especially for 
correct annular sizing.
(5) Lastly, some CCTA plaque features can 
also be useful as predictors of potential 
complications during PCI and the operator 
can take advantage of this information in 
planning the procedure.
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AbSTRACT
Purpose: The pathophysiology of acute coronary syndromes (ACS) after noncardiac surgery is not 
established yet. Thrombosis over a vulnerable plaque or decreased oxygen supply secondary 
to anemia or hypotension may be involved. The purpose of this study was to investigate the 
pathophysiology of ACS complicating noncardiac surgery.
Methods: Clinical and angiographic data were prospectively recorded into a database for 120 
consecutive patients that had an ACS after noncardiac surgery (PACS), for 120 patients with 
spontaneous ACS (SACS), and 240 patients with stable coronary artery disease (CAD). Coronary 
lesions with obstructions greater than 50% were classified based on two criteria: Ambrose’s 
classification and complex morphology. The presence of Ambrose’s type II or complex lesions 
were compared between the three groups.
Results: We analyzed 1470 lesions in 480 patients. In PACS group, 45% of patients had Ambrose’s 
type II lesions vs. 56.7% in SACS group and 16.4% in stable CAD group (P < 0.001). Both PACS and 
SACS patients had more complex lesions than patients in stable CAD group (56.7% vs. 79.2% 
vs. 31.8%, respectively; P < 0.001). Overall, the independent predictors of plaque rupture were 
being in the group PACS (P < 0.001, OR 2.86; CI, 1.82–4.52 for complex lesions and P < 0.001, OR 
3.43; CI, 2.1–5.6 for Ambrose’s type II lesions) or SACS (P < 0.001, OR 8.71; CI, 5.15–14.73 for 
complex lesions and P < 0.001, OR 5.99; CI, 3.66–9.81 for Ambrose’s type II lesions).
Conclusions: Nearly 50% of patients with perioperative ACS have evidence of coronary plaque 
rupture, characterizing a type 1 myocardial infarction.
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InTRoDUCTIon
Annually, more than 230 million noncardiac 
surgeries are performed worldwide [1]. De-
spite improvements in surgical and anesthetic 
techniques, mortality and cost related to these 
procedures are raising [2]. Cardiac complica-
tions are a major cause of morbidity and 
mortality after noncardiac surgeries, and 
patients experiencing a perioperative myo-
cardial infarction (MI) have a high mortality 
and prolonged hospital stay [3]. The etiology 
and pathophysiology of myocardial ischemia 
and infarction after noncardiac surgery is still 
subject of controversies [1,3–7]. In this setting, 
it may involve thrombosis over a vulnerable 
plaque or decreased oxygen supply second-
ary to anemia or hypotension, designated 
type 1 and type 2 by the universal definition 
of MI [8,9]. Depending on the predominant 
mechanism, prognosis and treatment may be 
different. Although two retrospective pathol-
ogy studies reported that nearly 50% of pa-
tients with fatal perioperative MI have plaque 
disruption [10,11], it has been suggested that, 
in patients who survive a perioperative MI, the 
incidence of type 2 MI would be much higher 
than type 1 [1]. However, there are no studies 
designed to establish the pathophysiology in 
patients that survived a perioperative acute 
coronary syndrome (ACS).
The presence of coronary plaques with 
complex morphologic features in coronary 
angiography is the angiographic hallmark of 
unstable coronary syndromes and correlates 
with pathologic plaque rupture and thrombus, 
characterizing a type 1 MI [12–19]. Ambrose’s 
type II eccentric lesions are strongly associated 
to disrupted plaques and their finding have 
92% specificity [17–20]. In order to determine 
the pathophysiology of ACS complicating 
noncardiac surgery we compared the presence 
of plaque rupture as a marker of type 1 MI 
in patients with ACS after noncardiac surgery 
(PACS), patients in the emergency room with 
spontaneous ACS (SACS), and patients with 
stable coronary artery disease (CAD). The 
present study was performed at the biggest 
University Hospital in Brazil where, roughly, 
40,000 non-cardiac surgeries are performed 
annually.
MeTHoDS
Between February 2006 and June 2010 clini-
cal and angiographic data were prospectively 
recorded into a database for 120 consecutive 
patients that had PACS after noncardiac sur-
gery, for 120 patients with SACS, and for 240 
patients with stable CAD. The study protocol 
was approved by the hospital’s ethics com-
mittee.
Inclusion criteria
Consecutive patients submitted to noncardiac 
surgery who presented with ACS within 30 
days after the procedure were included in the 
PACS group. Patients with suspected periop-
erative ACS were evaluated by a cardiologist 
and were included if they had unstable angina 
with electrocardiographic ischemic signs (ST 
segment depression or T wave abnormali-
ties) or MI, defined as follows: detection of 
a typical rise and fall of biochemical markers 
of myocardial necrosis (troponin) with at least 
one value above the 99th percentile of the up-
per reference limit together with: ischemic 
symptoms or development of pathological Q 
waves on the electrocardiogram (ECG) or ECG 
changes indicative of ischemia (ST segment 
elevation or depression) [21].
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For the SACS group, patients that had arrived 
in the emergency room on random days and 
met the same criteria of ACS were included 
at admission.
For the stable CAD group, patients that were 
submitted to elective coronary angiography on 
random days were included before the proce-
dure. Angiography was indicated by clinic’s 
physician based on symptoms of stable angina 
or evidence of CAD on complementary tests.
exclusion criteria
Patients in the PACS and SACS group were 
excluded if coronary angiography was not per-
formed. Patients in the stable CAD group were 
excluded if they had had an ACS diagnosis in 
the previous 2 months.
Clinical data
Clinical data such as age, gender, presence of 
diabetes, hypertension, smoking status, his-
tory of prior MI, stable angina, heart failure, 
prior myocardial revascularization procedures, 
and cardiovascular medication use were col-
lected for the three study groups.
Patients in the PACS and SACS groups 
were followed-up until hospital discharge, 
and information about recurrent unstable 
angina and myocardial infarction and death 
was obtained. The use of antiplatelet and anti-
coagulant agents prescribed for ACS treatment 
and bleeding episodes were also recorded. 
Bleeding episodes were classified as major or 
minor based on TIMI’s criteria [22].
Angiographic analysis
All angiographies were analyzed by a single 
experienced observer who was unaware of 
the patients’ clinical diagnosis. The number 
and location of coronary lesions with obstruc-
tions greater than 50% were recorded. Each 
lesion was classified based on Ambrose’s 
classification [17–19]. This classification 
divides the lesions into 4 types: concentric 
(symmetric and smooth narrowing), type I 
eccentric (asymmetric stenosis with smooth 
borders and a broad neck), type II eccentric 
(asymmetric stenosis in the form of a convex 
intraluminal obstruction with a narrow neck 
due to one or more overhanging edges or 
irregular or scalloped borders, or both) and 
multiple irregularities (three or more serial, 
closely spaced narrowing or severe diffuse 
irregularities within a vessel) [17–19].
Lesions were also categorized as complex 
or not using a classification adapted from 
Goldstein et al. [12]. Lesions were considered 
complex if they caused at least 50% stenosis 
and had one or more of the following morpho-
logic features:
- An intraluminal filling defect consistent 
with thrombus, defined as abrupt vessel 
cutoff with persistence of contrast, or 
an intraluminal filling defect in a vessel 
within or adjacent to a stenotic region 
with surrounding homogeneous contrast 
opacification;
- Plaque ulceration, defined by the presence 
of contrast and hazy contour beyond the 
vessel lumen;
- Plaque irregularity (haziness), defined by 
irregular margins or overhanging edges;
- Impaired flow (TIMI flow < 3, except lesions 
characteristic of chronic total occlusion, 
identified as tapering lesions with multiple 
fine collaterals).
The presence of at least one Ambrose’s type 
II lesion or a complex lesion per patient was 
compared between the three study groups.
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Statistical analysis
Base-line demographic characteristics, clinical 
and angiographic variables were compared 
between the three groups. Frequencies 
and percentages are given for categorical 
variables. These variables were compared by 
chi-square test when applicable and otherwise 
by Fisher’s exact test. Numerical variables are 
reported as means±standard deviation (SD). 
For continuous variables, statistical compari-
sons were made with use of Student’s t-test 
(normal distribution) or Mann–Whitney test 
(asymmetric distribution). Post hoc analysis 
for continuous variables was made by the 
Tukey-HSD (honest significant difference) test. 
Multivariate logistic regression analysis was 
performed to access independent clinical pre-
dictors for plaque rupture in patients from all 
three groups. All clinical variables with a value 
of P < 0.25 in univariate analysis were tested. 
Belonging to PACS or SACS group, presence of 
diabetes or anemia, age > 70 years old, and lack 
of use of aspirin, betablocker and statins were 
included in the multivariable model to test 
association with complex lesions. Belonging to 
PACS or SACS group, not having hypertension 
or history of prior MI, anemia, and lack of use of 
aspirin, betablocker, and statins were included 
in the multivariable model to test association 
with Ambrose’s type II lesions. Adjusted odds 
ratio (OR) is reported with corresponding 95% 
confidence intervals (CI). Model adequacy was 
measured by Hosmer & Lemeshow’s good-
ness of fit test. A P value of less than 0.05 was 
considered to indicate statistical significance. 
All analyses were performed using the SPSS 
15.0 software.
ReSUlTS
One hundred seventy patients with suspected 
PACS were evaluated. Nine patients were not 
included because they did not have ACS (eight 
had isolated troponin elevations and one had 
pulmonary thromboembolism). Forty patients 
were excluded because coronary angiography 
was not performed and one patient was ex-
cluded due to technical reasons in analyzing 
the angiography, leaving 120 patients that 
were included in the PACS group. In the SACS 
group, 145 patients were evaluated and 120 
were included. Overall, 480 patients and 1470 
lesions were analyzed.
Table 1 Baseline characteristics.
Table  1  Baseline  characteristics.  
  
  
Table  2.  Medication  at  admission.  
  
  
Table  3.  Acute  coronary  syndrome  treatment  medication.  
  
  
  
  
  
Table  4.  Angiographic  characteristics.  
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Clinical and laboratory characteristics of the 
480 patients and medications at the time of 
admission are listed in Tables 1 and 2, respec-
tively. There were no differences between the 
three groups in the prevalence of male gender, 
hypertension or diabetes. Patients in PACS 
group were older and had lower hemoglobin 
levels than patients in SACS or stable CAD 
groups. Patients in PACS group also had less 
prior history of known CAD (history of MI or 
prior myocardial revascularization procedures) 
than patients of the other two groups.
Clinical data and outcome
In PACS group, the mean time between the 
procedure and the ACS was 2.2±3.3 days 
and 71.7% of patients had an ACS within 
the first 72 h after surgery. Regarding the 
type of operation, 46 patients (38.3%) were 
submitted to vascular surgery, 25 (20.8%) 
to general abdominal surgery, 12 (10%) to 
urologic surgery, 10 (8.3%) to orthopedic 
surgery, 7 (5.8%) to head and neck surgery, 
7 (5.8%) to neurosurgery, 4 (3.3%) to kidney 
transplantation, and 9 (7.7%) to other pro-
cedures. Regarding anesthesia, 67 (60.4%) 
patients received general anesthesia, 20 
(18%) regional anesthesia and 24 (21.6%) 
combined general plus regional anesthesia. 
Mean anesthesia duration was 363 ±
212 min (range from 60 to 1425 min). Only 
48 (40.7%) patients presented with chest 
pain as the clinical manifestation of ACS. As 
for ACS classification, 19 (15.8%) patients had 
unstable angina, 94 (78.3%) had non-ST eleva-
tion MI and 7 (5.8%) had ST elevation MI. In 
SACS group, 19 (5.8%) patients had unstable 
angina, 78 (65%) had non-ST elevation MI and 
23 (19.2%) had ST elevation MI. Patients in the 
PACS group had a longer time from the ACS to 
angiography than patients in the SACS group 
(5.5 ± 8 days vs. 1.3 ±1.4 days, respectively; 
P < 0.001). During follow-up there was no dif-
ference between the PACS and SACS groups 
regarding recurrent angina (12.5% vs. 10%, 
respectively; P = 0.54) or myocardial infarc-
tion (10% vs. 5%, respectively; P = 0.14), but 
patients in PACS group were more frequently 
on Killip’s Classification III and IV than patients 
in SACS group (35% vs.12.5%, respectively; 
P < 0.001), and had higher mortality (15% vs. 
4.2%; P = 0.02).
The use of antiplatelet agents and antico-
agulant therapy in both groups are shown in 
Table 3. Eleven (9.2%) patients in the PACS 
group had a bleeding episode (6 major bleed-
ing, including 2 fatal, and 5 minor bleeding) 
whereas 10 (8.3%) patients in the SACS
Table 2. Medication at admission.
Table  1  Baseline  characteristics.  
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Table 3. Acute coronary syndrome treatment 
medication.
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group presented with bleeding (6 major and 
4 minor but none fatal; P = 0.09). Interestingly, 
only 3 patients on the PACS group presented 
with bleeding from the operative site and 5 
patients had gastrointestinal bleeding despite 
the use of ulcer prophylaxis.
Angiographic results
Twenty-eight patients did not have obstruc-
tions above 50%: 7 (5.8%) in PACS group, 3 
(2.5%) in SACS group and 18 (7.5%) in stable 
CAD group. Of the 1471 lesions analyzed, 349 
were in patients of the PACS group (mean 
2.86 ±1.71 lesions per patient), 404 were in 
patients of the SACS group (mean 3.31±1.71 
lesions per patient), and 717 were in patients 
of the stable CAD group (mean 2.94
±1.86 lesions per patient; P = 0.10). There 
was no difference between the three groups 
regarding the location of the lesions.
In PACS group, 45% of patients had Am-
brose’s type II lesions vs.56.7% in SACS group 
and 16.4% in stable CAD group (P < 0.001). 
Both PACS and SACS patients had more com-
plex lesions than patients in stable CAD group 
(56.7% vs. 79.2% vs. 31.8%, respectively; 
P < 0.001). Comparison between angiographic 
characteristics of patients is
shown in Table 4. After univariate analysis, 
applied to the entire cohort of 480 patients, 
the following variables were associated to 
the presence of complex lesions, and were 
included in the multivariable model: belong-
ing to PACS or SACS group (P < 0.001), presence 
of diabetes (P = 0.153), presence of anemia 
(P = 0.002), age > 70 years old (P = 0.002), and 
lack of medication use: aspirin (P < 0.001), be-
tablocker (P < 0.001) and statins (P = 0.001). The 
independent predictors of complex lesions 
were being in the group PACS (P < 0.001; OR, 
2.86; 95% CI, 1.82–4.52) or SACS (P < 0.001; 
OR, 8.71; 95% CI, 5.15–14.73) and the pres-
ence of diabetes (P = 0.025; OR, 1.58; 95% CI, 
1.06–2.36; Table 5). The variables associated 
to Ambrose’s type II lesions in the univariate 
model, that were included in the multivari-
able model, were: belonging to PACS or SACS 
group (P  <  0.001), not having hypertension 
(P = 0.221) or history of prior MI (P = 0.148), 
anemia (P = 0.004), and lack of medication use: 
aspirin (P < 0.001), betablocker (P = 0.004), and 
statins (P = 0.002). The independent predictors 
of Ambrose’s type II lesions were being in 
the group PACS (P < 0.001; OR, 3.43; 95% CI, 
2.1–5.6) or SACS (P < 0.001; OR, 5.99; 95% CI, 
3.66–9.81; Table 5).
Table 4. Angiographic characteristics.
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Table 5. Independent predictors of plaque rup-
ture in the multivariate logistic regression model.
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DISCUSSIon
This was the first prospective study that 
evaluated the presence of plaque rupture in 
consecutive patients with ACS a noncardiac 
surgery. Regarding the clinical and outcome 
characteristics of patients with perioperative 
ACS, our study confirmed previous findings 
that perioperative ACS occurs mainly within 
the first 72 h of the procedure, most events are 
non ST-elevation MI and only 40% of patients 
have thoracic pain [5,6,23–26]. As expected, 
inhospital mortality was higher in patients 
with perioperative ACS than spontaneous ACS. 
This finding could be attributed to baseline 
diseases (co-morbidities) that motivated 
surgery (malignant disease, vascular disease, 
trauma, etc.).
Our findings suggest that nearly 50% of 
patients with perioperative ACS have markers 
of plaque disruption, suggesting a type 1 MI. 
Our data is in line with the two retrospective 
autopsy studies that investigated coronary 
anatomy in patients with fatal perioperative 
MI. Dawood et al. [10] studied 42 patients with 
fatal perioperative MI and found out that 55% 
of patients had evidence of unstable plaques 
with disruption. Cohen et al. [11] also studied 
26 patients with fatal perioperative MI and 
detected plaque rupture on autopsy in 45% 
of them. In a retrospective study that used a 
catheterization laboratory database, Berger 
et al. [27] identified 48 patients referred for 
emergency coronary angiography for acute 
MI within 7 days of noncardiac surgery. Only 
critically ill patients with postoperative
MI were included: 33 patients (68.8%) had 
ST-segment elevation, and 21 patients had 
cardiogenic shock. Although the purpose 
of their study was to determine the clinical 
course and outcome of patients undergoing 
immediate angiography for perioperative MI 
and not to study the angiographic character-
istics, they reported the presence of thrombus 
in 30 patients (62.5%).
Differently from Berger et al. [27], Dawood 
et al. (28%) [10] and Cohen et al. (35%) [11] 
we found a low percentage of thrombus in 
angiography of patients in PACS group (7.5%). 
This result may be related to the long time 
between MI and angiography in this group (5.5 
days in average), consequently prolonged time 
under antiplatelet and anticoagulant agents, 
spontaneous lysis of some thrombi, and the 
small number of patients with ST-elevation MI 
(more prone to exhibit thrombus over culprit 
lesion). Indeed, patients with perioperative 
non-ST-elevation ACS usually are more 
severely ill than patients with spontaneous 
SCA, and before being referred to coronary 
angiography, physicians had to be sure that 
the patient could receive antiplatelet and 
anticoagulant therapy (considering the risk 
of bleeding) and that infections were under 
control. Reinforcing the presence of unstable 
coronary plaques in perioperative ACS, we 
found similar frequencies of haziness and 
ulceration on angiography in PACS and SACS 
groups, an unlikely finding in patients with 
stable CAD. Indeed, multivariate analysis 
indicated that belonging to PACS or SACS 
groups was associated to an increased risk of 
angiographic markers of plaque disruption.
Out of the perioperative setting and using 
intravascular ultrasound, Hong et al. also 
found that the only independent predictor of 
coronary plaque disruption among patients 
with stable angina and myocardial infarction 
was having the diagnosis of acute MI [28]. 
Conversely, previous authors have suggested 
that postoperative tachycardia, hypotension, 
hypertension, anemia, and hypoxemia are 
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common causes of prolonged ST-depression 
and type 2 infarction in patients with stable 
CAD undergoing noncardiac surgery [1]. The 
cornerstone of this hypothesis is the finding 
of prolonged ST depression in perioperative 
Holter monitoring preceding the ischemic 
event in previous studies [29]. In addition, the 
rare occurrence of ST elevation MI in PACS re-
inforces the theory that the incidence of type 
2 MI could be higher than type 1 MI [1,29]. In 
spite of its theoretical biological plausability, 
until now there was no clinical evidence about 
the true incidence of type 1 MI. The present 
study provided this missing evidence.
Our study has some limitations. Among 
the excluded patients, 18 (45%) died before 
the angiography could be done, reflecting 
their critical clinical status, and we missed 
their angiographic characteristics. We used 
coronary angiography for classifying lesions 
and determine the presence of plaque disrup-
tion. Although it is not the gold standard to 
diagnose plaque rupture, previous authors 
showed that complex angiographic lesion 
morphology and Ambrose’s type II lesions 
are strongly correlated with plaque rupture 
[20,16]. In conclusion, nearly 50% of patients 
with perioperative myocardial infarction have 
evidence of coronary plaque rupture, charac-
terizing a type 1 MI.
ClInICAl IMPlICATIonS
The present study indicates that, as well as 
in spontaneous ACS, plaque rupture plays 
an important role in the pathophysiology 
of perioperative ACS. At the bed side, this 
information is very useful, as antiplatelet and 
anticoagulant therapies and invasive evalu-
ation should be strongly considered. On the 
other hand, type 1 and type 2 MI mechanism 
are not mutually exclusive in the pathophysi-
ology of perioperative ACS. In consequence, 
preventing hypotension, tachycardia, anemia 
and hypertension remain important in the care 
of patients with perioperative ACS. Therefore, 
prevention and treatment measures that act in 
both mechanisms are essential for reducing 
the occurrence and mortality of perioperative 
ACS.
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AbSTRACT
Background—The distribution of thrombus containing lesions in an all-comer population 
admitted with a heterogeneous clinical presentation (stable, ustable angina or an acute coronary 
syndrome) and treated with PCI is yet unclear and the long-term prognostic implications are still 
disputed. This study sought to assess the distribution and prognostic implications of coronary 
thrombus, detected by coronary angiography, in an all-comer population recruited in all-comer 
percutaneous coronary intervention (PCI) trials.
Methods and Results—Patient-level data from 3 contemporary coronary stent trials were 
pooled by an independent academic research organization (Cardialysis, Rotterdam, the Neth-
erlands). Clinical outcomes in terms of major adverse cardiac events (MACE, a composite of 
death, myocardial infarction, and repeat revascularization), death, myocardial infarction (MI), 
and repeated revascularization were compared between patients with and without angiographic 
thrombus containing lesion (TCL). Pre-procedural TCL was present in 257 patients (5.8%) and 
absent in 4193 (94.2%). At 3-year follow-up, there was no difference for MACE (25.3 vs. 25.4%; 
P=0.683); all-cause death (7.4 vs. 6.8%; P=0.683); myocardial infarction (5.8 vs. 6.0%; P=0.962), 
and any revascularizations (17.5 vs. 17.7%; P=0.822), between patients with and without TCL. 
The comparison of outcomes in groups weighing the jeopardized myocardial by TCL also did 
not show a significant difference. TCL were seen more often in the first 2 segments of the right 
(43.6%) and left anterior descending (36.8%) coronary arteries. The association of TCL and 
bifurcation lesions was present in 40.1% of the pre-specified segments.
Conclusions—TCL involved mainly the proximal coronary segments and did not have any 
impact on clinical outcomes. A more detailed thrombus burden quantification is required to 
investigate its prognostic implications.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00114972, 
NCT01443104, NCT00617084.
Key Words: thrombus, PCI, drug-eluting stent, outcome, vulnerable plaque
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InTRoDUCTIon
Coronary thrombus has been associated 
with acute coronary syndromes and disease 
progression. The rupture of thin cap fibro-
atheromas allows the blood to come in contact 
with the highly thrombogenic contents of the 
plaque (e.g. necrotic core/collagen) favoring 
the occurrence of most of acute coronary 
syndromes 1, 2. In addition, invasive imaging 
studies have shown that coronary thrombosis 
can also be present in stable coronary artery 
disease (CAD) and has been associated with 
plaque progression 3, 4.
Thrombus containing lesions (TCL) appears 
to be associated with an increased risk of distal 
embolization and no or poor distal flow and 
low myocardial blush grades after percutane-
ous coronary intervention (PCI) 5, 6. However, 
the prognostic relevance of coronary thrombus 
as assessed by angiography is still unclear and 
the results presented in the literature are 
disputed 7-9.
The aim of the present study is to examine 
the angiographic anatomic characteristics 
of TCL and their correlations with clinical 
events (all-cause death, myocardial infarction 
[MI] and all revascularizations) in the largest 
ever pooled all-comer population enrolled in 
contemporary PCI trials.
MeTHoDS
Patient population: We analyzed patient-level 
data from 3 all-comer coronary drug-eluting 
stent (DES) trials: LEADERS (Limus Eluted From 
a Durable Versus Erodable Stent Coating) 
trial, RESOLUTE (Resolute All Comers) trial 
and SYNTAX (Synergy Between Percutaneous 
Coronary Intervention with Taxus and Cardiac 
Surgery). Detailed individual study design and 
trial results are available elsewhere 10-12. In 
brief, all studies included patients with ob-
structive CAD that was amendable to coronary 
stent implantation (Supplementary Table 1). 
These trials had an all-comers design, but, in 
the SYNTAX trial, the enrolled patients must 
had complex (three-vessel or left main) CAD 
to be enrolled. All studies complied with the 
Declaration of Helsinki and were approved 
by the ethical review board in each institu-
tion. All patients provided written, informed 
consent for participation in the individual 
study. The angiographic images were reviwed 
by independent core lab analysts (Cardialysis, 
Rotterdam, The Netherlands) who identify 
the presence or not of thrombus. Aiming to 
evaluate the clinical characteristics and prog-
nosis, the patients were divided in 2 groups 
according to the presence or not of at least 
one thrombus containing lesion as assessed 
by coronary angiography.
Clinical outcomes. Major adverse cardiac 
events (MACE) was defined as a composite of 
all-cause death, MI and any repeat revascu-
larization. There was a wide variation in the 
definition of MI among studies. This is due 
to each study inclusion criteria, variations in 
study design, and the different periods dur-
ing which studies were performed. Since all 
clinical events from each individual trial were 
adjudicated by independent clinical event 
committees, no attempt was made to read-
judicate MI events in the different trials to 
compensate for the differences in individual 
definition of MI. Therefore, all MIs reported in 
the current study are as per individual study 
protocol definitions.
Angiographic Assessment. The angiographic 
assessment was performed by an independent 
corelab (Cardialysis, Rotterdam, The Nether-
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lands) based on the SYNTAX score concept. The 
SYNTAX score for each patient was calculated 
by scoring all coronary lesions with a diameter 
stenosis ≥50%, in vessels ≥1.5 mm, using the 
SYNTAX score algorithm, which is described 
in full elsewhere 13. All angiographic variables 
were recorded prospectively by a team of 2 
core laboratory analysts.
A bifurcation was classified by a division 
of a main, parent, branch into two daughter 
branches of at least 1.5mm diameter according 
to the Medina classification 14. The smaller of 
the two daughter branches was designated as 
the ‘side branch’. Following the SYNTAX score 
recommendations, bifurcations were only 
scored for the following segment junctions: 
5/6/11, 6/7/9, 7/8/10, 11/13/12a, 13/14/14a, 
3/4/16 and 13/14/15. Coronary thrombus was 
defined according to the Academic Research 
Consortium (ARC) definition as spheric, ovoid 
or irregular intraluminal filling defect or 
lucency surrounded on three sides by con-
trast medium seen just distal or within the 
coronary stenosis in multiple projections or a 
visible embolization of intraluminal material 
downstream15. To further evaluate the prog-
nostic impact of thrombus, the summation of 
segment weighing factors (Table 1) used in the 
SYNTAX score was used if TCL were present.
Table 1. Segment weighing factor
Segment no Right dominance left dominance
1 1 0
2 1 0
3 1 0
4 1 n.a.
16 0.5 n.a.
16a 0.5 n.a.
16b 0.5 n.a.
16c 0.5 n.a.
5 5 6
6 3.5 3.5
7 2.5 2.5
8 1 1
9 1 1
9a 1 1
10 0.5 0.5
10a 0.5 0.5
11 1.5 2.5
12 1 1
12a 1 1
12b 1 1
13 0.5 1.5
14 0.5 1
14a 0.5 1
14b 0.5 1
15 n.a. 1
Chapter 1.5
91
C
hapter 1.5
Data analysis. All patients with a calculated 
SYNTAX score were included in the analysis. 
Discrete data were summarized as percent 
(frequencies) and were compared using 
the chi-squared test. Continuous data were 
expressed as mean±SD and were compared 
using Student’s t-test or Wilcoxon rank-sum 
test based on their distributions. Survival 
curves were constructed for time-to-event 
variables using Kaplan-Meier estimates and 
compared by the log-rank test. Comparison 
of events rates between groups were adjusted 
for confounding factors in a Cox-regression 
model. All variables were stratified accord-
ing to presence of at least one TCL using a 
Cox-regression model. The differences were 
regarded significant when p<0.05 (two-
tailed). The Breslow-Day chi-squared test was 
calculated to test the statistical evidence of 
heterogeneity across the studies (p<0.1). The 
chi-squared test and I2 statistic was calculated 
to test the statistical evidence of heterogeneity 
across the studies 16 (Supplementary Table 2, 
supplementary Figures 1-5). SPSS version 21.0 
(SPSS Inc., Chicago, Illinois) was used for all 
other statistical analyses.
Table 2. Baseline clinical characteristics
Pts without thrombus 
containing lesions
n=4193
Pts with thrombus 
containing lesions
n=257 P
Age 64.6±107 62.7±10.7 0.006
Male,% 3127 (74.6) 208 (80.9) 0.022
Diabetes Mellitus,% 1032 (24.6) 50 (19.5) 0.061
Body mass index, kg/m2 27.7±4.5 27.8±4.5 0.831
Hypertension,% 3061 (73.0) 150 (58.4) <0.001
Hyperlipidemia,% 2842 (67.8) 136 (52.9) <0.001
Current smoker,% 1279 (30.5) 132 (51.4) <0.001
Peripheral vascular disease,% 317 (7.6) 16 (6.2) 0.446
Family history of premature CAD,% 1443 (27.3) 87 (33.9) 0.518
History of Stroke/TIA,% 222 (5.3) 13 (5.1) 0.849
Creatinine>200 micromol/L 1.3 0.4 0.530
Creatinine clearance; ml/min 90.6±37.4 98.7±33.9 0.001
Previous myocardial infarction,% 1225 (29.2) 55 (21.4) 0.006
Previous PCI, % 1027 (24.5) 32 (12.5) <0.001
Presentation <0.001
NSTEMI,% 558 (13.3) 62 (24.1)
Stable CAD,% 2131 (50.8) 50 (14.0)
STEMI,% 539 (12.9) 112 (43.6)
Unstable angina,% 965 (23.0) 33 (12.8)
LVEF,% 56.8±11.9 54.7±11.9 0.052
Pts=patients; TIA= Transient Ischemic Attack; MI=myocardial infarction; PCI=percutaneous coronary intervention; 
NSTEMI= Non–ST-Segment Elevation Myocardial Infarction; STEMI= ST-Segment Elevation Myocardial Infarction; 
LVEF=left ventricular ejection fraction
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ReSUlTS
Baseline characteristics. Table 2 depicts pa-
tients’ baseline demographics. Pre-procedural 
thrombus was present in 257 patients (5.8%) 
and absent in 4193 (94.2%). Patients with at 
least one TCL were younger (62.7±10.7 vs. 
64.6±10.7; P=0.006), more frequently male 
(80.9% vs. 74.6%; P=0.022) and current smok-
ers (51.4% vs. 30.5%; P<0.001), less likely to 
suffer from hypertension (58.4% vs. 73.0%; 
P<0.001) and hyperlipidemia (52.9 vs. 67.8%; 
P<0.001). The left ventricular ejection fraction 
tended to be higher in patients without TCL 
(56.8±11.9 vs. 54.7±11.9; P=0.052). Presence 
of thrombus at baseline was more frequently 
related with an acute presentation (P<0.001).
Angiographic characteristics. Patients with 
and without TCL had similar angiographic 
characteristics (Table 3). There were differ-
ences for higher prevalence of total occlusions 
(0.37±0.56 vs. 0.27±0.49 total oclusions/
patient; P=0.010) and more frequent involve-
ment of the proximal right coronary artery 
(0.33±0.47 vs. 0.27±0.45 lesions/patient; 
P=0.045) in the thrombus group.
Table 3. Baseline angiographic characteristics
Pts without thrombus 
containing lesions
n=4193
Pts with thrombus 
containing lesions
n=257 P
Baseline SYNTAX score ±SD 17.7±11.6 18.6±10.7 0.239
Number of total occlusions/patient±SD 0.27±0.49 0.37±0.56 0.010
Number of aorto-ostial lesions/patient±SD 0.06±0.25 0.07±0.27 0.714
Number of lesions with severe tortuosity/patient±SD 0.81±1.09 0.73±1.07 0.265
Number of lesions with length>20mm/patient±SD 0.51±0.76 0.51±0.65 0.884
Number of lesions with heavy calcification/patient±SD 0.40±0.87 0.35±0.82 0.367
Number segments with diffuse disease/patient±SD 0.04±0.19 0.04±0.18 0.877
Lesions in left main/patient 0.10±0.31 0.07±0.26 0.086
Lesions in LAD proximal/patient 0.33±0.50 0.34±0.50 0.820
Lesions in LAD mid/patient 0.58±0.58 0.54±0.58 0.243
Lesions in LAD apical/patient 0.15±0.38 0.13±0.36 0.275
Lesions in 1st diagonal/patient 0.25±0.45 0.28±0.48 0.247
Lesions in 2nd diagonal/patient 0.01±0.11 0.02±0.12 0.722
Lesions in proximal circumflex/patient 0.19±0.40 0.17±0.37 0.481
Lesions in distal circumflex/patient 0.35±0.52 0.30±0.49 0.116
Lesions in intermediate/patient 0.08±0.27 0.09±0.31 0.416
Lesions in first obtuse marginal/patient 0.13±0.34 0.13±0.34 0.686
Lesions in second obtuse marginal/patient 0.12±0.34 0.09±0.29 0.107
Lesions in RCA proximal/patient 0.27±0.45 0.33±0.47 0.045
Lesions in RCA mid/patient 0.34±0.49 0.34±0.48 0.983
Lesions in RCA distal/patient 0.25±0.46 0.27±0.48 0.447
Lesions in Posterolateral/patient 0.07±0.25 0.05±0.23 0.21
Lesions in Posterior descending /patient 0.01±0.09 0.00±0.00 0.17
Pts=patients; TO=total occlusion; LM=left main coronary artery; LAD=left anterior descending coronary artery; 
LCX=left circumflex coronary artery; Mg=marginal; RCA=right coronary artery; Pl=posterolateral branch; PD=Posterior 
descending branch.
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Clinical Outcomes. There was no difference 
between the groups (Table 4 and Figure 1) for 
any of the studied outcomes up to 3-year 
follow-up. MACE occurred in 1067 patients 
(25.4%) in the group without thrombus at 
baseline and 65 (25.3%) in the group with 
thrombus (P=0.874). Consistently, all-cause 
death (P=0.683), MI (P=0.962) and any revas-
cularization (P=0.822) was not significantly 
different in the two groups.
Subgroup analysis. In the stratified analysis, 
the occurrence of MACE was homogenously 
distributed across the clinical and angiographic 
covariates with the only exception of clinical 
presentation (Figure 2). There was a significant 
interaction between the patients presenting 
with acute coronary syndrome (HR 0.881, CI 
0.65-1.19) and stable CAD (HR 1.637, 95% 
CI 1.04-2.59) with respect to the presence of 
thrombus at baseline (P= 0.028).
A more detailed analysis of the subgroup with 
stable CAD can be found in the Supplementary 
Table 3. The thrombus at baseline was related 
to a higher rate of MACE (38% vs 26%, P= 
0.03), mainly due to an increased rate of 
repeated revascularization (30% vs 18%, 
P=0.01). However, after adjustment for con-
founders (i.e. age, creatinine clearance, previ-
ous myocardial infarction, LVEF and number 
of total occlusions/patient) this effect was no 
longer present (supplementary Figures 6 [A-D] 
and 7 [A-D]).
Anatomic characteristics of thrombus 
containing lesions. In the subgroup of 
patients with TCL (n=257), 261 lesions had 
angiographic thrombus. As shown in Figure 3, 
the presence of TCL occurred preferentially in 
proximal segments. More specifically 43.6% 
of these complex lesions were seen in the first 
2 segments of the right coronary artery and 
Table 4. Kaplan-Meier Events Rate Comparison Between Groups
Pts without thrombus 
containing lesions
n=4193
Pts with thrombus 
containing lesions
n=257 P
30 days, n(%)
MACE 254 (6.1) 17 (6.6) 0.714
All-cause death 47 (1.1) 3 (1.2) 0.937
All MI 163 (3.9) 9 (3.5) 0.754
All Revascularization 114 (2.7) 11 (4.3) 0.131
1-year
MACE 669 (16.0) 48 (18.7) 0.229
All-cause death 127 (3.0) 10 (3.9) 0.423
All MI 196 (4.7) 11 (4.3) 0.778
All Revascularization 480 (11.5) 35 (13.7) 0.217
3-year
MACE 1067 (25.4) 65 (25.3) 0.874
All-cause death 287 (6.8) 19 (7.4) 0.683
All MI 250 (6.0) 15 (5.8) 0.962
All Revascularization 742 (17.7) 45 (17.5) 0.822
MACE= major adverse cardiac events (composite of all-cause death, myocardial infarction and all revascularization); 
MI=myocardial infarction
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figure 1. Kaplan-Meier cumulative curves for (A) MACE (composite of all-cause death, myocardial in-
farction and all revascularizations), (B) all-cause death, (C) myocardial infarction (MI) and (D) all revas-
cularizations.
figure 2. Stratified analysis for MACE (composite of all-cause death, all myocardial infarction and all 
revascularizations according to the presence or absence of thrombus containing lesions. DM=diabetes 
mellitus, CrCl=creatinine clearance, LVEF=left ventricular ejection fraction, ACS=acute coronary syn-
dromes, CAD=coronary artery disease; SS=anatomical SYNTAX score.
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36.8% in the first two segments of the left 
anterior descending coronary artery.
As demonstrated in Figure  4, TCL were 
seen quite often in coronary bifurcations. 
The association of thrombus containing and 
bifurcation lesions was present in 40.1% of 
the aforementioned pre-specified segments. 
In the left anterior descending coronary 
artery, there was appreciable coexistence of 
thrombus and bifurcation lesions (45.9% of 
the lesions). On the other hand, the combina-
tion thrombus-bifurcation was not frequent 
in the distal right coronary artery (8.6% of 
the lesions).
Clinical outcomes according to myocardium 
at risk. We divided the subgroup of patients 
figure 3. Distribution of angiographic thrombus containing lesions
 
figure 4. Per-segment association of thrombus and bifurcation lesions according to Medina 14 classifica-
tion. LM=left main coronary artery; LAD=left anterior descending coronary artery; Dg=diagonal branch; 
LCX=left circumflex coronary artery; Mg=marginal; RCA=right coronary artery; Pl=posterolateral branch; 
PD=Posterior descending branch
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with TCL into tertiles of the sum of segment 
weighing factors (Table 1). As shown in Figure 5, 
the weighting for myocardium at risk, did not 
produce significant difference in outcomes 
(MACE, all-cause death, MI or all revasculariza-
tions) for patients with TCL.
DISCUSSIon
The findings of our study can be summarized 
as follows: (i) TCL were seen more often 
in the proximal segments; (ii) there was a 
considerable coexistence of bifurcation and 
thrombus containing lesions; (iii) the presence 
of thrombus at baseline was not related to any 
additional risk of MACE, even after weighing 
for myocardium at risk.
Anatomy of angiographic coronary throm-
bus. Coronary thrombus is mostly formed 
following rupture of atherosclerotic lesions 
containing a large necrotic core and a thin 
fibrous cap 1, 2. In the present study we found 
that thrombus was angiographically detected 
in the proximal coronary segments and mainly 
in the right and left anterior descending coro-
nary arteries. Our results are similar to those 
reported by Wang et al. who analyzed coronary 
angiograms from 208 consecutive patients 
presented with ST-elevation MI 17. However, 
in their methodology they were evaluating 
the site of coronary occlusion. Although they 
used a slightly different coronary segmenta-
tion (BARI classification) they also have found 
that the two most proximal segments of right 
coronary artery and left anterior descend-
ing coronary artery were also responsible 
for the absolute majority (65.4%) of acute 
coronary occlusion 17. In the present analysis, 
it was studied a 25-fold larger population 
and included a population with a broader 
spectrum of the disease (also stable CAD and 
figure 5. Kaplan-Meier cumulative curves for (A) MACE (composite of all-cause death, myocardial in-
farction and all revascularizations), (B) all-cause death, (C) myocardial infarction (MI) and (D) all revas-
cularizations according to tertiles of the sum of segment weighing factors in patients with thrombus 
containing lesions
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NSTEMI); the vessel occlusion is not manda-
tory for thrombus diagnosis. Importantly, all 
angiographic assessments were performed by 
an experienced independent core laboratory 
which has proven to have a higher consistency 
and better prognostic discrimination than 
investigator reported angiographic findings 18.
Interestingly, distribution of TCFA, as as-
sessed by VH-IVUS and OCT, resembles the 
distribution of thrombus found in the present 
study; this may indicate that TCFAs are the 
underlying substrate of coronary thrombus 
found in this study 19, 20 (Table 5). These in-
vasive imaging findings are also in line with 
previous anatomopathological studies 2, 4, 21.
It has to be highlighted however that 
angiography, due to its limited resolution, 
is far from being the gold standard tool for 
coronary thrombus diagnosis. For instance, 
in the present analysis there was a low 
percentage (9.2%) of patients with acute 
coronary syndromes that were classified as 
Table 5. Distribution of complex coronary lesions
% in Proximal Segment % in Mid Segment % Total
Wang et al. 17
Observation:
Site of coronary occlusion Distribution, %
RCA 12.5 14.4 26.9
LAD 14.5 24.0 38.5
LCX 8.6 4.3 13.0
LM - - 0.5
Present Study
Observation:
Thrombus containing lesions Distribution, %
RCA 21.8 21.8 43.7
LAD 18.0 18.8 36.8
LCX 7.7 5.0 12.6
LM - - 2.7
PROSPECT sub study 19
Observation:
VH-TCFA–Containing Lesion Distribution, %
RCA 17.1 15.1 32.2
LAD 24.2 10.8 35
LCX 15.2 11.8 27
LM - - n.a.
Tian et al. 20
Observation:
OCT-TCFA–Containing Lesion Distribution,%
RCA n.a. n.a. 45.0
LAD n.a. n.a. 35.9
LCX n.a. n.a. 19.1
LM - - n.a.
LM=left main coronary artery; LAD=left anterior descending coronary artery; LCX=left circumflex coronary artery; 
RCA=right coronary artery; VH= virtual histology intravascular ultrasound; OCT=optical coherence tomography, 
TCFA=thin cap fibroatheroma
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having TCL. Similarly, Goto et al. detected 
angiographic thrombus in only 14.6% of 
patients in a population of exclusively acute 
coronary syndromes7. Importantly, while Goto 
et al. defined thrombus as “an intraluminal 
filling defect or an area of contrast staining 
noted within the target stenosis”7 and we used 
the definition recommended by the Academic 
Research Consortium15.
Another interesting aspect of our findings 
is the relatively frequent association between 
thrombus and bifurcation. In the LAD, a 
bifurcation lesion was present in almost half 
of the TCL. The most plausible explanations 
for this association are: 1. The most frequent 
location of TCFAs is in bifurcation 22 and 2. The 
endothelial shear stress in coronary bifurca-
tions has a particular distribution. In relatively 
straight segments, the endothelial shear stress 
is pulsatile and unidirectional 23. Conversely, 
in coronary bifurcations, disturbed laminar 
flow occurs, and pulsatile flow generates low 
and/or oscillatory endothelial shear stress 23. 
The role of endothelial shear stress in more 
advanced atherosclerosis was demonstrated 
45 years ago 24 and have been reproduced 
in autopsy-based coronary models, human 
in vivo studies in arterial models derived 
from intravascular ultrasound or magnetic 
resonance and in vivo animal experiments 23, 25.
Thrombus and clinical events. In the present 
study, the presence of thrombus did not have 
any impact on clinical events, even when it was 
adjusted for the amount of myocardial at risk. 
Corroborating our findings, Singh et al. have 
shown that the introduction of the coronary 
stents and the use of more contemporary 
anti-platelet therapy made the presence of 
thrombus irrelevant for long-term death and 
myocardial infarction 8. On the other hand, 
Sianos et al. have demonstrated that large 
thrombus burden is an independent predictor 
major adverse events (defined as death, repeat 
myocardial infarction infarct-related artery 
infarct-related artery) in patients treated with 
drug eluting stents for STEMI9. Additionally, 
large thrombus burden has been related to 
larger myocardial damage as detected by 
contrast-enhanced cardiac magnetic reso-
nance26. The aforementioned findings suggest 
that, for clinical prognostic discrimination, the 
angiographic thrombus assessment should 
be no longer classified as a binary variable 
but as a more detailed thrombotic burden 
quantification.
limitations
The present study has all inherent limitations 
of a post-hoc analysis. In addition, the number 
of stable patients with TCL was limited and 
may have hindered an accurate risk estimation 
in this subset. The classification of bifurcation 
lesions was restricted to those defined by 
the SYNTAX score and we could not stablish 
whether TCL could be associated with smaller 
side branches. However, the use of the SYNTAX 
score concepts have demonstrated consistent 
prognostic impact for PCI treated patients 12, 
27-29. Information on thrombus aspiration was 
not available in this study. Nevertheless, the 
recent Thrombus Aspiration in ST-Elevation 
Myocardial Infarction in Scandinavia (TASTE) 
trial showed that routine thrombus aspiration 
exclusively in a context of primary PCI did not 
reduce the rate of death from any cause or the 
composite of death from any cause, rehospi-
talization for myocardial infarction, or stent 
thrombosis at 1 year30.
Conclusion
In this patient-level pooled analysis of three 
contemporary, all-comers stent trials, coronary 
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TCL involved mainly the proximal coronary 
segments and frequently bifurcations. An-
giographic thrombus did not have any impact 
on 3-year MACE demonstrating that a more 
detailed thrombus burden quantification is 
required to investigate its prognostic implica-
tions.
Disclosures
None.
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SUPPleMenTAl MATeRIAl
Supplemental Methods:
Discrete data were summarized as percent 
(frequencies) and were compared using 
the chi-squared test. Continuous data were 
expressed as mean±SD and were compared 
using Student’s t-test or Wilcoxon rank-sum 
test based on their distributions. Survival 
curves were constructed for time-to-event 
variables using Kaplan-Meier estimates and 
compared by the log-rank test. Comparison 
of events rates between groups were adjusted 
for confounding factors in a Cox-regression 
model. All variables were stratified accord-
ing to presence of at least one TCL using a 
Cox-regression model. The differences were 
regarded significant when p<0.05 (two-
tailed). The Breslow-Day chi-squared test was 
calculated to test the statistical evidence of 
heterogeneity across the studies (p<0.1). The 
chi-squared test and I2 statistic was calculated 
to test the statistical evidence of heterogene-
ity across the studies 1 (Supplementary Table 2, 
supplementary Figures 1-5). SPSS version 21.0 
(SPSS Inc., Chicago, Illinois) was used for all 
other statistical analyses.
Supplemental figure 1. Combined OR using the 3 trials using fixed effects for patients with thrombus 
containing lesions (TCL)
Supplemental figure 2. When the LEADERS Trial was removed from the pooled analysis there was no 
longer heterogeneity:
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Supplemental figure 4. However, when we pool RESOLUTE and LEADERS and remove from the analysis 
the SYNTAX trial, the heterogeneity became even more evident:
Supplemental figure 5. Pooled trial results using Bayesian random effects in which TCL did not have 
impact on long-term occurrence of MACE:
Supplemental figure 3. Also when the RESOLUTE trial was removed from the pooling there was no 
significant heterogeneity:
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Supplemental figure 6A. Kaplan-Meier curve comparison for MACE (composite of all-cause death, all 
myocardial infarctions and all revascularizations) according to presence/absence of thrombus contain-
ing lesions in patients with stable coronary artery disease
Supplemental figure 6b. Kaplan-Meier curve comparison for all-cause death according to presence/
absence of thrombus containing lesions in patients with stable coronary artery disease
Supplemental figure 6C. Kaplan-Meier curve comparison for myocardial infarction according to pres-
ence/absence of thrombus containing lesions in patients with stable coronary artery disease
Supplemental figure 6D. Kaplan-Meier curve comparison for all revascularizations according to pres-
ence/absence of thrombus containing lesions in patients with stable coronary artery disease
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Supplemental figure 7A. Adjusted MACE (composite of all-cause death, all myocardial infarctions and 
all revascularizations) rate comparison according to presence/absence of thrombus containing lesions 
in patients with stable coronary artery disease
Supplemental figure 7b. Adjusted all-cause death rate comparison according to presence/absence of 
thrombus containing lesions in patients with stable coronary artery disease
Supplemental figure 7C. Adjusted all myocardial infarctions rate comparison according to presence/
absence of thrombus containing lesions in patients with stable coronary artery disease
Supplemental figure 7D. Adjusted all revascularizations rate comparison according to presence/ab-
sence of thrombus containing lesions in patients with stable coronary artery disease
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Supplemental Table 1. Summary of the trials included in the present analysis
leADeRS2 ReSolUTe3 SYnTAX4
enrolment Period 11/2006-05/2007 04/2008-10/2008 03/2005-04/2007
Study Design RCT RCT RCT
number of Patients 1707 2292 1101
number of Patients 
with SYnTAX score
Total (acute†)
1352
(535)
2026
(736)
1072
(0)
Stents Used SES , BES EES, ZES PES
Inclusion criteria Patients aged ≥18 years old AnD
Presentation: Stable angina, ACS, STEMI AnD
≥1 lesion ≥50% DS in vessel with RVD 2.25-
4.00mm*
No restriction on total number of treated lesions, 
treated vessels, lesion length or number of stents 
implanted.
Presentation: stable angina, 
unstable angina or silent 
ischaemia, AnD
>50% DS in three major epicardial 
coronary arteries and/or LMS
No restriction on the total 
implanted stent length.
exclusion criteria Inability to take dual anti-platelet therapy
Allergy to study medicines
Terminal illness <6 months life expectancy
Pregnancy
Participation in another trial
Previous PCI or CABG
Acute MI
Need for concomitant cardiac 
surgery
Study Procedure Stenting procedure at operator’s discretion;
Direct stenting was allowed
Aim for complete revascularisation
DAPT Aspirin† 100mg ≥75mg ≥70mg
Clopidogrel
(duration)
75mg
(12 months)
75 mg
(12 months)
75 mg
( ≥ 6 months)
*2.25-3.50mm in LEADERS
†Acute- ST-elevation and Non-ST elevation myocardial infarction
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Supplemental Table 2. Assessment of heterogeneity among the trials:
endpoint Chi-square P value I2
All-cause death 0.13 51%
All revascularizations 0.20 38%
Myocardial Infarction 0.69 0%
MACE (composite by death, 
myocardial infarction and all 
revascularizations)
0.02 74%
There was a significant heterogeneity for MACE (Supplemental Figure 1) but interestingly was not caused by the SYN-
TAX trial (Supplemental Figures 2-4). The Supplemental Figure 5 shows the combined OR using Bayesian random ef-
fects in which thrombus containing lesion (TCL) did not have impact on long-term occurrence of MACE
Supplemental Table 3. Baseline clinical and angiographic characteristics according the presence/ab-
sence of thrombus in patients with stable coronary artery disease
Without thrombus
n=2131
With thrombus
N=50 P
Age 63.6±11.2 61.8±11.9 0.031
Male,% 1610 (75.6) 39 (78.0) 0.868
Diabetes Mellitus,% 595 (27.9) 18 (36.0) 0.206
Body mass index, kg/m2 27.7±4.5 27.5±4.6 0.527
Hypertension,% 1613 (75.7) 40 (80.0) 0.616
Hyperlipidemia,% 1578 (74.0) 35 (70.0) 0.517
Current smoker,% 524 (24.6) 13 (26.0) 0.794
Peripheral vascular disease,% 190 (8.9) 4 (8.0) 0.767
Family history of premature CAD,% 1394 (65.4) 34 (68.0) 0.756
History of Stroke/TIA,% 128 (6.0) 5 (10.0) 0.209
Creatinine>200 micromol/L 32 (1.5) 0 (0.0) 1.000
Creatinine clearance; ml/min 93.2±41.4 100.1±34.6 0.012
Previous myocardial infarction,% 637 (29.9) 13 (26.0) 0.639
Previous PCI, % 583 (27.4) 10 (20.0) 0.334
LVEF,% 54.8±11.6 52.0±10.9 0.01
Anatomical Characteristics
Baseline SYNTAX score ±SD 17.1±11.3 18.0±10.2 0.276
Number of total occlusions/patient±SD 0.33±0.51 0.41±0.56 0.04
Number of aorto-ostial lesions/patient±SD 0.05±0.23 0.06±0.56 0.566
Number of lesions with severe tortuosity/patient±SD 0.74±1.07 0.68±1.02 0.425
Number of lesions with length>20mm/patient±SD 0.51±0.71 0.53±0.62 0.750
Number of lesions with heavy calcification/patient±SD 0.33±0.77 0.25±0.68 0.158
Number segments with diffuse disease/patient±SD 0.04±0.20 0.03±0.17 0.531
Lesions in left main/patient 0.08±0.29 0.06±0.26 0.246
Lesions in LAD proximal/patient 0.31±0.48 0.33±0.51 0.491
Lesions in LAD mid/patient 0.56±0.58 0.54±0.60 0.579
Lesions in LAD apical/patient 0.16±0.39 0.11±0.34 0.08
Lesions in 1st diagonal/patient 0.24±0.45 0.26±0.46 0.549
Lesions in 2nd diagonal/patient 0.01±0.12 0.01±0.12 0.875
Lesions in proximal circumflex/patient 0.18±0.40 0.16±0.37 0.587
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Supplemental Table 3. Baseline clinical and angiographic characteristics according the presence/ab-
sence of thrombus in patients with stable coronary artery disease (continued)
Without thrombus
n=2131
With thrombus
N=50 P
Lesions in distal circumflex/patient 0.32±0.50 0.27±0.47 0.178
Lesions in intermediate/patient 0.10±0.31 0.07±0.26 0.155
Lesions in first obtuse marginal/patient 0.13±0.34 0.10±0.32 0.319
Lesions in second obtuse marginal/patient 0.11±0.33 0.10±0.31 0.559
Lesions in RCA proximal/patient 0.25±0.44 0.32±0.48 0.026
Lesions in RCA mid/patient 0.33±0.48 0.32±0.47 0.734
Lesions in RCA distal/patient 0.23±0.45 0.26±0.46 0.333
Lesions in Posterolateral/patient 0.03±0.18 0.02±0.14 0.787
Lesions in Posterior descending /patient 0.11±0.32 0.12±0.33 0.351
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AbSTRACT
background
Coronary lesions precursors of acute events remain elusive, since they undergo continuous 
changes and their temporal changes are not very well characterized. In natural history studies, 
optical frequency domain imaging (OFDI) has been used only to assess fibroatheromas as a 
two-dimensional structure and sometimes in a single frame fashion.
Aim
We aim at describing the serial volumetric modifications of the fibrous cap (FC) of the fibroath-
eromas as determined by OFDI over a 6-month follow-up period.
Methods
In 49 patients, OFDI investigation was performed following treatment of culprit lesion and 
at 6-month follow-up in patients with ST-segment elevation myocardial infarction (STEMI). 
A fully automatic volumetric quantification of FC was done in all lipid-containing frames of 
non-culprit lesions in the infarct related artery. These lesions were matched at baseline and 
6-month follow-up.
Results
A total of 58 non-culprit lipid rich lesions (34 TCFAs and 24 thick-cap fibroatheroma [ThCFA]) were 
found in 34 patients at baseline. Overall, there was a FC volume decrease of 1.57 (Interquartile 
Range [IQR] -4.13 to 0.54) mm3 at 6-months. 27% of the lesions changed their phenotype over 
time (TCFA or thick-cap fibroatheroma ThCFA). TCFAs that became ThCFAs at follow-up had 
smaller mean and maximal FC as compared with lesions that remained TCFAs (P=0.01 for both).
Conclusions
Non-culprit fibroatheromas located in the infarct related artery of patients with STEMI had a 
volumetric reduction of the FC after 6-month follow-up. Quantitative FC assessment was able to 
differentiate high-risk lesions that became ThCFAs. There was a considerable change of plaque 
phenotype (TCFAs or ThCFAs) over time.
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InTRoDUCTIon
The characterization of culprit lesions and 
even more the identification of coronary le-
sions precursors of acute events remain the 
holy grail of intracoronary imaging (1). It has 
been shown that in patients receiving optimal 
pharmacological treatment, the presentation 
of acute coronary syndromes or death may 
be associated with the total number of seg-
ments with significant disease rather than the 
ischemic burden (2). This suggests that plaque 
disruption might be the main cause of major 
cardiac outcomes rather than the ischemia 
induced by obstructive plaques.
Coronary plaques have been scrutinized 
to understand characteristics related to the 
hazard of subsequent cardiovascular events 
(3-5). Traditionally, a plaque with a fibrous cap 
(FC) thickness <65 µm on top of a necrotic core 
is nominated thin cap fibroatheroma (TCFA) 
and is considered as a high risk plaque. More 
recently, a threshold for FC of 53.5 µm has 
also been correlated also to plaque rupture 
or TCFA (3, 4).
Optical coherence tomography (OCT) is an 
intravascular light-based imaging method 
with a near-histological resolution of 10-20 
µm. Currently, OCT is the only technology 
available in the clinical setting that provides 
spatial resolution sufficient to assess FC thick-
ness accurately (FCT) (6, 7). Consequently, 
OCT has been used to study the ability of 
pharmacological or interventional therapies 
to promote FC thickening (i.e. plaque stabiliza-
tion) (8, 9). However, in natural history studies, 
OCT has been used only to assess coronary 
fibroatheromas as a two-dimensional structure 
and sometimes the assessment is only perform 
in a single frame (8, 9). This approach is very 
limited and is not able to pick up changes that 
may occur in other dimensions in the FC. The 
recently developed optical frequency domain 
imaging (OFDI) technique, an analogue of the 
Fourier-domain OCT, is the state-of-the-art of 
this technology.
Accordingly, we sought to describe the 
changes of coronary fibroatheromas over a 
6-month follow-up period, describing the 
serial volumetric modifications of the FC as 
determined by OCT.
MeTHoDS
Study population
The TROFI (Thrombus Aspiration on Flow 
Area in Patients With ST-Elevation Myocar-
dial Infarction; ClinicalTrials.gov Identifier: 
NCT01271361) trial has been described in 
details previously (10, 11). In brief, the 
TROFI trial prospectively randomized STEMI 
patients to receive either primary percutane-
ous coronary intervention (PCI) with throm-
bectomy (n=71) or without thrombectomy 
(n=70) prior to biolimus-A9 eluting metallic 
stent (Nobori®, Terumo Europe N.V., Leuven, 
Belgium) implantation. STEMI patients hav-
ing an angiographically visible stenosis (>30 
%) or pre-procedural TIMI flow grade ≤2 in a 
single de-novo, native, unstented vessel were 
considered for enrollment. The study protocol 
was approved by the local ethics committees 
at each of the five European participating 
centers, and written informed consent was 
obtained from all enrolled patients.
optical frequency domain imaging 
(OFDI) acquisition
The present study included OFDI data regard-
less of the randomization arm. After the post-
procedural angiography, OFDI image acquisi-
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tion was performed with the TERUMO OFDI 
system (Terumo Europe N.V., Leuven, Belgium) 
with imaging element rotating at 9600 rpm 
allowing imaging at 160 frames/s. Intracoro-
nary nitroglycerin (0.2 mg) was administered 
before the OFDI acquisition. An automated 
OFDI pullback with a speed of 20 mm/s was 
performed during continuous intracoronary 
injection of 100% contrast medium using an 
injection pump at a pressure of 300 p.s.i with 
a flow rate of 3 to 4 ml/s for a maximum of 
4 seconds or manually. Imaging calibration 
was performed as previously described (12). 
At 6-month follow-up the same OFDI console 
and acquisition methodology was used in the 
infarct related coronary artery.
Off-line OFDI analysis
The OFDI raw data were transformed from the 
original 16 bits polar image to an 8 bits Carte-
sian image of 1024 by 1024 pixels. The off-line 
analysis was performed using the QCU-CMS 
software (LKEB, Leiden University, The Neth-
erlands). Four experienced image analysts 
were involved in the present evaluation (HG, 
JI, TM, SN). The first step was the delimitation 
of regions of interest (ROIs) by identifying lipid 
rich non-culprit lesions in the infarct related 
artery at the index procedure. The fibrous cap 
was identified as a signal-rich band overlying 
the lipid core. Serial OFDI images at baseline 
and 6-month follow-up were reviewed side 
by side on the screen, and ROIs were matched 
based on the distance from landmarks, such as 
branches, calcifications, and stents.
The quantification of FC was done in all corre-
sponding frames for volumetric analysis of cap 
thickness. After the lumen border detection in 
the transversal image, the operator delineated 
the lipid-rich sector laterally using the two 
rays which emanate from vertex localize in 
the center of the imaging catheter. (Figure 1). 
In case the guide-wire shadow was located 
within the defined sector, the shadow area was 
marked out and excluded from the analysis. 
Next the fully automatic fibrous cap segmenta-
tion was applied on (transversal OCT images), 
and the luminal- and abluminal boundaries of 
the fibrous cap within the manually defined 
sector were extracted automatically. (Figure 1). 
The detection of the fibrous cap was done us-
ing the largest gradient in pixel intensity (1st 
derivative) between the fibrous cap tissue and 
the lipid region (i.e. where the slope on the 
sigmoid curve changes fastest). To avoid false 
edge information, the pixels in front of the 
maximum intensity in the fibrous cap region 
(i.e. pixels originating from the lumen), were 
discarded. After segmentation, the distances 
between the lumen and fibrous cap borders 
were determined allowing the computation 
of the minimal, maximum, and mean fibrous 
cap thickness within the sector. The distance 
was calculated by dividing the lumen contour 
in 1 degrees intervals and next determine the 
shortest distance from each lumen point to 
the fibrous cap contours. This assessment for 
the minimal FCT has shown perfect agreement 
for both inter- and intra-observer assessments 
(κ=1.00) (In press report). An example is pre-
sented in Figure 1.
The presence of TCFA was defined as a mini-
mal FCT <65 µm in at least one frame of the 
longitudinal region of interest. Lesions with 
minimal FCT >65 µm were named thick-cap 
fibroatheromas (ThCFA). Lesions that were 
TCFAs at baseline and had FCT>65 µm at 
follow-up were named Pacified TCFAs. ThCFAs 
that became TCFAs at follow-up were Newly 
developed TCFAs.
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Data Analysis
Discrete data were summarized as percent 
(frequencies) and were compared using the 
chi-squared test. Continuous data were ex-
pressed as mean ± SD or median [interquartile 
range (IQR)] and were compared using Stu-
dent’s t-test or Wilcoxon rank-sum test based 
on their distributions. The distribution was 
tested using the Kolmogorov-Smirnov test. 
P <0.05 was considered statistically significant. 
SPSS version 21.0 (SPSS Inc., Chicago, Illinois) 
was used for all statistical analyses.
ReSUlTS
Between November 24th, 2010 and October 
11th, 2011, 141 patients (71 patients in the 
thrombectomy arm and 70 patients in the 
non-thrombectomy arm) were enrolled at 5 
European sites. In 3 predefined centers, the 
enrolled patients (n=51) were followed-up 
angiographically and with OFDI at 6 months. 
Paired (post-procedure and follow-up) OFDI 
recordings were available in 49 patients. The 
baseline clinical characteristics are depicted 
in the Table 1.
figure 1. Representation of fibrous cap (FC) measurement. (A) Two analysts identified non-culprit, lipid-
rich plaques at baseline. Thereafter, using anatomic landmarks, the two analysts found correspondent 
lesions at follow-up. (B) (1 and 2) the first step is lumen border detection; (3) Secondly the guidewire 
artefact is masked to avoid interference; (4) the software detects the FC by using the largest gradient in 
pixel intensity; (5) identification of minimal FC thickness (white arrow); mean FC thickness (green line); 
maximal FC thickness (yellow arrow); (C) The same steps are repeated in all frames involved in that 
region of interest. OFDI: optical frequency domain imaging; STEMI: ST elevation myocardial infarction; 
TCFA: thin-cap fibroatheroma
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ofDI Results
In 34 patients (69%), a total of 58 non-culprit 
lipid rich lesions were found in the infarct 
related artery. The table 2 presents the overall 
changes in these regions. 1624 frames were 
analyzed at baseline and 1596 at 6-month 
follow-up. It was found an overall stabiliza-
tion in these lipid-rich regions (Table 2). The 
minimal FCT increased significantly from 
0.07 (Interquartile Range [IQR] 0.018-0.096) 
mm at baseline to 0.12 (IQR 0.09-0.17) mm 
at 6-month follow-up (P<0.01). The number 
of frames with FCT smaller than 65 µm also 
decrease significantly (P<0.01). The mean 
FCT increased 0.03±0.07mm (P<0.01) and 
the lesion length decreased by 0.98±1.92mm 
Table 1. Baseline and procedure characteristics
Demographics
Thrombectomy
non
p
thrombectomy
n=26 n=25
Age 59 ± 10 57 ± 13 0.42
Male, % 77 76 0.94
Heart Rate 73.77± 21.59 71.76 ± 14.68 0.7
Risk factors, %   
Diabetes mellitus 7.7 8.0 0.97
Insulin 0.0 0.0  
Current Smoking 58 52 0.49
Hypercholesterolemia 42 20 0.08
Hypertension 38 28 0.43
Family history of CAD 50 56 0.66
Procedural details   
Stents implanted per lesion 1.23±0.6 1.36±0.8 0.5
Mean total stent length / lesion (mm) 23.2±10.5 25.4±13.1 0.52
Mean stent diameter (mm, nominal) 3.1±0.39 3.1±0.37 0.64
Number of aspiration / lesion 1.81± 0.40   
Device successfully reached, % 100   
Device successfully crossed, % 100   
Thrombus successfully removed, % 100   
Table 2. Overall changes in lipid-rich non-culprit lesions (n=58) as assessed by optical frequency do-
main imaging. Values are mean ± standard or median (Interquartile Range)
baseline follow-up Delta P
Minimal cap thickness ,mm 0.07(0.02-0.10) 0.12 (0.09-0.17) 0.06±0.06 <0.01
Number of Frames with Cap 
thickness <65 µm
1 (0-8.0) 1 (0-3) -2.91±6.7 <0.01
Maximal cap thickness, mm 0.511 (0.45-0.59) 0.529 (0.47-0.61) 0.01 (-0.03 to 0.07) 0.13
Mean cap thickness, mm 0.29±0.07 0.32±0.09 0.03±0.07 <0.01
Mean FC Angle, degrees 254.04±55.67 235.72±69.24 -18.31±54.78 0.03
Length, mm 7.47±2.84 6.48±2.75 -0.98±1.92 <0.01
Cap Volume, mm3 18.26 (8.23-40.21) 14.02(7.21-36.53) -1.57 (-4.13 to 0.54) <0.01
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after 6 months (P<0.01). Consequently, it was 
found a FC volume decrease of 1.57 (-4.13 to 
0.54) mm3 at follow-up mostly driven by the 
shortening of the lipid-rich regions at follow-
up (Figure 2).
Out of 58 lesions, 34 lesions were TCFA at 
baseline and 30 at 6-month follow-up. Ten 
lesions that were TCFA at baseline became 
ThCFAs at follow-up. Out of 24 lesions that 
were ThCFAs at baseline, 6 became TCFA at 
follow-up. Therefore, 28 lesions were ThCFA 
at 6-month follow-up (Figure 3). An example of 
the natural history of fibroatheromas is given 
in Figure 4.
figure 2. Schematic representation of the volumetric temporal change in the fibrous cap (FC). There 
was a significant decrease in the FC volume due to an reduction in FC angle, length, mean and minimal 
thicknesses. The maximal FC thickness did not change significantly
figure 3. Schematic representation of the natural history of lipid-rich; non-culprit lesions of the pres-
ent study
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The TCFAs at 6-month (n=30) had similar 
FC volume at baseline and follow-up (P=0.37) 
(Table  3). There was however a significant 
increase in the mean FCT (P=0.03) and a 
0.85±2.10mm decrease in the lesion length 
(P=0.03). There was also a trend to reduction 
in the number of frames with FCT  <65 µm 
(P=0.06).
At baseline, Pacified TCFAs had different 
OFDI findings as compared with lesions that 
remained TCFAs (Table 4; Figure 5). The maxi-
mal and the mean FCT were significantly larger 
figure 4. Temporal changes of 3 fibroatheromas in the same patient matched for the index procedure 
and 6-month follow-up. A two-dimensional map, color-coded by the fibrous cap thickness is given. 
There is better OFDI characteristics in all lesions. The X axis represents the distance from the distal 
to proximal segment of the coronary artery, while the Y axis represents the circumferential segment 
(angle). The Lesion 1 and Lesion 2 were thin-cap fibroatheromas (TCFA) that became a Pacified TCFA 6 
months later. The lesion 3 was found to be ThCFA in the two acquisitions. It has to be highlighted that 
the frames where the minimal thickness were located were different between the two time points.
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in Pacified TCFAs (P=0.01 for both). Pacified 
TCFAs has also a trend to have less frames with 
Cap thickness <65 µm. The cap volume was not 
different (P=0.69).
The lesions that were ThCFAs at follow-up 
demonstrated an increase of 0.03±0.06mm in 
the mean FCT (P=0.01), a decrease of 0.89 (IQR 
-1.53 to -0.08)mm in the lesion length and a 
median decrease of 16.9% of the FC volume 
(P<0.01 for all) (Table 5).
Newly TCFAs and lesions that remained 
ThCFAs did not have any significant difference 
in the OFDI findings at baseline. Newly TCFAs 
had however a trend to have longer lesions 
(P=0.16), with wider angle (P=0.17) and with 
a larger cap volume (P=0.17) (Table 6).
DISCUSSIon
The main findings of the present study can 
be summarized as follows: (1) Lipid-rich, non-
culprit lesions were frequently found in infarct 
related coronary arteries in STEMI patients; 
(2) there was an overall reduction in fibrous-
cap volume after 6 months mostly driven 
by shortening of the lesion length; (3) 27% 
of lesions changed their phenotype (TCFAs 
or ThCFAs) over time; (4) Pacified TCFAs had 
different plaque characteristics at baseline as 
compared with lesions that remained TCFAs.
The precise identification of plaques that are 
prone to rupture and cause a major coronary 
event is a field of major clinical relevance. In 
this regard OCT is the only clinically available 
method with enough resolution to measure 
the FCT in vivo accurately. Although TCFAs as 
Table 3. Optical frequency domain imaging findings of TCFAs at follow-up (n=30). Values are mean ± 
standard or median (Interquartile Range)
baseline follow-up Delta P
Minimal cap thickness,mm 0.05±0.043 0.05 ±0.034 0.01±0.04 0.99
Maximal cap thickness, mm 0.50 (0.44 to 0.54) 0.52 (0.47 to 0.60) 0.02 (-0.02 to 0.06) 0.18
Mean cap thickness 0.25 (0.22 to 0.30) 0.28 (0.24 to 0.32) 0.02 (-0.02 to 0.06) 0.03
Angle, degrees 274.88±42.04 266.53±54.68 -8.35±44.04 0.31
Lesion Length,mm 8.17±2.82 7.32±2.71 -0.85±2.10 0.03
Number of frames with FCT <65 µm 4 (1 to 17) 3 (1 to 11) -1.5 (-7.25 to 1.25) 0.06
FC volume , mm3 29.05 (11.33 to 43.72)27.88 (9.51 to 51.47) -1.72±8.65 0.37
Table 4. Baseline comparison of optical frequency domain imaging findings of lesions that remained 
thin-cap fibroatheromas (TCFA) versus lesions that became pacified TCFAs
Remained TCfA
(n=24)
Pacified TCFA
(n=10) P
Minimal cap thickness ,mm 0.03 (0.00 to 0.06) 0.05 (0.00 to 0.09) 0.38
Number of Frames with Cap thickness <65 µm 8 (2 to 21) 5 (1 to 13) 0.11
Maximal cap thickness, mm 0.49±0.07 0.56±0.10 0.01
Mean cap thickness, mm 0.25±0.05 0.30±0.06 0.01
Mean FC Angle, degrees 278.60±34.71 264.42±27.45 0.26
Lesion Length, mm 8.10±2.56 7.84±2.37 0.79
Cap Volume, mm3 40.65±36.66 35.43±30.97 0.69
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visualised by OCT are often diagnosed with 
confidence, some factors may preclude a cor-
rect diagnosis: those involving the qualitative 
classification (identification of a FAs) and those 
concerning the measurement of the FC with 
the aim to distinguish TCFAs from ThCFAs (13, 
14). The present work used a fully automatic 
FC volumetric assessment by OCT, a method 
that has shown to have a much more robust 
measurement than the manual assessment 
done by experienced analysts (In press report).
Another important aspect of imaging of 
coronary fibroatheromas is to assess their 
temporal changes and correlations with clini-
cal factors, laboratory findings and therapeu-
tics agents. Factors such as high circulating 
neopterin (a pteridine derivative secreted by 
activated macrophages), low eicosapentaenoic 
figure 5. Distribution of fibrous cap thickness at baseline between lesions that remained thin-cap fi-
broatheromas (TCFAs) versus lesions that became pacified TCFAs
Table 5. Optical frequency domain imaging findings of thick-cap fibroatheromas at baseline and 
6-month follow-up (n=28)
baseline follow-up Delta P
Minimal cap thickness,mm 0.09 (0.07 to 0.11) 0.09 (0.08 to 0.14) 0.04±0.05 0.07
Maximal cap thickness, mm 0.54±0.11 0.56±0.10 0.02±0.09 0.20
Mean cap thickness 0.31±0.07 0.34±0.08 0.03±0.06 0.01
Angle, degrees 231.70±60.37 202.72±68.75 -28.98±63.44 0.02
Lesion Length,mm 5.98 (4.75 to 8.96) 5.14 (3.60 to 7.06) -0.89 (-1.53 to -0.082) <0.01
FC volume , mm3 10.98 (4.82 to 20.58) 9.02 (3.89 to 17.78) -1.85 (-3.61 to -0.39) <0.01
Table 6. Baseline comparison of optical frequency domain imaging findings of lesions that remained 
thick-cap fibroatheromas (ThCFA) versus Newly TCFAs
Remained ThCfA
(n=18)
newly
TCfAs
(n=6) P
Minimal cap thickness ,mm 0.10 (0.08 to 0.13) 0.10 (0.07 to 0.12) 0.58
Maximal cap thickness, mm 0.53 (0.45 to 0.60) 0.51 (0.49 to 0.66) 0.58
Mean cap thickness, mm 0.31 (0.26 to 0.39) 0.31 (0.24 to 0.36) 0.87
Mean FC Angle, degrees 197.88 (162.20 to 250.87) 288.76 (183.17 to 309.24) 0.17
Lesion Length, mm 5.12 (4.18 to 8.20) 8.17 (5.15 to 12.21) 0.16
Cap Volume, mm3 9.29±7.54 14.41±9.25 0.17
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acid/arachidonic acid ratio, current smoking, 
low-density lipoprotein and presentation with 
acute coronary syndrome have been corre-
lated with thinner fibrous cap thickness by OCT 
or the presence of TCFAs (15-17). Conversely, 
high intensity atorvastatin therapy (20 mg/
day) has shown to increase the fibrous cap 
thickness in coronary plaques as compared 
with 5 mg/day (9). In addition, percutaneous 
coronary interventions with bioresorbable 
scaffolds or metallic stents have been tested 
to passivate vulnerable plaques over time 
with promising results (8, 18, 19). However, 
these invasive strategies still do not have 
evidence strong enough to be implemented 
in the clinical practice. The present work 
describes, for the first time, the volumetric 
temporal changes of FC by OFDI and can be 
used in future investigations of natural history 
of coronary atherosclerosis.
It has to be highlighted that it was found 58 
non-culprit fibroatheromas in the target vessel 
of 34 STEMI patients (1.7 lesions/patients). 
Moreover, 34 fibroatheromas were quantified 
as TCFAS at baseline (1.0/patient). Galon et 
al., using a similar automatic algorithm for FC 
assessment, have also found a considerable 
number of non-culprit fibroatheromas in 
the target vessel of 10 STEMI patients (2.11 
lesions/patient)(20). In their work however 
the overall minimal and mean cap thickness 
were about the half of the value we found 
in the present work (0.03±0.02 mm vs. 0.07 
and 0.14±0.03 vs. 0.29±0.07; respectively). 
Besides the relatively small sample sizes, as 
abovementioned, patients’ individual charac-
teristics may have influenced these discrepan-
cies.
Another important finding of the present 
study is the dynamic nature of the fibroath-
eromas. There was an overall improvement 
of these non-culprit plaques with significant 
increase of the minimal and mean FCT with 
reduction of the FC angle, lesion length and 
cap volume (P<0.01 for all). However, when 
these lesions were classified qualitatively 
(TCFAs or ThCFAs) 27% changed their pheno-
type over time and TCFAs still were present 
in a sizeable proportion (58% at baseline 
and 51% at 6-month follow-up (Figure  3). 
However the remaining TCFAs at 6-month 
also had signals of improvement with shorter 
lesion length and larger mean cap thickness 
(Table 3). Importantly, it was shown that the 
regions where the minimal FC was found in 
each lesion may change over time (Figure 4). 
Interestingly, pacified TCFAs had larger mean 
and maximum FC as compared with plaques 
that remained TCFAs over time (Table 4). The 
clinical explanation and prognostic implica-
tions of these quantitative measurements still 
have to be investigated.
lIMITATIonS
The TROFI trial was design to investigate the 
role of thrombectomy on improving the flow 
area in STEMI patients. Therefore the clinical 
variables (ex. lipid control, pharmacological 
adherence, etc) for plaque phenotype modi-
fications over time could not be explored. As 
abovementioned, the relatively small sample 
size does not allow for explore the prognostic 
implications of FC volume change still have 
to be established. Additionally, the present 
methodology does not takes into account the 
presence of OCT signal intensity that may be 
correlated with the presence of macrophages 
which may be a contributor to atherosclerotic 
plaque instability (21). Nonetheless, we dem-
onstrated for the first time a serial description 
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of a volumetric quantification of FC which 
allows for investigation of the natural history 
of high-risk coronary plaques.
ConClUSIon
Non-culprit fibroatheromas located in the in-
farct related artery of patients with STEMI had 
a volumetric reduction of the FC after 6-month 
follow-up. Quantitative FC assessment was 
able to differentiate high-risk lesions that 
became ThCFAs. There was a considerable 
change of plaque phenotype (TCFAs or ThCFAs) 
over time.
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EDITORIAL COMMENT
Women Are From SATURN and
Men Are From an ASTEROID
Deciphering the REVERSAL of Coronary Atheroma*
Hector M. Garcia-Garcia, MD, MSC, PHD,y Carlos M. Campos, MD,yz Patrick W. Serruys, MD, PHDy
W omen are under-represented (range from8% to 68%) in most lipid-lowering ran-domized clinical trials. Meta-analysis
data from 170,000 participants showed that women
had a significant proportional risk reduction of 16%
(99% confidence interval: 3% to 27%; p ¼ 0.002 per
1.0 mmol/l decrease in low-density lipoprotein
cholesterol [LDL-C]) of the combined endpoint of cor-
onary death, nonfatal myocardial infarction coronary
revascularization, and stroke (1). Is this because
women had a greater change in intravascular ultra-
sound (IVUS) percentage atheroma volume (PAV)
in progression/regression trials, as shown in this sub-
study of the SATURN (Study of Coronary Atheroma
by Intravascular Ultrasound: Effect of Rosuvastatin
Versus Atorvastatin) study (2)? This observation has
not been proven to be a consistent one. In the
ASTEROID (A Study To Evaluate the Effect of Rosu-
vastatin on Intravascular Ultrasound-Derived Coro-
nary Atheroma Burden) study, in which high dose
rosuvastatin was administered, the findings were at
variance with the current report (Table 1). Men had
slightly larger regression than women. Of note, the
IVUS analyses were performed under the same stan-
dard operating procedures in the same analysis core
laboratory in both studies. Why did the differential
impact of rosuvastatin and atorvastatin on plaque
regression in women was not reproduced?
In the SATURN trial subgroup analysis, overall
(taking both groups together: rosuvastatin- and
atorvastatin-treated patients) women had a greater
reduction in PAV (–1.52 � 0.18% vs. –1.07 � 0.10%, p ¼
0.03) (2), but only in cases with LDL-C levels <70 mg/
dl. Interestingly, the percentage of women that ach-
ieved LDL-C levels <70 mg/dl was smaller compared
to men (61.7% vs. 65.0%, respectively). Thus, women
showed more regression despite that they were fewer
achieving the target of LCL-C. Taken all together, it
is interesting to see that even in the best-case sce-
nario, namely in the context of a large randomized
clinical trial, less than two-thirds of patients achieved
the per protocol target (LDL-C levels <70 mg/dl).
Is percentage atheroma volume the best para-
meter to compare women versus men? The percent
atheroma volume with as numerator atheroma vol-
ume and as denominator vessel volume, may mask
the specific directional changes in its numerator and
denominator (3) when used as primary endpoint to
compare 2 pharmacological agents or 2 groups; it has,
though, a lower variation (smaller SD) than atheroma
volume and therefore has been used as a primary
endpoint in many IVUS studies. In Table 2, it can be
seen that, looking purely at the actual atheroma size
changes without normalizing for the vessel volume,
in all studies with the exception of the ASTEROID
TABLE 1 Sex-Related Changes in Percentage Atheroma Volume
at 24 Months in Different Progression/Regression Trials
SATURN SATURN ASTEROID
Rosuvastatin
40 mg
Atorvastatin
80 mg
Rosuvastatin
40 mg
Male –1.09 –1.03 –0.8
Female –1.76 –0.71 –0.7
ASTEROID ¼ A Study To Evaluate the Effect of Rosuvastatin on Intravascular
Ultrasound-Derived Coronary Atheroma Burden; SATURN ¼ Study of Coronary
Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
SEE PAGE 1013
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
From the yDepartment of Interventional Cardiology, Erasmus University
Medical Centre, Thoraxcenter, Rotterdam, the Netherlands; and the
zHeart Institute (InCor), University of São Paulo Medical School, São
Paulo, Brazil. All authors have reported that they have no relationships
relevant to the contents of this paper to disclose.
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trial, women showed more atheroma volume regres-
sion than men.
Additional lessons learned from previous progres-
sion/regression trials, in general:
1. The larger the PAV at baseline is, the larger the
regression in PAV is (4).
2. The larger the reduction in LDL-C is, the larger the
regression in PAV is (5).
3. The higher the increase in high-density lipoprotein
cholesterol (HDL-C) is, the larger the regression in
PAV is (5).
4. The larger the reduction in C-reactive protein (CRP)
levels is, the larger the regression in PAV is (6).
Yet, in this substudy from the SATURN trial,
women had a larger regression in PAV compared to
men, despite the fact that women had smaller plaques
at baseline and they had on average higher levels
of CRP. As mentioned previously, women, in lipid-
lowering trials, had a reduction of the combined
endpoint of coronary death, nonfatal myocardial
infarction coronary revascularization and stroke.
Moreover, in another substudy of the SATURN trial,
the CRP levels were associated with major adverse
cardiac events (MACE) (7), which makes it harder to
dissect this complex interplay between women and
CRP and their association with MACE.
Is it then the greater reduction in PAV in women
related to the fact that they had on treatment lower
LDL-C and higher HDL-C values? In this report
(SATURN trial gender analysis), compared with
men, women had higher HDL-C at baseline and
follow-up. In the REVERSAL (Reversing Athero-
sclerosis with Aggressive Lipid Lowering) trial (8),
the patients with HDL-C above the mean who were
treated with atorvastatin had a regression of –1.5%
(p ¼ 0.97 for the comparison with baseline), but not
their counterparts. At variance, in this SATURN trial
gender analysis, irrespective of the baseline HDL-C
(above or below the mean), there was a significant
reduction in PAV. Thus, the association of ath-
eroma changes and HDL-C need to be further
elucidated.
Many of the lessons learned in previous progres-
sion/regression trials have been challenged in this
gender report of the SATURN study. In order to get
clarity on whether there is a differential impact of
gender on coronary atheroma size or these changes
in plaque size are due to other potential confounding
factors, we would like to encourage the authors
to pool the data of the SATURN, ASTEROID, and
REVERSAL studies to further elucidate these
observations.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Hector M. Garcia-Garcia, Thoraxcenter – Erasmus
Medical Center, z120 Dr Molerwaterplein 40, 3015
GD Rotterdam, the Netherlands. E-mail: hect2701@
gmail.com.
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TABLE 2 Atheroma Volume Changes by Sex
SATURN SATURN ASTEROID REVERSAL
24 Months 24 Months 24 Months 18 Months
40 mg
Rosuvastatin*
80 mg
Atorvastatin*
40 mg
Rosuvastatin†
80 mg
Atorvastatin‡
Male –7.21 –5.62 –6.1 0.7
Female –9.68 –7.70 –4.2 –2.3
*Adjusted change from baseline in atheroma volume. †Atheroma volume in most diseased 10-mm subsegments.
‡Median percentage change in atheroma volume.
REVERSAL ¼ Reversing Atherosclerosis with Aggressive Lipid Lowering; other abbreviations as in Table 1.
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AbSTRACT
Background: Patients and plaque’s characteristics have been scrutinized to understand how 
risk factors relate to the hazard of subsequent cardiovascular events. However, the clinical and 
health outcomes measures assessed by the Seattle Angina Questionnaire (SAQ) have never 
been correlated with the characteristics of obstructive plaque determined by intravascular 
ultrasound (IVUS).
Objectives: To describe the pre-treatment intravascular ultrasound (IVUS grey scale and 
backscatter tissue data) findings of obstructive lesions according to patient demographics and 
health outcome measures in the ABSORB II trial (ClinicalTrials.gov, number NCT0142528).
Methods: An independent corelab (Cardialysis, Rotterdam, The Netherlands) analysed IVUS 
segments flanked by the presence of side branches beyond 5mm distally and 5mm proximally 
to the to be treated regions. Patient demographics, anthropometric measures, cardiovascular 
risk factors and baseline SAQ were correlated with IVUS findings.
Results: 464 patients had pre-procedural IVUS grey-scale and 438 patients had IVUS radio-
frequency assessment before device implantation. The mean age was 61.5±10.0 years old, 
23.3% were female and 25.0% were diabetics. Clinical characteristics were able to differentiate 
plaque features by IVUS and VH IVUS. Patients with abdominal obesity (P<0.01) and increase in 
body mass had more negative remodeling (P=0.01), a finding that was related to worse angina 
frequency scores by SAQ (P<0.01). Reduction in HDL-C (P=0.01), lesion in RCA (P<0.01), lesion in 
proximal LAD (P<0.01) and worse angina stability by SAQ (P=0.03) were independently correlated 
with plaque burden. Smaller lumen area (P<0.01), larger vessel area (P<0.01) and more physical 
limitation by SAQ (P=0.03) were independently correlated with the maximum necrotic core area.
Conclusions: IVUS assessment of obstructive lesions showed that clinical characteristics still 
were able to differentiate the manifestation of coronary artery disease. Negative remodelling 
was associated with worse angina frequency by the SAQ. Patient reported physical limitation 
and angina stability were, respectively, associated with necrotic core size and plaque burden.
Key words: intravascular ultrasound; virtual histology; atherosclerosis, clinical characteristics; 
angina; Seattle Angina Questionnaire.
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InTRoDUCTIon
Despite medical advances, coronary artery 
disease (CAD) remains a major public health 
problem as it has been the leading cause of 
death in the world in the last decade (1). As a 
consequence, the care of patients with CAD is 
costly since it implies careful ascertainment of 
the diagnosis and risk, control of symptoms, 
and therapies to improve survival (2).
Patients’ and plaque characteristics have 
been scrutinized to understand how risk 
factors relate to the hazard of subsequent 
cardiovascular events (3-5) and response 
to therapeutic agents in atherosclerosis 
progression/regression trials (6-9). In this 
regard, intravascular ultrasound (IVUS) – and 
its derived parameters - is the best invasive 
method for assessing the plaque burden, being 
able to study plaque temporal changes and 
features related to high risk plaques (5). The 
rationale for IVUS studies is based on the fact 
that the atherosclerotic plaque represents the 
pathological substrate for the occurrence of 
ischemic cardiovascular events. Plaque burden 
and necrotic core areas have been described in 
pathologic studies of vulnerable patients (10). 
However, so far, plaque characterization by 
IVUS findings is mostly related to non-culprit 
lesions (3,6,7).
Regarding patient’s risk stratification, health 
status assessment has proven to be a valu-
able tool, being independently associated 
with 1-year mortality and acute coronary 
syndromes among outpatients with CAD 
(1). Nevertheless, health status scores have 
never been correlated with IVUS (grey scale 
and backscatter tissue characteristics) plaque 
features. Thus, it is not known whether Seattle 
Angina Questionnaire (SAQ) parameters are 
correlated with the extent of the disease as 
assessed by IVUS characteristics of obstructive 
lesions.
Accordingly, we sought to describe the 
pre-treatment IVUS (grey scale and backscat-
ter tissue characteristics) findings of to be 
intervened lesions according to patient demo-
graphics, anthropometric measures, cardiovas-
cular risk factors and SAQ in the ABSORB II trial 
(ClinicalTrials.gov, number NCT01425281). 
In addition, we aimed to identify the clini-
cal characteristics independently related to 
plaque burden and the largest necrotic core 
area in these obstructive lesions.
MeTHoDS
Patient Population and Definitions: The 
design of the ABSORB II trial (ClinicalTrials.
gov ID: NCT01425281) has been described 
previously (11,12). In brief it is a randomised, 
active-controlled, single-blinded, multicentre 
clinical trial comparing the second-generation 
Absorb BVS with the XIENCE everolimus-
eluting metallic stent (12). The trial was 
sponsored by Abbott Vascular and enrolled 
501 subjects on a basis of 2:1 (Absorb: 
XIENCE) randomization in 46 centres across 
Europe and New Zealand. The trial protocol 
allowed the treatment of up to two de-novo 
native coronary artery lesions, each located 
in different major epicardial vessels, with a 
maximum lumen diameter between 2.25mm 
and 3.8 mm and a maximum lesion length of 
48 mm as assessed by online quantitative 
coronary angiography. All lesions had to have a 
visually estimated diameter stenosis of ≥50% 
and <100% with a TIMI flow of ≥1.
Low-density lipoprotein cholesterol (LDL-C) 
was considered high when ≥ 70mg/dl. HDL-C 
was considered low when ≤40mg/dl. Triglyc-
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erides was defined as high when ≥150 mg/
dL (13). Patients were considered as having 
abdominal obesity when waist circumfer-
ence >102 cm for men and >88cm for women. 
Abnormal renal function when creatinine 
clearance <90mL/min. Metabolic syndrome 
was identified by the presence of three or 
more of the components: abdominal obesity, 
HDL-C (Men <40 mg/dL and Women <50 mg/
dL); blood pressure ≥130/85 mmHg; fasting 
glucose≥110 mg/dL or triglycerides ≥150 mg/
dL (14).
Patient reported angina severity was as-
sessed at baseline (before IVUS) by the SAQ. 
The SAQ is a disease-specific measure for 
patients with CAD that represents assessment 
of a 4-week window (recall period). SAQ has 
demonstrated to be reproducible and related 
to clinical events (1,15). The SAQ quantifies 
patients’ physical limitations caused by an-
gina, symptom frequency, recent changes in 
symptoms, treatment satisfaction, and the 
degree to which the disease affects their qual-
ity of life. Each scale has a score from 0 to 100, 
where higher scores indicate better function 
(eg, less physical limitation, less angina, and 
better quality of life).
Laboratory tests. Blood samples were taken 
from all patients at baseline and were anal-
ysed at an independent core laboratory (ICON 
Plc, Dublin Ireland). Lipid profile (including 
total cholesterol, LDL-C calculated, HDL-C, 
and Triglycerides [TG]) was checked. The 
Friedewald formula was used for calculation of 
LDL-C concentration (16). If plasma TG levels 
were above 400 mg/dL the measured LDL-C 
concentration was then reported.
IVUS imaging. The present study reports 
as regions of interest the target lesion of the 
ABSORB II trial before the device implanta-
tion. All lesions were imaged for IVUS and 
IVUS radiofrequency (VH®- IVUS, Volcano 
Corporation, San Diego, California, USA) with 
the 45 MHz Revolution® catheter (Volcano 
Corporation, San Diego, California, USA)(17). 
The IVUS acquisition was performed at a 
pullback speed of 0.5 mm/sec following 
the administration of anticoagulation and 
intracoronary nitroglycerine. During the cath-
eter pullback, the radiofrequency data was 
captured at the peak of the R-wave, enabling 
the reconstruction of a colour-coded map of 
coronary plaque composition, via the VH-IVUS 
algorithm: red (indicating necrotic core), white 
(dense calcium), light green (fibro-fatty), and 
dark green (fibrous).
 The quantitative IVUS analysis was performed 
by a Core Imaging Laboratory (Cardialysis, 
Rotterdam, The Netherlands) using custom-
ized software (qIVUS® 3.0, Medis, Leiden, 
The Netherlands). The analyst selected the 
region of interest flanked by the presence 
of side branches beyond 5mm distally and 
5mm proximally to the stented/scafffolded 
regions. External elastic membrane (EEM) 
and lumen area data were obtained for every 
cross-section. Plaque area was determined as 
the area between the leading edges of the 
2 contours. The present study used previ-
ously described IVUS greyscale and VH-IVUS 
parameters that are shown in Figure 1.(18-20).
Data analysis. Discrete data were summarized 
as percent (frequencies) and were compared 
using the chi-squared test. Continuous data 
were expressed as mean ± SD or median [inter-
quartile range (IQR)] and were compared using 
Student’s t-test or Wilcoxon rank-sum test 
based on their distributions. Largest plaque 
burden (%) and largest necrotic core area 
(mm2) were the dependent variables explored 
in a lesion level linear regression analyses. The 
set of variables with a p value ≤0.10 in the uni-
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variate regression analyses were included in 
the multivariate regression analyses. Forward 
selection was used, and the entry criterion and 
stay criterion were set to 0.05. SPSS version 
21.0 (SPSS Inc., Chicago, Illinois) was used 
for all statistical analyses.   Sensitivity and 
specificity curves were used to identify the 
optimal threshold for defined as the cut-off 
that separated patients with necrotic core 
area≥3.45mm2 and plaque burden≥75% pre-
viously validated in histologic studies(10). For 
patient level analysis, when patient had more 
than one lesion, the average value of IVUS 
parameters were used for subgroup analysis 
except for Total Plaque Volume (in which the 
sum of patient atheroma volume values were 
used); largest necrotic core area and largest 
plaque burden (in which the highest absolute 
value was used).
ReSUlTS.
Out of 501 enrolled patients, 464 (498 lesions) 
had imaging of obstructive lesions (pre-
procedure), the IVUS study being the focus of 
the present study. In addition, 438 patients 
(471 lesions) had IVUS radiofrequency data 
analysis assessment before device implanta-
tion and are also herewith described. Table 1 
shows the baseline characteristics of patients 
enrolled in the present study. The mean age 
was 61.5±10.0 years old, 23.3% were female, 
67.9% had history of treated hypertension 
figure 1. (A)The analyst selected the region of interest flanked by the presence of side branches beyond 
5mm distally and 5mm proximally to the stented/scaffolded regions. (B) External elastic membrane 
(EEM) and lumen area data were obtained for every cross-section. Plaque area was determined as the 
area between the leading edges of the 2 contours. The parameters assessed in the present study are 
summarized in (C).
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and 25.0% were diabetics. The median fast-
ing HDL-C was 42.9 (Interquartile Range [IQR] 
36.7-51.8) mg/dL, the median fasting LDL-C 
was 92.8 (IQR 69.6-119.9) mg/dL.
Patient Level Grey Scale IVUS Findings and 
Clinical Characteristics. Figure 2 summarizes 
the main grey scale IVUS findings and details 
of these findings can be found in the supple-
mentary material (Table 1 and Figure 1). Of 
note, 90% of patients/lesions imaged in this 
study had a larger plaque burden compared 
to the classical previous IVUS studies, which 
included non-obstructive/non-intervened le-
sions. The percent atheroma volume (PAV) was 
higher in patients with low HDL-C (60.8±8.3 
vs 57.0±9.2%; P<0.01) and in patients with 
metabolic syndrome (59.5±8.7 vs. 57.7±9.2%; 
P=0.05). Patients with diabetes had signifi-
cantly smaller PAV (56.8±9.1 vs. 58.8±8.8%; 
P=0.04) (Figure 2A). Analysis of the frame with 
the largest plaque burden showed it to be 
significantly larger in patients with medically 
treated hypertension [82.6 (IQR 77.7-86.1) vs. 
80.9 (74.9-84.7)%; P=0.02) (Figure 2B).
The MLA was significantly smaller in male 
patients [2.0 (IQR 1.7-2.4) vs. 1.8 (IQR 1.5-2.4) 
figure 2. Patient level subgroups comparison of the main grey scale intravascular ultrasound findings. 
(A) Percent atheroma volume (PAV); (B) Largest plaque burden (PB); (C) Minimum lumen area (MLA) and 
(D) Positive remodelling. NAO= no abdominal obesity; AO=abdominal obesity; BMI= body mass index; 
DM= diabetes mellitus; HDL-C=high-density lipoprotein cholesterol; LDL-C= Low-density lipoprotein 
cholesterol; Tg= triglycerides; ACS=acute coronary syndrome; CAD=coronary artery disease. 
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Table 1. Baseline demographics and clinical characteristics of IVUS patients (n=464)
Female gender, n (%) 108 (23.3)
Age; mean±SD 61.5±10.0
Waist circumference, cm; median (IQR) 100 (92-108)
BMI, kg/m2 ; median (IQR) 27.5 (25.3-30.10)
Know family history of premature CAD 162 (34.9)
Current smokers 103 (22.2)
Diabetes Mellitus 116 (25.0)
Treated hypertension 315 (67.9)
Systolic pressure at rest, mmHg; median (IQR) 132 (120-145)
Diastolic pressure at rest, mmHg; median (IQR) 76 (70-82)
Previous PCI, n (%) 161 (34.7)
Previous CABG, n (%) 11 (2.4)
Diagnosis, n (%)
MI with normalized cardiac enzymes 12 (2.6) 
Unstable angina 99 (21.3) 
Silent ischemia 56 (12.1) 
Stable angina 297 (64.0) 
Total cholesterol, mg/dL; median (IQR) 158.5 (131.5-189.5)
Fasting HDL-C, mg/dL; median (IQR) 42.9 (36.7-51.8)
Fasting LDL-C, mg/dL; median (IQR) 92.8 (69.6-119.9)
Fasting TG, mg/dL; median (IQR) 91.7 (51.6-135.3)
Creatinine clearance, mL/min; median (IQR) 93.8 (78.7-113.6)
Fasting glucose, mg/dL; median (IQR) 100.9 (91.9-115.3)
SAQ PL; median (IQR) 78.5 (58.3-94.4)
SAQ AS; median (IQR) 50.0 (25.0-75.0)
SAQ AF; median (IQR) 80.0 (60.0-100.0)
SAQ TS; median (IQR) 94.0 (81.0-100.0)
SAQ QL; median (IQR) 50 (33.3-66.7)
Lipid lowering therapy use, n (%)*
Atorvastatin 187 (40.3) 
Dose (mg) ±SD 42.2±21.3 
Simvastatin 150 (32.3) 
Dose (mg) ±SD 33.6±9.5 
Rosuvastatin 55 (11.8) 
Dose (mg) ±SD 15.0±12.6 
Pravastatin 13 (2.8) 
Dose (mg) ±SD 26.9±19.3 
Other statin 4 (0.9%) 
Ezetimibe 19 (4.1) 
Dose (mg) ±SD 10.7±2.7 
Polyunsaturated fatty acid 10 (2.16) 
*Medication started before index procedure or at index procedure date, some of the medication may be com-
bined, . SD=standard deviation; IQR=interquartile range; BMI=body mass index; CAD=coronary artery disease; 
PCI=percutaneous coronary intervention; CABG= coronary artery bypass graft; MI=myocardial infarction; SAQ= Seattle 
Angina Questionnaire; PL=physical limitation; AS=angina stability; AF=angina frequency; TS=treatment satisfaction; 
QL=quality of life.
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mm2; P=0.02); in patients with low HDL-C [1.9 
(IQR 1.6-2.5) vs. 1.8 (1.5-2.1) mm2; P<0.01); 
and in patients with high triglycerides [1.8 
(IQR1.6-2.4) vs. 1.7 (1.5-2.3) mm2; P=0.05). 
Patients with high LDL-C had significantly 
larger MLA [1.7 (1.5-2.1) vs.1.9 (1.6-2.4); 
P=0.03) (Figure 2C).
 Coronary remodelling reflects to which 
extent the vessel was able to accommodate 
the plaque and cause reduction in lumen 
dimensions (Figure  2D). The prevalence of 
positive remodelling was significantly reduced 
in patients with abdominal obesity (P<0.01), 
decreased progressively with the increase in 
body mass index (P=0.01) and tended to be 
lower in patients with metabolic syndrome 
(P=0.10), abnormal renal function (P=0.09), 
males (P=0.12) and diabetes mellitus (P=.013). 
Specifically, in diabetics, although the nega-
tive remodelling did not reach the statistically 
significance margin, a significantly smaller PAV 
caused similar lumen reduction assessed by 
both MLA (P=0.56) (Figure 2C) and mean lumen 
area (P=0.96) (supplementary Table 1).
Patient Level VH IVUS findings and baseline 
characteristics. Figure 3 summarizes the main 
VH IVUS findings and supplementary Table 2 
details these findings. The maximum necrotic 
core area tended to be higher in males (P=0.06) 
and in patients with metabolic syndrome 
(P=0.08) (Figure  3A). The % necrotic core 
was higher in patients without treatment for 
hypertension (17.4±7.5 vs. 15.5±6.4; P<0.01). 
The mean dense calcium area was significantly 
larger in males (P=0.03) (Figure 3B). The % 
dense calcium was significantly larger in 
patients not treated for hypertension [4.1 (1.8-
7.8) vs. 3.2 (1.4-6.3); P=0.04)]. Current smok-
ers had lower % necrotic core (14.4±6.2% 
vs.16.6±6.9; P<0.01); smaller dense calcium 
areas [0.09 (0.03-0.23) vs. 0.13 (0.05-0.28) 
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mm2 ; P=0.02) and lower % dense calcium 
[3.6 (IQR 1.6-6.9) vs. 2.1 (1.2-5.0); P<0.01)] 
but a higher necrotic core/dense calcium 
ratio [5.0 (3.3-8.7) vs. 4.1 (2.7-6.7); P=0.03)] 
(supplementary Table 2).
Patient Level IVUS Grey Scale, VH IVUS and 
Health Status Assessment. Table  2 depicts 
figure 3. Patient level subgroups comparison of the main intravascular ultrasound radiofrequency find-
ings. (Upper panel) Largest necrotic core (NC) area. (Lower Panel) Mean dense calcium (DC) area. NAO= 
no abdominal obesity; AO=abdominal obesity; BMI= body mass index; DM= diabetes mellitus; HDL-
C=high-density lipoprotein cholesterol; LDL-C= Low-density lipoprotein cholesterol; Tg= triglycerides; 
ACS=acute coronary syndrome; CAD=coronary artery disease.
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the correlation coefficients between IVUS 
findings and SAQ domains. The mean lumen 
area had a significant correlation with SAQ 
angina frequency (P<0.01). The largest plaque 
burden trended to be correlated with the 
largest plaque burden and angina frequency 
(P=0.06 for both). The remodelling index had a 
positive and significant correlation with angina 
frequency (P=0.01) and trended to be corre-
lated with physical limitation (P=0.07); i.e. the 
bigger the vessel remodelling, the better was 
the patient’s symptomatology. Interestingly, 
the total plaque volume did not have any sig-
nificant correlation with angina severity. The 
largest necrotic core area and the mean dense 
calcium area were significantly correlated with 
SAQ physical limitation (P<0.01 and P=0.01; 
respectively). Interestingly, the total plaque 
volume did not have a significant correlation 
with any SAQ domain.
Lesion level predictors of the largest 
plaque burden and maximum necrotic core 
area. The list of variables (only those with a 
p value <0.10) and their univariate associa-
tion with maximum necrotic area and largest 
plaque burden is shown in Table  3. In the 
multivariate analysis (Table 4), lesions in the 
right coronary artery (RCA) and in the proximal 
left descending anterior artery (LAD) had a 
positive independent association with plaque 
burden. Fasting HDL-C and SAQ angina stabil-
ity had a negative independent association 
with plaque burden.
Regarding maximum necrotic core area, mean 
vessel area and lesions in the proximal LAD 
had a positive independent association. Mean 
lumen area and SAQ physical limitation had 
a negative independent association with 
maximum necrotic core area.
The assessment of receiver-operating char-
acteristic (ROC) for plaque burden higher than 
75% found SAQ angina stability score ≤25 as 
the best cut-off [area under the curve [AUC] 
0.59 (95% CI 0.55-0.64). For a necrotic core 
area >3.45mm2 the best cut-off point for SAQ 
Table 3. Variables (only with a p value<0.10) and their univariate association with largest plaque bur-
den and maximum necrotic core area
Largest Plaque Burden (%) Maximum necrotic Core Area
Parameter estimate 
(95%CI)
P Parameter estimate 
(95%CI)
P
Male Gender 2.094 (0.598 to 3.590) <0.01 0.155 (-0.24 to 0.33) 0.09
Treatment for Hypertension 2.055 (0.723 to 3.386) <0.01 - -
Fasting HDL (md/dl) -0.089 (-0.137 to -0.041) <0.01 - -
Fasting Triglycerides (mg/dl) 0.009 (0.001 to 0.016) 0.03 - -
Fasting Glucose (mg/dl) 0.016 (-0.002 to 0.033) 0.07 - -
Metabolic Syndrome 1.322 (-0.075 to 2.719) 0.06 0.143 (-0.012 to 0.298) 0.07
Lesion in RCA 1.450 (0.052 to 2.848) 0.04 0.281 (-0.041 to 0.603) 0.09
Lesion in Proximal LAD 2.395 (0.739 to 4.051) <0.01 0.466 (0.274 to 0.658) <0.01
Known family history of CAD - - -0.147 (-0.306 to 0.11) 0.07
Mean Lumen Area (mm2) - - 0.077 (0.025 to 0.129) <0.01
Mean Vessel Area - - 0.117 (0.099 to 0.136) <0.01
PAV - - 0.046 (0.038-0.053) <0.01
SAQ AS -0.027 (-0.049 to -0.005) 0.01 - -
SAQ PL -0.004 (-0.007 to 0.000) 0.03
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physical limitation was ≤60 points [AUC 0.58 
(95% CI 0.53-0.63)] (Figure 4).
DISCUSSIon.
The main findings of the present IVUS study, 
dedicated exclusively to obstructive lesions, 
can be summarized as follows: (1) clinical 
characteristics were able to differentiate the 
manifestation of CAD assessed by PAV, larg-
est plaque burden, minimal luminal area and 
vessel wall remodelling; (2) SAQ was able to 
identify plaque characteristics by IVUS grey 
scale and IVUS VH; (3) SAQ physical limitation 
and SAQ angina stability were found to have 
an independent association with necrotic core 
area and plaque burden, respectively.
Previous studies have mainly either cor-
related non-culprit -and non-obstructive le-
sions- to clinical characteristics in a transversal 
approach or explored the natural history of 
atherosclerosis by IVUS and its correlation 
with coronary events (3-5). The present study 
however, is unique in the sense that it explored 
exclusively obstructive plaques. Additionally, 
for the first time, we validated angina sever-
ity with plaque features. For instance, in the 
landmark PROSPECT (Providing Regional 
Observations to Study Predictors of Events in 
the Coronary Tree) trial (3) the prevalence of 
coronary lesions with plaque burden >70% 
was only 9% (n=283 lesions). Interestingly, 
demographic factors of PROSPECT’s patients 
had poor discrimination in detecting high-risk 
plaques (21). Herewith we report a population 
in which more than 90% of patients/lesions 
imaged had a larger plaque burden compared 
to the classical previous IVUS studies (supple-
mentary Table  1, supplementary Figure  1) 
which resulted in 498 lesions with a median 
plaque burden of 82.4% (IQR 76.2-85.7%) 
and a median MLA of 1.8 mm2 (IQR 1.6-2.4 
mm2).
Patient level IVUS findings and their cor-
relation with clinical characteristics and an-
gina patterns. In the present study abdominal 
obesity and increase in body mass index had 
less positive remodeling. In our sub-group 
analysis, we found that male patients had a 
trend to higher PAV and a significant smaller 
MLA. In the present study the male gender 
did not emerge as an independent variable 
related to plaque burden. Similarly, in non-
obstructive coronary lesions, male gender 
emerged as a factor related to higher PAV (22). 
Lipid disorders had a marked relevance in our 
findings. In addition to being independently 
Table 4. Variables (with P <0.05) and their multivariate association with largest plaque burden and 
maximum necrotic core area
Largest Plaque Burden (%) Maximum necrotic Core Area
Parameter estimate (95%CI) P Parameter estimate (95%CI) P
Fasting HDL (md/dl) -0.082 (-0.132 to -0.33) 0.01 - -
Lesion in RCA 2.278 (0.723 to 3.833) <0.01 - -
Lesion in Proximal LAD 3.511 (1.619 to 5.402) <0.01 0.184 (0.015 to 0.354) <0.01
Mean Lumen Area (mm2) - - -0.269 (-0.334 to -0.203) <0.01
Mean Vessel Area (mm2) - - 0.194 (0.168 to 0.221) <0.01
SAQ AS -1.762 (-3.309 to -0.215) 0.03 - -
SAQ PL - - -0.004 (-0.006 to -0.001) <0.01
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correlated to a large plaque burden, a HDL-C 
lower than 40mg/dL produced larger PAV 
and smaller lumen dimensions. On the other 
hand, a high LDL-C was found to be associated 
only with a larger MLA but not with PAV or 
the largest plaque burden. Both lipids have 
been demonstrated to have an impact in the 
natural history of atherosclerosis. The higher 
the increase in HDL-C, the larger the regression 
in PAV and the larger the reduction in LDL-C is, 
the larger the regression in PAV (23). However, 
for comparison of absolute atheroma burden, 
a sub study of the SATURN trial showed also 
that HDL-C, but not LDL-C, was able to dis-
criminate PAVs larger or smaller than 36.2% 
(24). In addition, the present study showed 
that metabolic syndrome was also related to 
higher PAV and to a larger absolute plaque 
burden. Compared with IVUS studies of non-
obstructive lesions, the impact of metabolic 
syndrome on atherosclerotic burden has been 
disputed (22,25). These findings reinforce the 
interest on HDL-targeted therapies in which 
the clinical role of drugs such as cholesteryl 
ester transfer protein inhibitors still need to 
be established (26).
It is worth mentioning that the necrotic core/
dense calcium ratio has been shown to be 
related to known risk factors of sudden death 
in a study of male patients and was higher 
in smokers(27). In the present study we also 
found correlation between necrotic core/
dense calcium ratio and current tobacco use.
The presence of systemic hypertension had 
a marked impact on our findings, being corre-
lated with a larger plaque burden, smaller MLA 
and trends to reduced prevalence of positive 
remodeling (P=0.12) and larger PAV (P=0.06).
Figure 5 summarizes the patient level char-
acteristics and the IVUS variables in this study. 
Regarding patient reported angina patterns, 
we found that mean lumen area, remodelling 
index, maximum necrotic core area and mean 
dense calcium area were associated with worse 
angina symptoms. Thus, the interplay between 
plaque and remodelling was responsible for 
patient symptoms. As expansive enlargement 
prevents luminal narrowing we found that a 
lack of positive remodeling reflected in lower 
SAQ angina frequency scores. Importantly the 
mean LA and not the MLA had correlation with 
angina.
Lesion level high risk IVUS findings and 
their correlation with clinical subgroups and 
angina patterns. Recently, Narula et al. (10) 
studied the histologic characteristics of 295 
coronary atherosclerotic plaques, including 
stable, vulnerable and disrupted plaques. 
figure 4. Receiver-operating characteristic (ROC) for (A) plaque burden higher than 75% using SAQ 
angina stability score found ≤25 as best cut-off. (B) For a necrotic core area >3.45mm2 the best cut-off 
point for SAQ physical limitation was ≤60 points [AUC 0.58 (95% CI 0.53-0.63)]
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figure 5. Schematic representation of the interplay among grey scale findings and clinical character-
istics (upper panels). The lower panel shows a schematic representation of IVUS and VH IVUS findings 
and their impact on angina patterns assessed by the Seattle Angina Questionnaire (SAQ). LA=lumen 
area; MLA= minimum lumen area; VA=vessel area; PAV=percent atheroma volume; PB= Plaque Bur-
den; NC=necrotic core; DC=dense calcium; SAQ=Seattle Angina Questionnaire; PL=physical limitation; 
AS=angina stability; AF=angina frequency; TS=treatment satisfaction; QL=quality of life
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Thickness of the fibrous cap, plaque burden 
(>73.67%), macrophage infiltration and 
necrotic core area (>3.45mm2) were used in 
two multivariate models for identification of 
complex lesions. Their conclusion confirmed 
the results of PROSPECT (3) where a plaque 
burden higher than 70-75% -combined with 
thin fibrous plaque- should alert the clinicians 
(10). The aforementioned facts explain why we 
used as the object of our multivariate analysis 
the maximum cross-sectional luminal area 
stenosis and the largest necrotic core areas.
Reduction in HDL-C, lesion in RCA, lesion 
in proximal LAD and worse angina stability 
by SAQ were independently correlated with 
plaque burden. These findings are in line with 
previous invasive investigations of coronary 
atheroma. In non-obstructive lesions, low HDL-
C has also been found to be independently 
related to larger PAV, and consequently to 
clinical events (24). In addition, it has been 
shown that the two most proximal segments 
of the right coronary artery and the left an-
terior descending coronary artery were also 
responsible for the majority (65.4%) of acute 
coronary occlusions(28) and resembles the 
distribution of optical coherence tomography 
thin cap fibroatheromas (29). However, for 
the first time, we demonstrated a strong cor-
relation between patient reported functional 
status and higher risk plaques. The best cut-off 
for a plaque burden>75% was SAQ angina 
stability score ≤25. This finding reinforces the 
results of Spertus et al. where outpatients with 
CAD had progressively worse outcomes with 
lower SAQ score (1). Specifically, a SAQ angina 
stability score ≤25 had a 2.9 fold higher 1-year 
mortality and a 2.3 fold higher ACS admission 
rate compared with patients with improved 
symptoms(1).
Smaller lumen area, larger vessel area 
and lower SAQ physical limitation were cor-
related with the maximum necrotic core area. 
Ruptured plaques of patients with ACSs also 
have smaller lumens, greater plaque burden 
and positive remodeling (30). Additionally, in 
the PROSPECT trial, the model with the best 
C-statistic for event prediction used minimum 
lumen area as a continuous variable. It was 
found that every 1mm2 reduction in lumen 
area increased the event rate by 44% (3). The 
reason for a larger vessel area being correlated 
with necrotic core area is that in vulnerable 
plaques, matrix metalloproteinases (MMPs), 
that are secreted by macrophages do not 
digest only the matrix components within the 
fibrous cap (5) but an increased MMP activity in 
atherosclerotic arteries with extreme expan-
sive remodeling was also demonstrated (31). 
Regarding the SAQ physical limitation score, 
our unprecedented findings are further sup-
ported by the work of Spertus et al. (1). In their 
study, the physical limitation score was the 
one with the best prognostic discrimination. 
Interestingly, Spertus et al. showed that quality 
of life had the worst prognostic discrimination 
among the SAQ scores. In the present study 
this score was not able to differentiate any 
IVUS or VH IVUS findings.
The main message of our findings on SAQ 
is that worse physical limitation and worse 
angina stability are continuously and strongly 
related to necrotic core area and plaque bur-
den. However, in addition, we explored the 
best cutoff in identifying plaques at highest 
risk. Both cutoffs for SAQ angina stability and 
physical limitation had low sensitivity and 
high specificity for detection of a large plaque 
burden and a large necrotic core, respectively. 
In other words, they may not serve to detect 
positive cases but help to identify patients 
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with a lower chance of high risk plaques. 
Despite the advances in imaging methods, 
features related to vulnerable plaque did 
not improve the risk predictions compared to 
clinical approaches. Therefore, the identifica-
tion and treatment of vulnerable plaque to 
avoid clinical events is so challenging that it 
has started to be considered a “myth”(32). In 
this regard, the correlations herewith demon-
strated between high risk plaque features and 
a consistent and reproducible patient report 
health status measure adds to the medical 
literature since they can be easily used in 
clinical practice(32).
Limitations. The present study limited the 
inclusion of myocardial infarction for patients 
with normalized enzymes. As consequence, 
the sub group of acute coronary syndromes 
herewith reported had mainly patients with 
unstable angina. Therefore, we were not able 
to reproduce previously reported differences 
of IVUS findings comparisons between sub-
jects with stable CAD and ACS. Nevertheless, 
the prevailing literature lacks an analysis dedi-
cated to obstructive lesions and their clinical 
correlations. In addition, as aforementioned, 
for the first time we validated patient reported 
health measures to an invasive assessment of 
coronary atherosclerosis.
As all studied lesions underwent percutane-
ous treatment, we could not explore their 
evolution. However, as in the inclusion criteria 
patients needed to have ischemic symptoms, 
in the context of a controlled randomized trial 
we assume that their clinicians interpreted 
that the revascularization was performed at 
the right time.
ConClUSIon.
In the present IVUS study dedicated to obstruc-
tive lesions, clinical characteristics were able 
to differentiate the manifestation of CAD as-
sessed by PAV, largest plaque burden, luminal 
area and remodelling. Negative remodelling 
was associated with worse angina frequency 
by the SAQ. Patient reported physical limita-
tion and angina stability were, respectively, 
associated with necrotic core size and plaque 
burden.
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Prognostic Value of Site SYNTAX Score
and Rationale for Combining Anatomic
and Clinical Factors in Decision Making
Insights From the SYNTAX Trial
Yao-Jun Zhang, PHD,*y Javaid Iqbal, MRCP, PHD,* Carlos M. Campos, MD,* David V. Klaveren, MSC,z
Christos V. Bourantas, MD,* Keith D. Dawkins, MD,x Adrian P. Banning, MD,k Javier Escaned, MD, PHD,{
Ton de Vries, MSC,# Marie-Angèle Morel, BSC,# Vasim Farooq, MD,* Yoshinobu Onuma, MD,*
Hector M. Garcia-Garcia, MD, PHD,* Gregg W. Stone, MD,** Ewout W. Steyerberg, PHD,z Friedrich W. Mohr, MD,yy
Patrick W. Serruys, MD, PHD*zz
ABSTRACT
BACKGROUND The results of SYNTAX trial have been reported based on “corelab” calculated SS (cSS). It has been
shown that reproducibility of SS is better among the core laboratory technicians than interventional cardiologists.
Thus, the prognostic value and clinical implication of the “site” SYNTAX SS (sSS) remain unknown.
OBJECTIVES The study sought to evaluate the prognostic value and clinical implication of the sSS after percutaneous
coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery in the randomized SYNTAX trial.
METHODS The sSS was calculated by the site investigators before randomization in the SYNTAX trial. New tertiles based
on the sSS were defined with low (0 to 19), intermediate (20 to 27), and high ($28) scores. The clinical endpoints were
compared between PCI and CABG by Kaplan-Meier estimates, log-rank comparison, and Cox regression analyses using the
new tertiles. The sSS-based SS II was calculated and its predictive performance was evaluated.
RESULTS The mean difference in cSS and sSS is 3.8 � 11.2, with a mean absolute difference of 8.9 � 7.8. In the overall
cohort, using sSS there was a higher incidence of major adverse cardiac and cerebrovascular events (MACCE) at 5-year
follow-up in the PCI group for low (31.9% vs. 24.5%; p ¼ 0.054), intermediate (39.5% vs. 29.5%; p ¼ 0.019), and high
(43.0% vs. 31.4%; p ¼ 0.003) tertiles, compared with the CABG group. Similarly, in the 3-vessel disease subgroup,
5-year MACCE rates were higher in PCI group in all tertiles. Conversely, in the left main subgroup, MACCE rates were
similar for PCI and CABG groups in all tertiles. The sSS-based SS II (c-index: 0.736) had predictive performance similar
to the cSS-based SS II (c-index: 0.744), with net reclassification index of –0.0062 (p ¼ 0.79).
CONCLUSIONS Appropriate training and unbiased assessment are needed when using SS in clinical decision making.
sSS and tertiles based on sSS showed poor discrimination among low, intermediate, and high-risk groups. However,
combining clinical factors with sSS retained the predictive performance of SS II. (SYNTAX Study: TAXUS Drug-Eluting
Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries; NCT00114972) (J Am Coll Cardiol
2014;64:423–32) © 2014 by the American College of Cardiology Foundation.
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University, Nanjing, China; zDepartment of Public Health, ErasmusMedical Center, Rotterdam, the Netherlands; xBoston Scientific
Corporation, Natick, Massachusetts; kOxford University Hospitals, Oxford, United Kingdom; {Clinico San Carlos University Hos-
pital, Madrid, Spain; #Cardialysis BV, Rotterdam, the Netherlands; **Columbia University Medical Center/New York-Presbyterian
Hospital, Cardiovascular Research Foundation, New York, New York; yyHerzzentrum Universität Leipzig, Leipzig, Germany;
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I nterventional cardiologists and sur-geons in the SYNTAX (SYNergy BetweenPCI With TAXUS and Cardiac Surgery)
trial originally used the SYNTAX score (SS)
to extract objective information from the
coronary angiogram on the technical chal-
lenges posed by coronary anatomy to percu-
taneous coronary intervention (PCI) and
to facilitate discussions made by the heart
team (1). Subsequently, it became apparent
that the SS had a prognostic value to predict
short- and long-term outcomes (2–4). The
European and American revascularization
guidelines currently recommend the SS to
guide the heart term in decision making
(5–7). Moreover, high-risk SS category is a
key inclusion/exclusion criterion, imposed
by the U.S. Food and Drug Administration,
in several ongoing randomized controlled
trials, including EXCEL (Evaluation of Xience
Prime or Xience V versus Coronary Artery
Bypass Surgery for Effectiveness of Left
Main Revascularization), PARTNER-II (Place-
ment of AoRtic TraNscathetER Valves), and
SURTAVI (Surgical Replacement and Transcatheter
Aortic Valve Implantation).
Knowledge of variability in calculating SS is of
paramount importance at a time of its widespread
use as a clinical decision-making tool. Risk stratifi-
cation of patients in the SYNTAX trial was based on
“corelab” SS (cSS), which was calculated by the core
laboratory technicians blinded to the treatment
group. However, all sites participating in SYNTAX
also had a “site” SS (sSS) calculated by the site in-
vestigators, who at that time had no knowledge of
the prognostic significance of the SS. The discrep-
ancy between cSS and sSS has been previously
highlighted in the SYNTAX trial (8). Recently, Gén-
éreux et al. (9) have demonstrated that interven-
tional cardiologists underestimate the number of
lesions, bifurcation, and the presence of small-vessel
disease, resulting in a lower SS than that reported
by the core laboratory technicians. The significance
and prognostic value of the sSS in the SYNTAX trial
have not been evaluated.
This study aimed to examine the difference be-
tween the cSS and sSS in the randomized SYNTAX
trial and the prognostic performance of the sSS in
assessing outcomes among patients undergoing PCI
or coronary artery bypass grafting (CABG). We also
investigated the predictive performance of the SYN-
TAX II score, a recently developed risk score that
combines the anatomic SS with clinical variables to
predict long-term outcome of PCI and CABG when
calculated using either cSS or sSS.
METHODS
THE SYNTAX RANDOMIZED TRIAL. The SYNTAX trial
(NCT00114972) was a prospective, multicenter, ran-
domized trial to investigate subjects with unprotected
left main coronary artery (ULMCA) disease (isolated or
associated with 1-vessel, 2-vessel, or 3-vessel disease),
or de novo 3-vessel disease (3VD) (10). Eligible pa-
tients were randomized on a 1:1 ratio to CABG (n ¼ 897)
or PCI with Taxus Express paclitaxel-eluting stent
(Boston Scientific Corporation, Natick, Massachusetts;
n ¼ 903) and followed up for 5 years. The primary
clinical endpoint of the SYNTAX trial was a composite
25
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FIGURE 1 Distribution and Individual Difference of the cSS
and the sSS
The mean SS was 28.7 � 11.4 for the corelab and 24.9 � 10.2 for
the site. cSS ¼ corelab SYNTAX score; SS ¼ SYNTAX score; sSS ¼
site SYNTAX score.
SEE PAGE 433
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AND ACRONYMS
AUC = area under the receiver
operating characteristic curves
CABG = coronary artery bypass
grafting
CI = confidence interval
cSS = ‘corelab’ SYNTAX score
HR = hazard ratio
MI = myocardial infarction
MACCE = major adverse
cardiac or cerebrovascular
event(s)
NRI = net reclassification index
PCI = percutaneous coronary
intervention
SS = SYNTAX score
sSS = ‘site’ SYNTAX score
SYNTAX = SYNergy Between
PCI With TAXUS and Cardiac
Surgery
ULMCA = unprotected left
main coronary artery
3VD = 3-vessel disease
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CENTRAL ILLUSTRATION Difference of the cSS and the sSS and Kaplan-Meier Curves for MACCE Using
Traditional (cSS-Based) Tertiles
(A) Distribution and individual difference of the cSS and the sSS. The absolute difference in cSS and sSS is 8.9 � 7.8. Cases on the left of the
y-axis had a higher sSS compared with the cSS; cases on the right of the y-axis had a lower sSS compared with cSS. (B) Kaplan-Meier cumulative
event curves for MACCE using traditional (cSS-based) tertiles. Kaplan-Meier curves are shown for MACCE between the PCI group and the CABG
group at 5-year follow-up by the sSS according to the traditional corelab tertiles in overall cohort (N¼ 1,800); sSS: 0 to 22 (n¼ 823); sSS: 23 to
32 (n ¼ 619); sSS:$33 (n ¼ 358). CABG¼ coronary artery bypass grafting; cSS¼ corelab SS; MACCE ¼major adverse cardiac or cerebrovascular
event(s); PCI ¼ percutaneous coronary intervention; sSS ¼ site SS.
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of major adverse cardiac or cerebrovascular events
(MACCE) (e.g., death from any cause, stroke, myocar-
dial infarction [MI], or repeat revascularization) at
1-year follow-up. Secondary endpoints included the
incidence of MACCE and its components at 1-month, 6-
month, 3-year, and 5-year follow-up. An independent
clinical event committee comprising interventional
cardiologists, cardiac surgeons, and a neurologist
adjudicated all events.
THE SS CALCULATION. During the local heart team
meeting, the cardiac surgeon and interventional
cardiologist systematically reviewed the coronary
angiogram and specified the number of coronary le-
sions, along with their angiographic location and
characteristics. Diagnostic angiograms were scored
according to the SS algorithm (1). Each significant
lesion (defined as a diameter stenosis of$50% in$1.5-
mm vessels) is visually assessed and awarded a score
related to location and severity of the coronary lesion.
Additional points are given for total occlusion, bifur-
cation or trifurcation lesion, aorto-ostial lesion, severe
tortuosity, heavy calcification, thrombus, and
diffusely diseased segment. The sSS was calculated
during the local heart team meeting before randomi-
zation. Calculation of the cSS was done by an inde-
pendent core laboratory (Cardialysis BV, Rotterdam,
the Netherlands), blinded to treatment assignment.
THE SS II CALCULATION. The SS II has been previ-
ously generated by a combination of anatomic cSS
and clinical factors (age, creatinine clearance, left
ventricular ejection fraction, presence of ULMCA
disease, peripheral vascular disease, sex, and
chronic obstructive pulmonary disease) to predict 4-
year mortality risk after PCI or CABG (11). Using the
same model, we also have calculated SS II using the
sSS and using the sSS-based SS II to predict 4-year
mortality and make a treatment recommendation.
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean � SD and categorical variables
are shown as counts and percentages of the total.
Bland-Altman plots were used to compare the cSS and
sSS. The predictive values of anatomic cSS and sSS
were compared by evaluating differences in the area
under the receiver operating characteristic curves
(AUC) and standard errors using the Delong method.
The agreement between observed and predicted risks
for cSS and sSS was assessed with the Hosmer-
Lemeshow test. Comparisons of 5-year clinical out-
comes betweenCABG and PCIwere conductedwith the
Kaplan-Meier method and the log-rank tests. By Cox
regression analyses, the relative risks were shown as
hazard ratios (HRs) and 95% confidence interval (CI).
Two patient subsets were predefined in this study:
patients with ULMCA (with or without additional
vessel involvement), and those with 3VD in the
absence of left main coronary disease. To calculate the
SS II, multiple imputations (5�) of missing values was
performed with an advanced imputation strategy,
which takes into account the correlation between all
potential predictors (11,12). The performance of the
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FIGURE 2 Correlation and Agreement Between the cSS and the sSS
(A) Relationship between the cSS (y-axis) and the sSS (x-axis), for all the patients in the
SYNTAX trial. Paired data were available for 1,789 of 1,800 subjects (99.4%). A total of
386 patients with high scores ($33) based on the cSS tertiles were calculated as low (0 to
22) or intermediate scores (23 to 32) by the investigate site. (B) Bland-Altman plots. The
measurements in cSS exceeded those of sSS by an average of 3.83 points (bias, as indicated
by the solid line). The limits of agreement (2 standard deviations [SDs], which describes
the range for 95% comparison points) ranged from –18.57 to þ26.23, represented by the
broken lines on the plot. This range is very wide from a clinical perspective, indicating poor
agreement existing between cSS and sSS. Abbreviations as in Figure 1.
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sSS-based SS II was evaluated using c-statistics (Har-
rell’s c-index) (13), calibration plots (14), reclassifica-
tion table, and net reclassification index (NRI) (15,16).
A probability value of less than 0.05 was considered
statistically significant. All analyses were undertaken
using SPSS 20.0 (IBMCorporation, Armonk, NewYork).
RESULTS
SS BY THE CORE LABORATORY AND SITE. The cSS
was calculated in 99.4% (n ¼ 1,789) of patients,
missed in 0.6% (n ¼ 11) of patients. The sSS was
available in 100% (n ¼ 1,800). The cSS and sSS dis-
tributions are shown in Figure 1. The mean SS was
28.7 � 11.4 (range: 0 to 83) for the corelab and 24.9 �
10.2 (range: 3 to 88) for the site. The mean difference
between cSS and sSS is 3.8 � 11.2, with an absolute
difference of 8.9 � 7.8 (Central Illustration). The sSS
was numerically identical to the cSS in 99 patients
(5.5%), underestimated in 1,106 (61.8%), and over-
estimated in 584 (32.7%). A significant correlation
(r ¼ 0.49; p < 0.05) was found between the cSS and
sSS as shown in Figure 2A. However, Bland-Altman
plots showed that the limits of agreement (2 SDs
that describe the range for 95% comparison points)
were very wide (–18.57 to þ26.23 score), indicating a
poor agreement between the corelab and site calcu-
lated SS (Fig. 2B). Only 882 (49.3%) patients have
concordant scores according to the corelab SS-
defined tertiles (Table 1).
CLINICAL ENDPOINTS USING sSS AND ESTABLISHED
SS TERTILES. Using the sSS, patients were grouped
into traditional SYNTAX tertiles of low (#22 score,
TABLE 1 Risk Stratification According to the Corelab SYNTAX Score Defined Tertiles
Corelab SYNTAX Score
In
Total
Low
(≤22)
Median
(>22–≤32)
High
(>32)
Site SYNTAX score Low (#22) 409 262 145 816
Median (>22–#32) 122 254 241 617
High (>32) 43 94 219 356
In total 574 610 605 1,789
Values in bold represent concordant scores.
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FIGURE 3 Kaplan-Meier Cumulative Event Curves for MACCE Using Traditional (cSS-Based) Tertiles
Kaplan-Meier curves are shown for MACCE between the PCI group and the CABG group at 5-year follow-up by the sSS according to the traditional corelab tertiles in the
left main coronary artery disease subgroup (A) and the 3-vessel disease subgroup (B). (A) Left main subgroup (N ¼ 705); sSS: 0 to 22 (n ¼ 266); sSS: 23 to 32 (n ¼ 245);
sSS: $33 (n ¼ 194). (B) Three-vessel disease subgroup (N ¼ 1,095); sSS: 0 to 22 (n ¼ 557); sSS: 23 to 32 (n ¼ 374); sSS: $33 (n ¼ 164). CABG ¼ coronary artery bypass
grafting; MACCE ¼ major adverse cardiac or cerebrovascular event(s); PCI ¼ percutaneous coronary intervention; other abbreviations as in Figure 1.
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n ¼ 823), intermediate (23 to 32 score, n ¼ 619), and
high ($33 score, n ¼ 358) scores (Central Illustration).
In the overall cohort, using the sSS, MACCE rates in
the low and intermediate tertiles were significantly
higher in the PCI group than in the CABG group (p ¼
0.016, p ¼ 0.002, respectively); MACCE rate in the
high-score tertile was numerically but not statistically
higher with PCI compared with CABG (42.0% vs.
33.8%; p ¼ 0.105) (Central Illustration). In the ULMCA
subgroup, the 2 revascularization strategies had
similar MACCE rates during the 5-year follow-up
period (Fig. 3A). In the 3VD subgroup, the incidence
of MACCE was significantly higher in the PCI group
than in the CABG group in all tertiles (low, 35.3% vs.
25.9%; p ¼ 0.024; intermediate, 40.1% vs. 26.4%;
p ¼ 0.005; high, 46.1% vs. 24.3%; p ¼ 0.006) (Fig. 3B).
CLINICAL ENDPOINTS USING sSS ANDNEWTERTILES
BASED ON sSS. The actual tertiles according to the
sSS were low (#19 score, n ¼ 616), intermediate (20 to
27 score, n ¼ 567), and high ($28 score, n ¼ 617).
In the overall cohort, there was a trend toward
higher incidence of MACCE in the PCI group for low
scores, compared with the CABG group, but this dif-
ference was not statistically significant (31.9% vs.
24.5%; p ¼ 0.054) (Fig. 4A). Risk of MACCE for inter-
mediate and high scores was significantly increased
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FIGURE 4 Kaplan-Meier Cumulative Event Curves for MACCE According to the New (sSS-Based) Tertiles
Kaplan-Meier curves are shown for MACCE between the PCI group and the CABG group at 5-year follow-up by the sSS according to the sSS-based new tertiles in overall
cohort (A), left main coronary artery disease subgroup (B), and 3-vessel disease subgroup (C). (A) Overall cohort (N ¼ 1,800); sSS: 0 to 19 (n ¼ 616); sSS: 20 to 27
(n ¼ 567); sSS: $28 (n ¼ 617). (B) Left main subgroup (N ¼ 705); sSS: 0 to 19 (n ¼ 211); sSS: 20 to 27 (n ¼ 182); sSS: $28 (n ¼ 312). (C) 3-vessel disease subgroup
(N ¼ 1,095); sSS: 0–19 (n ¼ 405); sSS: 20 to 27 (n ¼ 385); sSS: $28 (n ¼ 305). Abbreviations as in Figures 1 and 3.
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with PCI versus CABG (39.5% vs. 29.5%; p ¼ 0.019;
43.0% vs. 31.4%; p ¼ 0.003, respectively) (Fig. 4A).
In the ULCMA disease subgroup (n ¼ 705),
MACCE rates were comparable and did not differ
significantly between the 2 groups in each tertile
(Fig. 4B). In the 3VD subgroup (n ¼ 1,095), all groups
of low, intermediate, and high scores showed a
significantly higher incidence of MACCE in the PCI
group than those in the CABG group at 5-year follow-
up (Fig. 4C).
There was no significant difference in death,
stroke, and repeat revascularization between PCI
and CABG in the low tertiles, but a higher risk of MI
in the PCI group (p ¼ 0.002) (Fig. 5). In the interme-
diate tertiles, a significantly higher proportion of
patients had repeat revascularization after PCI than
after CABG (HR, 2.65; 95% CI: 1.72 to 4.08; p < 0.001).
In the high tertiles, there was a significantly higher
risk of death, MI, and repeat revascularization in the
PCI group, but an insignificantly lower risk of stroke
(p ¼ 0.177) (Fig. 5).
SUBSTANTIAL CHANGES IN TREATMENT DECISION
USING sSS. The predictive accuracy for 4-year mor-
tality was modest with cSS (AUC, 0.57; 95% CI: 0.54
to 0.59) and dropped further with sSS (AUC, 0.55; 95%
CI: 0.53 to 0.57). There was a poor agreement between
predicted and observed MACCE for the sSS and cSS,
using Hosmer-Lemeshow test (p ¼ 0.51, p ¼ 0.31,
respectively). Furthermore, the treatment decision
based on SS tertile changed in more than one-third of
patients depending on whether cSS or sSS is used
(Table 2). For 9.4% of patients, the treatment decision
changed from PCI or CABG to CABG and for 25.7% the
treatment recommendation changed from CABG to
PCI or CABG.
MINIMAL CHANGES IN TREATMENT DECISION USING
sSS-BASED SS II. The sSS-based SS II had predictive
power similar to the cSS-based SS II (Harrell’s c-index:
0.736, 0.744, respectively). The calibration plots of
the sSS-based SS II showed a good agreement be-
tween the observed and predicted risk of mortality
(Fig. 6). The recommendations according to the
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FIGURE 5 Clinical Outcomes at 5-Year Follow-Up According to the New Tertiles
HR was calculated for CABG versus PCI at 5-year follow-up for each clinical endpoint according to the sSS-based new tertiles. CI ¼ confidence
interval; HR ¼ hazard ratio; MI ¼ myocardial infarction; other abbreviations as in Figures 1 and 3.
TABLE 2 Change in Treatment Recommendations*
According to the cSS and the sSS Models
Recommendations
sSS
TotalCABG or PCI CABG
cSS CABG or PCI 601 (33.6%) 168 (9.4%) 769 (43.0%)
CABG 459 (25.7%) 561 (31.3%) 1,020 (57.0%)
Total 1,060 (59.3%) 729 (40.7%) 1,789 (100%)
*Based on following recommendation: 3VD and SS #22–PCI or CABG; 3VD and
SS >22–CABG; ULMCA and #32–PCI or CABG; ULMCA and SS >32–CABG.
CABG ¼ coronary artery bypass grafting; cSS ¼ corelab SYNTAX score;
PCI ¼ percutaneous coronary intervention; sSS ¼ site SYNTAX score; ULMCA ¼
unprotected left main coronary artery; 3VD ¼ three-vessel disease.
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original cSS- and the sSS-based SS II models did not
warrant a change in revascularization strategy (from
PCI to CABG or CABG to PCI) in a large majority of
patients (Table 3). A large majority (83%) of patients
had the same recommendation: only eligible for
CABG (n ¼ 346; 19.2%); only eligible for PCI (n ¼ 76;
4.2%); or potentially amenable to both types of
revascularization (n ¼ 1,070; 59.4%). Patients with or
without events are reclassified by the sSS-based SS
II model, and their results are presented in Table 4
(NRI, –0.0062; p ¼ 0.79).
DISCUSSION
This post-hoc study of the SYNTAX randomized
trial has highlighted a significant difference in the
anatomic SS calculated by the site and corelab and the
calculation of tertiles based on the sSS, which
compromised the ability of the SS to distinguish the
low-, intermediate-, and high-risk patients, especially
in the subgroup of 3VD. However, the prognostic
performance of SS II, which combines clinical vari-
ables with the SS, remained largely unaffected
whether the cSS or the sSS was used.
DIFFERENCES IN SITE AND CORELAB SS. There is a
significant absolute difference in the SS calculated
by the site investigators and the core laboratory
analysts in the SYNTAX trial. Lack of advanced
training at each site is a plausible underlying reason
for this difference (9,17). Appropriate training can
significantly reduce intraobserver and interobserver
variability of the SS calculation by interventional
cardiologists (9). A study comparing SS calculation
by interventional cardiologists and angiographic
core laboratory technicians has shown that inter-
observer agreement was initially poor among inter-
ventional cardiologists (k ¼ 0.33), but improved
substantially after advanced training (k ¼ 0.76).
Although SS is a continuous variable, in practice it
is used as a categorical variable, with 3 categories
determined by cSS cutoff values of 22 and 33. These
SS categories are being extensively used in clinical
practice and the guidelines to decide revasculariza-
tion strategy and in the ongoing randomized trials
(e.g., EXCEL, PARTNER-II, and SURTAVI) as inclu-
sion/exclusion criteria (18). However, our data high-
light the variability in calculating SS, which may have
a significant impact on decision making and potential
consequences on patient outcomes based on the
choice of revascularization strategy.
OUTCOMES BASED ON sSS TERTILES. Using the
new tertiles (based on sSS) in the ULMCA disease
subgroup, there were no statistical differences in
MACCE rates between CABG and PCI in all tertiles.
These findings are consistent with studies demon-
strating comparable clinical outcomes for patients
with left main disease undergoing either PCI or CABG,
especially in low-risk patients (19,20). Park et al. (19)
have reported that PCI with sirolimus-eluting stents
was noninferior to CABG with respect to MACCE at 2
years in the treatment of patientswith unprotected left
main coronary artery stenosis. Because the newer-
generation drug-eluting stents have been shown to
significantly reduce the stent-related adverse events
(21,22), we speculate that the ongoing EXCEL trial will
show noninferiority of PCI for treating the majority of
patients with ULMCA disease.
It is noteworthy that for new site-based tertiles,
not only was a comparable MACCE in the low tertile
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FIGURE 6 Calibration Plots for the sSS-Based SS II
Calibration plots are shown for the sSS-based SS II model
predicting 4-year risk of mortality. The triangles indicate the
observed frequencies by quintile of predicted probabilities. Good
agreement was found between the observed and predicted
mortality for each group. K-M ¼ Kaplan-Meier; other abbrevia-
tions as in Figures 1 and 3.
TABLE 3 Recommendations According to the cSS- and the sSS-Based SS II Models
Recommendations
sSS-Based SS II
TotalCABG CABG or PCI PCI
cSS-based SS II CABG 346 (19.2%) 173 (9.6%) 0 (0) 519 (28.8%)
CABG or PCI 71 (3.9%) 1,070 (59.4%) 42 (2.3%) 1,183 (65.7%)
PCI 0 (0) 22 (1.2%) 76 (4.2%) 98 (5.4%)
Total 417 (23.2%) 1,265 (70.3%) 118 (6.6%) 1,800 (100%)
A total of 82.8% of patients (bold) had same recommendations. No recommendation was completely shifted
from PCI to CABG or vice versa.
Abbreviations as in Table 2.
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but also the lowest incidence of MACCE was in the
intermediate tertile for both CABG and PCI groups.
This is somewhat similar to the findings in the
FREEDOM (Future Revascularization Evaluation in
Patients with Diabetes Mellitus: Optimal Management
of Multivessel Disease) trial, which suggested no
differential treatment effect according to the category
of the SS (#22 and $33) in patients with diabetes
and complex coronary artery disease (23). Indeed,
SS as an anatomic tool without taking into consider-
ation the clinical risk profile of an individual patient is
suboptimal in predicting all the clinical outcomes.
Therefore, attempts have been made to combine
anatomic SS with clinical factors (e.g., Logistic
Clinical SS) to accurately predict individual patients’
risk (24).
sSS–BASED SS II. Recently proposed SS II, using
anatomic and clinical variables, has been shown to
significantly improve decision making between CABG
and PCI compared with using anatomic SS alone (11).
In the present study, although the site investigators
frequently underestimated the sSS and using it
changed treatment decisions, its influence on the
overall capability of the SS II to predict prognosis and
guide decision making was limited. This suggests that
clinical variables were more powerful and counter-
acted any variability in calculating SS. It is plausible
that this superiority of SS II stems from the fact that it
used SS as a continuous variable and not as a cate-
gorical variable. This may circumvent the limitation,
outlined above, of the dependence of classification
agreement in categorical variables on variability in
repeated measurements and frequency distribution
of the studied population.
CLINICAL IMPLICATION AND FUTURE PERSPECTIVE.
This study has many potential implications on clinical
practice. Revascularization guidelines strongly re-
commend that heart teams use SS for decision
making. However, it is essential to highlight that
adequate training of the staff calculating SS is vital.
It also may be possible in the near future to develop
automated algorithms and software to calculate SS
from coronary angiography or noninvasive multislice
computed tomography (25). Furthermore, it is note-
worthy that the uptake of anatomic SS in clinical
practice has been modest, despite recommendation
by the guidelines. It is probably attributable to vari-
ability in calculating SS and lack of clinical risk fac-
tors, which physicians generally believe to be equal
or more important. Finally, it is appropriate to sug-
gest that the heart teams use SS II, instead of
anatomic SS, for decision making to refer the patients
for either surgery or PCI.
STUDY LIMITATIONS. This is a post-hoc study from
the SYNTAX randomized trial. At the time of the trial,
an online calculator for SS was not available, and the
trial sites may have had limited or varying experience
in calculating SS, which may have potential influence
on the observed variability.
CONCLUSIONS
The anatomic SS was frequently underestimated
by the site. Advanced training and unbiased as-
sessment is mandatory in clinical use of the SS.
The sSS and tertiles based on sSS showed poor
discrimination between low-, intermediate-, and
high-risk groups. However, combining clinical factors
with sSS retained the predictive performance of SS II.
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TABLE 4 Reclassification Table Comparing 4-Year Mortality Risk Strata for
Original cSS- and the sSS-Based SS II
SS II Model
Using the cSS
SS II Model
Using the sSS
Total0% to 5% 5% to 10% $10%
0% to <5%
Persons included 600.0 (93.8) 40.0 (6.3) 0.0 (0.0) 640.0 (35.6)
Case patients 18.0 (77.9) 5.1 (22.1) 0.0 (0.0) 23.1 (12.2)
Control participants 582.0 (94.3) 34.9 (5.7) 0.0 (0.0) 616.9 (38.3)
Observed risk, %* 3.0 12.8 0.0
5% to <10%
Persons included 58.0 (10.2) 476.0 (83.4) 37.0 (6.5) 571.0 (31.7)
Case patients 5.0 (12.1) 35.2 (85.3) 1.1 (2.6) 41.3 (21.8)
Control participants 53.0 (10.0) 440.8 (83.2) 35.9 (6.8) 529.7 (32.9)
Observed risk, %* 8.6 7.4 2.9
$10%
Persons included 1.0 (0.2) 64.0 (10.9) 524.0 (89.0) 589.0 (32.7)
Case patients 0.0 (0.0) 7.1 (5.7) 117.9 (94.3) 125.0 (66.0)
Control participants 1.0 (0.2) 56.9 (12.3) 406.1 (87.5) 464.0 (28.8)
Observed risk, %* 0.0 11.1 22.5
Total
Persons included 659.0 (36.6) 580.0 (32.2) 561.0 (31.2) 1,800.0 (100.0)
Case patients 23.0 (12.1) 47.5 (25.1) 119.0 (62.8) 189.4 (100.0)
Control participants 636.0 (39.5) 532.6 (33.1) 442.0 (27.4) 1,610.6 (100.0)
Observed risk, %* 3.5 8.2 21.2 10.5
Values are n (%). In patients who died, the SS II model using the sSS reclassification declined by 3.11%, whereas in
nonevent patients the reclassification improved by 2.49%. The net reclassification index was –0.0062 (p¼ 0.79).
*Observed risk at 4 years is estimated from the Kaplan-Meier curve by using observations in each cell.
Abbreviations as in Table 2.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Training
and unbiased assessment are needed to apply the
coronary anatomic SYNTAX score in clinical decision
making. Combining clinical factors with the SYNTAX
score (referred to as the SYNTAX-II score) reduces
variability.
TRANSLATIONAL OUTLOOK: The ongoing SYNTAX-II
study will prospectively evaluate the predictive value of
the SYNTAX-II score with regard to both short- and long-
term clinical outcomes as a guide to referral of patients
with coronary artery disease for either surgical or percu-
taneous revascularization.
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clinical events at 4 years after zotarolimus-eluting 
vs sirolimus-eluting coronary stent implantation: 
an analysis from the PROTECT randomized trial
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AbSTRACT
objectives
We compared diabetic vs non diabetic patients with regards to definite or probable stent 
thrombosis (primary endpoint) and major clinical coronary events at 5 years. Diabetes was a 
pre-specified subgroup analysis within the PROTECT Trial.
background
Stent thrombosis is a potential catastrophic complication, which could be prevented by tailoring 
antiplatelet treatment.
Methods
The PROTECT randomized trial compared the Endeavor zotarolimus-eluting stent (E-ZES) and the 
Cypher sirolimus-eluting stent (C-SES). A total of 8709 patients were enrolled, including 2411 
diabetics of whom 1174 were allocated to the E-ZES group and 1237 patients to the C- SES group.
Results
At 5 years, the primary endpoint, definite or probable stent thrombosis, was higher among 
patients with diabetes mellitus (DM) than those without DM (non DM) (3.0% vs 1.9%, p=0.004). 
The rate of cardiac death was 7.3% vs 2.6%, p<0.001, all myocardial infarction was 6.5% vs. 
5.5%, p=0.104, for diabetics and non diabetics respectively.
Definite or probable stent thrombosis rate was lower among non DM than non insulin-
dependent DM (NIDDM) (1.9% vs. 2.7%, p=0.035) and insulin-dependent DM (IDDM) (1.9% vs. 
4.0%, p<0.001). Cardiac death rates were also different in these 3 groups, in non DM was 2.5%, 
in NIDDM was 6.0% (vs. non DM, p<0.001) and in IDDM 11.2% (vs. non DM, p<0.001).
Conclusions
At 5-year, stent thrombosis rates and cardiac death / large non-fatal MI rates were much higher 
among diabetics than non diabetics. These events appeared to be especially higher in patients 
with insulin-dependent diabetes.
Chapter 2.4
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InTRoDUCTIon
About a quarter of patients treated with percu-
taneous coronary interventions are diabetics.1 
These patients have a greater likelihood of 
follow-up events such restenosis and the 
fast-developing new lesions in non-treated 
coronary segments. These subsequent events 
result in an increased long-term mortality of 
diabetic patients compared with their coun-
terparts. 2 Therefore, many guidelines recom-
mend an intensive treatment of patients with 
diabetes since they are considered to be at a 
higher risk of cardiovascular events 3, 4. Specifi-
cally, in patients treated with percutaneous 
coronary interventions, diabetes mellitus 
has been associated with an increase rate of 
death, non-fatal myocardial infarction (MI) 
and stent thrombosis 5. Current guidelines 
for myocardial revascularization mentioned 
that diabetics may require a longer duration 
of DAPT.6 Is there enough evidence to support 
this practice?
The PROTECT study which randomised 8709 
to either the Endeavor zotarolimus-eluting 
stent (E-ZES; Medtronic, Inc) group and to 
the Cypher sirolimus-eluting stent (C-SES; 
Cordis, Johnson & Johnson) group concluded 
that no evidence of superiority of E-ZES 
compared with C-SES in definite or probable 
stent thrombosis rates was noted at 3 years. 7 
The PROTECT study brings an opportunity to 
investigate whether stent thrombosis rate is 
different between diabetic patients and their 
counterparts since it is the largest contempo-
rary well controlled trial in which the central 
point was stent thrombosis.
MeTHoDS
Study design
The PROTECT study design has been previ-
ously reported8. Briefly, this was a randomised, 
open-label, two-arm, multinational superiority 
trial, with the hypothesis being that E-ZES 
was superior to C-SES in respect of definite 
or probable stent thrombosis at 3 years, with 
a prospective randomised open-label blinded-
endpoints design. Patients were randomly 
assigned to a stent type (1:1 ratio) after signed 
patient informed consent was obtained and all 
protocol inclusion and exclusion criteria were 
confirmed. Patients aged 18 years or older 
undergoing elective, unplanned, or emergency 
procedures in native coronary arteries were 
eligible for enrolment. Patients who had had 
bare-metal stent implantation in the preced-
ing 12 months, a previous drug-eluting stent, 
or brachytherapy were excluded. The protocol 
was approved by the institutional ethical 
committee and/or centralised national ethical 
board in accordance with local regulations.
Patients and investigators were aware of 
treatment assignment. Assignment was con-
cealed to the clinical event committee, core 
lab staff responsible for ECG and angiogram 
analyses, data management, and statistical 
analysis, and sponsor staff , excluding a small 
number responsible for vigilance reporting.
Procedures
Treatment of coronary lesions was done in ac-
cordance with the manufacturer’s instructions 
and local or national guidelines. Antiplatelet 
therapy with aspirin and clopidogrel (75 mg) or 
another thienopyridine derivative was either 
started 3 days before the procedure or through 
a loading dose (clopidogrel 300–600 mg or 
its equivalent for other thienopyridine) for 
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patients not yet taking these medications. Post 
procedure, aspirin was prescribed indefinitely 
and thienopyridine therapy for a minimum 
of 3 months up to 12 months, according to 
guidelines, or for longer as per the physician’s 
decision. Prolongation or reinstitution of 
thienopyridine therapy was allowed where 
clinically indicated.
Data collection, source document veri-
fication of all reported events, and on-site 
monitoring were performed by three inde-
pendent clinical contract research organisa-
tions (CROMSOURCE, Kraainem, Belgium; 
Pacific Clinical Research Group, Mosman, 
NSW, Australia; Vibgyor Scientific Research, 
Ahmedabad, India)
Sites in the USA and Canada were monitored 
by Medtronic monitors. Patient informed con-
sent and source documentation of all reported 
events were monitored in all patients. Other 
data monitoring was done in 30% of randomly 
selected patients at all participating centres.
All deaths and all triggers for suspected 
myocardial infarction, stent thrombosis, or 
bleeding were adjudicated by and indepen-
dent clinical events committee. Revascularisa-
tions and strokes (not related to a bleeding) 
were not adjudicated.
Cardiac biomarker data (creatine kinase, 
creatine kinase myocardial-band if creatine 
kinase was outside of the normal range, and 
troponin) were to be obtained within 72 h 
of the procedure and at least once after the 
procedure. Centres were instructed to report 
all obtained biomarker values for event 
adjudication. At 3-year follow-up visit with 
electrocardiograph was mandatory.
Statistical analysis
The primary outcome was the composite of 
definite or probable stent thrombosis, ac-
cording to the Academic Research Consortium 
definition, (22) at 3 years in the intention-to-
treat population. Diabetes was a pre-specified 
subgroup analysis within the PROTECT Trial.
The main secondary outcomes were chosen to 
identify sequelae of stent thrombosis: (1) total 
death and large non-fatal myocardial infarc-
tion, (2) total death and nonfatal myocardial 
infarction, (3) cardiac death and large non-fatal 
myocardial infarction, and (4) cardiac death 
and non-fatal myocardial infarction. Cardiac 
death was defined according to the Academic 
Research Consortium definition as any death 
unless an unequivocal non-cardiac cause could 
be established. Myocardial infarctions are re-
ported according to the historical WHO and the 
Academic Research Consortium definitions. 
The WHO definition was used for the related 
composite endpoints to be consistent with 
other contemporary studies comparing drug-
eluting stents. A large myocardial infarction 
was defined as acute ST-elevation myocardial 
infarction, new pathological Q-waves not pres-
ent on the baseline electrocardiograph, or 
creatine kinase more than five times the upper 
limits of normal. We obtained prospective data 
on bleeding complications, according to the 
Thrombolysis In Myocardial Infarction criteria. 
Lesion success was defined as the attainment 
of less than 50% residual stenosis of the 
target lesion with any percutaneous method; 
device success as the attainment of less than 
50% residual stenosis of the target lesion 
with only the assigned device; and procedure 
success as the attainment of less than 50% 
residual stenosis of all the target lesions and 
no in hospital major adverse cardiac events.
The sample size assumptions were previ-
ously published in the main report of the 
study. Dichotomous and categorical variables 
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are reported as counts and percentages; be-
tween-group differences were assessed with 
Fisher’s exact test for dichotomous variables 
and Cochran-Mantel-Haenszel Modified Ridit 
Scores for categorical variables. Continuous 
variables are reported as means (SD) and were 
compared with the use of a two-sample t test. 
We did the analysis according to the intention-
to-treat principle in the entire enrolled study 
population. We used the Kaplan-Meier method 
to study the time to clinical outcomes and 
applied the logrank test to time-to-event 
between groups. For all outcomes, a two-sided 
p value lower than 0·05 represented statistical 
significance.
All significant variables in the univariable 
analysis (p<0.20) were put into the multi-
variable Cox proportional hazard regression 
models: Gender; Age >=75; diabetes; Prior MI; 
Prior Stroke; Smoked cigarette within 90 days; 
Serum Creatinine (µmol/l); Time dependent 
covariate for DAPT; Assigned Treatment Code; 
Total stent length per patient (mm); At least 1 
stent <=2.75 mm in diameter; At least 1 lesion 
overlapping stent; At least 1 lesion with throm-
bus; At least 1 lesion calcification (moderate/
severe); At least 1 lesion tortuosity (moderate/
severe); At least 1 lesion pre procedure TIMI 
0-1-2.
We did the analyses with SAS, version 9.3 
(SAS Institute Inc, Cary, NC, USA). This trial 
is registered with Clinicaltrials.gov, number 
NCT00476957.
ReSUlTS
Between May 21, 2007 and Dec 22, 2008, 8791 
patients from 36 countries were recruited, but 
only 8709 patients provided a valid signed 
consent and were eligible for inclusion in 
the analysis. Out of these patients, 2411 had 
diabetes and 6298 non diabetes.
The baseline clinical characteristics were very 
dissimilar between diabetes and non diabetes 
groups (table 1). Patients with diabetes were 
older, mean age 63.5±10.1 vs. 61.7±10.8, 
p< 0.001, more hypertensive 78.3 vs. 58.5%, 
p<0.001, more dyslipidemic 66.3 vs. 60.8%, 
p<0.001 and also had more peripheral vascu-
lar disease 7.0 vs. 4.0%, p<0.001 compared to 
their counterparts. On the other hand, patients 
with diabetes were less frequently male 73.3 
vs. 77.5%, p<0.001 and presented also less 
frequently with acute MI 22.6 vs. 27.1%, 
p<0.001, than the non diabetes patients.
The most common treated vessel was the 
left anterior descending in both groups. Lesion 
characteristics were similar between groups 
with the exception of severe calcification, 
which was more common in patients with 
diabetes (table 2). Procedure characteristics 
were also similar between groups, with the 
exception of number of lesions per patient, 
stents per patient, multilesion/vessel stenting 
and longer stented segment per lesion/patient 
which was greater in patients with diabetes. 
Interestingly, diabetic patients stayed longer 
period in hospital compared to non diabetics 
(2.11±4.34 vs. 1.82±2.06 days, p< 0.001)
The use of antiplatelet drugs at 30 days and 
up to 360 days was similar in both DM and 
non DM groups (table 3, figure 1). At 1800 days, 
this was different; patients using DAPT were 
33.9% and 20.7% in non diabetics (p<0.001) 
(Figure 1).
At 5 years, the primary endpoint, definite 
or probable stent thrombosis, was higher 
among diabetics than non diabetics (3.0% vs 
1.9%, p<0.004). (table 4 and figure 1). The rate 
of definite or probable stent thrombosis was 
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also higher for diabetics over the first 30 days 
and between 31 and 360 days, but thereafter 
(between 1 and 5 years), it was not statistically 
different between diabetics and non diabetics 
(table 4 and figure 1).
The rate of cardiac death was 7.3% vs 2.6%, 
p<0.001; all myocardial infarction rate was 
6.5% vs. 5.5%, p=0.104 (and large, non-fatal 
MI was 3.1% vs 2.3%, p=0.042), for diabetics 
and non diabetics respectively (Table 5 and 
Figure 3).
By insulin-dependent status, at 5 years, the 
primary endpoint, definite or probable stent 
thrombosis, was lower among non diabet-
ics (non DM) than non insulin-dependent 
diabetics (NIDDM) (1.9% vs. 2.7%, p=0.035) 
Table 1. Baseline Demographics and Clinical Characteristics
Patient Characteristics
Diabetes
n=2411
non Diabetes
N=6298 P-value
Age (Years) 63.5±10.1 61.7±10.8 < 0.001
BMI (kg/m²) 29.1±4.9 27.3±4.2 < 0.001
Male 73.3 (1767/2411) 77.5 (4881/6298) <0.001
History of smoking 51.9 (1251/2411) 59.8 (3764/6298) <0.001
Current smoker 19.0 (458/2411) 27.4 (1724/6298) <0.001
Diabetes Mellitus 100.0 (2411/2411) 0.0 (0/6298) <0.001
Insulin Dependent 25.1 (606/2411) 0.0 (0/6298) <0.001
Hypertension 78.3 (1889/2411) 58.5 (3686/6298) <0.001
Hyperlipidemia 66.3 (1598/2411) 60.8 (3831/6298) <0.001
Prior MI 23.6 (570/2411) 19.4 (1222/6298) <0.001
Prior CABG 7.2 (173/2411) 4.0 (250/6298) <0.001
Prior PCI 15.8 (382/2411) 11.2 (708/6298) <0.001
Prior Stroke 4.8 (116/2411) 2.4 (154/6298) <0.001
Current Cardiac Status
Silent Ischemia 9.5 (228/2411) 5.3 (333/6298) <0.001
Stable Angina 47.0 (1132/2411) 49.6 (3125/6298) 0.026
Unstable Angina 20.9 (505/2411) 18.0 (1133/6298) 0.002
(Acute) MI 22.6 (546/2411) 27.1 (1707/6298) <0.001
ST elevation (STEMI) 7.0 (169/2411) 9.1 (571/6298) 0.002
Non ST elevation (NON STEMI) 15.6 (377/2411) 18.0 (1136/6298) 0.008
Left Ventricular Ejection Fraction <0.001
< 30 2.2 (31/1383) 0.9 (28/3106)
30-50 32.6 (451/1383) 24.7 (768/3106)
> 50 65.1 (901/1383) 74.4 (2310/3106)
Serum Creatinine (µmol/l) 90.8±45.4 86.9±30.2 < 0.001
Renal Function1 0.213
Stage 0/1 46.4 (1061/2286) 46.2 (2707/5865)
Stage 2 36.1 (826/2286) 39.6 (2325/5865)
Stage 3 16.2 (371/2286) 13.8 (807/5865)
Stage 4 0.9 (21/2286) 0.3 (18/5865)
Stage 5 0.3 (7/2286) 0.1 (8/5865)
1GFR according to Cockcroft-Gault formula: estimated GFR, without RACE
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and than insulin-dependent diabetics (IDDM) 
(1.9% vs. 4.0%, p<0.001). Cardiac death rates 
were also different in these 3 groups, in non 
DM was 2.6%, in NIDDM was 6.0% (vs. non 
DM, p<0.001) and in IDDM 11.3% (vs. non DM, 
p<0.001) (Figures 2, 4 and 5).
 Within the group of patients with diabetes, 
the population was divided according to the 
stent type (E-ZES vs. C-SES). The baseline, 
procedure and lesion (with the exception of 
calcification that was higher in E-ZES group) 
characteristics were similar between the E-
ZES and C-SES. Among diabetics, the primary 
endpoint did not differ between groups (2.5% 
for E-ZES vs 3.5% for C-SES; p=0.214).
After adjustment for all significant uni-
variate predictors, in the COX multivariate 
analysis, insulin dependent diabetes mellitus 
(HR 1.96, 95%CI [1.2,3.1], p=0.0037), smoking 
(HR 1.86, 95%CI [1.35,2.54], p=0.0001) and 
total stent length (HR 1.01, 95%CI [1.00,1.02], 
p=0.0008) among others were associated with 
an increase rate of definite/probable stent 
thrombosis at 5 years. Table  6. Conversely, 
DAPT in patients randomized to C-SES (HR 
0.37, 95%CI [0.22,0.60], p=<0.0001) was 
associated with less stent thrombosis events.
DISCUSSIon
The main findings in this post-hoc analysis 
of the PROTECT study are: 1. Patients with 
diabetes mellitus have an increased risk of 
stent thrombosis after adjusting for baseline, 
procedural and lesion characteristics; 2. 
Diabetics have also higher rates of death, MI, 
TVF and TLF compared to their counterparts; 
3. Insulin dependent DM showed the highest 
rates of death, MI, TVF and TLF compared to 
non-insulin dependent diabetes and non 
diabetes patients.
The trial (PROTECT trial) and stent 
thrombosis
The PROTECT trial has been the largest ever 
contemporary trial powered to explore 
differences in stent thrombosis using drug-
eluting stents. This study included a “nearly” 
all comers population. Patient with diabetes 
mellitus were 27.7%, which is higher than that 
enrolled in other all-comer trials (LEADERS and 
RESOLUTE trials). 9, 10 In the PROTECT study 
also a higher percentage of patients with acute 
myocardial infarction, compared with LEADERS 
trial, were included. Although the number of 
Table 2. Procedural Characteristics
Measures
Diabetes
(N=2411 Patients, 
3627 Lesions)
non Diabetes
(N=6298 Patients, 
8663 Lesions) P-value
Lesions with Pre-Dilatation 68.5 (2486/3627) 68.4 (5927/8663) 0.898
Number of lesions treated per patient 1.49±0.79 1.36±0.67 < 0.001
No Lesions/Vessels Treated 0.7 (17/2409) 0.7 (45/6297) 1.000
Multiple Lesions Treated 35.8 (862/2409) 28.2 (1773/6297) <0.001
Number of vessels treated per patient 1.26±0.51 1.18±0.44 < 0.001
Multiple Vessels Treated 23.7 (572/2409) 17.0 (1072/6297) <0.001
Number of stents per patient 1.70±1.04 1.58±0.95 < 0.001
Number of stents per lesion 1.13±0.46 1.15±0.48 0.080
Total Stent Length per patient (mm) 32.95±22.19 30.58±20.17 < 0.001
Total Stent Length per lesion (mm) 21.89±11.42 22.23±11.61 0.133
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Table 3. Medication use
Drug
Diabetes
(N=2411)
non Diabetes
(N=6298) P-value
Procedure Medication
GP IIb/IIIa 20.9 (503/2409) 17.1 (1076/6298) <0.001
Heparin or LMWH 95.4 (2298/2409) 96.0 (6049/6298) 0.185
LMWH 5.8 (139/2409) 4.9 (311/6298) 0.117
Bivalirudin or other direct thrombin inhibitor 4.3 (104/2409) 3.9 (245/6298) 0.360
Aspirin 95.8 (2308/2409) 97.0 (6110/6298) 0.006
Clopidogrel 95.5 (2301/2409) 97.3 (6125/6298) <0.001
Ticlopidine 0.6 (14/2409) 0.3 (16/6298) 0.025
Other anti-platelet/anti-thrombin drug 7.1 (172/2409) 5.2 (326/6298) <0.001
At Discharge
Aspirin 97.9 (2359/2409) 97.6 (6147/6297) 0.424
Clopidogrel 98.0 (2362/2409) 98.3 (6188/6297) 0.472
Ticlopidine 0.3 (7/2409) 0.2 (12/6297) 0.440
Other anti-platelet/anti-thrombin drug 4.5 (109/2409) 3.0 (186/6297) <0.001
Aspirin and (Clopidogrel or Ticlopidine) 96.5 (2324/2409) 96.4 (6070/6297) 0.898
Aspirin and (Clop, Ticl or other AP/AT) 96.6 (2326/2409) 96.5 (6076/6297) 0.948
At 30 Days
Aspirin 97.7 (2332/2386) 97.5 (6114/6268) 0.638
Clopidogrel 98.1 (2342/2387) 98.3 (6162/6269) 0.583
Aspirin and (Clopidogrel or Ticlopidine) 96.6 (2304/2386) 96.3 (6037/6268) 0.607
Aspirin and (Clop, Ticl or other AP/AT) 96.6 (2306/2386) 96.4 (6044/6268) 0.648
At 180 Day
Aspirin 97.8 (2304/2357) 97.1 (6043/6224) 0.102
Clopidogrel 97.0 (2289/2360) 96.9 (6036/6226) 0.944
Aspirin and (Clopidogrel or Ticlopidine) 95.6 (2253/2357) 94.8 (5898/6224) 0.121
Aspirin and (Clop, Ticl or other AP/AT) 95.7 (2256/2357) 94.9 (5905/6224) 0.116
At 360 Day
Aspirin 96.6 (2245/2324) 96.6 (5975/6184) 0.946
Clopidogrel 90.0 (2094/2327) 89.9 (5562/6188) 0.904
Aspirin and (Clopidogrel or Ticlopidine) 87.8 (2040/2323) 87.4 (5402/6184) 0.581
Aspirin and (Clop, Ticl or other AP/AT) 88.1 (2046/2323) 87.6 (5417/6184) 0.578
At 1800 Day
Aspirin 89.4 (1776/1987) 90.6 (5134/5667) 0.123
Clopidogrel 39.9 (793/1988) 25.6 (1448/5667) <0.001
Aspirin and (Clopidogrel or Ticlopidine) 33.9 (673/1987) 20.7 (1173/5666) <0.001
Aspirin and (Clop, Ticl or other AP/AT) 35.6 (707/1987) 22.7 (1286/5666) <0.001
Average Duration (days)
Aspirin 1528.0±517.3 1604.7±454.0 < 0.001
Anti-Platelet (Clopidogrel or Ticlopidin) 925.9±637.2 767.1±581.5 < 0.001
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figure 1. Incidence of stent thrombosis (ST) and dual antiplatelet therapy (DAPT). At the top, the inci-
dence of stent thrombosis at different time points (at all time points for the comparison diabetes vs. 
non diabetes, there is a significant p value <0.05, except for the period between 360 and 1800 days). 
At the bottom, the DAPT therapy which was statically significant less used for non diabetics patients 
until 1800 days.
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Table 4. Stent Thrombosis According to Academic Research Consortium Definition
Complications
Diabetes
(N=2411)
non Diabetes
(N=6298) P-value
Stent Thrombosis to 1800 Days
ARC Definite ST 1.7 (40/2300) 1.4 (83/6068) 0.222
ARC Definite + Probable ST 3.0 (70/2300) 1.9 (118/6068) 0.004
ARC Definite + Probable + Possible ST 7.7 (178/2300) 3.6 (218/6068) <0.001
Acute (0 to 1 Days)
ARC Definite ST 0.1 (3/2300) 0.1 (4/6068) 0.402
ARC Definite + Probable ST 0.1 (3/2300) 0.1 (6/6068) 0.713
ARC Definite + Probable + Possible ST 0.1 (3/2300) 0.1 (6/6068) 0.713
Sub-Acute (2 to 30 Days)
ARC Definite ST 0.6 (13/2300) 0.2 (14/6068) 0.028
ARC Definite + Probable ST 1.1 (25/2300) 0.4 (23/6068) <0.001
ARC Definite + Probable + Possible ST 1.1 (25/2300) 0.4 (23/6068) <0.001
Early (0 to 30 Days)
ARC Definite ST 0.7 (16/2300) 0.3 (18/6068) 0.019
ARC Definite + Probable ST 1.2 (28/2300) 0.5 (29/6068) <0.001
ARC Definite + Probable + Possible ST 1.2 (28/2300) 0.5 (29/6068) <0.001
Late (31 to 360 Days)
ARC Definite ST 0.3 (6/2300) 0.1 (6/6068) 0.103
ARC Definite + Probable ST 0.5 (11/2300) 0.2 (12/6068) 0.036
ARC Definite + Probable + Possible ST 1.4 (33/2300) 0.5 (30/6068) <0.001
Very Late (361 to 1800 days)
ARC Definite ST 0.8 (19/2300) 1.0 (59/6068) 0.611
ARC Definite + Probable ST 1.4 (32/2300) 1.3 (77/6068) 0.666
ARC Definite + Probable + Possible ST 5.2 (119/2300) 2.6 (160/6068) <0.001
Table 5. Cumulative events rate at 5-year follow-up
Diabetes
(N=2411)
non Diabetes
(N=6298 Patients) P-value
TLF2 16.4 (377/2300) 10.5 (638/6068) <0.001
TVF3 20.4 (470/2300) 13.6 (824/6068) <0.001
MACE4 21.9 (503/2300) 14.0 (850/6068) <0.001
MACCE5 23.7 (546/2300) 15.5 (942/6068) <0.001
Death 12.4 (285/2300) 5.3 (324/6068) <0.001
Cardiac Death 7.3 (168/2300) 2.6 (155/6068) <0.001
Non Cardiac Death 5.1 (117/2300) 2.8 (169/6068) <0.001
Vascular Death 1.0 (22/2300) 0.5 (29/6068) 0.017
Non Cardiovascular Death 4.1 (95/2300) 2.3 (140/6068) <0.001
All MI6(Extended historical definition) 6.5 (149/2300) 5.5 (336/6068) 0.104
Q Wave 2.2 (51/2300) 1.5 (89/6068) 0.022
TV MI 5.5 (127/2300) 4.6 (277/6068) 0.076
Q Wave 1.8 (42/2300) 1.1 (67/6068) 0.013
Non TV MI 1.0 (23/2300) 1.0 (63/6068) 1.000
Q Wave 0.4 (9/2300) 0.4 (23/6068) 1.000
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Diabetes
(N=2411)
non Diabetes
(N=6298 Patients) P-value
Large MI 2.9 (67/2300) 2.2 (135/6068) 0.079
Q Wave 2.2 (50/2300) 1.4 (87/6068) 0.020
All MI6(ARC Definition) 18.0 (413/2300) 15.9 (967/6068) 0.027
Q Wave 2.0 (47/2300) 1.4 (85/6068) 0.039
Sudden Death 0.1 (2/2300) 0.1 (7/6068) 1.000
Target Vessel MI7 16.7 (384/2300) 14.8 (897/6068) 0.032
Q Wave 1.7 (39/2300) 1.1 (64/6068) 0.020
Sudden Death 0.1 (2/2300) 0.1 (6/6068) 1.000
Non TV MI 1.6 (36/2300) 1.4 (85/6068) 0.608
Q Wave 0.3 (8/2300) 0.4 (22/6068) 1.000
Sudden Death 0.0 (0/2300) 0.0 (1/6068) 1.000
Large MI8 3.1 (71/2300) 2.3 (139/6068) 0.042
Q Wave 2.0 (47/2300) 1.3 (81/6068) 0.022
Sudden Death 0.1 (2/2300) 0.1 (7/6068) 1.000
All Revascularizations9 20.5 (472/2300) 16.2 (985/6068) <0.001
Emergent CABG 0.7 (15/2300) 0.4 (22/6068) 0.095
TLR 7.7 (177/2300) 5.2 (318/6068) <0.001
Clinically Driven TLR 7.3 (167/2300) 5.0 (306/6068) <0.001
CABG 1.5 (35/2300) 0.7 (45/6068) 0.002
RePCI 6.0 (139/2300) 4.4 (270/6068) 0.003
Non Clinically Driven TLR 0.5 (12/2300) 0.2 (14/6068) 0.045
CABG 0.0 (1/2300) 0.0 (0/6068) 0.275
RePCI 0.5 (11/2300) 0.2 (14/6068) 0.073
TVR 12.9 (296/2300) 9.2 (556/6068) <0.001
Clinically Driven TVR 12.3 (282/2300) 8.8 (536/6068) <0.001
CABG 2.3 (54/2300) 1.3 (77/6068) <0.001
RePCI 10.4 (240/2300) 7.8 (474/6068) <0.001
Non Clinically Driven TVR 0.9 (20/2300) 0.6 (34/6068) 0.126
CABG 0.1 (3/2300) 0.1 (6/6068) 0.713
RePCI 0.7 (17/2300) 0.5 (28/6068) 0.132
Non-TV Revascularization 12.0 (277/2300) 10.0 (609/6068) 0.009
CABG 1.8 (42/2300) 1.4 (83/6068) 0.130
RePCI 10.4 (240/2300) 8.9 (543/6068) 0.039
Death/MI/Revascularization 32.3 (742/2300) 23.1 (1400/6068) <0.001
Hemorraghic Stroke on Clopidogrel 0.5 (11/2300) 0.3 (17/6068) 0.201
Bleeding (GUSTO) 6.4 (148/2300) 5.7 (346/6068) 0.212
Bleeding (TIMI) 6.3 (145/2300) 5.6 (339/6068) 0.208
Bleeding (CURE) 5.4 (125/2300) 4.3 (258/6068) 0.022
1 All composite endpoints containing MI are based upon extended historical definition. 2 TLF= cardiac death, target 
vessel myocardial infarction (Q wave and non-Q wave) or clinically-driven target lesion revascularization (TLR) by 
percutaneous or surgical methods.3 TVF= cardiac death, target vessel myocardial infarction (Q wave and non-Q wave) 
or clinically-driven target vessel revascularization (TVR) by percutaneous or surgical methods.4 MACE= Major Adverse 
Cardiac Events defined as death, MI, emergent cardiac bypass surgery, or clinically driven target lesion revasculariza-
tion (repeat PTCA or CABG). 5 MACCE= Major Adverse Cardiac and Cerebral Events defined as death, MI, emergent 
cardiac bypass surgery, or clinically driven target lesion revascularization (repeat PTCA or CABG) and stroke. 6 MI= 
Myocardial Infarction (Target Vessel and Non-target Vessel). 7 TV MI= MI not clearly attributable to a non target vessel. 
Non TV MI = MI clearly attributable to a non target vessel. 8 Large MI= Myocardial Infarction with ST elevation ACS, or 
discharged with a new Q-waves on the ECG or a CPK >5 ULN. 9 TLR= Target Lesion Revascularization Per Site Reported, 
TVR= Target Vessel Revascularization Per Site Reported.
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figure 2. Clinical outcomes up to 5 years by diabetes status.
figure 3. Kaplan-Meier curves showing stent thrombosis (A), cardiac death (B), All myocardial infarc-
tions (C) and all revascularizations (D)
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lesions per patient was comparable in the 
3 studies, total stent length per lesion was 
longer in the PROTECT trial than in the other 2 
all-comer trials. Thus, we could claim that the 
PROTECT population represents our current 
clinical practice. This is one of the reasons why 
the overall incidence of stent thrombosis is not 
much different than the observed in the other 
2 all-comer trials.
In the PROTECT study, a higher rate of 
stent thrombosis was observed diabetic 
population compared their counterparts. The 
reasons for these differences could partly be 
attributed to the fact that known predictors 
of stent thrombosis (more calcified lesions 
and longer stented regions) were present in 
the diabetes group, despite the higher use 
of DAPT in diabetics at nearly all time points. 
After adjustment for all the significant uni-
variate variables, insulin dependent diabetes 
mellitus was associated with an increased 
risk of stent thrombosis in this report. It could 
be, therefore, speculated that prolonged 
DAPT in diabetic patients (especially insulin 
dependent DM) may be desirable to prevent 
stent thrombosis. Supportive evidence for 
figure 4. Kaplan-Meier curves showing stent 
thrombosis (definite and probable) rates in dia-
betics (by insulin status) and non diabetics
figure 5. Kaplan-Meier curves showing cardiac 
death rate in diabetics (by insulin status) and non 
diabetics
Table 6. Predictors of definite/probable stent thrombosis at 5 years
Covariates HR (95% CI) P value
DAPT in patients randomized to E-ZES 1.12 [0.60;2.08] 0.7238
DAPT in patients randomized to C-SES 0.37 [0.22;0.60] <.0001
At least 1 stent <=2.75 mm in diameter 1.86 [1.36;2.55] 0.0001
Smoked cigarette within 90 days 1.86 [1.35;2.54] 0.0001
Total stent length per patient (mm) 1.01 [1.00;1.02] 0.0008
Diabetes Dummy: IDDM vs rest 1.96 [1.24;3.10] 0.0037
At least 1 lesion with thrombus 1.60 [1.07;2.40] 0.0213
Serum Creatinine (µmol/l) 1.00 [1.00;1.01] 0.0308
Prior MI 1.42 [1.03;1.95] 0.0337
Age >=75 1.49 [1.00;2.22] 0.0497
Prior Stroke 1.67 [0.88;3.18] 0.1153
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prolonged DAPT comes from the DAPT study 
in which dual antiplatelet therapy beyond 1 
year was associated with reduction in stent 
thrombosis. 11
The disease (diabetes mellitus) and 
stent thrombosis
Patients with diabetes mellitus treated with 
percutaneous coronary interventions have a 
higher likelihood to experience stent throm-
bosis (>30d)12. Diabetic patients commonly 
present a prothrombotic state (increased 
plasminogen activator inhibitor-1, factor VII 
and XII, fibrinogen and reduced tissue plas-
minogen activator levels). Further, intense 
platelet reactivity in diabetic patients has 
been associated with an increased risk of ma-
jor coronary events. 13 The two main reasons 
for platelet hyperreactivity are the presence 
insulin resistance and hyperglycaemia.14 
Specifically, hyperglycaemia alters platelet 
calcium homeostasis, leading to cytoskeleton 
abnormalities and increased secretion of pro-
aggregant factors. Moreover, hyperglycaemia-
induced up-regulation of glycoproteins (Ib 
and IIb/IIIa), P-selectin and enhanced P2Y12 
signalling which are known contributors of 
atherothrombotic events. Having said this, 
currently, only aspirin daily is recommended 
as a secondary prevention in diabetic patients. 
It is only in patients that were treated with 
PCI for ACS that prasugrel and ticagrelor are 
recommended for 1 year. 15
Diabetics with nephropathy who received 
clopidogrel experienced significantly in-
creased cardiovascular and overall mortality 
compared with their counterparts.16 In this 
report, the stages of chronic kidney disease ≥2 
were in more than 50% of the diabetic popula-
tion. Whether this contributed to the increased 
rate of outcomes in diabetics was in this report 
not explored.
The antiplatelet medication 
(clopidogrel vs. others) and stent 
thrombosis
At 5 years, in the diabetes group roughly 35% 
of patients are taking clopidogrel (compared 
to 22.5% in the non diabetic group, p<0.001), 
which means either that the diabetic patients 
have got more CV events over the follow-up 
time that required restarting of clopidogrel 
or that treating physicians considered this 
population at a higher risk of events. There 
is, however, no evidence to support this latter 
attitude, so this is a gap in knowledge. In the 
multivariate analysis we have introduced DAPT 
as a time dependent covariate, which after 
adjustment for other variables, showed that 
the continue use of DAPT was associated with a 
HR 0.51. This means that if the diabetic group 
was not taking for longer time DAPT, the ST 
event rate would have been even higher.
Nevertheless, the increased rate of stent 
thrombosis could be also then partly attributed 
to the fact that a less potent drug (clopidogrel) 
has been mostly given and to the fact that 
clopidogrel-induced antiplatelet effects have 
a wide interindividual variability.17 Prasugrel 
was superior to clopidogrel in the subgroup 
diabetes mellitus analysis of TRITON-TIMI 38 
study. The stent thrombosis rate in clopido-
grel group was 3.6% vs. 2.0 in the prasugrel 
group (HR 0.52, 95%CI: 0.33–0.84). 18 Also 
in the diabetes analysis of the PLATO study, 
ticagrelor showed superiority to clopidogrel, 
stent thrombosis rate was 1.3% vs. 2.0% 
(HR: 0.62, 95% CI: 0.39–1.00), particularly in 
patient with HbA1c ≥ 6.0%. 19
In diabetics patients, there is no a head-to-
head comparison in terms of effectiveness to 
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reduce stent thrombosis between clopidogrel, 
ticagrelor and prasugrel. There is, however, an 
adjusted indirect comparison meta-analysis 
of prasugrel versus ticagrelor in a broader 
population. 20 These authors showed that there 
was a 36% reduction of stent thrombosis in 
patients treated with prasugrel compared to ti-
cagrelor (OR= 0.64 [0.43–0.93], p= 0.020). One 
report considered that this might have attrib-
uted to the fact that a considerably number of 
patients received double doses of clopidogrel 
before PCI in the clopidogrel arm of the PLATO 
study;21 double-dose of clopidogrel has been 
proved to reduce stent thrombosis (HR 0.68; 
95% CI, 0.55 to 0.85; P=0.001).22 This might 
have avoided observing a greater difference 
between clopidogrel and ticagrelor. In turn, in 
the stent thrombosis PLATO study dedicated 
report, ticagrelor reduced stent thrombosis 
events across a broad list of subgroups, includ-
ing diabetes meelitus. 23
The time course and stent thrombosis
At 5 years, the primary endpoint, definite or 
probable stent thrombosis, was higher among 
diabetics than non diabetics. This difference 
is due to an increased rate of definite or 
probable stent thrombosis in diabetics over 
the first 30 days and between 31 and 360 
days, because thereafter (between 1 and 5 
years), there was no a statistically significant 
difference between diabetics and non diabet-
ics. In this regard, there are in the literature 
contrasting reports, on one hand, in the 
HORIZONS-AMI study, insulin-dependent DM 
was a independent predictor of ST within 30 
days, but not in period between 31 and 360 
days, and again independent predictor of 
ST between 1-2 years. 24 While in the Dutch 
stent thrombosis registry, diabetes mellitus 
was associated with late (>30d) but not with 
early stent thrombosis. 12
Study limitations
There are a number of limitations worth con-
sidering; firstly, C-SES is no longer available. 
Secondly, due to the nature of this predefined 
post hoc analysis, the baseline characteris-
tics of the two compared groups are rather 
different. Therefore, we have performed a 
multivariable analysis to adjust for potential 
confounders.
Patients were not randomized to different 
durations of DAPT according to the diabetic 
status. The differences of DAPT duration (lon-
ger for diabetic patients) might have masked 
the real incidence of clinical adverse outcomes 
in such population.
ConClUSIonS
In this large trial, so far the only powered for 
stent thrombosis, 5-year stent thrombosis 
rates and cardiac death / large non-fatal MI 
rates were much higher among diabetics 
than non diabetics. These events appeared 
to be especially higher in patients with 
insulin-dependent diabetes. This report may 
indicate the need for customizing antiplatelet 
treatment in the diabetic population.
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INTRODUCTION
In a non-emergency setting, an accurate risk estima-
tion of patients with multivessel coronary artery disease
(CAD) is fundamental to determine whether the patient
should be treated either by percutaneous coronary inter-
vention (PCI) or coronary artery bypass surgery (CABG)
[1]. This decision has to balance risk–benefit ratios of
these therapeutic strategies, weighting the risks of death,
myocardial infarction and stroke against improvements
in health-related quality of life, and the need for repeat
revascularization. Currently, for patients with complex
CAD, international guidelines recommend a multidisci-
plinary approach referred to as the Heart Team (HT)
[2–4]. The HT has become an integral part of the con-
temporary practice of cardiovascular medicine with the
aim to provide an evidence-based, unbiased, multidisci-
plinary, decision-making process.
Aiming to help the HT to decide between CABG
and PCI in patients with complex CAD, the SYNTAX
Score II (SSII) combines anatomic and clinical factors
and predicts long-term mortality. The SSII was devel-
oped in the landmark, all-comers, randomized SYN-
TAX (Synergy between PCI with Taxus and Cardiac
Surgery) Trial [5,6], being externally applied in more
than 10,000 patients and implemented in the most
recent international guidelines [3,7–10].
The ongoing single-arm SYNTAX II Trial
(NCT02015832) uses the SSII to prospectively screen
the patients who can potentially be revascularized by
PCI with an equipoised prognosis of survival at 4-years
when compared to CABG.
However, the SSII does not contemplate all variables
that may influence the final choice of revascularization
strategy such as frailty, bleeding risk, or the preference
of the patient. The aim of the present interim report is
to assess the applicability of the SSII recommendations
in conjunction with the HT decision-making process
regarding the revascularization strategy in patients with
3-vessel CAD screened for the SYNTAX II trial, a
concept that has not yet been tested previously.
METHODS
The ongoing SYNTAX II Trial is a multicenter, all-
comers, open-label, single-arm trial that will recruit
450 patients with 3-vessel CAD in 25 European
interventional cardiology centers. All patients will be
selected and treated following the SYNTAX II strategy
described as follows: All patients will be treated with
the everolimus-eluting stent with biodegradable ablu-
minal coating (SYNERGY, Boston Scientific); the
lesions will be treated only after interrogation of ische-
mia with the use of pressure wire; intravascular ultra-
sound (IVUS) guidance to optimize drug-eluting stent
deployment, and the treatment of (chronic) total occlu-
sion lesions with contemporary techniques, and will be
compared with the PCI outcome of the original SYN-
TAX trial. The primary endpoint is the composite of
all-cause death; cerebrovascular event (stroke); docu-
mented myocardial infarction or all-cause revasculari-
zation at 1-year follow-up. Secondary endpoints
includes: (1) composite of all-cause death, cerebrovas-
cular event (stroke), documented myocardial infarction
(MI) at 1-year follow-up compared to the PCI arm of
SYNTAX I; (safety endpoint); (2) composite of cardio-
vascular death, documented target-vessel MI and repeat
target lesion revascularization at 1-year follow-up com-
pared to the PCI arm of SYNTAX I; (device oriented
clinical endpoint); (3) rates of individual components
of Major Adverse Cardiac and cerebrovascular event
(MACCE) (all-cause death, cerebrovascular event
(stroke), documented MI, and repeat revascularization)
at 1 year; (4) composite of MACCE rate and its indi-
vidual components at 2–5 years follow-up (patient
reported); (5) MI—according to Universal MI defini-
tion 2012 at all timepoints; (6) stent thrombosis—
according to ARC definitions at all timepoints; and (7)
retrospective validation of the residual SYNTAX score.
Patients were excluded, if: (1) Under the age of 21
years; (2) Known pregnancy at time of enrolment, (3)
Female of childbearing potential, and last menstruation
within the last 12 months, who are not taking adequate
contraceptives; (4) Female who is breastfeeding at time
of enrolment; (5) Prior PCI or CABG; (6) Ongoing
acute MI and enzymes (CKMB) more than 2 upper
limit of normal; (7) Concomitant cardiac valve disease
requiring surgical therapy, reconstruction, or replace-
ment; (8) Single or two-vessel disease at time of HT
consensus; (9) Participation or planned participation in
another cardiovascular clinical study before 1-year fol-
low-up is completed; (10) Mental condition, psychiatric
or organ cerebral disease, rendering the subject unable
to understand the nature, scope, and possible conse-
quences of the study or mental retardation or language
2 Campos et al.
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tion of patients with multivessel coronary artery disease
(CAD) is fundamental to determine whether the patient
should be treated either by percutaneous coronary inter-
vention (PCI) or coronary artery bypass surgery (CABG)
[1]. This decision has to balance risk–benefit ratios of
these therapeutic strategies, weighting the risks of death,
myocardial infarction and stroke against improvements
in health-related quality of life, and the need for repeat
revascularization. Currently, for patients with complex
CAD, international guidelines recommend a multidisci-
plinary approach referred to as the Heart Team (HT)
[2–4]. The HT has become an integral part of the con-
temporary practice of cardiovascular medicine with the
aim to provide an evidence-based, unbiased, multidisci-
plinary, decision-making process.
Aiming to help the HT to decide between CABG
and PCI in patients with complex CAD, the SYNTAX
Score II (SSII) combines anatomic and clinical factors
and predicts long-term mortality. The SSII was devel-
oped in the landmark, all-comers, randomized SYN-
TAX (Synergy between PCI with Taxus and Cardiac
Surgery) Trial [5,6], being externally applied in more
than 10,000 patients and implemented in the most
recent international guidelines [3,7–10].
The ongoing single-arm SYNTAX II Trial
(NCT02015832) uses the SSII to prospectively screen
the patients who can potentially be revascularized by
PCI with an equipoised prognosis of survival at 4-years
when compared to CABG.
However, the SSII does not contemplate all variables
that may influence the final choice of revascularization
strategy such as frailty, bleeding risk, or the preference
of the patient. The aim of the present interim report is
to assess the applicability of the SSII recommendations
in conjunction with the HT decision-making process
regarding the revascularization strategy in patients with
3-vessel CAD screened for the SYNTAX II trial, a
concept that has not yet been tested previously.
METHODS
The ongoing SYNTAX II Trial is a multicenter, all-
comers, open-label, single-arm trial that will recruit
450 patients with 3-vessel CAD in 25 European
interventional cardiology centers. All patients will be
selected and treated following the SYNTAX II strategy
described as follows: All patients will be treated with
the everolimus-eluting stent with biodegradable ablu-
minal coating (SYNERGY, Boston Scientific); the
lesions will be treated only after interrogation of ische-
mia with the use of pressure wire; intravascular ultra-
sound (IVUS) guidance to optimize drug-eluting stent
deployment, and the treatment of (chronic) total occlu-
sion lesions with contemporary techniques, and will be
compared with the PCI outcome of the original SYN-
TAX trial. The primary endpoint is the composite of
all-cause death; cerebrovascular event (stroke); docu-
mented myocardial infarction or all-cause revasculari-
zation at 1-year follow-up. Secondary endpoints
includes: (1) composite of all-cause death, cerebrovas-
cular event (stroke), documented myocardial infarction
(MI) at 1-year follow-up compared to the PCI arm of
SYNTAX I; (safety endpoint); (2) composite of cardio-
vascular death, documented target-vessel MI and repeat
target lesion revascularization at 1-year follow-up com-
pared to the PCI arm of SYNTAX I; (device oriented
clinical endpoint); (3) rates of individual components
of Major Adverse Cardiac and cerebrovascular event
(MACCE) (all-cause death, cerebrovascular event
(stroke), documented MI, and repeat revascularization)
at 1 year; (4) composite of MACCE rate and its indi-
vidual components at 2–5 years follow-up (patient
reported); (5) MI—according to Universal MI defini-
tion 2012 at all timepoints; (6) stent thrombosis—
according to ARC definitions at all timepoints; and (7)
retrospective validation of the residual SYNTAX score.
Patients were excluded, if: (1) Under the age of 21
years; (2) Known pregnancy at time of enrolment, (3)
Female of childbearing potential, and last menstruation
within the last 12 months, who are not taking adequate
contraceptives; (4) Female who is breastfeeding at time
of enrolment; (5) Prior PCI or CABG; (6) Ongoing
acute MI and enzymes (CKMB) more than 2 upper
limit of normal; (7) Concomitant cardiac valve disease
requiring surgical therapy, reconstruction, or replace-
ment; (8) Single or two-vessel disease at time of HT
consensus; (9) Participation or planned participation in
another cardiovascular clinical study before 1-year fol-
low-up is completed; (10) Mental condition, psychiatric
or organ cerebral disease, rendering the subject unable
to understand the nature, scope, and possible conse-
quences of the study or mental retardation or language
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barrier such that the patient is unable to give informed
consent and potential for non-compliance toward the
requirement in the study protocol.
The SYNTAX Score II and the Heart Team
Decision-Making Process
The SSII has been described in detail previously [8].
Briefly, SSII score uses two anatomical (anatomical SYN-
TAX score and presence of unprotected left main CAD)
and six clinical variables (age, creatinine clearance, left
ventricular ejection fraction, gender, chronic obstructive
pulmonary disease, and peripheral vascular disease) to pre-
dict 4-year mortality after revascularization with CABG or
PCI. The Cockcroft–Gault formula was used to estimate
the creatinine clearance [11]. The presence of COPD was
determined according to the EuroSCORE definition, as the
long-term use of bronchodilators or steroids for lung dis-
ease [12]. PVD was defined as one or more of the follow-
ing: claudication, carotid occlusion or >50% stenosis,
amputation for arterial disease or/and previous or planned
intervention on the abdominal aorta, limb arteries, or caro-
tids [13]. To mimic conventional clinical practice, investi-
gator reported anatomical SYNTAX Scores were used in
the analysis [14].
Using the actual baseline clinical and angiographic
data from every screened patient in the trial, SSII was
calculated for each patient using an electronic calcula-
tor available only to the investigators. In the assess-
ment of a single, individual patient, the SSII generates
different scores and distinct predicted mortalities
according to the potentially applied mode of revascu-
larization, percutaneous or surgical (Fig. 1). The SSII
recommends CABG if the difference in the predicted
mortality risk was in favor of CABG with 95% confi-
dence. The SSII recommends PCI if the difference in
mortality risk predictions was in favor of PCI with
95% confidence. Conversely, the SSII recommends
PCI or CABG if mortality risk predictions are within
the 95% confidence interval of the difference in mor-
tality risk predictions.
Aiming to quantify and compare the predicted mor-
tality risk between CABG and PCI, we calculated the
delta predicted 4-year mortality and the delta SSII as
follows:
Delta SYNTAX score II ¼ SYNTAX score II PCI
– SYNTAX score II CABG
Delta Predicted 4-year mortality %ð Þ
¼ Predicted 4-year mortality PCI %ð Þ
–Predicted 4-year mortality CABG %ð Þ
In the SYNTAX II trial, patients can be enrolled
only when the SSII shows an equipoised long-term
mortality risk prediction between CABG and PCI or
favors PCI. Having the SSII recommendation, each
patient is assessed by the HT as to whether “equivalent
anatomical revascularization” could be potentially
achieved between CABG and PCI. However, the HT
can overrule the SSII recommendation and preclude
the enrollment in the trial (Fig. 1).
Statistical Analysis
Categorical variables are presented as numbers and
percentages and are compared with the Chi-square test.
Continuous variables are expressed as mean�SD or
median with interquartile range (IQR), and are com-
pared using the Student’s t-test or Wilcoxon rank-sum
test based on their distributions. All statistical analyses
were performed using IBM SPSS Statistics for Win-
dows, Version 21.0 (IBM Corporation; Armonk, NY).
RESULTS
Table I depicts the SSII baseline demographics in
the SYNTAX II trial. From February 2014 to Novem-
ber 2014, 202 patients were screened in the SYNTAX
II trial. Overall the median age was 67 (interquartile
range [IQR] 59.0–73.3) years, 82.7% were male, 7.9%
had peripheral vascular disease, and 9.9% chronic ob-
structive pulmonary disease. Twenty-four patients
(11.9%) had exclusion criteria as listed in the Fig. 2
and were not enrolled in the study.
The SSII and the Heart Team Discussion
Figure 2 shows the current screening process of the
SYNTAX II trial. One hundred and seventy-eight
patients met the inclusion criteria of the SYNTAX II
trial and went through the HT assessment. The HT
endorsed the SSII recommendations in 152 patients
(85.4%). The HT decided for CABG in 25 patients
(14.1%) and these patients could not be enrolled in the
trial. A HT consensus could not be achieved in one
subject (0.5%) and the patient decided for PCI. In 43
patients, the SSII recommendation was CABG, the HT
agreed, but 2 subjects denied CABG and ultimately
underwent PCI. However, as the SYNTAX II trial
aims to recruit patients with 3-vessel disease based on
patient safety, the inclusion of these two patients was
retrospectively considered protocol violation. One
patient was considered as adequate for PCI by the
SSII, but allocated to CABG by the HT, but the patient
denied surgery and was ultimately enrolled in the trial.
There was a consensus to perform PCI in 109 (80.7%)
patients.
The reasons for the HT to choose CABG were:
CABG would provide a more complete revascularization
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subject (0.5%) and the patient decided for PCI. In 43
patients, the SSII recommendation was CABG, the HT
agreed, but 2 subjects denied CABG and ultimately
underwent PCI. However, as the SYNTAX II trial
aims to recruit patients with 3-vessel disease based on
patient safety, the inclusion of these two patients was
retrospectively considered protocol violation. One
patient was considered as adequate for PCI by the
SSII, but allocated to CABG by the HT, but the patient
denied surgery and was ultimately enrolled in the trial.
There was a consensus to perform PCI in 109 (80.7%)
patients.
The reasons for the HT to choose CABG were:
CABG would provide a more complete revascularization
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in 21 patients (83.3%); there was association of complex
coronary anatomy and diabetes in two patients (8.3%);
one patient had poor ventricular function (4.2%), and
one followed the advice of his clinical cardiologist
(4.2%).
Patients recommended to CABG by the SSII were
mostly female, had a significantly higher anatomical
complexity, and a higher predicted risk for PCI (delta
4-year predicted mortality¼PCI 4-year predicted mor-
tality�CABG 4-year predicted mortality]) (8.0% [5.5–
13.5]; P< 0.01) (Table I).
The comparison between the group of patients that
was enrolled in the trial and those who were excluded
by the HT is shown in Table I. Patients recommended
to CABG had significantly higher anatomical SYN-
TAX score (22, IQR: 18–27 versus 20, IQR: 16–24),
delta SYNTAX score II (SYNTAX score II
PCI�SYNTAX score II CABG; 2.1� 5.2 vs.
1.6� 5.2; P¼ 0.04) and a higher delta in the predicted
mortality favoring CABG in the overruled patients
(1.0%, IQR: 0.0–2.8% vs. 0.0, IQR: �1 to 2.0%;
P¼ 0.04).
DISCUSSION
The main findings of the present study can be sum-
marized as follows: (i) the SSII risk stratification dem-
onstrated to be an useful decision-making tool for
patients with complex coronary artery disease; (ii) the
SSII treatment recommendation was endorsed by the
Fig. 1. SYNTAX Score II calculator. In the SYNTAX II trial, the
HT uses an online electronic calculator to predict the risk of
each patient if they are submitted to coronary artery bypass
graft (CABG) or percutaneous coronary intervention (PCI). Af-
ter entering the angiographic and clinical characteristics the
calculator provides four outputs: SYNTAX score II PCI (points),
4-year predicted mortality if the patient is submitted to PCI;
SYNTAX score II CABG (points), and 4-year predicted mortal-
ity if the patient is submitted to CABG. The SYNTAX Score II
treatment recommendation is based on the difference in
these mortality predictions: CABG (right panel; A), PCI (right
panel; B), or CABG or PCI (right panel; C). The HT can overrule
the SYNTAX score II calculator but patients with CABG rec-
ommended by the SYNTAX score II cannot be enrolled in the
SYNTAX II trial. CrCl5creatinine clearance; LVEF5 left ven-
tricular ejection fraction; COPD5chronic obstructive pulmo-
nary disease; PVD5peripheral vascular disease;
SSII5SYNTAX Score II; MP5mortality prediction. [Color fig-
ure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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HT discussion in the large majority of the cases; (iii)
the main reason for the HT to overrule the SSII was
high anatomical complexity that would have preclude
more complete revascularization with CABG.
The Heart Team and the SSII
The concept of multidisciplinary teams is not new in
medicine and has been practiced in oncology, palliative
care, transplant medicine, and geriatric medicine
[15,16]. In cardiovascular medicine, multidisciplinary
teams are also established for heart failure and congeni-
tal heart diseases. Initially, this concept of multidiscipli-
nary “Heart-Team” was extended to coronary artery
disease in randomized trials comparing CABG with
medical therapy for stable CAD, to select patients eligi-
ble for randomization [17,18]. With the advances of PCI
techniques, interventional cardiologists and surgeons
started to increasingly target the same patients. This new
scenario has prompted them to work in close collabora-
tion to ensure the best evidence-based patient selection,
assuming clinical equipoise between treatments. The im-
portance of this multidisciplinary approach lies in the
fact that non-compliance to guidelines may result in
inappropriate revascularization [4,19].
Our study is the first report of the SSII implementa-
tion in the HT decision-making process, for stratifica-
tion of complex CAD [3]. We showed a high agreement
between the SSII treatment recommendation and the
HT final decision: only 18.5% of the patients for whom
the SSII considered PCI as reasonable revascularization
treatment underwent CABG and out of 43 patients rec-
ommended to CABG by the SSII only 2 (4.7%) under-
went PCI (Fig. 2). These findings highlight the
importance of the SSII that provides objective individ-
ual risk stratification in the decision making (Fig. 3).
Currently, the online calculator of the SSII is available
only to the investigators of the SYNTAX II trial. How-
ever, it will be available soon for other physicians that
may want to use it, as the online tool of the anatomical
SYNTAX score (www.syntaxscore.com).
The main reason for the HT to overrule the SSII was a
high anatomical complexity only amenable to CABG.
The complete revascularization takes into account the
operators experience and individual judicious judgment.
Indeed, in patients with complex CAD, the completeness
Fig. 2. Current screening of patients with complex coronary artery disease in the SYNTAX II
trial. PCI5percutaneous coronary intervention; CABG5coronary artery bypass graft;
SSII5SYNTAX score II; HT5Heart Team. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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of revascularization has proven to reduce late all-cause
mortality [20–23]. Specifically, total occlusion may play
an important role in this regard. Although, it did not
reach the statistical significance margin we could notice
a progressive increase in the number of total occlusions
in patients recommended to CABG by the Heart-Team
or the SSII (Table I).
Patient Information and the Decision Making
Process
Another key step in the process of decision-making
is adequate patient information. The process of medical
decision-making and patient information is guided by
the “four principles”: autonomy, beneficence, non-
maleficence, and justice [24]. Therefore, the informa-
tion provided needs to be unbiased, evidence-based,
up-to-date, reliable, accessible, relevant, and consistent
with legal requirements [3]. In our series, three patients
(4.4%) denied CABG when it was recommended by
the HT (n¼ 25) or the SSII (n¼ 43) (Fig. 2). The sec-
ond condition constituted a protocol violation since
patients recommended to CABG by the SSII can be
overruled (by the HT or patient will) and treated by
PCI, but not enrolled in the SYNTAX II trial. The
investigators were notified accordingly on this matter.
Fig. 3. Scatter plots showing SYNTAX Score II mortality pre-
dictions between (A) patients enrolled in the trial; (B) patients
in whom the HT overruled SYNTAX Score II treatment recom-
mendation; (C) patients who had SYNTAX Score II treatment
recommendation CABG. The dashed circles in (A) represent
patient that were recommended to CABG by the SYNTAX
score II but denied surgery. PCI5percutaneous coronary
intervention; CABG5coronary artery bypass graft; 4yMP5 4-
year mortality prediction; HT5Heart Team; SSII5SYNTAX
Score II. [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
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It has been shown that up to 68% of patients are not
aware of an alternative revascularization strategy [25]
and the SSII represents an advance in this matter as
well. Instead of a simplistic description of prognosis
according to an anatomical SYNTAX score tertile, the
SSII provides an individual estimation of long-term
prognosis for each revascularization strategy, helping
to better enlighten the patient [26,27].
Innovations of the SYNTAX II Trial
The SYNTAX II trial has been enrolling patients
with 3-vessel coronary artery disease in the light of the
most recent evidence-based medical practices: (a)
establishment of revascularization appropriateness on
the grounds of HT discussion using the SYNTAX II
score; (b) ischemia-driven revascularization based on
pressure guidewire interrogation; (c) use of a second
generation drug-eluting stent (DES) with thin struts
and biodegradable matrix; (d) DES deployment guided
by intracoronary imaging; and (e) treatment at centers
with expertise in chronic total oclusion (CTO) recanali-
zation. As shown in Fig. 4, although the SYNTAX II
trial has been enrolling only 3-vessel CAD, the selec-
tion of the patient for appropriate PCI based on SSII
generates a population with a combined lower anatomi-
cal and clinical risk profile than in the original SYN-
TAX trial. In other words, there exists a 3-vessel
patient population—to be carefully identified—that
could benefit at long-term from percutaneous revascu-
larization. Beyond the anatomical and clinical selection
of the patients, the ischemic driven treatment optimized
Fig. 4. Distribution and comparison of (A) anatomical SYNTAX Score and (B) SYNTAX score
II PCI, between the current enrolment in the SYNTAX II trial and the previous SYNTAX trial
(PCI 3-vessel disease cohort) [5]. Patients that have been included in the SYNTAX II trial have
lower risk to percutaneous coronary intervention as assessed by the SSII as well as by ana-
tomical SYNTAX score. IQR5 interquartile range. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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by intravascular ultrasound is expected to further
improve the patient outcomes. Needless to say that the
3rd generation DES used in this trial will abrogate
many of the drawbacks of the first generation.
Limitations
The SSII, as all other risk scores implemented in
medical guidelines [3], does not contemplates all indi-
vidual procedural outcomes such as relief of angina,
quality of life, stroke, and potential need for late re-
intervention. Therefore, it is important to inform these
long-term risks and benefits to the patient. However,
the use of long-term all-cause mortality as goal permits
a reproducible endpoint not subject to adjudication bias
or definitional variation.
CONCLUSION
The SYNTAX score II showed to be a suitable tool
for guiding treatment decisions of patients with
3-vessel coronary artery disease being endorsed by the
HT in the vast majority of the patients that have been
enrolled in the SYNTAX II trial.
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vance in PCI technology has been scrutinized and compared 
against CABG, generating debate as to whether a patient should 
be referred to CABG or PCI, with advantages for one or the 
other depending on context.4–10 Therefore, the accurate risk 
estimation of multivessel CAD remains a fundamental step in 
the decision-making process.11
Presently, for patients with ULMCA or complex CAD, the 
prevailing guidelines recommend a multidisciplinary approach 
referred to as the heart team.12,13 These guidelines also advise 
ercutaneous coronary intervention (PCI), until recently, 
has been considered a class III indication (ie, poten-
tially harmful) for patients with unprotected left main 
(ULMCA) and 3-vessel coronary artery disease (CAD).1,2 Cor-
onary artery bypass grafting (CABG) has been the standard 
treatment for these patients with complex CAD for more than 
50 years. Over the last decade, PCI has undergone a number 
of technical and technological advancements and hence has 
challenged the superiority of CABG.3 Consequently, every ad-
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Predictive Performance of SYNTAX Score II in Patients 
With Left Main and Multivessel Coronary Artery Disease
– Analysis of CREDO-Kyoto Registry –
Carlos M. Campos, MD; David van Klaveren; Javaid Iqbal, MD, PhD; Yoshinobu Onuma, MD, PhD;  
Yao-Jun Zhang, MD, PhD; Hector M. Garcia-Garcia, MD, PhD; Marie-Angele Morel, BSc;  
Vasim Farooq, MD, PhD; Hiroki Shiomi, MD; Yutaka Furukawa, MD; Yoshihisa Nakagawa, MD;  
Kazushige Kadota, MD; Pedro A. Lemos, MD, PhD; Takeshi Kimura, MD;  
Ewout W. Steyerberg, PhD; Patrick W. Serruys, MD, PhD
Background: SYNTAX score II (SSII) provides individualized estimates of 4-year mortality after coronary artery 
bypass grafting (CABG) and percutaneous coronary intervention (PCI) in order to facilitate decision-making between 
these revascularization methods. The purpose of the present study was to assess SSII in a real-world multicenter 
registry with distinct regional and epidemiological characteristics.
Methods and Results: Long-term mortality was analyzed in 3,896 patients undergoing PCI (n=2,190) or CABG 
(n=1,796) from the Coronary REvascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) PCI/CABG 
registry cohort-2. SSII discriminated well in both CABG and PCI patient groups (concordance index [c-index], 0.70; 
95% CI: 0.68–0.72; and 0.75, 95% CI: 0.72–0.78) surpassing anatomical SYNTAX score (SS; c-index, 0.50; 95% 
CI: 0.47–0.53; and 0.59, 95% CI: 0.57–0.61). SSII had the best discriminative ability to separate low-, medium- and 
high-risk tertiles, and calibration plots showed good predictive performance for CABG and PCI groups. Use of ana-
tomical SS as a reference improved the overall reclassification provided by SSII, with a net reclassification index of 
0.5 (P<0.01).
Conclusions: SSII has robust prognostic accuracy, both in CABG and in PCI patient groups and, compared with 
the anatomical SS alone, was more accurate in stratifying patients for late mortality in a real-world complex coronary 
artery disease Eastern population.
Key Words: Coronary artery bypass grafting; Percutaneous coronary intervention; Risk stratification; SYNTAX 
score; SYNTAX score II
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systemic atherosclerosis and therefore are at greater longer-
term cardiovascular risk.16 This score has not been assessed in 
an Eastern population with complex 3-vessel CAD.
The purpose of the present study was therefore to assess 
SSII in patients with 3-vessel and/or ULMCA disease in a 
real-world multicenter registry with distinct regional and epi-
demiological characteristics.
Methods
Subjects
The Coronary REvascularization Demonstrating Outcome Study 
in Kyoto (CREDO-Kyoto) PCI/CABG registry cohort-2 has 
been previously described in detail.17 Briefly, this was a phy-
sician-initiated non-industry-sponsored multicenter registry en-
rolling consecutive patients undergoing first coronary revascu-
larization among 26 centers in Japan between January 2005 
and December 2007. The relevant ethics committees in all 
participating centers approved the research protocol. Because 
of retrospective enrolment, written informed consent from the 
the heart team to use synergy between PCI with taxus and 
cardiac surgery (SYNTAX) score alone or combined with the 
Society of Thoracic Surgeons (STS) score as a tool to make an 
objective risk stratification.12,13 The SYNTAX score II (SSII) 
has been recently developed by applying a Cox proportional 
hazards model to the results of the SYNTAX trial, obtaining 
a combination of clinical and anatomical predictors.9,14 Given 
that the SSII has been derived from an all-comers randomized 
trial of PCI vs. CABG, it has the potential to assess individual 
risk estimation between these revascularization strategies and 
facilitate multidisciplinary decision-making.
SSII has been shown to provide reliable predictions of 4-year 
mortality for complex CAD in an external validation of the 
Drug Eluting stent for LefT main coronary Artery disease 
(DELTA) registry.14,15 The DELTA registry consisted of pre-
dominantly Western patients with ULMCA disease. In patients 
with 3-vessel disease and no left main involvement, however, 
SYNTAX score (SS) would represent more complex down-
stream coronary anatomical disease. This may be a signal of a 
more adverse risk profile, in patients who have evidence of 
Figure 1.  SYNTAX score II nomo-
gram for bedside application. 
Total number of points for 8 factors 
can be used to accurately predict 
4-year mortality for the individual 
patient preparing to undergo 
CABG or PCI. 3VD, 3-vessel dis-
ease; CABG, coronary artery by-
pass grafting; COPD, chronic ob-
structive pulmonary disease; CrCl, 
creatinine clearance; left main, 
unprotected left main coronary ar-
tery disease; LVEF, left ventricular 
ejection fraction; PCI, percutaneous 
coronary intervention; PVD, periph-
eral vascular disease. (Adapted 
with permission from Farooq V, et 
al.14)
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taken using an imputation strategy that takes into account the 
correlation between all potential predictors. To obtain 4-year 
mortality predictions based on anatomical SS alone, Cox logis-
tic regression analysis was used with anatomical SS as a sole 
linear predictor.
SSII for PCI (in patients undergoing PCI) and for CABG (in 
patients undergoing CABG) was evaluated using 4 metrics: 
c-statistics; calibration plots; reclassification tables; and net 
reclassification index (NRI). Outcome was analyzed using 
Kaplan-Meier curves with a 4-year time horizon. Discrimina-
tion was studied with the concordance index (c-index).18 Cal-
ibration was assessed by plotting the observed 4-year mortal-
ity by quintiles of the predicted 4-year mortality.19 Comparison 
between the anatomical and II SYNTAX scores was further 
quantified using a reclassification table and its NRI.20,21 The 
NRI uses reclassification tables constructed separately for 
participants with and without events, and quantifies the correct 
movement in categories: upwards for events and downwards 
for non-events as follows: NRI=([percentage of events moved 
to higher risk category in event group]−[percentage of events 
moved to lower risk category in event group])−([percentage of 
non-events moved to higher risk category in non-event group]−
[percentage of non-events moved to lower risk category in non-
event group]). Given that not all persons had follow-up com-
pleted to 4 years, the present reclassification was based on the 
expected number of case and control patients calculated using 
the Kaplan-Meier estimator.21 All statistical analysis was done 
using IBM SPSS Statistics for Windows, version 21.0 (IBM, 
Armonk, NY, USA).
patients was waived, excluding those patients who refused 
participation in the study when contacted for follow-up.
Among 15,939 patients enrolled in the registry, 3,986 par-
ticipants had 3-vessel and/or ULMCA and were included in 
current analyses.
SSII
The SSII has been described in detail previously.14 Briefly, 
SSII uses the 2 anatomical variables (anatomical SS and 
ULMCA disease) and 6 clinical variables (age, creatinine 
clearance, left ventricular ejection fraction [LVEF], sex, chron-
ic obstructive pulmonary disease, and peripheral vascular dis-
ease) to predict 4-year mortality after revascularization with 
CABG or PCI. 
For the present study, SSII was calculated using a nomogram, 
with scores assigned for the presence and magnitude of each 
predictor directly based on the Cox proportional hazards model 
coefficients (Figure 1), generating different scores for PCI and 
CABG.14 The 4-year mortality estimates were obtained in ac-
cordance with the revascularization procedure that each pa-
tient underwent: PCI or CABG.
Statistical Analysis
Categorical variables are presented as numbers and percentages 
and were compared using the chi-squared test. Continuous 
variables are expressed as mean ± SD or median with inter-
quartile range (IQR), and were compared using Student’s t-test 
or Wilcoxon rank-sum test based on their distributions.
SSII predictor data were all present in at least 90% of the 
patients. Multiple imputation (5×) of missing data was under-
Table 1. Subject Baseline Characteristics
PCI (n=2,190) CABG (n=1,796) P-value
Clinical caracteristics
  Age (years) 71 (63–77)　　　 70 (63–75)　　　 <0.01
  Male 1,554 (71)　　　　　　 1,336 (74.4)　　　 　0.02
  BMI 23.7 (21.5–25.8) 23.3 (21.1–25.8) <0.01
  Diabetes 1,066 (48.7)　　　 935 (52.1) 　0.03
    On insulin therapy 287 (13.1) 309 (17.2) <0.01
  Hypertension 1,907 (87.1)　　　 1,514 (84.3)　　　 　0.01
  Current smoking 541 (24.7) 437 (24.3) 　0.79
  Heart failure 454 (20.7) 387 (21.5) 　0.53
  Prior MI 415 (18.9) 396 (22)　　　 　0.02
  Prior symptomatic stroke 346 (15.8) 248 (13.8) 　0.08
  Hemodialysis 124 (5.7)　　 119 (6.6)　　 　0.21
  COPD 70 (3.2) 60 (3.3) 1
  PVD 227 (12.6) 256 (11.7) 　0.36
  Ejection fraction (%) 60 (50–67)　　　 60 (49–68)　　　 　0.85
  Creatinine clearance (mg/dl) 61.7 (44.2–80.9) 61.4 (43.7–78.9) 　0.22
Procedural characteristics
  CAD extension <0.01
    3-vessel disease 1,825 (83.3)　　　 1,156 (64.4)　　　
    LM isolated 57 (3.2) 31 (1.4)
    LM and 1-vessel disease 89 (4.1) 108 (6)　　　　　
    LM and 2-vessel disease 132 (6)　　　　　 182 (10.1)
    LM and 3-vessel disease 113 (5.2)　　 293 (16.3)
  SYNTAX score 24 (17–30)　　　 29 (23–37)　　　 <0.01
Data given as median (IQR) or n (%).
BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstruc-
tive pulmonary disease; LM, left main; MI, myocardial infarction; PCI, percutaneous coronary intervention; PVD, 
peripheral vascular disease.
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Figure 2.  Kaplan-Meier curves for tertiles of ana-
tomical SYNTAX score and SYNTAX score II for the 
percutaneous coronary intervention (PCI) and 
coronary artery bypass grafting (CABG) groups.
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Figure 2.  Kaplan-Meier curves for tertiles of ana-
tomical SYNTAX score and SYNTAX score II for the 
percutaneous coronary intervention (PCI) and 
coronary artery bypass grafting (CABG) groups.
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Patients in the PCI group were older, and more often had hy-
pertension, while patients in the CABG group more often had 
smaller body mass index, diabetes and prior myocardial in-
farction. Participants treated with CABG had more complex 
anatomical characteristics and a higher prevalence of associ-
ated ULMCA-triple vessel disease and higher anatomical SS. 
Results
Patient Characteristics
Out of 3,986 patients included in the current study, 2,190 pa-
tients received PCI and 1,796 patients underwent CABG. 
Baseline characteristics of these patients are listed in Table 1. 
Figure 3.  Calibration plots comparing (red circles) anatomical SYNTAX score against (green triangles) SYNTAX score II for the 
percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) groups.
Table 2. Reclassification Table: 4-Year Mortality Risk Strata‡
PCI and CABG cohorts Predicted mortality by SS
Predicted mortality by SSII
<5% >5–10% >10% Total
0–5%
  Persons included 　    0*  0  0  0
  Death 　    0*  0  0  0
  Survival 　    0*  0  0  0
  Observed risk (%)‡‡ 　    0*  0  0  0
>5–10%
  Persons included 778 　678*　　　 1,128　　　　　　 2,584　　　　　　
  Death 　　     28.0††   　57.0* 　270.7† 355.7
  Survival 　   750.0§ 　621.0* 　　857.3** 2,228.3　　　
  Observed risk (%)‡‡        3.6     　8.4*   24.0   13.8
>10%
  Persons included 359 365　　　 　678*　　　 1,402　　　　　　
  Death 　　     19.0†† 　　  29.2†† 　183.7* 232.0
  Survival 　   340.0§ 　335.8§ 　494.3* 1,170.0　　　
  Observed risk (%)‡‡        5.3     8.0   　27.1*   16.5
Total
  Persons included 1,137　　　 1,043　　　　　　 1,806　　　　　　 3,986　　　　　　
  Death      47.0   86.2 454.5 587.6
  Survival 1,090.0 956.8 1,351.5　　　 3,398.4　　　
  Observed risk (%)‡‡        4.1     8.3   25.2   14.7
*Patients classified as having the same risk by both scores; **patients classified as having higher risk by SSII who 
survived; †patients classified as having higher risk by SSII who died; ††patients classified as having lower risk by SSII 
who died; §patients classified as having lower risk by SSII who died survived.
‡For patients who died the SSII reclassification improved by 33% whereas in non-event patients the reclassification 
improved by 16.7%. The net reclassification index was 0.5 (P<0.01). ‡‡Estimated from the Kaplan-Meier curve using 
observations in each cell.
SS, SYNTAX score; SSII, SYNTAX score II. Other abbreviations as in Table 1.
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score, subtracting, from a better risk grouping, a penalty if it 
lowers the estimated risk category of a patient with event or 
raises the estimated risk category of a patient without event. 
The overall NRI of 0.5 (P<0.01) indicates that 50% of patients 
had a net better classification for higher and lower risk catego-
ries using the SSII vs. the anatomical SS. Also, when reclas-
sified separately for type of revascularization – PCI or CABG 
– the reclassification of SSII was more accurate, indicating its 
potential as an integrated prediction tool (Table S1). Group-
ing patients in tertiles according to SSII, a separation of the 
Kaplan-Meier curves for the occurrence of deaths is evident 
(Figure 2). The same approach for anatomical SS showed a 
poor risk stratification (Figure 2).
Previously, SSII was predominantly evaluated in Western 
patients.15 Therefore, doubts may have existed over the utility 
of this tool in other populations. The present analysis confirms 
the potential to apply this model globally, given that we have 
now validated it in a population with unique epidemiological 
characteristics. Japan has the longest life expectancy at birth 
worldwide and a substantially lower proportion of mortality 
from cardiovascular diseases, compared with Western coun-
tries.29,30 Despite recent changes in the lifestyle and dietary 
habits of Japanese people, the incidence of myocardial infarc-
tion in Japan is still much lower than in other industrialized 
countries.31,32 Furthermore, even after revascularization – by 
either PCI or CABG – Japanese patients have been shown to 
have better long-term outcomes than US patients33 and, regard-
ing PCI, a significantly lower definite stent thrombosis than in 
Western countries.34 All the aforementioned reasons could 
suggest that a score developed and validated mainly in Western 
populations may be less appropriate for global use. In the present 
cohort SSII discriminated well in both CABG and PCI patient 
groups (c-index, 0.70; 95% CI: 0.68–0.72 and 0.75, 95% CI: 
0.72–0.78, respectively), a performance similar to its internal 
(c-index, 0.72) and external validations (DELTA registry; c-
index, 0.71) in mainly Western patients.
Once more, the SSII predictions were consistent despite the 
fact that it does not include in its model diabetes mellitus. This 
could be questioned as a paradox because in the exclusively 
diabetic patients of the FREEDOM trial, CABG was superior 
to PCI by significantly reducing rates of death and myocardial 
infarction.10 Diabetes, however, was not a useful variable in 
the SSII, despite medically treated diabetes being stratified at 
randomization in the SYNTAX trial and reported in 26% of 
patients. Numerous arguments might explain this apparent di-
vergence. First, diabetes was not an independent predictor of 
mortality in the SYNTAX trial.35 Second, diabetes did not have 
an interaction effect (P=0.67) with CABG or PCI for long-
term mortality.14 Diabetes is a systemic disease, the severity 
and duration of which have a specific effect on organs such as 
the heart (detected on complex coronary anatomy and LVEF); 
peripheral vascular disease (a sign of systemic atherosclero-
sis); kidney (detected on creatinine clearance); and age (older 
patients are representative of a longer diabetes multi-organ 
effect). These arguments may be exemplified by a large popu-
lation-based cohort study and meta-analysis involving 128,505 
individuals with diabetes in which patients without diabetes but 
with chronic kidney disease and proteinuria had a stronger as-
sociation with risk of myocardial infarction, and a higher rate 
of mortality, compared with those with diabetes.36
Finally, it must be acknowledged that no risk-scoring system 
is perfect and that careful multidisciplinary clinical reasoning 
remains vital for decision-making.11 SSII, however, can be a 
useful instrument in this process.
Overall Kaplan-Meier estimated mortality at 4-year follow-up 
was 14.7% (15.9% for PCI and 12.6% for CABG).
Predictive Performance of SSII
Discrimination  The c-index of SSII was 0.70 (95% CI: 
0.68–0.72) in the CABG group and 0.75 (95% CI: 0.72–078) 
in the PCI group. On comparison of discrimination, anatomi-
cal SYNTAX showed a significant improvement for CABG 
and PCI groups (c-index, 0.50; 95% CI: 0.47–0.53 and 0.59, 
95% CI: 0.57–0.61; respectively). Additionally, the SSII model 
was able to separate low-, medium- and high-risk tertiles bet-
ter than anatomical SS for both groups (Figure 2).
Calibration  The validation plots (Figure 3) of SSII indi-
cated a reasonably good agreement between the observed and 
predicted risks for both the CABG and PCI groups. The ana-
tomical SS showed disparity between predicted and observed 
mortality.
Reclassification  Reclassification for all patients (both PCI 
and CABG patient groups), with and without events is summa-
rized in Table 2. SSII showed a significant improvement in risk 
stratification (NRI, 0.5; P<0.01). This was also observed when 
analyzing the PCI and CABG groups separately (Table S1).
Discussion
In this study, SSII was assessed in a large all-comers registry 
of Eastern patients with predominantly high-risk CAD. The 
findings can be summarized as follows: (1) SSII showed agree-
ment between observed outcomes and predictions; (2) the met-
rics used showed similar risk stratification for both treatment 
cohorts (PCI and CABG); and (3) SSII substantially improved 
the predictive accuracy of long-term mortality predictions if 
compared with the anatomical SS alone.
SSII was developed from comparison between CABG and 
PCI in the SYNTAX trial.14 Its concept permits the composi-
tion of 1 single score to predict – based on randomized data 
– mortality if a patient is assigned to either CABG or PCI. 
Indeed, in the present study, SSII had similar and consistent 
predictive performance for both revascularization strategies in 
a real world population. In contrast, the current guidelines ad-
vise the heart team to use the anatomical SS alone or combined 
with the STS score as a tool to make objective risk stratifica-
tion in the decision-making process between CABG and PCI.12,13 
This concept, however, does not allow unified risk assessment. 
The anatomical SS has prognostic relevance only for patients 
assigned to PCI.9,19,22 Despite the fact that the STS score has 
been widely used for risk stratification in cardiac surgery,23–25 
it was not formally validated as a predictive tool for PCI.
The metrics used to perform the present analysis reinforce 
the importance of comprehensive assessment with a combina-
tion of angiographic and key clinical characteristics for patients 
with complex CAD.26 SSII had a significantly higher accuracy 
compared to anatomical SS for all-cause death measured by 
the c-statistic. It has been argued, however, that c-statistic is 
insensitive to systematic errors in calibration such as differences 
in average outcome.20,27 Therefore, we studied calibration using 
a graphical representation where predicted risk matched ob-
served risk. In this comparison the SSII also had a more re-
fined pattern (Figure 2). Indeed, a better discriminating model 
has more spread between quintiles of predicted risk than a 
poorly discriminating model.20,28
Additionally, it is important for risk prediction as to wheth-
er a model can accurately stratify individuals into higher or lower 
risk categories. Therefore, we used the methodology described 
previously,20,21 which balances the reclassification of a new 
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score, subtracting, from a better risk grouping, a penalty if it 
lowers the estimated risk category of a patient with event or 
raises the estimated risk category of a patient without event. 
The overall NRI of 0.5 (P<0.01) indicates that 50% of patients 
had a net better classification for higher and lower risk catego-
ries using the SSII vs. the anatomical SS. Also, when reclas-
sified separately for type of revascularization – PCI or CABG 
– the reclassification of SSII was more accurate, indicating its 
potential as an integrated prediction tool (Table S1). Group-
ing patients in tertiles according to SSII, a separation of the 
Kaplan-Meier curves for the occurrence of deaths is evident 
(Figure 2). The same approach for anatomical SS showed a 
poor risk stratification (Figure 2).
Previously, SSII was predominantly evaluated in Western 
patients.15 Therefore, doubts may have existed over the utility 
of this tool in other populations. The present analysis confirms 
the potential to apply this model globally, given that we have 
now validated it in a population with unique epidemiological 
characteristics. Japan has the longest life expectancy at birth 
worldwide and a substantially lower proportion of mortality 
from cardiovascular diseases, compared with Western coun-
tries.29,30 Despite recent changes in the lifestyle and dietary 
habits of Japanese people, the incidence of myocardial infarc-
tion in Japan is still much lower than in other industrialized 
countries.31,32 Furthermore, even after revascularization – by 
either PCI or CABG – Japanese patients have been shown to 
have better long-term outcomes than US patients33 and, regard-
ing PCI, a significantly lower definite stent thrombosis than in 
Western countries.34 All the aforementioned reasons could 
suggest that a score developed and validated mainly in Western 
populations may be less appropriate for global use. In the present 
cohort SSII discriminated well in both CABG and PCI patient 
groups (c-index, 0.70; 95% CI: 0.68–0.72 and 0.75, 95% CI: 
0.72–0.78, respectively), a performance similar to its internal 
(c-index, 0.72) and external validations (DELTA registry; c-
index, 0.71) in mainly Western patients.
Once more, the SSII predictions were consistent despite the 
fact that it does not include in its model diabetes mellitus. This 
could be questioned as a paradox because in the exclusively 
diabetic patients of the FREEDOM trial, CABG was superior 
to PCI by significantly reducing rates of death and myocardial 
infarction.10 Diabetes, however, was not a useful variable in 
the SSII, despite medically treated diabetes being stratified at 
randomization in the SYNTAX trial and reported in 26% of 
patients. Numerous arguments might explain this apparent di-
vergence. First, diabetes was not an independent predictor of 
mortality in the SYNTAX trial.35 Second, diabetes did not have 
an interaction effect (P=0.67) with CABG or PCI for long-
term mortality.14 Diabetes is a systemic disease, the severity 
and duration of which have a specific effect on organs such as 
the heart (detected on complex coronary anatomy and LVEF); 
peripheral vascular disease (a sign of systemic atherosclero-
sis); kidney (detected on creatinine clearance); and age (older 
patients are representative of a longer diabetes multi-organ 
effect). These arguments may be exemplified by a large popu-
lation-based cohort study and meta-analysis involving 128,505 
individuals with diabetes in which patients without diabetes but 
with chronic kidney disease and proteinuria had a stronger as-
sociation with risk of myocardial infarction, and a higher rate 
of mortality, compared with those with diabetes.36
Finally, it must be acknowledged that no risk-scoring system 
is perfect and that careful multidisciplinary clinical reasoning 
remains vital for decision-making.11 SSII, however, can be a 
useful instrument in this process.
Overall Kaplan-Meier estimated mortality at 4-year follow-up 
was 14.7% (15.9% for PCI and 12.6% for CABG).
Predictive Performance of SSII
Discrimination  The c-index of SSII was 0.70 (95% CI: 
0.68–0.72) in the CABG group and 0.75 (95% CI: 0.72–078) 
in the PCI group. On comparison of discrimination, anatomi-
cal SYNTAX showed a significant improvement for CABG 
and PCI groups (c-index, 0.50; 95% CI: 0.47–0.53 and 0.59, 
95% CI: 0.57–0.61; respectively). Additionally, the SSII model 
was able to separate low-, medium- and high-risk tertiles bet-
ter than anatomical SS for both groups (Figure 2).
Calibration  The validation plots (Figure 3) of SSII indi-
cated a reasonably good agreement between the observed and 
predicted risks for both the CABG and PCI groups. The ana-
tomical SS showed disparity between predicted and observed 
mortality.
Reclassification  Reclassification for all patients (both PCI 
and CABG patient groups), with and without events is summa-
rized in Table 2. SSII showed a significant improvement in risk 
stratification (NRI, 0.5; P<0.01). This was also observed when 
analyzing the PCI and CABG groups separately (Table S1).
Discussion
In this study, SSII was assessed in a large all-comers registry 
of Eastern patients with predominantly high-risk CAD. The 
findings can be summarized as follows: (1) SSII showed agree-
ment between observed outcomes and predictions; (2) the met-
rics used showed similar risk stratification for both treatment 
cohorts (PCI and CABG); and (3) SSII substantially improved 
the predictive accuracy of long-term mortality predictions if 
compared with the anatomical SS alone.
SSII was developed from comparison between CABG and 
PCI in the SYNTAX trial.14 Its concept permits the composi-
tion of 1 single score to predict – based on randomized data 
– mortality if a patient is assigned to either CABG or PCI. 
Indeed, in the present study, SSII had similar and consistent 
predictive performance for both revascularization strategies in 
a real world population. In contrast, the current guidelines ad-
vise the heart team to use the anatomical SS alone or combined 
with the STS score as a tool to make objective risk stratifica-
tion in the decision-making process between CABG and PCI.12,13 
This concept, however, does not allow unified risk assessment. 
The anatomical SS has prognostic relevance only for patients 
assigned to PCI.9,19,22 Despite the fact that the STS score has 
been widely used for risk stratification in cardiac surgery,23–25 
it was not formally validated as a predictive tool for PCI.
The metrics used to perform the present analysis reinforce 
the importance of comprehensive assessment with a combina-
tion of angiographic and key clinical characteristics for patients 
with complex CAD.26 SSII had a significantly higher accuracy 
compared to anatomical SS for all-cause death measured by 
the c-statistic. It has been argued, however, that c-statistic is 
insensitive to systematic errors in calibration such as differences 
in average outcome.20,27 Therefore, we studied calibration using 
a graphical representation where predicted risk matched ob-
served risk. In this comparison the SSII also had a more re-
fined pattern (Figure 2). Indeed, a better discriminating model 
has more spread between quintiles of predicted risk than a 
poorly discriminating model.20,28
Additionally, it is important for risk prediction as to wheth-
er a model can accurately stratify individuals into higher or lower 
risk categories. Therefore, we used the methodology described 
previously,20,21 which balances the reclassification of a new 
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eluting stenting for the treatment of left main and/or three-vessel 
disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 2011; 
32: 2125 – 2134.
20. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Eval-
uating the added predictive ability of a new marker: From area under 
the ROC curve to reclassification and beyond. Stat Med 2008; 27: 
157 – 172; discussion 207 – 212.
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22. Shiomi H, Tamura T, Niki S, Tada T, Tazaki J, Toma M, et al. Inter- 
and intra-observer variability for assessment of the synergy between 
percutaneous coronary intervention with TAXUS and cardiac sur-
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Study Limitations
This study has the inherent limitations of a retrospective anal-
ysis. The ultimate goal of SSII is to assist the heart team in the 
decision-making process between CABG and PCI.37 Thus, a 
prospective study would be needed to achieve true validation 
of SSII, where the decision between CABG and PCI is random-
ized. The present analysis, being retrospective, cannot assess 
the treatment recommendation based on SSII for the simple fact 
that the decision was likely made based on a combination of 
measured variables (as included in SSII) and unmeasured vari-
ables (eg, bleeding risk, duration of dual antiplatelet therapy, 
frailty etc). Presently, validation of SSII is a pre-specified end-
point in the ongoing randomized EXCEL trial (NCT01205776), 
and SYNTAX trial II, which will use SSII to recruit partici-
pants based on patient safety. In the latest trial, functional le-
sion assessment was added to improve late PCI outcomes and 
it is plausible that this approach may improve the discrimina-
tion of anatomical SS.38
In the PCI cohort of the CREDO-Kyoto registry patients 
were treated mainly with first-generation drug-eluting stent 
(DES). It is possible that its performance will be affected by 
the use of newer generation DES. SSII, however, focuses on 
4-year overall mortality, an outcome that, apparently, is not 
affected by the type of stent used. For instance, in a recent 
meta-analysis of 20 clinical trials that included 20,005 patients, 
stent type did not alter the overall mortality, unlike late-lumen 
loss and stent thrombosis rate.39 Therefore, we do not expect 
that the type of DES prescribed will affect the predictions 
made by the PCI model of SSII.
Conclusions
SSII has robust prognostic accuracy, both in CABG and PCI 
patient groups and – compared with the anatomical SS alone 
– was able to stratify patients for late mortality in a real-world 
complex CAD Eastern population.
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Objectives: To assess the clinical profile and long-termmortality in SYNTAX score II based strata of patients who
received percutaneous coronary interventions (PCI) in contemporary randomized trials.
Background: The SYNTAX score II was developed in the randomized, all-comers' SYNTAX trial population and is
composed by 2 anatomical and 6 clinical variables. The interaction of these variableswith the treatment provides
individual long-termmortality predictions if a patient undergoes coronary artery bypass grafting (CABG) or PCI.
Methods: Patient-level (n = 5433) data from 7 contemporary coronary drug-eluting stent (DES) trials were
pooled. The mortality for CABG or PCI was estimated for every patient. The difference in mortality estimates
for these two revascularization strategies was used to divide the patients into three groups of theoretical treat-
ment recommendations: PCI, CABG or PCI/CABG (the latter means equipoise between CABG and PCI for long
term mortality).
Results: The three groups hadmarked differences in their baseline characteristics. According to the predicted risk
differences, 5115 patients could be treated either by PCI or CABG, 271 should be treated only by PCI and, rarely,
CABG (n = 47) was recommended. At 3-year follow-up, according to the SYNTAX score II recommendations,
patients recommended for CABG had higher mortality compared to the PCI and PCI/CABG groups (17.4%; 6.1%
and 5.3%, respectively; P b 0.01).
Conclusions: The SYNTAX score II demonstrated capability to help in stratifying PCI procedures.
© 2015 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
The SYNTAX score [1–3] was developed for the randomized com-
parison of coronary artery bypass grafting (CABG) versus percutaneous
coronary intervention (PCI) in the Percutaneous Coronary Intervention
with Taxus and Cardiac Surgery (SYNTAX) trial [2]. The SYNTAX score
provides objective quantification on the diseased coronary artery
segment in terms of its severity, anatomical location and importance
in supplying blood to the myocardium. Based on the results of the
SYNTAX trial [2,4,5] the SYNTAX score has been implemented as a wa-
tershed between CABG and PCI in prevailing guidelines [6,7]. However,
the SYNTAX score cannot account for the effect related to clinical factors
which arewidely acknowledged to impact on long-termoutcomes, such
as a patients' age, left ventricular ejection fraction, and renal function
[8–10].
Recently, the SYNTAX score II was developed by applying a Cox pro-
portional hazardsmodel to the SYNTAX trial data. A combination of clin-
ical and anatomical predictors [5,11], together with their interaction
with the treatment modality (CABG or PCI), enables estimation of the
absolute risk difference between CABG and PCI and has the potential
to assist the multidisciplinary decision-making process between these
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two strategies. The SYNTAX score II has been shown to provide reliable
predictions of 4-year mortality for complex coronary artery disease,
being externally applied inmore than 10,000 patients and implemented
in the most recent international guidelines [11–14].
We aim to assess the stratification by the SYNTAX score II theoretical
treatment recommendation in heterogeneous patients treatedwith PCI.
Additionally, we intend to evaluate the predictive performance of the
SYNTAX score II in recent randomized trials in different clinical scenar-
ios using different types of stents.
2. Methods
2.1. Study population
We pooled 7 contemporary coronary drug-eluting stent (DES)
trials for which the independent core lab analysis assessment of
SYNTAX scores were available: ARTS II (Arterial Revascularization
Therapies Study II) trial, STRATEGY (Single High-Dose Bolus Tirofiban
and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in
Myocardial Infarction) trial, EXCELLA II (Elixir Medical Clinical Evaluation
of the Novolimus-Eluting Coronary Stent System) trial, LEADERS
(Limus Eluted From a Durable Versus Erodable Stent Coating) trial,
MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus
Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal
Stent in Acute Myocardial Infarction) trial, RESOLUTE (Resolute All
Comers) trial, and SIRTAX (Sirolimus-Eluting Stent Compared With
Paclitaxel-Eluting Stent for Coronary Revascularization) [15–21]. Detailed
individual study design and trial results are available elsewhere. In brief,
all studies included patients with obstructive coronary artery disease
(CAD) that was amendable to coronary stent implantation. Study inclu-
sion criteria were deliberately heterogeneous ranging from low risk PCI
to studies with an all-comers' design (Supplementary Table 1).
2.2. SYNTAX score II
The recent SYNTAX score II has been described in detail previously
[11]. Briefly, the SYNTAX score II consists of 2 anatomical (unprotected
leftmain coronary artery disease and anatomical SYNTAX score) and six
clinical variables (age, creatinine clearance, left ventricular ejection frac-
tion, sex, chronic obstructive pulmonary disease, and peripheral vascu-
lar disease).
Using the actual baseline clinical and angiographic data from each
enrolled patient the SYNTAX score II was calculated for each patient.
The SYNTAX score II generates different scores and distinct estimated
mortalities for PCI and CABG. Patients were theoretically recommended
for CABG if the difference in the predictedmortality riskwas in favour of
CABG with 95% confidence. Patients were theoretically recommended
for PCI if the difference in mortality risk predictions was in favour
of PCI with 95% confidence. In addition, patients were classified as PCI/
CABG if zero (equal risk predictions) was within the 95% confidence in-
terval of the difference in mortality risk predictions.
2.3. Data analysis
Categorical variables are presented as numbers and percentages
and are compared with the Chi-square test. Continuous variables are
expressed as mean ± SD or median with interquartile range (IQR),
and are compared using the Student's t-test or Wilcoxon rank-sum
test based on their distributions. The long-termmortalitywas compared
amongst the aforementioned three groups using the log rank test for
Kaplan–Meier estimates. All statistical analyses were done with IBM
SPSS Statistics for Windows, Version 21.0 (IBM Corporation, Armonk,
NY).
3. Results
As shown in Table 1, pooled data from the seven trials contained
5433 patients with a mean age 63.3 ± 10.8 years, 75.3% were male,
21.8% had diabetes mellitus, 56.8% presented acute coronary syndrome
and the mean body mass index was 27.52 ± 4.1. The mean creatinine
clearance was 92.1 ± 36.2 mg/dl, ejection fraction 56 ± 11.1% and
SYNTAX score 14.2 ± 9.1. There were 399 deaths (6.3%) over 3-year
follow-up.
3.1. Treatment recommendation and long term mortality
According to the SYNTAX score II recommendations, 5115 patients
could have undergone either CABG or PCI, 271 should have been treated
exclusively by PCI and 47 by CABG (Table 1). There was a substantial
heterogeneity between groups. The PCI recommended group was
older, with better ejection fraction, higher prevalence of COPD and
lower anatomical SYNTAX score. On the contrary, patients theoretically
recommended to CABG (but treated by PCI)were youngermale patients
with higher anatomical SYNTAX, lower ejection fraction and 17% had
peripheral vascular disease. After 3 years of follow-up the mortality
(Fig. 1) was significantly higher in the CABG recommended group treat-
ed with PCI and mortality curves were similar for PCI and CABG/PCI
groups (17.4%; 5.3% and 6.1%, respectively P b 0.01). Fig. 2 shows the
cumulative distribution of the anatomical SYNTAX score according to
the treatment recommendation. Although there was clear impact on
the treatment recommendations – since the anatomical SYNTAX score
is one of the components of the SYNTAX score II – there were patients
Table 1
Baseline characteristics.
Total
N = 5433
PCI
N = 271
CABG or PCI
N = 5115
CABG
N = 47
P
Male, % 75.3 70 79 100 b0.01
Age, years ± SD 63.33 ± 10.83 74.19 ± 6.32 62.84 ± 10.67 53.97 ± 12.14 b0.01
Hypertension, % 68.5 84.1 67.9 51.1 b0.01
Diabetes, % 21.8 26.9 21.6 17 0.09
BMI ± SD 27.52 ± 4.1 28.72 ± 5.08 27.47 ± 4.04 25.58 ± 3.38 b0.01
Acute coronary syndromes, % 56.8 41 57.5 72.3 b0.01
Family history premature CAD, % 33.2 32.5 33.2 40.4 0.55
Previous TIA/CVA, % 1.9 3 1.8 4.3 0.21
Hyperlipidemia, % 63.2 67.2 63.1 53.2 0.145
COPD, % 5.7 16.2 5.1 0 b0.01
PVD, % 4 7.7 3.7 17 b0.01
Current smokers, % 32.4 18.8 32.9 53.2 b0.01
Previous PCI, % 24.8 29.2 24.4 34 0.07
Previous MI, % 27.5 18.1 27.8 40.1 b0.01
Creatinine Cl, ml/min ± SD 92.16 ± 36.24 81.63 ± 66.74 92.78 ± 33.7 85.82 ± 43.41 b0.01
LVEF, % ± SD 56.07 ± 11.1 61.29 ± 7.85 55.99 ± 10.99 34.09 ± 9.66 b0.01
SYNTAX score ± SD 14.21 ± 9.12 7.68 ± 5.10 14.42 ± 9.03 29.28 ± 10.84 b0.01
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with low anatomical SYNTAX score (b22) recommended to CABG and
patients with high (N33) where PCI could be considered.
4. Discussion
The data presented in this paper can be summarized as follows:
(1) the SYNTAX score II based treatment recommendation for CABG
was an uncommon finding in contemporary DES trials and (2) the
SYNTAX score II showed clinical relevance through its ability to identify
patients at higher risk for PCI.
4.1. PCI prescription based on SYNTAX score II
The ultimate goal of the SYNTAX score II is not only the isolated risk
prediction for PCI or CABG [22]. As aforementioned, this score was de-
veloped in a randomized comparison between CABG andPCI to evaluate
the interactions of risk factors that could help in the decision making
process between these revascularization strategies [11,22]. In these
contemporary PCI trials the SYNTAX score II recommendation for
CABG was present in only 47 patients (0.9% of total). The exclusively
PCI suggestionwasmade in 271 (4.98%). Put into perspective with pop-
ulations with complex CAD (Table 2), the treatment recommendations
for CABG and PCI amongst the 3-vessel disease group in the SYNTAX
trial were, respectively, 40.7% and 0.5% (the remaining 58.8% was in
the CABG or PCI). For the left main cohort 11.5% was recommended to
have CABG and 8.8% PCI [11]. The difference in these proportions of
treatment recommendations confirms that the present group has a
lower risk profile for PCI when compared to the SYNTAX trial.
The divergence of mortality curves, showing disadvantage for the
CABG recommended group, was observed from onset of follow-up. It
may be argued that these patients have higher mortality as they have
worse left ventricular function and a higher SYNTAX score. On the
Fig. 1. Long-term survival probability according to SYNTAX score II treatment recommendations.
Fig. 2.Distribution of anatomical SYNTAX score according to the Theoretical Treatment Recommendation provided by the SYNTAX score II. Despite the SYNTAX score having a clear impact
on recommendations, there were patients with low SYNTAX score (b22) recommended to CABG and patients with high (N33) SYNTAX score where PCI could be considered.
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other hand these patients were, on average, almost 20 years younger
than patients in the PCI recommended group. In fact, this is the argu-
ment that strengthens this analysis: to balance clinical and angiographic
characteristics, identifying deltas of individual risk to distinguishing
patients who could potentially have higher or lower benefit with PCI
(Supplementary Figs. 1–3).
The SYNTAX score II interactions showed that some anatomical
and clinical characteristics could have different impact in the type of
treatment (CABG or PCI). This gives the clinician vital information for
decision making: i.e., younger age favours CABG, older age favours PCI,
COPD favours PCI, lower creatinine clearance favours CABG, unprotect-
ed left main coronary artery disease favours PCI, higher SYNTAX scores
favours CABG, lower SYNTAX scores favours PCI and female gender
favours CABG [11]. Interestingly, in the present paper all patients that
theoretically selected for CABG were male. This can be explained by
the high risk profile for PCI of this population that overruled gender:
mean ejection fraction 34.09± 9.66, age 53.97± 12.14 and anatomical
SYNTAX score 29.28 ± 10.84.
It must be acknowledged that no risk scoring system is perfect
and careful multidisciplinary clinical reasoning remains vital for the
decision-making process [23]. The heart team decision has to be sover-
eign over the SYNTAX score II since the latter does not assess numerous
variables that are present in clinical practice as, for instance, frailty and
emergency procedures. Although itwould be tempting to assert that the
CABG recommended patients treated by PCI should go to CABG, we can-
not state that based only on the present findings. It has to be reinforced
that we do not have a CABG control group to establish definitive com-
parisons. However, these findings highlight the importance of a com-
prehensive patient evaluation and not only a simplistic angiographic-
based PCI prescription (Fig. 2). The higher clinical complexity of patients
recommended to CABGmay indicate individuals that deservemeticulous
revascularization plan, using established strategies that may improve re-
sults and minimize the risks: e.g., intravascular ultrasound guided PCI
[24,25], careful judgement of the chances to obtain complete revasculari-
zation [26], closemonitoring of optimalmedical treatment and adherence
[27,28], and minimize the risk of bleeding [29]. On the other hand, the
event rates for patients recommended to PCI and CABG/PCIwere relative-
ly low (6.1 and 5.3%, respectively).
5. Limitations
This study has the inherent limitations of a not pre-specified retro-
spective analysis. As previously discussed, the ultimate objective of the
SYNTAX score II is to assist the heart team in the decision-making pro-
cess between CABG and PCI [22]. Thus true validation of the SYNTAX
score II would require a prospective study where the decision between
CABG and PCI is done randomly. The present study, being retrospective,
cannot assess the treatment recommendation based on the SYNTAX
score II for the simple fact that the decision was made based on the
inclusion criteria of each PCI trial, not having a CABG control group,
which limits the complete interpretation of the outcomes. Presently,
the validation of the SYNTAX score II has been prospectively applied
in the ongoing randomized EXCEL trial (NCT01205776) [12], and the
ongoing SYNTAX II trial whichwill use the SYNTAX score II to recruit par-
ticipants based on patient safety (SYNTAX II trial lacks a CABGarm). How-
ever, we have shown consistently in a large controlled cohort that this
tool can help to stratify PCI in clinical practice.
6. Conclusions
The SYNTAX score II demonstrated solid predictive performance and
aptness to help in stratifying and prescribing PCI procedures.
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InTRoDUCTIon
Over the last few decades the optimal revas-
cularisation modality of patients with complex 
coronary artery disease has been coronary 
artery bypass graft (CABG) surgery. However, 
percutaneous coronary intervention (PCI) has 
experienced a large number of technical and 
technological improvements, and hence, has 
challenged the superiority of CABG. Recent 
studies have shown that in certain groups 
of patients, PCI may be a safe and effective 
alternative (1-3).
The widespread adoption of PCI has led to 
the need for evidence-based clinical tools 
to aid decision-making on the most optimal 
revascularisation modality in patients with 
complex coronary artery disease (CAD). One 
of the first clinical tools to objectively deter-
mine which patients with complex CAD were 
suitable for PCI or CABG was the anatomical 
SYNTAX Score (4,5). The anatomical SYNTAX 
Score is an angiographic-based tool that al-
lows for the objective quantification of the 
complexity of CAD (4,5,6,7). However, the 
anatomical SYNTAX Score does not incorporate 
clinical factors, which are widely confirmed 
to impact on mid- and long-term outcomes 
(8,9,10), and therefore influence on decision-
making between CABG and PCI (11,12,13). In 
addition, the anatomical SYNTAX Score does 
not provide an individualised risk assessment 
due to the fact that patients are grouped into 
three risk groups.
Recently, the SYNTAX Score II was developed 
by applying a cox proportional hazards model 
to the results of all-comers, randomised SYN-
TAX Trial (10). This score unifies the anatomical 
SYNTAX Score with six clinical variables to 
form a single score for CABG and PCI, and 
gives long-term mortality predictions for 
individual patient following CABG or PCI to aid 
decision-making by the Heart Team, composed 
of at least one interventional cardiologist, one 
cardiac surgeon and one clinical cardiologist, 
as recommended in the European Society of 
Cardiology (ESC) guidelines on myocardial re-
vascularisation (14). However, recent literature 
suggests that the Heart Team concept is not 
systematically implemented in daily practice 
(15,16) or even inappropriately applied in 
patients with stable CAD (17,18).
Every cardiologist being interventional and 
clinical has dilemmas if CABG or PCI was the 
right decision, especially in case of complica-
tions that may strike their self-confidence on 
the knowledge and clinical skills. Very often 
asked by the patients, cardiologists today are 
struggling to find out the best myocardial 
revascularisation modality for their patients.
The purpose of the present study was to in-
vestigate whether indications for PCI or CABG 
based on the most educated intuitive judg-
ment of PCI-operators without cardiac surgery 
on-site in routine clinical practice (without a 
Heart Team evaluation) in the era before the 
SYNTAX Score II approximate to the treatment 
recommendation of the recently published 
SYNTAX Score II. Our working hypothesis was 
that the SYNTAX Score II could help in better 
guiding myocardial revascularisation if it 
would have existed at the time of treatment, 
and is superior to the approach based on 
oculostenotic reflex which might be corrected 
by using a unique and organised system that 
SYNTAX Score II proposes.
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MeTHoDS
Database and study population
Between January 1, 2008, and May 30, 2010 
patients from the University Hospital Clinical 
Centre Banja Luka, Bosnia and Herzegovina 
were retrospectively recruited using the hospi-
tal information system. The study group com-
prised consecutive, hemodynamically stable 
patients with angiographically proven 3-vessel 
CAD (≥50% diameter stenosis) or significant 
unprotected left main coronary artery (ULMCA) 
disease (≥50% diameter stenosis), who were 
treated locally with PCI or referred to other 
institutions abroad for CABG. The research 
protocol was approved by the relevant local 
ethics committee. Due to the retrospective 
nature of the study, written informed consent 
from the patients was waived, excluding those 
who refused participation in the study when 
contacted for follow-up.
Baseline angiographic and demographic 
characteristics were prospectively entered into 
a dedicated database. Patients with ST segment 
elevation myocardial infarction, previous CABG 
or PCI, terminal illnesses with projected life 
expectancy less than one year or patients with 
need for concomitant cardiac surgery were 
excluded from the study. All-cause mortality 
was ascertained by telephone contacts.
SYnTAX Score II
The SYNTAX Score II consists of eight variables, 
two anatomical (anatomical SYNTAX Score and 
ULMCA disease) and six clinical (age, creatinine 
clearance, left ventricular ejection fraction 
[LVEF]), gender, chronic obstructive pulmonary 
disease [COPD] and peripheral vascular disease 
[PVD]). The SYNTAX Score has been described 
in detail previously (4). In brief, the anatomical 
SYNTAX Score is derived from the summation 
of the individual scorings for each separate 
lesion (defined as 50% diameter stenosis in 
vessel larger than 1.5 mm). For each patient, 
the anatomical SYNTAX Score calculation was 
based on the initial diagnostic angiogram and 
was calculated using the SYNTAX Score calcula-
tor available online (www.syntaxscore.com).
Estimated glomerular filtration rate (eGFR) 
was calculated using the Cockcroft-Gault for-
mula (21). LVEF was assessed by transthoracic 
echocardiography. COPD was defined as the 
long-term use of bronchodilators or steroids 
for lung disease (EuroSCORE definition [22]). 
PVD was defined as one or more of the follow-
ing: claudication, carotid occlusion or >50% 
diameter stenosis, amputation for arterial 
disease or/and previous or planned interven-
tion on the abdominal aorta, limb arteries or 
carotids (Arterial Revascularisation Therapies 
Study Part I definition [23]).
Using the aforementioned data the SYNTAX 
Score II was calculated for each patient using an 
electronic calculator available only to the inves-
tigators of the SYNTAX II Trial. The SYNTAX Score 
II generates scores for PCI and CABG, and provides 
estimated all-cause mortality predictions follow-
ing CABG or PCI to aid the Heart Team in decision-
making on the most appropriate revascularisation 
modality. Patients were recommended for CABG if 
the difference in the predicted mortality risk was 
in favour of CABG with 95% confidence. Patients 
were recommended for PCI if the difference in 
mortality risk predictions was in favour of PCI 
with 95% confidence. In addition, patients were 
recommended for CABG or PCI if the predicted 
mortalities could not be separated with 95% 
confidence.
Statistical analysis
Categorical variables are presented as numbers 
and percentages and compared using the chi-
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square test. Continuous variables are expressed 
as mean with standard deviation (SD) or median 
with inter-quartile range (IQR) and compared 
using a Student T test or Mann-Whitney U test 
according to the data distribution. The differ-
ences between revascularisation modality 
recommendations were analysed using a chi-
square test. Differences in outcomes were ana-
lysed using Kaplan-Meier estimates at 4-year 
follow-up and compared with the log rank test. 
All statistical analyses were performed using 
IBM SPSS Statistics for Macintosh, version 21.0 
(IBM, Armonk, NY, USA).
ReSUlTS
Patients characteristics
Using the hospital information system, 3122 
consecutive patients were screened and 2562 
elected not to follow the inclusion criteria. 
Out of 560 patients included in this study, 
362 (64.6%) patients underwent PCI and 198 
(35.4) patients were referred to other institu-
tions abroad for CABG (Figure 1). The mean age 
was 60.5±9.1 years, 73.0% were men, 81.6% 
had 3-vessel CAD and 18.4% ULMCA disease. 
Baseline characteristics of the study population 
classified according to the performed treat-
ment modality are listed in Table 1. Patients in 
whom CABG was performed were more likely 
to be older, to have diabetes mellitus, arterial 
hypertension and more complex anatomical 
characteristics (higher anatomical SYNTAX 
scores) as well as a higher eGFR, compared to 
patients treated with PCI.
Comparison of clinical judgment 
and SYnTAX Score II treatment 
recommendation
Based on the SYNTAX Score II assessments, 
CABG was shown to be the treatment of choice 
in 232/560 (41.4%) patients, PCI in 3/560 
(0.6%) patients and CABG or PCI in 325/560 
(58.0%) patients (Table 2).
figure 1. Study flow chart.
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As shown in Table  2, 232 patients had 
treatment recommendations by the SYNTAX 
Score II for CABG, of which 99/232 (42.7%) 
patients had actually CABG, with the remain-
der (133/232, 57.3%) undergoing PCI. Three 
patients had SYNTAX Score II recommenda-
tions exclusively favouring PCI, 2/3 patients 
(66.7%) were treated with PCI and 1/3 
patients (33.3%) underwent CABG. Further, 
325 patients had SYNTAX Score II recom-
mendations favouring CABG or PCI, 98/325 
(30.2%) underwent CABG and 227/325 
(69.8%) underwent PCI.
The discordance between clinical judg-
ments and SYNTAX Score II recommendations 
was mainly evident in patients treated with 
PCI. Comparisons of baseline characteristics 
of patients treated with PCI stratified accord-
ing to treatment recommendation provided 
by the SYNTAX score II are listed in Table 3. The 
PCI recommended patients by the SYNTAX 
Score II were significantly older, had greater 
left ventricular function and eGFR, were more 
likely to be male, have COPD and less complex 
CAD expressed thought anatomical SYNTAX 
score. In contrary, patients recommended by 
the SYNTAX Score II to CABG (but treated with 
PCI) were younger, more likely to be female 
patients with higher anatomical SYNTAX, 
lower ejection fraction and less likely to have 
COPD.
As shown in Figure 2, patients treated with 
PCI in whom the SYNTAX Score II recommen-
dation was CABG, had a significantly higher 
SYNTAX Score II compared to patients with 
concordant recommendation (median [IQR]: 
Table 1. Baseline characteristics according to the actual performed revascularisation modality (CABG 
or PCI) (n=560).
Revascularisation performed according to the clinical judgment of the 
interventional cardiologists
CABG n=198 PCI n=362 P-value (2-tailed)
Age 62.3 ± 8.3 59.0 ± 9.6 < 0.001
Male 179 (90.4%) 296 (81.8%) 0.82
Diabetes on medical therapy 103 (52.0%) 108 (29.8%) < 0.001
History of hypercholesterinemia 160 (80.8%) 261 (72.1%) 0.68
History of hypertension 192 (97.0%) 295 (81.5%) 0.011
Smoking history 95 (48.0%) 184 (50.8%) 0.12
familiar history of CAD 116 (58.6%) 166 (45.9%) 0.087
History of heart failure 10 (5.1%) 14 (3.9%) 0.32
Previous MI 42 (21.2%) 85 (23.5%) 0.31
Previous stroke 14 (7.1%) 17 (4.7%) 0.16
CoPD 9 (4.5%) 21 (5.8%) 0.39
PVD 31 (15.7%) 40 (11.1%) 0.25
lVef 54.5 (45.0-60.0) 55.0 (45.0-60.0) 0.037
eGFR (ml/min) 89.5 (76.0-97.3) 83.0 (70.8-95.0) 0.006
lM 82 (41.4%) 21 (5.8%) < 0.001
Anatomical SYnTAX Score 33.8 (26.0-43.1) 17.0 (10.0-24.0) < 0.001
Data given as n (%) or mean ± SD or median (IQR). CAD, coronary artery disease; MI, myocardial infarction; COPD, 
chronic obstructive pulmonary disease; PVD, peripheral vascular disease; LVEF, left ventricular ejection fraction; CrCl, 
creatinine clearance; LM, left main; SYNTAX, Synergy between percutaneous coronary intervention with Taxus and 
cardiac surgery; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
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33.4 [27.9-42.1], median [IQR]: 24.3 [19.0-
30.2]), respectively, P<0.01), suggesting a 
higher risk of death if PCI was performed.
SYnTAX Score II and Mortality 
outcome
Overall mortality in the entire cohort of 560 
patients at 4-year follow-up was 8.4%. Signifi-
cantly higher all-cause mortality was shown in 
the CABG recommended group treated with 
PCI compared with CABG/PCI and PCI recom-
mended group treated with PCI (12.8% vs. 
4.7% vs. 0.0%, respectively, log rank P=0.04, 
Figure 3).
Table 2. Concordance or discordance between SYNTAX score II recommendation of revascularisation 
strategy (CABG or PCI) and the clinical judgment of the interventional cardiologists (chi square P<0.001).
SYnTAX II recommendation
Revascularisation performed according to the clinical judgment of the 
interventional cardiologists
CAbG PCI Total
CAbG 99/560 (17.7%) 133/560 (23.8%) 232/560 (41.4%)
PCI 1/560 (0.2%) 2/560 (0.4%) 3/560 (0.6%)
CAbG or PCI 98/560 (17.5%) 227/560 (40.5%) 325/560 (58.0%)
Total 198/560 (35.4%) 362/560 (64.6%) 560 (100%)
green: concordance between clinical judgment and SYNTAX score II recommendation;
red: discordance between clinical judgment and SYNTAX score II recommendation;
orange: equipoise of 4-year mortality between CABG and PCI (based on comparisons of mortality predictions not 
separated with 95% confidence).
Table 3. Comparisons of baseline characteristics of patients treated with PCI stratified according to 
treatment recommendation provided by the SYNTAX score II.
Total
n=362
CAbG
n=133
CAbG or PCI
n=227
PCI
n=2 P-value
Age 59.0 ± 9.6 58.1 ± 9.3 59.4 ± 9.6 76.5 ± 2.1 0.02
Male, % 72.9 38.3 93.0 100.0 <0.01
Diabetes on medical therapy, 
%
26.5 28.6 25.6 0.0 0.57
History of 
hypercholesterinemia, %
61.3 65.4 59.0 50.0 0.46
History of hypertension, % 71.3 72.9 70.5 50.0 0.71
Smoking history, % 44.5 44.4 44.5 50.0 0.99
Familiar history of CAD, % 39.8 39.8 39.6 50.0 0.96
COPD, % 5.2 1.5 7.0 50.0 <0.01
PVD, % 9.7 7.5 11.0 0.0 0.50
lVef 52.3 (45.0-60.0)50.0 (40.0-60.0)55.0 (50.0-60.0)54.5 (54.0-) < 0.01
eGFR (ml/min) 83.1 ± 20.3 76.7 ± 17.3 86.8 ± 21.0 93.5 ± 10.6 < 0.01
LM, % 5.2 3.8 5.7 50.0 0.01
SYnTAX Score 18.1 (10.0-24.0)21.0 (14.0-30.0)13.0 (11.0-20.0)23.5 (23.0-) < 0.01
Data given as mean ± standard deviation, % or median (IQR). CAD, coronary artery disease; COPD, chronic obstructive 
pulmonary disease; PVD, peripheral vascular disease; LVEF, left ventricular ejection fraction; CrCl, creatinine clearance; 
LM, left main; SYNTAX, Synergy between percutaneous coronary intervention with Taxus and CABG.
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DISCUSSIon
The main findings of the present study are: 1. 
The clinical judgment of PCI-operators without 
evaluation by the Heart Team deviated in 1/3 
of the total population from the treatment 
modality recommended by the SYNTAX Score 
II; 2. The most striking deviation of 57% was 
noted in patients in whom SYNTAX Score II 
exclusively recommended CABG; 3. When 
stratified according to the SYNTAX Score II 
recommendation, patients treated with PCI 
in concordance with SYNTAX Score II treatment 
recommendation had different baseline char-
acteristics from the patients with discordant 
treatment; 4. Within PCI group, patients in 
whom SYNTAX score II exclusively recom-
mended CABG showed higher mortality at 4 
years compared to patients with concordant 
decision-making.
Unilateral decision-making
In spite of the fact that almost every tertiary 
referral hospital in Europe is equipped with 
cardiac surgery, University Hospital Clinical 
Centre Banja Luka in Bosnia and Herzegovi-
na – the largest tertiary care institution in Re-
publika Srpska, Bosnia and Herzegovina – has a 
high volume catheterisation laboratory (1500 
procedures/year performing 400 PCIs/year) 
without cardiac surgery facilities being avail-
able in the country. Due to Republika Srpska’s 
political and economic conditions being a 
country in transition, and the fact that surgical 
myocardial revascularisation is not possible 
in the country, the choice of the method of 
revascularisation is left to the clinical judg-
ment of the local PCI-operators without the 
consensus of a local Heart Team. The current 
study retrospectively reviewed in this hospital 
the revascularisation recommendations based 
on the SYNTAX Score II.
This is the first review of its kind to evaluate 
SYNTAX Score II treatment recommendation 
in “real world” population confronted with 
conditions which are far away from those in de-
veloped countries. Results of the present study 
demonstrated that only 42.7% of patients with 
estimated mortality predictions by the SYNTAX 
Score II clearly in favour of CABG were referred 
figure 2. Cumulative percentage distribution of 
the SYNTAX Scores II (PCI) between SYNTAX Score 
II recommendation of revascularisation strategy 
in study population treated with PCI.
figure 3. Comparisons of observed mortality at 4 
years (Kaplan-Meier estimates and log-rank com-
parisons) in patients treated with PCI classified 
by SYNTAX Score II recommendation of revascu-
larisation strategy (CABG; PCI; CABG or PCI).
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to other institutions for CABG, whereas the 
remaining patients with CABG recommenda-
tion were treated locally with PCI. It is strongly 
comparable with findings of Hannan et al. (15) 
that interventional cardiologists in United 
States followed guideline recommendations 
regarding CABG in only 53% of patients (43% 
in our study with follow-up of 4 years despite 
the differences in size, economical strength and 
living standard between USA and Bosnia and 
Herzegovina). In the present study, patients 
with discordant decision-making not only had a 
higher mortality at 4 years, but also significantly 
higher SYNTAX Score II, thus demonstrating the 
robust predictive ability of the SYNTAX Score 
II. In addition, the present study highlights the 
need for a multidisciplinary Heart Team ap-
proach to prevent unilateral decision-making 
on the most appropriate revascularisation 
modality (14,16).
Multidisciplinary decision-making improved 
patients outcome and is recommended in se-
lecting the most appropriate treatment strat-
egy for individual patients with stable complex 
CAD (14,16). Despite the fact that the so-called 
“Heart Team” concept was introduced in 2010, 
it has not yet been widely implemented, lead-
ing to suboptimal decision-making as well as 
to inappropriate revascularisation (14-17). 
Recently published studies presented a large 
variability in PCI-to-CABG ratios between 
centres, which may predominantly be the 
consequence of physician-related factors 
(16, 27, 28). Our study investigated an ideal 
experimental population treated by strong 
independent interventional cardiologists 
without a Heart Team available. We believe 
that this study could encourage PCI-centres 
without cardiac surgery on-site to provide an 
evaluation of the Heart Team and to apply the 
SYNTAX Score II in patients with complex CAD.
Performance of the SYnTAX Score II
The SYNTAX Score II has been developed 
in the landmark, all-comers, randomised 
SYNTAX (Synergy between percutaneous 
coronary intervention with Taxus and cardiac 
surgery) trial (10) and externally validated in 
a total number of 8,405 patients from three 
large multicenter registries (10,19,20). The 
SYNTAX Score II showed a robust predictive 
performance with a high discriminatory 
ability. Moreover, the most recent ESC/EACTS 
guidelines on myocardial revascularisation 
(14) have endorsed the implementation of the 
SYNTAX Score II (Class IIa; Level of evidence 
B) in decision-making process between CABG 
and PCI. Therefore, our work represents an 
retrospective application of the SYNTAX score 
II in the clinical practice investigating whether 
the intuitive decision-making by interven-
tional cardiologists is enough as good. The 
advantage of this approach is that all-cause 
mortality is not subject to any adjucation bias. 
Moreover, it is an endpoint hardly influenced 
by the recent advances in cardiology. As it 
was well summarised by Stephen S. Gottlieb 
“Dead is dead—artificial definitions are no 
substitute” (29).
Ultimate goal of the SYnTAX Score II
The SYNTAX score II provides not only the 
long-term mortality prediction after PCI or 
CABG, but also offers a unique treatment rec-
ommendation taking into account complexity 
of CAD and 6 clinical factors (10). As afore-
mentioned, this score could assist the Heart 
Team in the decision-making process between 
two revascularization strategies (10,19,20). In 
the recently published pooled analysis from 
7 contemporary PCI trials (n=5,433) authors 
stratified patients according to the SYNTAX 
score II recommendation, and concluded, 
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similarly to the present study, that patients 
with discordant treatment had significantly 
higher mortality at 3 years (CABG: 17.4%; PCI: 
5.3% and CABG/PCI: 6.1% [24]).
Our findings are similar to the results from 
which the SYNTAX Score II was derived (10) 
and underline the concept that the decision 
between CABG and PCI in complex CAD should, 
in addition to anatomical characteristics, 
balance the clinical characteristics that may 
favour one therapy over the other. Using the 
SYNTAX Score II, younger age, female gender 
and reduced LVEF were shown to favour CABG 
compared to PCI on long-term mortality. 
Hence, in such patients a lower anatomical 
SYNTAX Score would be required in order for 
the long-term mortality risk to be similar be-
tween CABG and PCI. Nevertheless, older age, 
COPD or significant ULMCA disease favoured 
PCI compared to CABG. Thus, in this type of 
patient, a higher anatomical SYNTAX Score 
would be needed for the long-term mortality 
risks to be similar.
Finally, the present study, although limited 
due to small sample size, showed clearly 
benefit for patients treated with PCI in concor-
dance with SYNTAX Score II recommendation. 
On the other hand, patients recommended for 
CABG (but treated with PCI) presented not only 
higher mortality at 4 years, but were younger 
making this analysis even more important.
limitations
Firstly, the study has an unavoidable limita-
tion on account of its retrospective nature. 
Currently the on-going EXCEL (Evaluation 
of XIENCE PRIME™ or XIENCE V® Everolimus 
Eluting Stent System Versus Coronary Artery 
Bypass Surgery for Effectiveness of Left Main 
Revascularisation) trial (25) and SYNTAX II trial 
(26) will better quantify the performance of 
the SYNTAX Score II. Our study, being retro-
spective and based on the metrics used in the 
SYNTAX Score II, cannot assess other reasons 
that PCI-operators without on-site cardiac 
surgery used in making decisions. There is no 
data regarding other variables that may guide 
clinicians in the decision-making process, such 
as bleeding risk, frailty or socioeconomic rea-
sons including a total CABG-cost for patients 
in another country. The value of the study is 
also limited due to the small sample size and 
single-centre analysis.
ConClUSIon
The present study demonstrated that intuitive 
(most educated) decision-making process 
by interventional cardiologists for choosing 
optimal myocardial revascularisation method 
for individual patient (CABG or PCI) differed in 
57% from the SYNTAX Score II recommenda-
tion for CABG only. Discordance between the 
SYNTAX Score II recommended revascularisa-
tion strategy and the clinical decision was 
met with a higher long-term 4-year mortality. 
Therefore, it appears that the SYNTAX Score 
II may potentially ameliorate traditional 
oculostenotic reflex triggering inappropriate 
PCI, and serve as a surrogate of objective Heart 
Team decision-making in PCI centres without 
cardiac surgery on-site.
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Cost-Effectiveness of Percutaneous Coronary 
Intervention vs. Bypass Surgery from a Dutch 
Perspective
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Patrick W. Serruys, Carlos M. Campos, Kaijun Wang, David van Klaveren, 
Vasim Farooq, Mouin S. Abdallah, Haiyan Li, Katherine A. Vilain, Ewout W. Steyerberg, 
Marie-Claude Morice, Keith D. Dawkins, Friedrich W. Mohr, A. Pieter Kappetein, 
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AbSTRACT
Aims. Recent cost-effectiveness analyses of percutaneous coronary intervention (PCI) vs. 
coronary artery bypass grafting (CABG) have been limited by a short time-horizon or were 
restricted to the U.S. healthcare perspective. We therefore used individual patient-level data 
from the SYNTAX trial to evaluate the cost-effectiveness of PCI vs. CABG from a European (Dutch) 
perspective.
Methods and results. Between 2005 and 2007, 1800 patients with three-vessel or left main 
CAD were randomized to either CABG (n=897) or PCI with drug-eluting stents (DES;n=903). Costs 
were estimated for all patients based on observed healthcare resource utilisation over 5 years of 
follow-up. Health state utilities were evaluated with the EuroQOL questionnaire. A patient-level 
microsimulation model based on Dutch life-tables was used to extrapolate the 5-year in-trial 
data to a lifetime horizon.
Although initial procedural costs were lower for CABG, total initial hospitalisation costs per 
patient were higher (€17506 vs. €14037, p<0.001). PCI was more costly during the next 5 years 
of follow-up, due to more frequent hospitalisations, repeat revascularisation procedures, and 
higher medication costs. Nevertheless, total 5 year costs remained €2465/patient higher with 
CABG. When the in-trial results were extrapolated to a lifetime horizon, CABG was projected to 
be economically attractive relative to DES-PCI, with gains in both life expectancy and quality-
adjusted life expectancy. The incremental cost-effectiveness ratio (€5390/QALY gained) was 
favourable and remained <€80000/QALY in >90% of the bootstrap replicates. Outcomes were 
similar when incorporating the prognostic impact of non-fatal MI and stroke, as well as across 
a broad range of assumptions regarding the effect of CABG on post-trial survival and costs. 
However, DES-PCI was economically dominant compared with CABG in patients with a SYNTAX 
Score ≤22 or in those with left main disease. In patients for whom the SYNTAX Score II favoured 
PCI based on lower predicted 4 year mortality, PCI was also economically dominant, whereas in 
those patients for whom the SYNTAX Score II favoured surgery, CABG was highly economically 
attractive (ICER range, €2967 to €3737/QALY gained).
Conclusions. For the broad population with three-vessel or left main disease who are candidates 
for either CABG or PCI, we found that CABG is a clinically and economically attractive revascularisa-
tion strategy compared with DES-PCI from a Dutch healthcare perspective. The cost-effectiveness 
of CABG vs. PCI differed according to several anatomic factors, however. The newly developed 
SYNTAX Score II provides enhanced prognostic discrimination in this population and may be a 
useful tool to guide resource allocation as well.
Trial registration: Clinical trial unique identifier: NCT00114972 (www.clinical-trials.gov)
Keywords: Coronary artery bypass grafting; drug-eluting stents; percutaneous coronary 
intervention; cost-benefit analysis; randomized clinical trial
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InTRoDUCTIon
Approximately 2% of the total healthcare 
expenditure in the European Union is spent on 
the treatment of coronary artery disease (CAD).
[1] Percutaneous coronary intervention (PCI) 
and coronary artery bypass grafting (CABG) 
for multivessel CAD have been compared in 
several studies. For patients without diabetes 
mellitus, these studies have demonstrated 
similar short- and long-term survival with 
either procedure, but CABG provided better 
angina relief and fewer repeat revascularisa-
tion procedures.[2, 3, 4, 5, 6, 7, 8] Long-term 
economic evaluations have found that while 
PCI is cost-saving in the short term, CABG is 
an economically attractive treatment option 
compared with balloon angioplasty or PCI 
using bare metal stents.[9]
The Synergy between PCI with TAXUS and 
Cardiac Surgery (SYNTAX) trial is the largest 
trial to date to compare PCI with CABG in a 
broad patient population. In contrast to earlier 
studies, the SYNTAX trial recruited patients 
with complex CAD (three-vessel or left main 
disease), used drug-eluting stents (DES), 
and applied an all-comers design. At 5-year 
follow-up, CABG had a lower rate of the com-
posite endpoint of all-cause death, myocardial 
infarction, stroke or repeat revascularisation 
compared with DES-PCI- driven mainly by 
lower rates of non-fatal myocardial infarction 
(MI) and repeat revascularisation.
Although the U.S. and European healthcare 
systems differ significantly with respect to clini-
cal practice patterns, availability of resources 
and prices, few economic evaluations of CABG 
vs. PCI have been performed from a European 
perspective.[7, 10, 11] Moreover, the available 
European economic substudies of randomized 
trials are >10 years old and have incorporated 
only a brief time horizon. We therefore per-
formed a prospective health economic study 
alongside the SYNTAX trial, adopting a Dutch 
perspective and using disease-simulation 
techniques to extrapolate the 5-year trial 
results to a lifetime horizon. In addition, we 
analysed the economic outcomes in subgroups 
defined on the basis of the new SYNTAX Score 
II[12] – a validated tool for combining clinical 
and anatomic factors to predict long-term 
survival after PCI or CABG. We hypothesized 
that this tool would be a good discriminator 
of economic outcomes and healthcare value.
MeTHoDS
Between 2005 and 2007, 1800 patients with 
three-vessel or left main CAD were random-
ized to either CABG (n=897) or PCI with DES 
(n=903). Costs for the index hospitalisation 
and the five-year follow-up period were as-
sessed by combining detailed resource-based 
and event-based methods. Quality of life was 
assessed directly from patients at baseline, 1, 
6, 12, 36, and 60 months using the three-level 
EuroQOL (EQ-5D) health status instrument 
and converted to utility weights (range 0-1) 
using an algorithm developed for the Dutch 
population.[13]
Cost-effectiveness. The cost-effectiveness 
of CABG vs. PCI was assessed over a life-time 
horizon. Health benefits were expressed in 
QALYs in the primary analysis and as life-years 
in secondary analyses.[14, 15] Life-years and 
QALYs were discounted at 1.5% annually, and 
costs at 4% annually, as recommended by the 
Dutch Manual for Cost-analysis in Healthcare.
[16] The analyses were based on a combina-
tion of (1) observed in-trial cost and quality 
of life data and (2) projections of post-trial 
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costs, life expectancy and quality-adjusted life 
expectancy obtained from a Markov disease-
simulation model. As recommended by the 
Dutch Council for Public Health, a willingness-
to-pay (WTP) threshold level of €80 000 per 
quality-adjusted life year (QALY) gained was 
used to assess cost effectiveness.[17]
ReSUlTS
Patient Population. In SYNTAX, 1800 patients 
with de novo three-vessel or left main CAD 
were randomized to either CABG (n=897) or 
PCI (n=903). Of the randomized patients, 27 
assigned to CABG and 7 assigned to PCI did 
not undergo any revascularisation procedure 
and were excluded from the primary modified 
intention-to-treat ( mITT) population (eFig-
ure 1). There were no significant differences 
in any observed baseline characteristics be-
tween the CABG and PCI groups for the mITT 
population. Of the mITT patients, 148 (8.4%) 
were enrolled in The Netherlands, 39% had 
left main CAD, and the median follow-up was 
60 months.
Initial Treatment Costs. Of the patients that 
were assigned to PCI, 885 (98.8%) underwent 
PCI and 11 (1.2%) underwent CABG. Among 
patients assigned to CABG, 854 (98.2%) 
underwent CABG, and 16 (1.8%) underwent 
PCI. Resource utilisation for the initial revascu-
larisation procedures is summarised in eTable 
2 (per protocol [PP] population). In the PCI 
group, 13.6% underwent staged procedures. 
On average, 2.1 guiding catheters, 3.5 guide-
wires, 3.7 angioplasty balloons, and 4.5 drug-
eluting stents were used during the initial PCI 
procedure. Although procedure duration was 
longer for CABG, initial procedure costs were 
€1351 lower with CABG as compared with PCI 
(€6472 vs. €7823, P<0.001), owing to higher 
costs associated with disposable resources 
in the PCI group. For the mITT population, 
the difference in initial procedural costs was 
similar (€1354; €6444 vs. €7798, P<0.001) to 
the results in the PP population.
Clinical events, resource utilisation, and 
costs during the initial hospitalisation are sum-
marized in Table 1. Post-procedural hospital 
costs were higher for the CABG group com-
pared with the PCI group (€8725 vs. €3996, 
P<0.001), as were physician fees (€2264 
vs. €2111, P<0.001). As a result, total initial 
hospitalisation costs were ~€3500/patient 
higher in the CABG group compared with the 
PCI group (€17506 vs. €14037, P<0.001).
Follow-up Resource Utilisation and Costs. 
Follow-up clinical outcomes, resource utilisa-
tion, and costs are summarised in eTable 3. 
During each year of follow-up, the annual rates 
of diagnostic catheterisation, repeat revascu-
larisation, hospitalisation, and their associated 
costs were higher for patients assigned to 
initial PCI. In addition, costs for outpatient 
services and medications were consistently 
higher in the PCI group compared with the 
CABG group. Rehabilitation costs were greater 
in the first year after CABG and were similar 
between treatments in the subsequent years. 
Overall, the difference in cumulative medical 
care costs between the CABG and PCI narrowed 
from €3469 after the index hospitalisation to 
€2465 after 5 years of follow-up (Table 2 and 
Figure 1).
Utility Weights and QALYs. For both treat-
ment groups, utility weights improved sub-
stantially over the course of the trial (eTable 
5). At 1 month follow-up, utility weights were 
significantly lower after CABG than PCI (0.74 
vs. 0.83, P<0.001), reflecting longer recovery 
after CABG. However, this early utility benefit 
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Table 1. Index Hospitalisation Events, Resource Utilisation, and Costs (mITT population)
CABG (n=870) PCI (n=896) Difference (95% CI) P value
Death, % 1.4  (12)) 1.8  (16) -0.4 (-1.6, 0.8) 0.49
MI, % 2.4  (21)) 2.7  (24) -0.3 (-1.7, 1.2) 0.72
Stroke, % 1.0  (9)) 0.1  (1) 0.9 (0.2, 1.6) 0.01
Unplanned CABG, % 1.1  (10)) 0.8  (7) 0.4 (-0.5, 1.3) 0.42
Unplanned PCI, % 0.5  (4)) 1.8  (16) -1.3 (-2.3, -0.3) 0.008
Complications, %
Major bleeding 4.8  (42) 4.5  (40) 0.4 (-1.6, 2.3) 0.72
Respiratory failure 1.6  (14) 0.0  (0) 1.6 (0.8, 2.4) < 0.001
Renal failure 2.4  (21) 0.7  (6) 1.7 (0.6, 2.9) 0.003
Wound infection 4.1 (36) 0 (0) 4.1 (2.8, 5.5) < 0.001
Other infection 6.2  (54) 0.4 (4) 5.8 (4.1, 7.4) < 0.001
Atrial fibrillation 17.9 (156) 1.3 (12) 16.6 (13.9, 19.2) < 0.001
Cardiac tamponade 0.8 (7) 0.3 (3) 0.5 (-0.2, 1.2) 0.22
Other procedures, %
Permanent pacemaker 0.6  (5) 0.2  (2) 0.4 (-0.2, 0.9) 0.28
ICD implantation 0.2  (2) 0.0  (0) 0.2 (-0.1, 0.5) 0.24
Carotid endarterectomy 0.5  (4) 0.0  (0) 0.5 (0.0, 0.9) 0.06
Length of stay*
ICU/CCU 3.0 ± 5.2  1.6 ± 2.9  1.5 (1.1, 1.9) < 0.001
Total 13.9 ± 10.1  6.7 ± 7.7  7.2 (6.4, 8.0) < 0.001
Initial hospitalisation costs, €
Revascularisation procedures 6517 ± 1691 [6347] 7930 ± 4404 [7374] -1413 (-1726, -1100) < 0.001
Hospital stay + ancillary services 8725 ± 4818 [7117] 3996 ± 3816 [2143] 4729 (4324, 5134) < 0.001
Physician fees 2264 ± 370 [2126] 2111 ± 587 [1887] 153 (107, 199) < 0.001
Total 17506 ± 5621 [16214] 14037 ± 6850 [12597] 3469 (2883, 4054) < 0.001
Values in brackets are medians. CCU, cardiac care unit; CI, confidence interval; ICD, implantable cardioverter-defribilla-
tor; ICU, intensive care unit; mITT, modified intention-to-treat. * Length of stay in the different countries was converted 
to the Dutch perspective using a regression modelling approach (eTable 4).
Table 2. Cumulative In-Trial Costs, QALYs, and Life-Years, Adjusted for Censoring
Time Since 
Randomisation
Cumulative Costs, € Cumulative qAlYs Cumulative life-Years
CAbG PCI ∆ CAbG PCI ∆ CAbG PCI ∆
1 year 20868 17495 3373 0.762 0.791 -0.029 0.975 0.965 0.009
2 years 22193 19156 3037 1.547 1.600 -0.022 1.933 1.912 0.022
3 years 23364 20507 2857 2.323 2.329 -0.005 2.877 2.832 0.045
4 years 24454 21879 2575 3.074 3.058 0.016 3.800 3.732 0.069
5 years 25680 23215 2465 3.802 3.762 0.040 4.701 4.601 0.100
CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; QALY, quality-adjusted life-years gained. 
∆=difference between CABG and PCI group; , difference between CABG and PCI groups
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of PCI was no longer significant at 6 months and 
longer follow-up. As a result of the early utility 
benefit of PCI, cumulative quality-adjusted 
life-years were higher with PCI than with CABG 
through 3 years of follow-up (Table 2). At 5 
years, however, life expectancy (4.70 vs. 4.60 
years) and quality-adjusted life expectancy 
(3.80 vs. 3.76 QALYs) were both greater with 
CABG than with PCI.
Lifetime Cost-Effectiveness- Overall Popula-
tion. Results from lifetime cost-effectiveness 
analyses are shown in Table 3. Despite reduc-
tions in annual follow-up costs over the first 5 
years of follow-up, patients in the CABG group 
were projected to incur €1929 higher overall 
healthcare costs over a lifetime horizon. 
Although CABG was only associated with a 
small gain in life expectancy (0.100 life-years) 
and quality-adjusted life expectancy (0.040 
QALY) over the first 5 years of follow-up, 
extrapolation of the observed benefits over 
a lifetime horizon resulted in an increase in 
life expectancy of 0.488 years and an increase 
in quality-adjusted life expectancy of 0.358 
QALYs with CABG as compared with PCI.
The resulting incremental cost-effectiveness 
ratio (ICER) for CABG vs. PCI was €5390/QALY 
gained, with 92.8% of bootstrap replicates 
figure 1.
Mean cumulative medical costs (lines) and mean annual 
follow-up costs (bars) in 2012 euros, for the PCI and 
CABG groups. CABG, coronary artery bypass grafting; 
PCI, percutaneous coronary intervention. Note that the 
first set of bars represents the costs of the index hos-
pitalisation.
figure 2.
Joint distribution of projected lifetime incremental 
costs and quality-adjusted life expectancy for CABG vs. 
PCI based on bootstrap replication of the SYNTAX trial 
population, plotted on the cost-effectiveness plane. The 
red circle represents the estimated mean values (in-
cremental cost=€1929, incremental QALYs=0.358). The 
green line represents the €80000/QALY cost-effective-
ness threshold. CABG, coronary artery bypass grafting; 
PCI, percutaneous coronary intervention; QALY, quality-
adjusted life-year.
figure 3.
Cost effectiveness acceptability curve of CABG vs. PCI. 
The probability that CABG is cost-effective is calculated 
as the proportion of bootstrap-derived estimates fall-
ing below a given cost-effectiveness threshold and is 
plotted across a range of possible cost-effectiveness 
thresholds. The solid blue line represents the base-case 
analysis, while the dashed red line indicates the analy-
sis in which the impact of MI and stroke were taken into 
account.
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falling below a societal willingness-to-pay 
threshold of €80000/QALY (Figures  2 and 
3, and Table 3/row 1). When outcomes were 
expressed in life-years, CABG was associated 
an ICER of €3953/life-year gained (Table 3/
row 2). In the analysis accounting for the 
prognostic impact of non-fatal MI and stroke, 
the benefit of CABG increased modestly to 
0.399 QALYs, and the ICER was €5092/QALY 
gained with 94.2% of bootstrap replicates 
below a societal willingness-to-pay threshold 
of €80,000 (Figure 3, Table 3/row 4).
Results were robust across a wide range of 
alternative assumptions regarding the duration 
and magnitude of the benefit of CABG over PCI 
on both costs and survival beyond the 5 year 
timeframe observed in the trial. Assuming that 
the benefits of CABG would remain constant 
from year 5 to year 10, with no further benefit 
beyond 10 years, the ICER for CABG vs. PCI was 
€3505/QALY gained. When we conservatively 
assumed that there would be no benefit of 
CABG beyond the 5-year trial period, the ICER 
increased to €8815/QALY gained with 90.7% 
of the bootstrap replicates below the €80000/
QALY threshold. Results were similar when the 
analysis incorporated the prognostic impact of 
non-fatal MI and stroke, or when effectiveness 
was expressed in life-years rather than QALYs 
(eTables 8 and 9).
Subgroup Analyses. Results from the pre-
specified subgroup analyses are summarised 
in Table 4. For most subgroups, the results were 
similar to those of the overall trial population 
albeit with greater uncertainty due to the 
reduced sample sizes. However, the results 
in several subgroups differed substantially 
from those of the overall trial. For patients 
with less complex coronary anatomy (SYNTAX 
Score ≤22), PCI was projected to increase 
quality-adjusted life expectancy and to reduce 
costs compared with CABG. Conversely, for 
patients with SYNTAX Scores of 23-32 and ≥33, 
the ICERs for CABG vs. PCI were €54475/QALY 
gained and €1787/QALY gained, respectively.
PCI was an economically dominant strategy 
for patients with left main CAD, whereas CABG 
was highly economically attractive compared 
with PCI for patients with three-vessel dis-
ease (ICER €1174/QALY gained). For all other 
subgroups, CABG was economically attractive 
compared with PCI with ICERs <€20,000/QALY 
gained. Importantly, results for the popula-
tion of patients enrolled in the Netherlands 
(n=148) were consistent with those for the 
overall population as well. Results for sub-
groups were unchanged when we considered 
the impact of non-fatal MI and stroke on 
mortality (eTable 8).
When stratified according to differences in 
predicted 4-year mortality based on the SYN-
TAX score II, we found that the tool not only 
discriminates well for 4-year mortality but also 
for long-term economic outcomes (Figure 4). 
For patients for whom PCI was estimated to 
result in better 4-year survival, PCI was also 
economically dominant. For patients for whom 
CABG was predicted to result in better 4 year 
survival, CABG was also highly economically 
attractive (ICERs ranging from €2967 to €3737 
per QALY gained).
Impact of Stent Pricing and Productiv-
ity Losses. We also performed a sensitivity 
analysis varying the acquisition cost of DES 
(eFigure 3). Although the ICER for CABG vs. 
PCI increased as the acquisition cost of DES 
decreased, even at a DES price of €0, the ICER 
for CABG remained <€20,000/QALY gained in 
the overall trial population. When this analy-
sis was repeated within strata according to 
SYNTAX Score, only the intermediate SYNTAX 
Score tertile was sensitive to stent price 
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(eFigure 3 and eTable 10). For patients with a 
SYNTAX Score ≤22, the PCI strategy remained 
economically attractive unless the stent price 
exceeded €1400/stent, while for patients with 
a SYNTAX Score ≥33, CABG remained economi-
cally attractive at all stent acquisition costs. 
However, among patients with SYNTAX Scores 
between 23 and 32, the ICER for CABG vs. PCI 
remained <€80,000/QALY gained only if the 
DES acquisition cost was >€675/stent.
Finally, we performed a sensitivity analysis to 
assess the impact of productivity loss on the 
cost-effectiveness of CABG vs. DES-PCI. Since 
no data on employment were collected from 
the SYNTAX trial patients, we used several 
external sources to estimate the proportion 
of patients employed at baseline, the timing 
of return to work according to the type of 
revascularization procedure, and the average 
earning for a Dutch worker.[18, 19] After incor-
porating these factors in our analysis, the cost 
difference between the treatments increased 
by ~€400 for the overall population, reflect-
ing the greater productivity loss with CABG 
compared to PCI, but the ICER for CABG vs. PCI 
remained <€7000/QALY gained (eTable 11). 
Also for subgroups according to SYNTAX Score 
tertile and LM or 3-vessel disease subgroups, 
figure 4.
Joint distribution of projected lifetime incremental costs and quality-adjusted life expectancy for CABG vs. PCI within 
subgroups stratified according to differences in predicted 4-year mortality based on the SYNTAX Score II. For each 
stratum, the red circle represents the estimated mean values. The green line represents the €80000/QALY cost-effec-
tiveness threshold. Horizontal axes: difference in quality-adjusted life years (CABG-PCI). CABG, coronary artery bypass 
grafting; PCI, percutaneous coronary intervention.
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the results were similar to the main analyses 
that did not incorporate productivity losses.
DISCUSSIon
This economic substudy of the SYNTAX trial is 
the first to directly compare long-term clinical 
and economic outcomes of DES-PCI vs. CABG 
among patients with three-vessel or left main 
CAD from a European (Dutch) healthcare 
perspective. . Our results reveal that initial 
hospitalisation costs were higher with CABG, 
and these up-front costs were only partially 
offset by improved clinical outcomes and 
lower resource utilisation during follow-up. 
Over the first 5 years of follow-up, CABG 
improved life expectancy and quality-adjusted 
life expectancy (by 0.10 years and 0.040 
QALYs, respectively) while increasing costs 
by ~€2500 compared with DES-PCI. These in-
trial life expectancy results were magnified 
when extrapolated over a patient’s lifetime 
(0.358 QALYs and 0.488 life years gained with 
CABG vs. DES-PCI), while the cost difference 
narrowed further (~€1900 higher costs with 
CABG vs. DES-PCI). In the base case analysis, 
the resulting lifetime cost-effectiveness ratios 
for CABG vs. DES-PCI were €5390/QALY gained 
and €3953/life year gained, values that are 
considered highly cost-effective from a Dutch 
perspective. These results were robust to a 
variety of alternative assumptions regarding 
the duration and magnitude of the benefit of 
CABG over PCI, stent pricing, and the prognos-
tic impact of non-fatal myocardial infarction 
and stroke.
For most subgroups, the results were 
similar to those of the overall trial popula-
tion albeit with more uncertainty due to 
the reduced sample sizes. In patients with 
a SYNTAX Score ≤22, however, DES-PCI was 
associated with a small lifetime gain of 0.004 
QALY compared with CABG, resulting in an eco-
nomically dominant position compared with 
CABG. These results suggest that for patients 
with relatively straightforward 3-vessel or left 
main CAD, DES-PCI might be the preferred 
revascularisation strategy on both clinical and 
economic grounds. A more definitive answer 
regarding the optimal treatment for left main 
CAD will be provided by the results of the on-
going EXCEL trial (NCT01205776 clinicaltrials.
gov). In contrast, in the subgroup with highly 
complex CAD (SYNTAX Score ≥32), CABG was 
strongly favoured on clinical and economic 
grounds (1.109 QALY gain, €1982 higher costs 
compared with DES-PCI). In the intermediate 
SYNTAX Score group, CABG was associated 
with a small 0.049 QALY gain, surrounded by 
large uncertainty.
While device prices are often perceived 
to be an important driver of cost-effective-
ness,[20] our results were not sensitive to the 
stent price. Indeed, the major determinant of 
cost-effectiveness in our DES-PCI vs. CABG 
comparison was the gain in (quality-adjusted) 
life expectancy rather than the cost difference. 
Therefore, we found no device cost at which 
DES-PCI would have been an economically at-
tractive treatment option in the overall popu-
lation, or in patients with a SYNTAX Score ≥32. 
Only in the intermediate SYNTAX Score group 
did stent price affect the ICER materially. 
Indeed, for that subgroup, reducing the stent 
price by ~25% from current levels would make 
DES-PCI the preferred treatment option on 
economic grounds. .
Role of the SYNTAX Score II. Our paper is 
the first to examine the economic implications 
of the SYNTAX Score II, which was recently 
developed in order to provide an objective, 
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evidence-based tool to enhance individualized 
decision making for patients with complex 
CAD.[12] This score predicts 4 year mortality 
with PCI or CABG and was constructed using 
both anatomical predictors (i.e. the anatomical 
SYNTAX Score) and clinical factors including 
age, gender, renal function, left ventricular 
ejection fraction, chronic obstructive pulmo-
nary disease and peripheral vascular disease. 
Because of the small differences in costs 
between treatments and the resultant large 
impact of mortality differences on the ICER, we 
hypothesized that the SYNTAX Score II would 
also be a good discriminator of economic 
outcomes. In this analysis, we confirmed our 
hypothesis by showing that selecting patients 
for PCI vs. CABG based on 4-year mortality 
projections leads to treatment decisions that 
are both clinically and economically attractive.
Comparison with previous studies. Our 
results differ substantially from the cost-
effectiveness of DES-PCI vs. CABG based on the 
1-year SYNTAX data.[21] In that early analysis, 
DES-PCI was associated with a small QALY gain 
and ~$3600 lower costs, suggesting that DES 
PCI was economically dominant compared 
with CABG. This discrepancy between the 1 
year and lifetime cost-effectiveness of DES-PCI 
and CABG, emphasizes the importance of bas-
ing policy decisions on studies with long-term 
follow-up in order to capture benefits that 
emerge at later time points.
Few studies on the cost-effectiveness of CABG 
vs. PCI have been performed from a Euro-
pean country perspective.[9] The economic 
substudy of the Arterial Revascularisation 
Therapy Study (ARTS) trial found that after 
3 year follow-up CABG was associated with 
€1798 higher costs than PCI using bare 
metal stents, but did not use QALYs to express 
benefits and did not project their findings 
over a lifetime horizon.[22] Recently, a small 
(n=199) observational study examined the 
cost-effectiveness of CABG vs. DES-PCI from 
the perspective of the Austrian healthcare 
system. In that study, CABG was associated 
with €5400 higher costs at 5 years, leading 
to an ICER of €45615 per death, myocardial 
infarction, stroke or repeat revascularisation 
avoided.[11] The ICER was more favourable for 
CABG in those subgroups with a higher SYNTAX 
Scores—similar to the results of our study.
Limitations. Although the SYNTAX trial en-
rolled patients from 18 countries, the current 
analysis was performed from the perspective 
of a single country. We were careful to assign 
costs at levels of resource utilisation that were 
unlikely to differ by country, but this was not 
possible for length of stay. We therefore used 
regression modelling to adjust length of stay 
at the individual country level to Dutch norms. 
Following recommendations for economic 
analyses alongside multinational trials, all 
clinical outcomes were assumed to be similar 
across countries.[23] Restricting our analysis 
to Dutch patients only would have severely 
reduced our sample size and increased un-
certainty in the results. Nonetheless, it is reas-
suring that our results were very similar when 
restricted to only Dutch trial participants.
In addition, our extrapolations necessitated as-
sumptions on the impact of CABG on long-term 
survival, quality-of-life and healthcare costs. 
We used all possible data from the trial to 
inform these extrapolations and tested these 
assumptions in sensitivity analyses. Finally, 
DES-PCI was performed using first generation 
(paclitaxel-eluting) DES. Therefore, our results 
may not be generalisable to settings where 
second generation DES are used.
Conclusions. In this economic analysis 
based on the data from the SYNTAX trial, we 
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found that from a Dutch healthcare perspec-
tive, CABG is an economically attractive 
revascularisation strategy compared with 
DES-PCI. However, among patients with 
anatomically less complex disease, DES-PCI 
appears to be preferred on both clinical and 
economical grounds. Finally, we found that the 
newly developed SYNTAX Score II is a useful 
discriminator of economic value for revascu-
larisation decisions, providing further support 
for its incorporation in clinical guidelines and 
economic policies.
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Abstract
Unprotected left main coronary artery (ULMCA) stenosis has relatively high prevalence and exposes patients 
to a high risk for adverse cardiovascular events. The optimal revascularisation strategy (coronary artery bypass 
surgery [CABG] or percutaneous coronary intervention [PCI]) for patients with complex coronary artery dis-
ease is a topic of continuing debate. The introduction of the newer-generation drug-eluting stents (DES) –
with documented improvements in both safety and efficacy – has prompted the interventional community 
to design two new dedicated randomised trials comparing CABG and PCI: the NOBLE (Coronary Artery 
Bypass Grafting Vs Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected 
Left Main Stenosis) and EXCEL (Evaluation of XIENCE Everolimus Eluting Stent Versus Coronary Artery 
Bypass Surgery for Effectiveness of Left Main Revascularization) trials. The aims of the present review are 
to describe the similarities and contrasts between these two trials as well to explore their future implications 
in ULMCA treatment.
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Introduction
The relevance of an unprotected left main coronary artery 
(ULMCA) stenosis was first described more than 100 years ago1. 
James Herrick reported the story of a 55-year-old male who died in 
cardiogenic shock after a period of 52 hours. The autopsy found an 
extensive necrosis of the left ventricle associated with total occlu-
sion of the left main coronary artery by a thrombus overlying an 
area of atherosclerotic narrowing1. The explanation for this mas-
sive necrosis is the large area of myocardium at risk in patients with 
ULMCA. It has been shown that, in a usual right dominant coro-
nary anatomy, the left coronary artery supplies approximately 84% 
of the flow to the left ventricle2-4.
Currently, the prevalence of significant ULMCA disease –
diameter stenosis greater than 50 percent – may vary from 4-6% 
of all patients who undergo coronary arteriography to 24% of 
patients with acute coronary syndrome5,6. Most of these patients 
are symptomatic and at high risk of cardiovascular events4,5,7. 
In that sense, for over 30 years, coronary artery bypass grafting 
(CABG) has been regarded as the standard of care for ULMCA 
by improving long-term prognosis when compared with optimal 
medical therapy8.
Since its clinical introduction in 19779, percutaneous coronary 
intervention (PCI) has gradually matured. The advent of drug-elut-
ing stents (DES) has markedly improved the long-term outcomes 
in patients with complex coronary anatomy. Numerous studies 
have compared outcomes in subjects treated with either CABG or 
PCI10-12. Meta-analytic combinations of these studies have basi-
cally shown that PCI has similar five-year mortality and myocar-
dial infarction, with a lower incidence of stroke and increased risk 
of repeat revascularisation when compared to CABG11,12.
The relatively high prevalence and substantial prognostic impact 
of ULMCA with an unclear optimal therapeutic option added to the 
introduction of the newer-generation DES – with proven improve-
ments in both safety and efficacy13-19 – has prompted the design of 
two new dedicated randomised trials comparing CABG and PCI. 
The aim of the present manuscript is to describe the design and 
future perspectives proposed by the ongoing EXCEL (Evaluation 
of XIENCE Everolimus Eluting Stent Versus Coronary Artery 
Bypass Surgery for Effectiveness of Left Main Revascularization) 
and NOBLE (Coronary Artery Bypass Grafting Vs Drug Eluting 
Stent Percutaneous Coronary Angioplasty in the Treatment of 
Unprotected Left Main Stenosis) trials.
EXCEL and NOBLE: similarities and contrasts
The EXCEL trial (ClinicalTrials.gov identifier: NCT01205776) 
is an international, prospective, unblinded, randomised multicen-
tre trial which enrolled 1,905 subjects in 131 centres (Figure 1). 
EXCEL was designed to establish the safety and efficacy of the 
everolimus-eluting stent (XIENCE PRIME™ or XIENCE V® or 
XIENCE Xpedition™ or XIENCE PRO™; Abbott Vascular, Santa 
Clara, CA, USA) in patients with significant ULMCA disease.
The NOBLE trial (ClinicalTrials.gov identifier: NCT01496651) 
is an international, prospective, unblinded, randomised multicentre 
2,909 patients assessed 
for eligibility 
21 underwent medical treatment
4 randomisation errors
1,905 underwent
randomisation
979 eligible for enrolment
in parallel registry
957 assigned to
undergo CABG
948 assigned to
undergo PCI
649 enrolled in
CABG registry
330 enrolled in
PCI registry
Figure 1. Enrolment and randomisation of patients with previously 
untreated left main coronary artery disease in the EXCEL trial.
trial which randomised 1,200 patients in 36 centres. The biolimus-
eluting stent BioMatrix™ (Biosensors, Morges, Switzerland) is the 
recommended study stent but other CE-marked DES may be used 
at operators’ discretion. As shown in Table 1, although both trials 
aim to compare PCI versus CABG for ULMCA treatment, they do 
not have exactly the same design.
Comparison of anatomic selection criteria in the 
EXCEL and NOBLE trials
The EXCEL and NOBLE trials have, as core for inclusion, an equi-
poised treatment for PCI and CABG as assessed by the local Heart 
Team. It is mandatory in both trials that the interventional cardiolo-
gist and surgeon determine appropriateness and eligibility in their 
respective area of expertise.
The first difference between EXCEL and NOBLE is how the 
Heart Team assesses the ULMCA as being significant. The NOBLE 
trial adopted as significant an ULMCA with a visually assessed 
diameter stenosis (DS) >50% or fractional flow reserve (FFR) 
<0.80. The EXCEL trial defines significant ULMCA as one of the 
following: DS ≥70% (visually estimated) or DS ≥50% but <70% 
(requiring non-invasive or invasive [FFR ≤0.80] evidence of ischae-
mia or intravascular ultrasound [IVUS] minimal lumen area [MLA] 
≤6.0 mm2). Additionally, the EXCEL trial has enrolled patients 
with left main equivalent disease defined as Medina classification 
0,1,1 bifurcation disease with both the ostial left anterior descend-
ing artery (LAD) and ostial left circumflex artery (LCX) stenoses 
having ≥70% DS. If one or both of the ostial LAD and ostial LCX 
stenoses are ≥50% and <70% stenotic by visual estimation, then this 
lesion(s) is demonstrated to be significant either by non-invasive or 
invasive (FFR ≤0.80) evidence of ischaemia in its myocardial distri-
bution or IVUS MLA ≤4.0 mm2. By protocol, in EXCEL, FFR was 
the preferred strategy to stratify lesion significance.
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ULMCA disease should be regarded as a heterogeneous pathol-
ogy when considering the choice of revascularisation modality. 
The anatomical complexity of the left main may vary from a sin-
gle lesion in the shaft to distal trifurcation disease and its associ-
ation with more complex downstream (three-vessel) disease, and 
may have been directly correlated to incomplete revascularisation 
and to late all-cause mortality following PCI20-22. The prevailing 
international revascularisation guidelines recommend revasculari-
sation of ULMCA with CABG or PCI in subjects with SYNTAX 
scores which are low (SYNTAX score <23: class I recommendation 
for CABG or PCI [level of evidence B for both]) and intermedi-
ate (SYNTAX score 23-32: class I for CABG and class IIa for PCI 
[level of evidence B for both]). The same guidelines recommend 
against revascularisation with PCI of ULMCA disease with high 
SYNTAX scores (SYNTAX score ≥33: class I for CABG and class 
III for PCI [level of evidence B for both])7.
The EXCEL trial adopted an enrolment criterion of subjects with 
ULMCA disease up to intermediate anatomical complexity defined 
by a SYNTAX score <33 (assessed by the local Heart Team)23. On 
the other hand, the NOBLE trial has been enrolling patients with 
ostium, mid-shaft and/or bifurcation and with no more than three 
additional non-complex PCI lesions. Non-complex lesions in the 
NOBLE trial were defined as length <25 mm, non-chronic total 
occlusion, non-two-stent bifurcation, non-calcified and non-tortu-
ous coronary lesions.
Study device
The EXCEL and NOBLE trials were designed to study the impact 
of revascularisation on ULMCA disease, incorporating changes in 
medical therapies, PCI technology and techniques, and advances 
in CABG which had been introduced since the completion of the 
SYNTAX and FREEDOM studies24-26. In EXCEL, the workhorse 
stent was the everolimus-eluting stent (EES) (XIENCE). The ran-
domised comparisons of everolimus- versus paclitaxel-eluting 
stents were designed and powered for a combination of angio-
graphic, ischaemic and safety outcomes, and have consistently 
shown the EES to be associated with more favourable outcomes 
compared to paclitaxel-eluting stents13-16. In addition, the largest 
patient-level meta-analysis (n=4,989) of the SPIRIT clinical pro-
gramme has shown that EES were superior to paclitaxel-eluting 
stents in reducing all-cause mortality (3.2% vs. 5.1%, HR: 0.65, 
95% CI: 0.49 to 0.86; p=0.003)17.
Table 1. Design of the EXCEL and NOBLE trials.
EXCEL trial NOBLE trial
Main inclusion 
criteria
 – Significant unprotected left main coronary artery (ULMCA) disease or left main 
equivalent disease
 – Clinical and anatomic eligibility for both PCI and CABG as agreed to by the 
local Heart Team
 – Silent ischaemia, stable angina, unstable angina or recent MI (if recent MI, 
CK-MB must have returned to normal)
 – The subject must be ≥18 years of age
 – Stable, unstable angina pectoris or ACS
 – Significant unprotected left main coronary artery (ULMCA) with no more 
than three additional non-complex PCI lesions
 – Patient eligible to be treated by CABG and by PCI
Key clinical 
exclusion criteria
 – Prior PCI of the left main at any time prior to randomisation or prior PCI of any 
other (non-left main) coronary artery lesions within one year prior to 
randomisation
 – Prior CABG
 – Need for any concomitant cardiac surgery
 – Subjects unable to receive dual antiplatelet therapy for at least one year
 – Subjects requiring or who may require additional surgery within one year
 – Pregnancy or intention to become pregnant
 – Non-cardiac comorbidities with life expectancy less than 3 years
 – Other investigational drug or device studies that have not reached their 
primary endpoint
 – ST-elevation infarction within 24 hours
 – Patient is too high risk for CABG
 – Expected survival <1 year
 – Allergy to aspirin, clopidogrel or ticlopidine
 – Allergy to biolimus
Key angiographic 
exclusion criteria
 – SYNTAX score ≥33, as determined by the consensus of the local Heart Team
 – Visually estimated left main reference vessel diameter <2.25 mm or 
>4.25 mm (post-dilatation up to 4.5 mm is allowed)
 – CABG clearly better treatment option (LMCA stenosis and >3, or complex 
additional coronary lesions)
Primary endpoint Death, MI and stroke (modified Rankin scale [mRS] ≥1 and increase by ≥1 from 
baseline at 3 years)
Death, stroke, non-index treatment-related MI and new revascularisation 
(PCI or CABG)
Secondary 
endpoint
 – Composite measure of all-cause mortality, myocardial infarction, stroke or 
unplanned revascularisation for ischaemia at 3 years post index procedure
 – Stroke at 30 days
 – Unplanned revascularisation for ischaemia at 3 years post index procedure
 – Health-related quality of life and treatment costs
 – Combined endpoint of death, stroke and non-index treatment-related MI
 – Individual endpoints of death, stroke and non-index treatment-related MI
 – New revascularisation by CABG or PCI
 – Definite stent thrombosis/symptomatic graft occlusion
 – Canadian Cardiovascular Society angina score
 – New York Heart Association functional class
 – Duration of admission for index treatment 
Sample size 1,905 patients 1,200 patients
Participating 
centres
131 active sites worldwide 36
Current status Enrolment complete (03/June/2014). Report of the primary endpoint is expected in 
2016
Enrolment complete (22/January/2015). Report of the primary endpoint is 
expected in 2016
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In NOBLE, the workhorse drug-eluting stent is a biolimus-elut-
ing stent (BES) (BioMatrix) with bioabsorbable polymer. The stent 
was selected due to its high radial strength and expansion capacity, 
especially cell opening27. Furthermore, the biolimus-eluting stent 
with bioabsorbable polymer has shown excellent results in compar-
ison with first28-30 as well as second-generation DES31,32. The results 
of NOBLE and EXCEL may help to understand the clinical impact 
of EES and BES specifically for ULMCA.
Intravascular imaging to guide ULMCA PCI
IVUS guidance compared with angiography guidance has been 
associated with reduced one-year rates of definite/probable stent 
thrombosis, myocardial infarction and composite adjudicated 
major adverse cardiac events (i.e., cardiac death, myocardial infarc-
tion, or stent thrombosis)33,34. Specifically for ULMCA PCI, a pro-
pensity score matching of the MAIN-COMPARE registry (n=201) 
has associated IVUS-guided PCI to lower three-year mortality35. In 
both NOBLE and EXCEL, IVUS-guided PCI is strongly recom-
mended pre-treatment and post-treatment to optimise lumen dimen-
sions in the left main segment and for all non-left main lesions36. 
An exception is made for distal lesions or tortuous vessels. All left 
main lesions in which IVUS is used will undergo rigorous core 
laboratory evaluation (Cardiovascular Research Foundation, New 
York, USA in the EXCEL trial and Belfast Health & Social Care 
Trust, Belfast, Northern Ireland in the NOBLE trial).
In this regard, these trials will help to understand the PCI results 
according to the baseline IVUS criteria and IVUS post-PCI predic-
tors of clinical events. Although a two by two randomised trial for 
IVUS guidance would be ideal, the EXCEL and NOBLE protocols 
are already sufficiently complex that adding another level of ran-
domisation is not practical. Moreover, although IVUS assessment 
is relatively simple, not all sites are expert in the use of IVUS guid-
ance for complex left main stenosis.
Primary endpoints
EXCEL and NOBLE had different sample size calculation due to 
the difference in their respective primary endpoints. In NOBLE, the 
sample size calculation is based on the combined primary endpoint 
of death, stroke (defined as ischaemic or haemorrhagic cerebrovas-
cular event verified by brain CT), non-index treatment-related MI 
and new revascularisation (MACCE) after two years (Table 1). In 
EXCEL, the primary endpoint is defined as death, MI and stroke 
(modified Rankin scale [mRS] ≥1 and increase by ≥1 from baseline 
at three years). EXCEL has completed its enrolment with a total 
number of 1,905 patients (Figure 1).
Recommendations on bifurcation treatment
Bifurcation lesions may be present in about 70% of ULMCA 
cases and have been associated with the occurrence of ischaemic 
events after PCI37. In EXCEL and NOBLE protocols, a single-stent 
crossover provisional technique is recommended whenever pos-
sible for treatment of bifurcations. After implantation of the first 
stent, if there is uncertainty concerning the adequacy of side branch 
patency, an FFR determination is recommended, with a value of 
≤0.80 indicating that side branch dilatation should be performed.
The decision to use a primary two-stent technique is left to the 
operator’s best judgement. However, a primary two-stent strategy 
rather than a single crossover stent technique should be considered 
when the side branch (usually the left circumflex) is large (>3 mm), 
with significant disease (by angiographic or IVUS assessment) and 
lesion length >5 mm, or when there are other special anatomic con-
siderations (e.g., heavy calcification).
In both trials, the strategy of a two-stent technique (crossover or 
primary two stents) for bifurcation treatment may include any of 
the following: T-stent, TAP, mini-crush (reverse crush), or culotte 
bifurcation stent techniques. The final decision is made according to 
the lesion morphology and the experience of the operator. The use 
of kissing balloons after provisional second stents is strongly rec-
ommended in a two-stent strategy. However, based on the Nordic 
Bifurcation study38, in NOBLE the culotte technique is preferred in 
case a two-stent strategy is needed.
Long-term forecasting and comparison of 
mortality in the EXCEL trial using the SYNTAX 
score II (SSII)
The SSII was developed in the landmark, all-comers, randomised 
SYNTAX (Synergy between PCI with TAXUS and Cardiac 
Surgery) trial (n=1,800)24,25 where selection bias would have 
been minimal. The SSII is composed of the anatomical SYNTAX 
score, presence of ULMCA disease, and six clinical characteristics 
(age, creatinine clearance [CrCl], left ventricular ejection fraction 
[LVEF], sex, chronic obstructive pulmonary disease [COPD], and 
peripheral vascular disease [PVD]). SSII has been externally vali-
dated in the multinational DELTA (n=2,891) and CREDO-Kyoto 
(n=3,896) registries39,40. Moreover, international guidelines have 
implemented the SSII as a risk stratification tool for complex coro-
nary artery disease (class IIa, level of evidence B)7.
Recently, a prospective validation of the SYNTAX score II has 
been proposed to forecast and compare the four-year mortality 
in the EXCEL trial41. After completion of patient recruitment in 
EXCEL, using the actual baseline clinical and angiographic data 
from each enrolled patient, the SYNTAX score II was calculated. 
Scores were assigned for the presence and magnitude of each 
predictor directly based on the Cox proportional hazards model 
coefficients generating different scores and four-year mortality 
predictions for PCI and CABG40. To determine the 95% prediction 
intervals (PI), the trial was simulated 10,000 times based on con-
secutive bootstrap samples42.
The SYNTAX score II indicated at least an equipoise for long-
term mortality between CABG and PCI in subjects with ULMCA in 
the EXCEL trial. For the entire study cohort, the four-year predicted 
mortalities were 8.5% and 10.5% in the PCI and CABG arms, 
respectively (odds ratios [OR] 0.79; 95% PI: 0.43-1.50). Figure 2 
demonstrates the first 1,000 trial simulations. It has been found that 
there is a 40.4% (n=4,040) chance that the mortality predictions will 
be significantly lower in favour of PCI, a 4.4% (n=440) chance that 
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Favours PCI: 77.9%
With p<0.05: 40.4%
With p<0.05: 55.2%
Favours CABG: 16.0%
With p<0.05: 2.1%
Favours PCI: 84.0%
With p<0.05: 43.7%
With p<0.05:
54.2%
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Favours CABG: 41.3%
With p<0.05: 4.6%
Favours PCI: 58.7%
With p<0.05: 11.3%
With p<0.05:
84.2%
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Figure 2. First 1,000 four-year mortality simulations of the EXCEL 
trial on the SYNTAX score II. Each dot represents one simulated trial 
mortality in both randomisation arms based on individual 
predictions. The diagonal line represents identical mortality for 
CABG and PCI. A dot plotted to the left of the diagonal line favours 
CABG (actual percentages shown in top left corner), and one to the 
right favours PCI (actual percentages shown in bottom right corner). 
Simulated trials with a significant (p<0.05) mortality difference 
between CABG and PCI are coloured black (actual percentage 
shown in parentheses in respective corners). Simulated trials with 
a non-significant (p≥0.05) mortality difference between CABG and 
PCI are coloured grey. (Modified from Campos et al41)
Table 2. Four-year mortality prediction comparisons between CABG and PCI in the EXCEL trial41.
Overall
SYNTAX score Age* CrCl, mL/min LVEF, % Gender COPD PVD
≤22 23-32 ≤66 >66 ≤60 >60 ≤50 >50 Female Male No Yes No Yes
PCI,  
n (%)
948 563
(59%)
385
(40.6%)
483
(50.9%)
465
(49.1%)
168
(17.7%)
780
(82.3%)
118
(12.4%)
830
(87.6%)
226
(23.8%)
722
(76.2%)
881
(92.9%)
67
(7.1%)
851
(89.8%)
97
(10.2%)
CABG,  
n (%)
957 589
(61.5%)
368
(38.5%)
486
(50.8%)
471
(49.2%)
147
(15.4%)
810
(84.6%)
119
(12.4%)
838
(87.6%)
214
(22.4%)
743
(77.6%)
876
(91.5%)
81
(8.5%)
873
(91.2%)
84
(8.8%)
Predicted 4-year 
mortality PCI,  
% (95% PI)
8.5
(5.4-11.9)
7.3
(4.2-11.0)
10.1
(6.2-14.6)
5.4
(2.7-8.5)
11.8
(7.3-16.8)
19.7
(11.9-28.7)
6.1
(3.5-9.2)
18.3
(9.3-28.0)
7.1
(4.3-10.4)
13.1
(7.1-19.9)
7.1
(4.0-10.5)
7.9
(4.9-11.2)
16.7
(6.0-29.9)
6.9
(4.2-10.1)
22.5
(11.3-36.1)
Predicted 4-year 
mortality CABG, 
% (95% PI)
10.5
(6.6-15.1)
10.3
(5.9-15.6)
10.8
(6.5-15.5)
5.8
(2.7-9.5)
15.41
(9.3-22.5)
18.4
(9.5-28.6)
9.1
(5.2-13.6)
15.2
(6.1-25.8)
9.9
(5.9-14.4)
8.7
(3.3-15.9)
11.1
(6.7-15.9)
9.1
(5.3-13.5)
26.1
(12.4-40.7)
9.0
(5.3-13.3)
26.5
(13.1-41.7)
OR PCI:CABG 
(95% PI)
0.79
(0.43-1.50)
0.69
(0.34-1.45)
0.93
(0.53-1.62)
0.92
(0.38-2.25)
0.73
(0.37-1.48)
1.08
(0.48-2.64)
0.65
(0.31-1.35)
1.25
(0.49-3.27)
0.70
(0.36-1.39)
1.59
(0.61-5.00)
0.61
(0.30-1.23)
0.86
(0.44-1.72)
0.57
(0.16-1.75)
0.75
(0.38-1.54)
0.81
(0.27-2.32)
*Separated by the median. CABG: coronary artery bypass graft surgery; COPD: chronic obstructive pulmonary disease; CrCl: creatinine clearance; LVEF: left ventricular ejection fraction; 
PCI: percutaneous coronary intervention; PI: prediction intervals; PVD: peripheral vascular disease
the mortality will significantly favour CABG, and a 55.2% chance 
of having neutral results. In subjects with low (≤22) anatomical 
SYNTAX scores, the predicted OR was 0.69 (95% PI: 0.34-1.45); 
in intermediate anatomical SYNTAX scores23-32, the predicted OR 
was 0.93 (95% PI: 0.53-1.62) (Figure 2).
Based on four-year mortality predictions in EXCEL, clinical 
characteristics shifted long-term mortality predictions either in 
favour of PCI (older age, male gender, COPD) or CABG (younger 
age, lower creatinine clearance, female gender, reduced LVEF) 
(Table 2). The explanation for these predictions is that, as men-
tioned previously, ULMCA revascularisation, when limited to 
intermediate anatomical complexity, may have adequate results 
with PCI7.
The major limitation of these predictions is also their great-
est strength: the complete absence of the EXCEL trial outcomes. 
Therefore, at present, it not possible to assess whether these predic-
tions are accurate. On the other hand, it enables unbiased validation 
of the SYNTAX score II, promoting understanding of the multiple 
risk factors involved in ULMCA disease and decision making on 
the most appropriate revascularisation modality.
Conclusion
The main results of both the EXCEL and the NOBLE trials are 
expected in 2016, which will therefore be a promising year for 
cardiology. The similarities and differences between these studies 
will, in the end, be complementary in the sense of throwing light on 
numerous aspects of revascularisation strategies and increasing our 
understanding of the role and mechanisms of their risk stratification 
and correlated therapeutic adjunctive tools.
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Long-term forecasting and comparison of
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Everolimus Eluting Stent vs. Coronary Artery
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validation of the SYNTAX Score II
Carlos M. Campos1,2†, David van Klaveren1†, Vasim Farooq3, Charles A. Simonton4,
Arie-PieterKappetein1, JosephF. Sabik III5, EwoutW.Steyerberg1,GreggW.Stone6,7,
and PatrickW. Serruys1,8*, On Behalf of the EXCELTrial Investigators
1Erasmus University Medical Center, s-Gravendijkwal 230, Rotterdam 3015, The Netherlands; 2Heart Institute (InCor), University of Sa˜o Paulo Medical School, Sao Paulo, Brazil;
3Manchester Heart Centre, Manchester Royal Infirmary, Central ManchesterUniversity Hospitals NHS Trust, Manchester, UK; 4Abbott Vascular, Santa Clara, CA, USA; 5Department of
CardiothoracicSurgery,Heart andVascular Institute,ClevelandClinic,Cleveland,USA; 6ColumbiaUniversityMedicalCenter,NewYork,NY,USA; 7CardiovascularResearchFoundation,
New York, NY, USA; and 8International Centre for Circulatory Health, NHLI, Imperial College London, London, UK
Received 9 October 2014; revised 9 December 2014; accepted 22 December 2014
Aims To prospectively validate the SYNTAX Score II and forecast the outcomes of the randomized Evaluation of the Xience
Everolimus-Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization
(EXCEL) Trial.
Methods
and results
Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main
Revascularization is a prospective, randomizedmulticenter trial designed to establish the efficacy and safety of percutan-
eous coronary intervention (PCI)with the everolimus-eluting stent comparedwith coronary artery bypass graft (CABG)
surgery in subjects with unprotected left-main coronary artery (ULMCA) disease and low-intermediate anatomical
SYNTAX scores (,33). After completion of patient recruitment in EXCEL, the SYNTAX Score II was prospectively
applied topredict 4-yearmortality in theCABGandPCI arms. The 95%prediction intervals (PIs) formortalitywere com-
puted using simulationwith bootstrap resampling (10 000 times). For the entire study cohort, the 4-year predictedmor-
talitieswere 8.5 and 10.5% in the PCI andCABGarms, respectively [odds ratios (OR) 0.79; 95%PI 0.43–1.50). In subjects
with low (≤22) anatomical SYNTAX scores, the predictedORwas 0.69 (95% PI 0.34–1.45); in intermediate anatomical
SYNTAX scores (23–32), the predicted OR was 0.93 (95% PI 0.53–1.62). Based on 4-year mortality predictions in
EXCEL, clinical characteristics shifted long-term mortality predictions either in favour of PCI (older age, male gender
andCOPD)orCABG(youngerage, lowercreatinine clearance, female gender, reduced left ventricular ejection fraction).
Conclusion The SYNTAX Score II indicates at least an equipoise for long-term mortality between CABG and PCI in subjects with
ULMCA disease up to an intermediate anatomical complexity. Both anatomical and clinical characteristics had a clear
impact on long-term mortality predictions and decision making between CABG and PCI.
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Introduction
Coronary artery bypass graft (CABG) surgery was introduced in
19671 with the aim of relieving angina pectoris, enhancing quality of
life and improving survival. In patients with unprotected left-main
coronary artery (ULMCA) disease, the superiority of CABG over
optimal medical treatment has been demonstrated in multiple
studies and meta-analyses2,3 and has been the standard of care for
over 30 years.
Percutaneous coronary intervention (PCI) was introduced into
clinical practice in 19774 and was initially considered appropriate
only for single-vessel disease. With the advent of drug-eluting
stents (DES), long-termoutcomes after PCI havemarkedly improved
in patients with more complex coronary artery disease. Specifically
for ULMCA disease, numerous registries and three randomized
trials have compared outcomes in subjects treated with either
CABGorPCI.5–7Consequently, theprevailing international revascu-
larization guidelines recommend revascularization of ULMCA with
CABG or PCI in subjects with SYNTAX scores that are low
[SYNTAX score ,23: class I recommendation for CABG or PCI
(level of evidence B for both)] and intermediate [SYNTAX score
23–32: class I for CABG and class IIa for PCI (level of evidence B
for both)]. The same guidelines recommend against revascularization
with PCI of ULMCA disease with high SYNTAX scores [SYNTAX
score ≥33: class I for CABG and class III for PCI (level of evidence
B for both)].8 These recommendations are based on similar 5-year
mortality and myocardial infarction, with a lower incidence of
stroke and increased risk of repeat revascularization with PCI com-
pared with CABG in subjects with ULMCA disease and lower ana-
tomical complexity.6,7
The introduction of the newer-generation everolimus-eluting
stent (EES)—with proven marked improvements in both safety and
efficacy9–13—hasprompted thedesignof the randomizedEvaluation
of Xience Everolimus-Eluting Stent Versus Coronary Artery Bypass
Surgery for Effectiveness of Left-Main Revascularization (EXCEL)
Trial.
Aiming to improve decision making between CABG and PCI in
patients with complex coronary artery disease, the SYNTAX Score
II combines anatomic and clinical factors.14,15 Importantly, the
SYNTAX Score II was developed in the landmark, all-comers, rando-
mized SYNTAX (Synergy between PCI with Taxus and Cardiac
Surgery) Trial where selection bias would have been minimal, and
externally validated in two real world registries.14,16 In addition, the
SYNTAXScore II hasbeen included in international revascularization
guidelines.8
Although numerous risk scores and prospective trials are avail-
able in the medical literature, their performances are reported
when the outcomes are already known. The aim of the present
study is to apply the SYNTAX Score II in the ongoing EXCEL trial,
in order to prospectively validate the SYNTAX Score II before
independent reporting of the outcomes of the trial, forecast the
4-year mortality outcomes in the PCI and CABG arms, and to de-
scribe how anatomical and clinical characteristics impact on the
long-term mortality predictions and decision making between
CABG and PCI.
Methods
Study population
The EXCEL trial (clinicaltrials.gov identifier: NCT01205776) is an inter-
national, prospective, unblinded, randomized multicenter trial that
enrolled 1905 subjects in 131 centres. Evaluation of the Xience
Everolimus-Eluting Stent vs. Coronary Artery Bypass Surgery for Effect-
iveness of Left-Main Revascularization was designed to establish
the safety and efficacy of the EES (XIENCE PRIMETM or XIENCE Vw or
XIENCE XpeditionTM or XIENCE PROTM; Abbott Vascular, Santa
Clara, CA, USA)) in patients with ULMCA disease. Evaluation of the
Xience Everolimus-Eluting Stent vs. Coronary Artery Bypass Surgery
for Effectiveness of Left-Main Revascularization adopted an enrolment
criteria of subjects with ULMCA disease up to intermediate anatomical
complexity (SYNTAX Score ,33), with minimal exclusion criteria to
allow meaningful comparisons between revascularization modalities
(Supplementary material online, Table S1). The information on the trial
endpoints and sample size calculation is also available in the Supplemen-
tary material online.
Following diagnostic angiography demonstrating significant ULMCA
disease and the consensusof the localHeartTeam (qualified participating
interventional cardiologist and cardiac surgeon), subjects were con-
sented and randomized 1 : 1 to: (i) PCI with the EES or (ii) CABG.All ran-
domized patients were scheduled to undergo follow-up telephone
contact or office visit up to 5 years post-procedure.
The primary endpoint of the EXCEL trial is the composite measure of
all-cause mortality, myocardial infarction or stroke [modified Rankin
Scale (mRS)≥1 and increase by≥1 frombaseline] at amedian follow-up
interval of 3 years post-index procedure.
SYNTAX Score II
The SYNTAX Score II has been described previously.14 In brief, the
SYNTAX Score II augments the purely anatomical SYNTAX score with
anatomical and clinical factors that were shown to alter the threshold
value of the anatomical SYNTAX score in order for equipoise to
be achieved between CABG and PCI for long-term mortality. The
SYNTAX Score II is composed of the anatomical SYNTAX score, pres-
ence of ULMCA disease, and six clinical characteristics [age, creatinine
clearance (CrCl), left ventricular ejection fraction (LVEF), gender,
chronic obstructive pulmonary disease (COPD) and peripheral vascular
disease (PVD)]. The SYNTAXScore II allows for 4-yearmortality predic-
tions to bemade following revascularizationwithCABGor PCI to aid de-
cision making between CABG and PCI. Importantly, the SYNTAX
Score II was developed in the randomized SYNTAX Trial (n ¼ 1800),
and externally validated in the multinational DELTA (n ¼ 2891) and
Credo-KYOTO (n ¼ 3896) registries.14,16,17
Using the actual baseline clinical and angiographic data from each en-
rolled patient in EXCEL, the SYNTAX Score II was calculated for each
patient. Scores were assigned for the presence and magnitude of each
predictor directly based on the Cox proportional hazards model coeffi-
cients generating different scores and 4-year mortality predictions for
PCI and CABG.14 To mirror conventional clinical practice, investigator
reported anatomical SYNTAX Scores were used in the analysis.18
Statistical analysis
Categorical variables are presented as numbers and percentages and
are compared with the x2 test. Continuous variables are expressed as
mean+ SD ormedian with interquartile range (IQR), and are compared
using the Student’s t-test or Wilcoxon rank-sum test based on their
C.M. Campos et al.Page 2 of 11
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distributions. Within EXCEL, SYNTAX Score II predictor values were
.99% completewith the exception of LVEFwhich was 95.1% complete.
An advanced multiple imputation strategy which takes the correlation
between all potential predictors (method of chained equations) was
used to account for missing values as previously described.19
Comparison of predicted 4-year mortality between
CABG and PCI arms
The individual predicted mortality and the odds ratio (OR) of the two
randomized revascularization strategies were calculated using the
SYNTAX Score II. To determine the 95% PIs, the trial was simulated
10 000 times and generated 4-year mortality from predictions based
on consecutive bootstrap samples20 of the original SYNTAX trial
(Figure 1).17,21 A prediction interval is an estimate of an interval in
which future observations will fall, with a certain probability, compared
with what has already been observed (SYNTAX trial).22 All data analyses
were performed using R version 2.15.3.23
Results
Between 29 September 2010 and 6 March 2014, 2909 patients with
ULMCA disease were screened and 1905 subjects randomized to
CABG (n ¼ 957) or PCI (n ¼ 948) (Figure 2).
Subjects in the two randomization armswerewell balancedwith
regards to baseline demographic and clinical characteristics
included in the SYNTAX Score II (Table 1). Overall, the median
age was 66.0 (IQR 59.0–73.0) years, 76.3% male, 24.7% female,
7.8% COPD and 8.6% PVD. The median LVEF was 60.0% (IQR
52.0–63.0%), median CrCl 85.0 mL/min (IQR 66.8–106.2 mL/
min) and the median anatomical SYNTAX score 21.0 (IQR 15.0–
26.0).
SYNTAX Score II 4-year mortality
predictions in the cohorts
The predicted mortality was 8.5% (95% PI 5.4–11.9%) in the PCI
arm and 10.5% (95% PI 6.6–15.1%) in the CABG arm (OR 0.79;
95% PI 0.43–1.50%) (Table 2).
Figure 3 demonstrates the first 1000 trial simulations. Based on nu-
merical differences in 4-year mortality predictions, 77.9% of trial
simulations (n ¼ 7790) favoured PCI and 22.1% of trial simulations
(n ¼ 2210) favoured CABG. In 55.2% of trial simulations (n ¼
5520) 4-year mortality predictions between CABG and PCI could
not be separated with statistical significance (P. 0.05). 40.4% (n ¼
4040) of trial simulations had mortality predictions separated with
statistical significance (P, 0.05) in favour of PCI, and 4.4% (n ¼
440) had mortality predictions separated with statistical significance
(P, 0.05) in favour of CABG.
Anatomical complexity
Anatomical complexity had a clear impact on mortality predictions.
In subjects with low (≤22) and intermediate,23–32 anatomical
SYNTAX scores the predicted OR were 0.69 (95% PI 0.34–1.45)
and 0.93 (95% PI 0.53–1.62), respectively (Table 2).
In the low SYNTAX score group, 54.2% (n ¼ 5420) of mortality
predictions were similar (P. 0.05) between CABG and PCI; in the
intermediate SYNTAX score group, 84.1% (n ¼ 8410) of mortality
predictions were similar (P. 0.05) between CABG and PCI
(Figure 3).
Mortality predictions that were separated with statistical signifi-
cance (P, 0.05) in favour of PCI were 43.7% (n ¼ 4370) in the
low SYNTAX score group, compared with 11.3% (n ¼ 1130) in
the intermediate SYNTAX score group. Conversely, mortality pre-
dictions that were separated with statistical significance (P, 0.05)
in favour of CABG were 2.1% (n ¼ 210) in the low SYNTAX
score group, compared with 4.6% (n ¼ 460) in the intermediate
SYNTAX score group.
Impact of clinical characteristics
Clinical characteristics had a clear impact on 4-yearmortality predic-
tions (Table 2, Figure 4). In both arms the subgroup with the highest
predicted mortalities was PVD [22.5% (95% PI 11.3–36.1%) in the
PCI arm and 26.5% (95% PI 13.1–41.7 in the CABG arm)].
Based on 4-year mortality predictions, older age, male gender and
COPD favoured PCI, whereas younger age, lower CrCl, impaired
LVEF and female gender favoured CABG (Figure 4).
Diabetes
In subjects with diabetes, predicted mortality was 9.9% (95% PI 5.6–
14.7%) in the PCI arm and 11.4% (95% PI 6.4–17.3%) in the CABG
arm [OR 0.86 (PI 0.40–1.90; Table 2]. Similar analyses in non-
diabetics yielded predicted mortalities of 7.9% (95% PI 4.8–11.3%)
in the PCI arm and 10.2% (95% PI 6.2–14.8%) in the CABG arm
[0.75 (PI 0.39–1.48)]. The presence of diabetes had a clear impact
on mortality predictions (Figure 5). Trial simulations were separated
with statistical significance (P, 0.05) in favour of PCI in 14.2%
(n ¼ 1420) of diabetics, compared with 37.5% (n ¼ 3750) in
non-diabetics. Comparatively, trial mortality predictions were sepa-
ratedwith statistical significance (P, 0.05) in favourofCABG in3.3%
(n ¼ 330), compared with 2.5% (n ¼ 250) in non-diabetics.
Discussion
The main findings of the study are: (i) The prospective use of a deci-
sion making and risk prediction tool (SYNTAX Score II) was feasible
in a large-scale randomized trial on completion of enrolment of sub-
jects, in which the follow-up results were unknown and blinded;
(ii) based on the SYNTAX Score II, we predicted a 77.9% chance of
a lower 4-year mortality in the PCI arm of the EXCEL trial, with a
40% chance that this will achieve statistical significance in favour of
PCI; (iii) The interplay between angiographic and clinical characteris-
tics has an important impactondecision-making and risk stratification
of patients with ULMCA disease.
SYNTAX Score II and prospective
mortality predictions
Theunprecedented aspect of the present studywas to prospectively
validate the SYNTAX Score II in a randomized trial that is still
ongoing, despite completion of enrolment of patients, with
expected reporting of the primary outcome in another 2 years. It
is important to emphasize that outcomes of EXCEL are being
collected, analysed and reported by an independent clinical
events committee (CEC), and that the current analyses were per-
formed with all authors completely blinded to any outcome data.
A second unique aspect of the present study was to report the
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Figure 1 Schematic representation of the SYNTAX Score II predictions used in the Evaluation of the Xience Everolimus-Eluting Stent vs. Cor-
onaryArtery Bypass Surgery for Effectiveness of Left-Main Revascularization trial. (A) Themortality predictions of percutaneous coronary interven-
tion and coronary artery bypass graft for each patient enrolled in the Evaluation of the Xience Everolimus-Eluting Stent vs. Coronary Artery Bypass
Surgery for Effectiveness of Left-Main Revascularization trial were calculated using the SYNTAXScore II. The pie chart represents the individual risk
of 4-yearmortality (red slice). (B) Basedon individualmortality predictions, patients’ outcomeswere simulated toobtain the 4-yearmortality in both
trial arms. (C ) To determine the 95% prediction intervals steps A and B were repeated 10 000 times with 4-year mortality predictions based on
consecutive bootstrap samples of the original SYNTAX trial.
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predicted long-term mortality of a randomized trial following com-
pletion of patient enrolment, blinded and prior to the actual reporting
of the trial. This was only possible because the SYNTAX Score II was
developed in the randomized SYNTAX trial—consisting of
a population with complex coronary artery disease (ULMCA
disease or de novo three-vessel disease)—and importantly where se-
lectionbiaswasminimal secondary to theunique all-comers designof
SYNTAX. In addition, the SYNTAX Score II has shown consistent
and solid predictive performances in two multicenter registries
for CABG and PCI-treated patients with left-main and/or complex
coronary artery disease.14,16
The SYNTAX Score II predicted a 55.2% likelihood that there
will not be a statistically significant difference in mortality
between the PCI and CABG arms of EXCEL at 4 years. This is
likely to be secondary to the clinical profile of the patients
recruited in EXCEL. On average subjects in EXCEL had preserved
LVEF, reasonable renal function, were predominantlymale, and im-
portantly more complex coronary artery disease (SYNTAX score
≥33) was a key exclusion criteria. In the SYNTAX trial, female
gender, reduced LVEF, lower CrCl, higher anatomical SYNTAX
scores and younger age were all shown to favour CABG.14,16,22
The combination of these angiographic and clinical profiles is
therefore likely to explain the predicted favourable results for
PCI, despite similar baseline clinical characteristics in the CABG
and PCI arms of EXCEL. The present study therefore does not
imply that PCI reduces mortality in all ULMCA revascularization,
but predicts that subjects with ULMCA disease with a lower ana-
tomical and risk profile may potentially derive a prognostic
benefit from undergoing PCI, whilst more complex disease and a
higher risk clinical profile would remain the domain of CABG on
the grounds of prognosis.
Figure 2 Enrolment and randomization of patients with previously untreated left-main coronary artery disease in the Evaluation of the Xience
Everolimus-Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left-Main Revascularization trial.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 SYNTAX score II baseline variables
PCI
N 5 948
CABG
N5 957
Anatomical SYNTAX
score (IQR)
21.0 (15–26) 20.0 (15.0–25)
Age (years) (IQR) 66.0 (59.0–73.0) 66.0 (60.0–73.0)
Creatinine clearance
(mL/min) (IQR)
85.7 (66.2–107.5) 84.6 (67.1–105.0)
LVEF (IQR) 60.0 (52.0–62.0) 60.0 (52.0–63.0)
Left main coronary artery
disease, n (%)
948 (100) 957 (100)
Female, n (%) 226 (23.8) 214 (22.4)
COPD, n (%) 67 (7.1) 81 (8.5)
PVD, n (%) 97 (10.3) 84 (8.8)
PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft;
LVEF, left ventricular ejection fraction; IQR, interquartile range; COPD, chronic
pulmonary obstructive disease; PVD, peripheral vascular disease.
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Impact of anatomic complexity in risk
predictions
Unprotected left-main coronary artery disease should be regarded
as a heterogeneous pathology when considering the choice of revas-
cularizationmodality. The anatomical complexityof the leftmainmay
vary from a single lesion in the shaft to distal trifurcation disease and
its association with more complex downstream (three-vessel)
disease. These variances may influence the capacity of PCI to
achieve complete revascularization, the number of stents implanted
and complexity of interventional techniques employed. Moreover,
incomplete revascularization and anatomical complexity have been
directly correlated to late all-cause mortality following PCI.24–26
This was exemplified in the PCI arm of the left-main subgroup of
SYNTAX, where the incidence of 5-year all-cause mortality was
shown to markedly increase in subjects with a SYNTAX score ≥33
(5-year mortality 20.9%) compared with subjects with a SYNTAX
score ,33 (5-year mortality 7.9%).
Conversely, in subjects undergoingCABG, anatomical complexity
has been shown to not affect long-term prognosis, as exemplified in
the CABG arm of the left-main subgroup of SYNTAX, where the in-
cidence of 5-year all-cause mortality remained almost unchanged in
subjects with a SYNTAX score ≥33 (5-year mortality 14.1%) com-
pared with subjects with a SYNTAX Score ,33 (5-year mortality
15.1%).24 In the present analysis, although the PIs were wide, the
expected mortality favoured PCI in the low (≤22) anatomical
SYNTAX score group (7.3 vs. 10.3%), and was practically equipoised
between PCI and CABG in the moderate (.22) anatomical
SYNTAX score group (10.1 vs. 10.8%; Table 2).
The aforementioned reasons explain why the risk predictions in
EXCEL are not at variancewith results of the recent randomized com-
parisons between CABG and PCI.6 Al Ali et al. pooled the results of
three randomized trials of first-generation DES vs. CABG in left-main
coronary artery disease and demonstrated that PCI did not reduce the
overall mortality (HR 1.08; 95% CI 0.75–1.57), since the global out-
comes reflected a composite of lower and higher mortality related
to simple and more complex coronary anatomy.6 In contrast,
EXCEL set an exclusion criteria of a SYNTAX score ≥33, thereby
selectingsubjectswith lesscomplexcoronaryarterydiseaseandthere-
fore potentially more favourable results for PCI.
Impact of clinical characteristics in risk
predictions
The predictions provided by the SYNTAX Score II displayed in the
Figure 4 deserve detailed examination since clinical characteristics
markedly affect the simulation patterns. Although it was shown that
certain subsetsofpatientsweremore likely tohave amortality reduc-
tion with PCI or CABG, it is important to emphasize that the asso-
ciated mortality impact was not exclusively derived from these
factors alone. The underlying principle of the SYNTAX Score II
being that it balances the interaction of anatomical complexity and
six clinical variables that were shown to directly effect decision
making on the most appropriate revascularization modality, and
not each individual anatomical/clinical characteristic (Supplementary
material online, Figure S1).Within the SYNTAXScore II, younger age,
female gender, impaired renal function and reduced LVEF were
shown to favourCABG comparedwith PCI on long-term prognostic
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Figure 3 First 1000 4-year mortality simulations of the Evaluation of the Xience Everolimus-Eluting Stent vs. Coronary Artery Bypass Surgery
for Effectiveness of Left-Main Revascularization trial on the SYNTAX Score II. Each dot represents one simulated trial mortality in both randomiza-
tion arms based on individual predictions. The diagonal line represents identical mortality for coronary artery bypass graft and percutaneous cor-
onary intervention. A dot plotted to the left of the diagonal line favours coronary artery bypass graft (actual percentages shown in top left corner),
and to the right favours percutaneous coronary intervention (actual percentages shown in bottom right corner). Simulated trials with a significant
(P ≤ 0.05)mortality differencebetweencoronary arterybypass graft andpercutaneous coronary intervention arecolouredblack (actual percentage
shown in parentheses in respective corners). Simulated trials with a non-significant (P . 0.05)mortality difference between coronary artery bypass
graft and percutaneous coronary intervention are coloured grey.
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grounds. As a result, patients with these specific characteristics were
shown to derive a prognostic benefit from CABG, even when the
anatomical complexity was lower. Conversely, older age, preserved
renal and left ventricular function, and COPDwere shown to favour
PCI compared with CABG on long-term prognostic grounds. As a
result, patients with these specific characteristics were shown to
derive aprognostic benefit formPCI, evenwhen the anatomical com-
plexity was higher.
Diabetes
Diabetes has previously been shown not to be an independent pre-
dictor of mortality in the CABG or PCI arms of the SYNTAX trial,
nor to have an interaction effect between CABG and PCI for long-
term mortality when the end organ manifestations of diabetes
were accounted for, as exemplified in the SYNTAX Score II.14,22
Conversely, the FREEDOM trial demonstrated a reduction in
Figure4 First 1000 4-yearmortality simulations of the Evaluation of the Xience Everolimus-Eluting Stent vs. Coronary Artery Bypass Surgery for
Effectiveness of Left-Main Revascularization trial on the SYNTAX Score II according to clinical characteristics. Each dot represents one simulated
trialmortality in both randomization armsbasedon individual predictions. Thediagonal line represents identicalmortality for coronary artery bypass
graft and percutaneous coronary intervention. A dot plotted to the left of the diagonal line favours coronary artery bypass graft and to the right
favours percutaneous coronary intervention. Simulated trials with a significant (P ≤ 0.05) mortality difference between coronary artery bypass
graft and percutaneous coronary intervention are coloured black (actual percentage shown in parentheses in respective corners). Simulated
trials with a non-significant (P . 0.05) mortality difference between coronary artery bypass graft and percutaneous coronary intervention are
coloured grey. Some factors are more favourable for percutaneous coronary intervention and others for coronary artery bypass graft and had dif-
ferent impact in the simulation pattern. CrCl, creatinine clearance; LVEF, left ventricular ejection fraction; COPD, chronic obstructive pulmonary
disease; PVD, peripheral vascular disease.
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mortality in diabetics with predominantly three-vessel disease
treated by CABG compared with first-generation drug-eluting
stents at a median follow-up of 3.8 years.27 Importantly, ULMCA
diseasewas an exclusion criteria in FREEDOMand is what prompted
the presentation of mortality predictions in the diabetic subset of
EXCEL. Notably in EXCEL, the presence of diabetes was associated
with an increase in predicted mortality within both the CABG and
PCI arms. Additionally, the predicted benefits of PCI were less pro-
nounced in diabetics compared to non-diabetics, but remained
similar to CABG (Figure 5; Table 2). In essence, despite the fact that
diabeteswas not containedwithin the SYNTAXScore II, the systemic
metabolic effect of diabetes (such as age, CrCl, LVEF and other
factors in the SYNTAX Score II) were associated with an increase
in the patient risk profile and less favourable mortality predictions
for PCI.14,28,29
The SYNTAX Score II and medical
advances
Evaluation of the Xience Everolimus-Eluting Stent vs. Coronary
Artery Bypass Surgery for Effectiveness of Left-Main Revasculariza-
tion was designed to study the impact of revascularization on
ULMCA disease, incorporating changes in medical therapies, PCI
technology and techniques, and advances in CABG that were intro-
duced since the completion of the SYNTAX trial. For example, as
the SYNTAX Score II was developed in the SYNTAX trial which—
exclusively used the first-generation paclitaxel-eluting TAXUS
stent, it is not inconceivable that the PCI arm of EXCEL may out-
perform the mortality predictions made in the present study. In
EXCEL, the workhorse drug-eluting stent was the EES (XIENCE).
The randomized comparisons of everolimus- vs. paclitaxel-eluting
stentsweredesignedandpowered for acombinationof angiographic,
ischemic and safety outcomes, and have consistently shown the EES
to be associated with more favourable outcomes compared with
paclitaxel-eluting stents.9–12 In addition, the largest patient level
meta-analysis (n ¼ 4989) of the SPIRIT clinical program has shown
that EESwas superior topaclitaxel-eluting stents in reducing all-cause
mortality (3.2 vs. 5.1%, HR: 0.65, 95% CI: 0.49–0.86; P ¼ 0.003.13 It
is however important to emphasize that this difference was only
driven by a lower non-cardiac mortality in the EES group and left-
main revascularization was an exclusion criteria.13 More specifically
in subjects undergoingULMCArevascularization, a recent systematic
review comparing EES with first-generation DES (n ¼ 2231) and a
propensity match study (n ¼ 344) have shown no statistically signifi-
cant differences in all-cause mortality.30,31 Furthermore, even within
the SYNTAX Trial, when all stent thrombosis related deaths were
removed, the impact on mortality reductions was shown to be
modest (definite stent 0.5% reduction in mortality, definite to prob-
able stent thrombosis 1.5% reduction in mortality).32,33
Limitations
Themajor limitation of the present study is also its greatest strength,
namely the complete absence of the EXCEL trial outcomes
(expected in the fall of 2016). We therefore cannot verify that the
SYNTAX Score II predictions are accurate. However, predicting
today the results of a randomized trial which will not be known for
2 years, assuming these predictions are reasonably borne out,
opens the door for how future randomized trials may be considered
whilst the longer-term (5 year) results of EXCEL are awaited.
In addition, the present study will also enable unbiased validation of
the SYNTAX Score II, fostering understanding of the multiple risk
factors involved in ULMCA disease and decision making on the
Figure 5 First 1000 4-year mortality simulations of the Evaluation of the Xience Everolimus-Eluting Stent vs. Coronary Artery Bypass Surgery
for Effectiveness of Left-Main Revascularization trial on the SYNTAX Score II according to the presence or absence of diabetes mellitus. See
Figure 4 legend for text in interpreting figure. As illustrated, the presence of diabetes was associated with an increase in predicted mortality
within both the coronary artery bypass graft and percutaneous coronary intervention arms, with the predicted benefits of percutaneous coronary
intervention being less pronounced in diabetics compared with non-diabetics. DM, diabetes mellitus.
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most appropriate revascularization modality. Although we are not
using risk prediction for the primary endpoint of the trial, all-cause
death is a hard, reproducible endpoint not subject to adjudication
bias or definitional variation.
Conclusions
In the large-scale, prospective randomizedEXCEL trial, the SYNTAX
Score II indicated at least an equipoise for long-term mortality
between CABG and PCI in subjects with ULMCA disease with low
and intermediate anatomical complexity. Clinical characteristics
had a clear impact on long-term mortality predictions and decision
making between CABG and PCI. The accuracy of these mortality
predictions will be compared with the actual individual outcome
data from EXCEL in the coming years.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Over the last decades, during which coronary angio-
plasty was extensively scrutinized as a therapeutic option
for patients with multivessel disease, the concept of com-
pleteness of revascularization naturally emerged as a
central issue of concern [1]. At first, the revascularization
completeness was simply estimated by the reduction of
luminal stenosis to values lower than 50% in all “major
epicardial vessels” with significant lesions by angiogra-
phy, and procedures were categorized in a binary fashion
into those resulting in complete or incomplete revascu-
larization. That definition has several obvious caveats
and was questioned since its inception. Nevertheless,
even when applying such a strict classification, a clear
evolution in the effectiveness of interventional cardiol-
ogy over time could be clearly seen, moving from a 25%
rate of complete revascularization with early balloon-
only angioplasty to about 70% with current stent-based
interventions, with impact on prognosis [1,2].
The recently developed residual SYNTAX Score is a
quantitative measure of the degree and complexity of
the residual disease left untreated after an invasive coro-
nary procedure. It was validated in datasets derived from
two randomized studies with over 3,500 patients, includ-
ing an all-comers population (for which selection bias
would have been minimal), and with a clinical follow-
up of up to 5 years [3,4]. Most importantly, instead of
only providing a dichotomous view of the completeness
of revascularization, the residual SYNTAX Score
appeared as a continuous metric that, eventually, would
be able to assess the level of the atherosclerotic burden
that could not be managed by an invasive approach.
In this issue of CCI, Capodanno et al. evaluated the
prognostic impact of baseline and residual SYNTAX
scores, as well as the change in the SYNTAX score
after the procedure, for patients treated with left main
coronary stenting. The authors demonstrated that both
the baseline and the residual SYNTAX scores had a
statistical correlation with late mortality. In particular,
the residual score yielded a predictive model of similar
discrimination but better calibration than the baseline
score. At first glance, these findings put into perspec-
tive the impact of incomplete revascularization on
prognosis, suggesting that the more is left untreated,
the worse is the prognosis. However, in the work of
Capodanno et al., patients with that were grossly
undertreated (i.e., high residual SYNTAX Score) were
also older, had more diabetes, worse left ventricular
function, higher EuroScore, and more extensive coro-
nary disease. Indeed, patients with high residual
SYNTAX score had worse prognosis because of the
incomplete revascularization or simply because they
were intrinsically a high risk population?
The analysis of residual SYNTAX score in the arti-
cle of Capodanno et al. provided a (only) moderate
predictive ability for late mortality. An issue of
utmost importance in current days is the development
of reliable tools to forecast the risk of adverse events.
The SYNTAX score (both baseline and residual) is an
indirect measure of the residual ischaemia burden. It
is quite plausible that the prognostic value of residual
SYNTAX score could be improved if enhanced by in-
formation from the functional significance of the re-
spective coronary stenosis. Finally, it should not be
forgot that the SYNTAX score is essentially an
instrument created to assess the technical complexity
of percutaneous coronary interventions. It is conceiva-
ble, therefore, that some of the features used to calcu-
late the score have a marked impact on the success
of the procedure (e.g., tortuosity of calcification) but
may not add in prognostic information for future
atherosclerosis-related events.
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Abstract
Aims: Incomplete revascularisation is common after percutaneous coronary intervention (PCI). While the 
absolute amount of residual coronary artery disease (CAD) after PCI has been shown to be associated with 
worse outcomes, whether the proportion of treated CAD is prognostically important remains to be deter-
mined. We sought to quantify the proportion of CAD burden treated by PCI and to evaluate its impact on out-
comes using a new prognostic instrument - the SYNTAX Revascularisation Index (SRI).
Methods and results: The baseline SYNTAX score (bSS) and residual SYNTAX score (rSS) were deter-
mined from 2,618 angiograms of patients enrolled in the prospective ACUITY trial. The SRI was then cal-
culated for each patient using the following formula: SRI=(1–[rSS/bSS])×100. Outcomes were examined 
according to three SRI groups (SRI=100% [complete revascularisation], 50-99%, and <50%). The median 
bSS was nine (IQR 5, 16), and after PCI the median rSS was one (IQR 0, 6). The median SRI was 85% (IQR 
50, 100), and was 100% in 1,079 patients (41.2%), 50-99% in 907 patients (34.6%), and <50% in 632 patients 
(24.1%). One-year adverse outcomes, including death, were inversely proportional to the SRI. An SRI cut-off 
of <80% (present in 1,189 [45.4%] patients after PCI) had the best prognostic accuracy for prediction of death 
(area under the curve 0.60, 95% confidence interval [CI]: 0.53-0.67, p<0.0001). By multivariable analysis, 
SRI was an independent predictor of one-year mortality (hazard ratio [HR] 2.17, 95% CI: 1.05-4.35, p=0.03). 
However, when compared to other scores, the rSS showed superior accuracy and predictive capability for 
one-year mortality.
Conclusions: The SRI is a newly described method for quantifying the proportion of CAD burden treated by 
PCI. Given its correlation with mortality, and pending external validation, the SRI may be useful in assessing 
the degree of revascularisation after PCI, with SRI ≥80% representing a reasonable goal. However, the rSS 
showed superior predictive capability for one-year mortality.
KEYWORDS
• incomplete
revascularisation
• percutaneous
coronary
intervention
• SYNTAX
Revascularisation
Index
• SYNTAX score
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Introduction
Achievement of complete revascularisation is intuitively desir-
able in patients with coronary artery disease (CAD) undergo-
ing percutaneous coronary intervention (PCI). However, despite 
major advances in PCI technology and technique, complete 
revascularisation is often not achieved (e.g., diffuse disease in 
small vessels, complex calcified lesions, chronic total occlu-
sions), and whether it is always necessary is a matter of consid-
erable debate1-5. Indeed, whereas incomplete revascularisation 
may be unavoidable and detrimental in patients with complex 
coronary artery disease5-7, in other cases (e.g., low CAD burden) 
the long-term prognosis may be reasonable with optimal medi-
cal therapy8. Among patients treated by PCI in the SYNTAX 
(SYNergy Between PCI With TAXUS and Cardiac Surgery) and 
ACUITY (Acute Catheterization and Urgent Intervention Triage 
StrategY) trials, approximately 40-60% achieved complete 
revascularisation1,2,9. Recently, we proposed a novel approach 
to characterise and quantify the completeness of revascularisa-
tion better – the residual SYNTAX score (rSS)1. This score has 
subsequently been validated by other groups and been shown to 
have good prognostic accuracy for adverse ischaemic outcomes 
after PCI2,10-12. Undetermined, however, is whether a thresh-
old level exists for a reasonable degree of incomplete revas-
cularisation. In the current report, we propose a novel index, 
the SYNTAX Revascularisation Index (SRI), which takes into 
account the severity and extent of baseline CAD (as assessed by 
the baseline SYNTAX score [bSS]) and the residual CAD after 
PCI (as assessed by the rSS) in determining the proportion of 
CAD that has been treated. We sought to determine the prognos-
tic utility of the SRI among patients undergoing PCI from the 
large, prospective, randomised ACUITY trial.
Methods
STUDY PROTOCOL
The ACUITY trial design has previously been described in 
detail13. Briefly, ACUITY was a multicentre, prospective, ran-
domised trial in which 13,819 patients were enrolled with mod-
erate and high-risk non-ST-segment elevation acute coronary 
syndromes (NSTE-ACS) undergoing an early invasive strategy. 
Prior to coronary angiography, patients were randomly assigned 
to heparin (unfractionated or low-molecular-weight) plus a gly-
coprotein IIb/IIIa inhibitor, bivalirudin plus a glycoprotein IIb/
IIIa inhibitor, or bivalirudin monotherapy. Angiography was per-
formed within 72 hours of randomisation, after which patients 
were triaged to PCI, coronary artery bypass graft (CABG) sur-
gery, or medical therapy. For patients who underwent PCI, stent 
type (bare metal or drug-eluting) was per operator discretion. 
Dual antiplatelet therapy with aspirin and clopidogrel was rec-
ommended for at least one year. An independent clinical events 
committee, blinded to treatment assignment, adjudicated all major 
adverse events. The institutional review board/ethics committee at 
each participating centre approved the study, and all patients pro-
vided written informed consent.
OBJECTIVES, PATIENT POPULATION, AND ANGIOGRAPHIC 
ANALYSIS
Our primary objective was to quantify the disease burden treated 
by PCI using the SRI and to evaluate its impact on adverse ischae-
mic outcomes, including all-cause death, cardiac death, myocardial 
infarction (MI), and unplanned repeat revascularisation for ischae-
mia. The present study was limited to patients undergoing PCI in 
whom quantitative coronary angiography was performed as part 
of a formal substudy by experienced core laboratory technicians 
blinded to randomisation and clinical outcomes (Cardiovascular 
Research Foundation, New York, NY, USA)14,15. Patients with prior 
CABG were excluded as the SYNTAX score (SS) had not been 
validated in this cohort at the time of analysis16.
SYNTAX REVASCULARISATION INDEX
For the present study, three experienced interventional cardiolo-
gists (PG, TP, and AC) blinded to randomisation and clinical out-
comes assessed the bSS17,18 and rSS1 for each angiogram (www.
SYNTAXscore.org). The Fleiss κstatistic19 (tertile partitioning), 
determined from 50 independently read films, was 0.57 for bSS 
signifying a moderate level of interobserver agreement20. The SRI, 
representing the proportion of CAD burden treated by PCI, was 
calculated using the following formula: SRI=(1–[rSS/bSS])×100. 
Patients were stratified into three groups and compared: SRI=100% 
(complete revascularisation), 50-99%, and <50%. Adverse ischae-
mic outcomes between groups were compared at one year.
ENDPOINT DEFINITIONS AND STATISTICAL ANALYSIS
Composite major adverse cardiovascular events (MACE) were 
defined as death from any cause, MI, or unplanned revascularisation 
for ischaemia. Definitions of the components of the MACE end-
point have been previously detailed15. All MACE endpoints were 
adjudicated by an independent committee blinded to randomisation.
Continuous data are presented as mean±SD or median (interquar-
tile range; IQR) and were compared using the ANOVA or Kruskal-
Wallis test as appropriate. Categorical variables were compared 
using the χ2 test. Correlation (Spearman) between rSS and SRI was 
examined. Comparisons of one-year outcomes were performed 
(Kaplan-Meier curves) with the log-rank test between the three 
groups of SRI. Major subgroup analyses were examined for poten-
tial interaction. Receiver operating characteristic (ROC) curves 
for SRI were determined to assess the relative predictive accuracy 
for one-year all-cause mortality. Area under the curve for the SRI 
was computed to identify the Youden index (best cut-off) for one-
year all-cause death. Differences in discrimination power between 
scores were evaluated using the χ2 test. Stepwise Cox multivari-
able regression analysis was performed to ascertain variables inde-
pendently associated with one-year mortality, with variable entry/
stay criteria of 0.1/0.1. In addition to the SRI, variables historically 
known to be associated with these adverse events were included 
in the models, with the number carefully chosen to avoid overfit-
ting1. The following variables were included in the model: SRI, age, 
insulin-treated diabetes, renal insufficiency, baseline white blood 
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cell count, and baseline cardiac biomarker elevation or ST-segment 
deviation. A p-value <0.05 was considered statistically significant 
for all analyses. Statistical analyses were performed using SAS ver-
sion 9.2 (SAS Institute, Cary, NC, USA).
Results
PATIENT AND BASELINE CHARACTERISTICS
Of 6,921 patients included in the angiographic substudy of 
ACUITY, 3,826 underwent PCI. After excluding patients with 
a history of CABG (n=862) and those in whom the bSS or rSS 
could not be calculated due to technical reasons (n=346), 2,618 
patients remained, comprising the current study population. No sig-
nificant differences in baseline characteristics or one-year adverse 
outcomes were observed between the 346 excluded patients and the 
study cohort (data not shown). The SYNTAX score ranged from 
one to 59, with a median of nine (IQR 5, 16). After PCI, the median 
of rSS was one (IQR 0, 6) ranging from zero to 47.5. The calculated 
SRI thus ranged from 0% to 100%, with a median of 85% (IQR 50, 
100). The SRI was 100% in 1,079 patients (41.2%), 50-99% in 907 
patients (34.6%), and <50% in 632 patients (24.1%).
Table 1 and Table 2 present clinical characteristics and angio-
graphic findings, stratified by SRI. Patients with lower SRI were 
older and had a higher prevalence of diabetes, hyperlipidaemia, and 
hypertension. They were also more likely to have a history of prior 
MI and reduced baseline haemoglobin levels and creatinine clear-
ance. Angiographically, patients with lower SRI were more likely to 
have multivessel disease, a greater number of lesions, and more exten-
sive disease. They were also more likely to have baseline TIMI 0/1 
flow, collaterals, and lesions with severe calcification or thrombus. 
Thienopyridines were less frequently used in the patients in the lowest 
SRI group at discharge and at 30-day follow-up, but not at one year.
The correlations between rSS and SRI are shown in Figure 1. 
There was a moderate significant negative correlation between rSS 
and SRI.
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Figure 1. Correlation between the residual SYNTAX score and the SYNTAX Revascularisation Index. Scatter plot graph showing a significant 
moderate negative correlation between rSS and SRI (lower rSS is associated with higher SRI). One dot represents more than one patient. rSS: 
residual SYNTAX score; SRI: SYNTAX Revascularisation Index.
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SRI <50% 632 599 595 586 425
SRI 50-99% 907 866 859 851 617
SRI 100% 1,079 1,042 1,039 1,033 752
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SYNTAX Revascularisation Index 50-99%
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Figure 2. Kaplan-Meier curves showing cumulative mortality rates 
through one year. The rate of death significantly increased with less 
complete revascularisation as assessed by SRI.
CLINICAL OUTCOMES
The one-year rates of MACE were inversely correlated with SRI, with 
the lowest MACE rates in the group with complete revascularisation 
and the highest MACE rate in the group with SRI <50%. Similar find-
ings were seen for death, cardiac death, and MI, with non-significant 
trends for higher rates of unplanned revascularisation and definite/
probable stent thrombosis in patients with the greatest degree of incom-
plete revascularisation (Table 3, Figure 2). By multivariable analysis, 
lower SRI was a strong independent predictor of one-year mortality 
(along with insulin-treated diabetes and advanced age) (Table 4).
ROC CURVE ANALYSIS
ROC curve analysis demonstrated a significant association between 
the SRI and one-year all-cause mortality. An SRI cut-off of 80% 
had the best prognostic accuracy for risk prediction of death (area 
Chapter 4.2
293
C
hapter 4.2
4
EuroIntervention 2
0
1
4
;1
0
-on
lin
e p
u
b
lish
-ah
ead
-of-p
rin
t O
ctob
er 2
0
1
4
under the curve [AUC] 0.60, 95% CI: 0.53-0.67, p<0.0001). When 
compared with the bSS and the rSS, the SRI demonstrated a slightly 
better sensitivity compared to the bSS and rSS (Table 5); however, 
the rSS, especially an rSS >8, demonstrated the best specificity and 
accuracy for one-year mortality when compared to other scores.
SUBGROUP ANALYSIS
The impact of SRI <80% was consistent in all subgroups exam-
ined except for sex (p-value for interaction=0.03) (Figure 3). SRI 
had a significant impact on one-year mortality in men, but not in 
women.
Table 1. Baseline characteristics according to the SYNTAX Revascularisation Index.
SRI, 100% 
n=1,079
SRI, 50-99% 
n=907
SRI <50% 
n=632
p-value 
for trend
SRI, % 100 (100, 100) 75 (63, 85) 23 (0, 36) <0.0001
Age, years 59.0 (51.0, 68.0) 59.00 (52.00, 69.00) 62.0 (54.5, 71.0) <0.0001
Male 720/1,079 (66.7) 625/907 (68.9) 432/632 (66.9) 0.55
Weight, kg 88.0 (75.0, 102.0) 86.00 (75.0, 99.0) 86.0 (76.9, 99.9) 0.43
Diabetes 270/1,074 (25.1) 266/902 (29.5) 207/629 (32.9) 0.002
Insulin-treated 69/1,074 (6.4) 78/903 (8.6) 58/632 (9.2) 0.07
Hypertension 667/1,074 (62.1) 597/904 (66.6) 449/632 (71.0) 0.0008
Hyperlipidaemia 574/1,062 (54.0) 493/891 (55.3) 382/626 (61.0) 0.02
Current smoker 382/1,076 (35.5) 325/905 (35.9) 213/628 (33.9) 0.71
Previous myocardial infarction 272/1,058 (25.7) 266/891 (29.9) 209/618 (33.8) 0.002
Previous PCI 474/1,078 (44.0) 388/904 (42.9) 286/632 (45.3) 0.66
Renal insufficiency 143/1,014 (14.1) 134/854 (15.7) 104/581 (17.9) 0.07
Baseline biomarker elevation 580/1,009 (57.5) 518/841 (61.6) 368/583 (63.1) 0.13
ST-segment deviation ≥1 mm 274/1,079 (25.4) 227/907 (25.0) 166/632 (26.3) 0.86
TIMI 
risk 
score
Low (0-2) 156/862 (18.1) 124/740 (16.8) 64/521 (12.3) 0.02
Intermediate (3-4) 526/862 (61.0) 440/740 (59.5) 290/521 (55.7) 0.14
High (5-7) 180/862 (20.9) 176/740 (23.8) 167/521 (32.1) <0.0001
Haemoglobin, g/dL 14.1 (13.0, 15.1) 14.0 (12.9, 15.2) 13.8 (12.7, 15.0) 0.04
White blood cells, ×106 8.0 (6.5, 9.7) 8.1 (6.5, 9.9) 8.3 (6.5, 10.2) 0.15
Platelets (×103) 234.0 (195.0, 274.0) 232.0 (194.0, 277.0) 229.0 (192.0, 283.0) 0.86
Creatinine clearance, mL/min 96.8 (71.7, 123.1) 94.1 (71.8, 119.0) 86.8 (66.6, 115.1) 0.001
2-vessel disease 437/1,079 (40.5) 364/907 (40.1) 193/632 (30.5) <0.0001
3-vessel disease 272/1,079 (25.2) 398/907 (43.9) 377/632 (59.7) <0.0001
Extent of disease (mm) 28.9 (17.0, 42.4) 38.0 (23.0, 58.0) 41.6 (25.0, 62.4) <0.0001
Lesions per patient 3.0±1.8 3.9±2.0 4.6±2.4 <0.0001
PCI 
vessel
Left anterior descending 534/1,079 (49.5) 494/906 (54.5) 80/534 (15.0) <0.0001
Right coronary artery 387/1,079 (35.9) 342/906 (37.7) 269/534 (50.4) <0.0001
Left circumflex 347/1,079 (32.2) 311/906 (34.3) 224/534 (41.9) 0.0005
TIMI 0/1 flow, any lesion 124/1,078 (11.5) 214/907 (23.6) 207/630 (32.9) <0.0001
Collateral vessels present 134/1,079 (12.4) 214/907 (23.6) 226/632 (35.8) <0.0001
Severe calcification, any lesion 49/1,078 (4.5) 60/906 (6.6) 56/631 (8.9) 0.002
Thrombus, any lesion 0/1,079 (0.0) 15/907 (1.7) 60/632 (9.5) <0.0001
Ulceration, any lesion 54/1,078 (5.0) 67/907 (7.4) 52/631 (8.2) 0.02
Drug-eluting stent(s) implanted 939/1,079 (87.0) 791/907 (87.2) 495/632 (78.3) <0.0001
Baseline SYNTAX score 6.0 (3.0, 10.0) 11.0 (7.0, 18.0) 14.0 (9.0, 21.0) <0.0001
Residual SYNTAX score 11.0 (7.0, 16.0) 2.0 (1.0, 5.0) 11.0 (7.0, 16.0) <0.0001
Delta SYNTAX score 6.0 (3.0, 10.0) 8.0 (5.0, 13.0) 3.0 (0.0, 5.0) <0.0001
Ejection fraction, % 66.7 (58.9, 73.5) 66.1 (57.8, 72.6) 65.7 (56.8, 72.9) 0.13
Data presented as n/N (%), mean±standard deviation or median (interquartile range). MI: myocardial infarction; PCI: percutaneous coronary 
intervention; SRI: SYNTAX Revascularisation Index; TIMI: Thrombolysis In Myocardial Infarction
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Table 2. Medication use according to the SYNTAX Revascularisation Index.
SRI, 100% 
n=1,079
SRI, 50-99% 
n=907
SRI <50% 
n=632
p-value  
for trend
Pre-PCI medications Aspirin 807/1,079 (74.8) 697/907 (76.8) 488/632 (77.2) 0.42
Thienopyridine 364/1,079 (33.7) 308/907 (34.0) 225/632 (35.6) 0.71
Procedural 
antithrombin agents
Bivalirudin 731/1,079 (67.7) 586/907 (64.5) 403/632 (63.8) 0.16
Unfractionated heparin 212/1,079 (19.6) 164/907 (18.1) 140/632 (22.2) 0.14
Enoxaparin 130/1,079 (12.0) 142/907 (15.7) 75/632 (11.9) 0.03
Glycoprotein IIb/IIIa inhibitor 723/1,079 (67.0) 619/907 (68.2) 425/632 (67.2) 0.83
Discharge medications Aspirin 950/1,066 (89.1) 793/900 (88.1) 546/625 (87.4) 0.54
Thienopyridine 938/1,066 (88.0) 756/900 (84.0) 500/625 (80.0) <0.0001
30-day medications Aspirin 1,023/1,054 (97.1) 858/877 (97.8) 584/605 (96.5) 0.31
Thienopyridine 991/1,054 (94.0) 833/877 (95.0) 554/605 (91.6) 0.03
Statins 890/1,054 (84.4) 723/876 (82.5) 512/605 (84.6) 0.44
Beta-blockers 814/1,054 (77.2) 686/876 (78.3) 477/605 (78.8) 0.72
ACE inhibitors 552/1,054 (52.4) 498/875 (56.9) 358/605 (59.2) 0.02
1-year medications Aspirin 941/1,029 (91.4) 771/848 (90.9) 536/585 (91.6) 0.88
Thienopyridine 693/1,028 (67.4) 584/848 (68.9) 394/585 (67.4) 0.76
Statins 817/1,029 (79.4) 650/848 (76.7) 480/585 (82.1) 0.044
Beta-blockers 705/1,029 (68.5) 583/848 (68.8) 428/585 (73.2) 0.11
ACE inhibitors 520/1,029 (50.5) 441/848 (52.0) 305/585 (52.1) 0.76
Data presented as n/N (%). ACE: angiotensin-converting enzyme; PCI: percutaneous coronary intervention; SRI: SYNTAX Revascularisation Index
Table 3. One-year outcomes according to the SYNTAX Revascularisation Index.
SRI 100% (a) 
n=1,079
SRI 50-99% (b) 
n=907
SRI <50% (c) 
n=632
p-value 
(a) vs. (b)
p-value 
(a) vs. (c)
p-value 
(b) vs. (c)
p-value  
for trend
Major adverse cardiac events* 167 (16.4) 171 (19.2) 136 (22.1) 0.04 0.0009 0.19 0.004
Death 15 (1.4) 24 (2.7) 23 (3.8) 0.04 0.002 0.26 0.009
Cardiac death 4 (0.4) 18 (2.0) 12 (1.9) 0.0006 0.002 0.92 0.002
Myocardial infarction 75 (7.1) 97 (10.8) 67 (10.8) 0.003 0.007 0.96 0.005
Death or myocardial infarction 86 (8.2) 110 (12.3) 82 (13.2) 0.002 0.0007 0.64 0.0009
Unplanned revascularisation for ischaemia 109 (11.0) 99 (11.4) 86 (14.3) 0.51 0.02 0.09 0.052
Definite/probable stent thrombosis 12 (1.1) 17 (1.9) 12 (2.0) 0.16 0.18 0.96 0.29
Data presented as n (%). *Includes death, myocardial infarction, or unplanned revascularisation for ischaemia. SRI: SYNTAX Revascularisation Index
Discussion
The present report describes a new prognostic tool, the SRI, which 
may be used to quantitate the effectiveness of a revascularisation pro-
cedure in “removing” the angiographic burden of CAD. As such, the 
SRI may be useful to examine the extent of incomplete revasculari-
sation which may be considered reasonable. The SRI was developed 
and studied in a cohort of 2,618 patients with moderate and high-risk 
NSTE-ACS who underwent PCI. The principal findings of the pre-
sent study are as follows. (1) The SRI was associated with one-year 
adverse ischaemic outcomes, with mortality, MI, and MACE being 
inversely correlated with SRI. (2) The SRI was a strong and inde-
pendent predictor of one-year mortality. (3) In this regard, achieve-
ment of an SRI ≥80% may be considered a reasonable goal for PCI. 
(4) However, among our low-risk population, the rSS had better 
predictive capability for one-year mortality when compared to SRI.
Table 4. Independent predictors of one-year mortality.
Variables
Hazard Ratio [95% 
confidence interval]
p-value
SYNTAX Revascularisation Index 2.17 [1.05, 4.35] 0.03
Insulin-treated diabetes 3.92 [2.17, 7.06] <0.0001
Age (per 10-year increment) 1.48 [1.13, 1.94] 0.004
The following variables were included in the model: SYNTAX 
Revascularisation as a continuous variable, age, insulin-treated diabetes, 
renal insufficiency, baseline white blood cell count, and baseline cardiac 
biomarker elevation or ST-segment deviation.
Achieving complete revascularisation is not always possible, and 
whether it is necessary for favourable outcomes is still a matter of 
debate. Using a different definition of incomplete revascularisa-
tion, ~40% of PCI patients in the SYNTAX trial had incomplete 
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revascularisation, underlining the difficulty of achieving complete 
revascularisation with PCI in some patients with extensive CAD2,5,21. 
As such, the construct of “reasonably incomplete revascularisation” 
has been proposed22-24. However, the extent of jeopardised myo-
cardium which must be treated by PCI to improve prognosis has 
never been examined. It is well accepted that the amount of myo-
cardium at risk at baseline and the complexity and extent of CAD 
are directly correlated with the occurrence of adverse events after 
revascularisation17,25,26. Several studies have now shown that the 
amount of residual CAD after revascularisation is prognostically 
important, with an rSS >8 after PCI being associated with worse 
outcomes1,2,9,10. While achieving an rSS <8 after PCI might thus be 
seen as a reasonable goal, for patients with extensive CAD (e.g., 
bSS >32), characterisation of the proportion of CAD treated (SRI) 
may be more appropriate and informative when considering revas-
cularisation options and for procedural planning.
The SRI represents a novel and complementary tool developed 
to characterise better the proportion of CAD treated by PCI and 
to describe the completeness of revascularisation better. Given 
its strong association with mortality, an SRI ≥80% could be seen 
as a reasonable goal when achieving incomplete revascularisa-
tion after PCI among patients presenting with NSTE-ACS and 
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Figure 3. Major subgroup analysis and the impact of the SYNTAX Revascularisation Index on one-year mortality. The detrimental impact of 
incomplete revascularisation (SRI <80%) was consistent in all subgroups examined except for sex.
Table 5. Comparison of predictive capability of the baseline SYNTAX score, residual SYNTAX score, and SYNTAX Revascularisation 
Index for one-year mortality.
AUC [95% CI] p-value Optimal cut-off Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
bSS* 0.64 [0.56,0.71] 0.0004 13 59.7 64.4 3.9 98.5 64.3
rSS* 0.63 [0.56,0.71] 0.0003 5 51.6 69.6 4.0 98.3 69.1
SRI* 0.60 [0.53,0.67] 0.004 80% 62.9 53.6 3.2 98.4 53.9
rSS >8¶ 0.59 [0.53,0.65] 0.005 8¶ 37.1 80.2 4.4 98.1 79.2
SRI <80%¶ 0.56 [0.50,0.63] 0.04 80%¶ 58.6 54.9 3.0 98.2 55.0
* Predictive metrics derived using score as a continuous variable and using the best cut-off as determined by the Youden index from the current studied 
cohort. ¶ Predictive metrics derived using score as a binary variable (rSS >8 and SRI <80%) and using historical proven cut-off1,2. Overall comparison of 
AUC for bSS, rSS, and SRI: p=0.003. Pairwise comparison of AUC SRI vs. rSS: p=0.0014. Pairwise comparison of AUC SRI vs. bSS: p=0.30. 
AUC: area under the curve; bSS: baseline SYNTAX score; NPV: negative predictive value; PPV: positive predictive value; rSS: residual SYNTAX score; 
SRI: SYNTAX Revascularisation Index
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relatively low-risk CAD. However, the rSS, characterising the 
absolute amount of residual CAD after PCI, remains the most spe-
cific and accurate score for prediction of one-year mortality. That 
being said, the bSS, rSS and SRI have different meanings and 
roles during the patient assessment and clinical decision-making 
process, and therefore each may have utility in practice and dur-
ing clinical trials (Table 6). The bSS is an important prognos-
tic tool to assess patient outcomes prior to revascularisation and 
helps discriminate between the choice of PCI and CABG for indi-
vidual patients. Alternatively, the rSS and the SRI not only have 
post-procedural prognostic utility, but can also serve as a guide 
for clinical decision making, depending on the expected degree of 
revascularisation. Unless at least a reasonable and appropriate27 
level of revascularisation can be achieved, CABG may be a better 
alternative to PCI.
Table 6. SYNTAX score concepts at different times relative to 
revascularisation.
Scores Definition
Baseline SYNTAX score (bSS) Quantification of CAD 
pre-revascularisation
Residual SYNTAX score (rSS) Quantification of CAD 
post-revascularisation
Delta SYNTAX score (∆SS) Quantification of the absolute 
CAD burden treated
SYNTAX Revascularisation Index 
(SRI)*
Quantification of the proportion 
of CAD burden treated
*SRI: (1–[rSS/bSS])×100. CAD: coronary artery disease
It is important to emphasise that, while an SRI of ≥80% might 
be used as a benchmark for “reasonably incomplete” revascularisa-
tion, the ACUITY trial represents a population with angiographi-
cally low-risk CAD (median bSS of nine). External validation of 
the SRI concept in a population of patients involving more com-
plex CAD would be interesting, especially to determine the stabil-
ity of its predictability among different levels of CAD complexity 
(as previously demonstrated by an rSS <8)2. The extent of incom-
plete revascularisation (SRI) in SYNTAX is not known, and would 
be useful both to validate the concepts presented in the present 
report, and to examine the extent to which more complete revascu-
larisation after PCI might have narrowed the differences observed 
between PCI and CABG in that trial. That being said, the impact 
of incomplete revascularisation on mortality has been shown to be 
significantly lower with CABG when compared to PCI21,27,28, and 
using a different method to quantify the incompleteness of revascu-
larisation will probably not result in different findings.
Limitations
Despite being conducted in a large cohort of patients from a ran-
domised controlled trial with detailed angiographic core labora-
tory analysis, several limitations should be acknowledged. First, 
the ACUITY trial enrolled patients with NSTE-ACS. Whether 
achieving an SRI ≥80% in an external population of patients with 
NSTE-ACS or stable CAD has similar prognostic implications 
remains to be proven. Second, the baseline anatomic complexity 
in the ACUITY trial was low (median bSS of nine); whether the 
SRI cut-off of 80% is optimal in a more complex CAD popula-
tion (e.g., SYNTAX trial cohort) is unknown. Third, the SYNTAX 
score (bSS, rSS and SRI) is based on identifying lesions with 
diameter stenosis ≥50% in vessels ≥1.5 mm in diameter. Using 
a different threshold for vessel diameter (e.g., 2 mm) and lesion 
severity (e.g., diameter stenosis ≥70%) would lead to different 
results9, although whether the prognostic accuracy would be 
greater is unknown. Fourth, assessment of the SYNTAX score is 
well known to have high variability, an issue that could be over-
come by appropriate training20 or by consensus of several read-
ers29. While the three readers involved in the current study were 
appropriately trained and achieved an excellent level of agreement 
before initiating the SYNTAX score evaluation20, each SYNTAX 
score was not performed by consensus of the three readers, but 
rather by a single reader. Given that the rSS, the delta SS, and 
the SRI are all derived from the bSS, different results might have 
been obtained if carried out by consensus29. Fifth, CABG patients 
were not included in our analysis, and the results of the present 
analysis do not apply to this group. Sixth, the relatively short fol-
low-up (one year), the modest number of deaths (n=62), and the 
retrospective nature of this study preclude definitive conclusions. 
The findings from this study are hypothesis-generating, and await 
external validation from other databases. In this regard, the sub-
group interaction implying that SRI may be of greater utility in 
men as compared to women deserves further study. Finally, the 
SYNTAX score concept (bSS, rSS and SRI) is based on coronary 
anatomy complexity only, and recent studies have demonstrated 
the value of an ischaemic-oriented revascularisation30 or a com-
bination of both (angiographic and ischaemic)31. Future studies 
are necessary to determine whether greater prognostic accuracy 
can be achieved by assessing the degree of functional or ischae-
mic revascularisation. The ongoing ISCHEMIA (NCT01471522), 
EXCEL (NCT01205776) and COMPLETE (NCT01740479) tri-
als are prospectively examining this issue in different patient 
populations.
Conclusion
In conclusion, derived from a population of NSTE-ACS with 
low complexity of CAD at baseline, the SRI is a newly described 
method for quantifying the proportion of CAD burden successfully 
treated by PCI. Pending external validation, the SRI may be use-
ful in anticipating or assessing the degree of revascularisation in 
patients with CAD, with SRI ≥80% a reasonable goal. Nonetheless, 
the rSS remains the best metric for completeness of revascularisa-
tion, showing the best predictive capability and accuracy for one-
year mortality.
Guest Editor
This paper was guest edited by Antonio Colombo, MD, San 
Raffaele Scientific Institute, Milan, Italy.
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Impact on daily practice
Complete revascularisation after percutaneous coronary interven-
tion is often not achieved, especially in patients with complex 
multivessel coronary artery disease. Derived from the baseline 
and residual SYNTAX scores, the current report proposes a new 
index, the SYNTAX Revascularisation Index (SRI), which pro-
vides insight into what might constitute a reasonable level of 
complete revascularisation. The SRI, paired with the two previ-
ously developed scores, offers the full quantitative language nec-
essary to characterise the baseline, residual, and treated burden of 
coronary disease appropriately at any stage of revascularisation. 
Anticipating the SRI after PCI may be useful for clinical decision 
making, when choosing between revascularisation modalities.
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Validation of the SYNTAX Revascularization Index
to Quantify Reasonable Level of Incomplete
Revascularization After Percutaneous Coronary Intervention
Philippe Généreux, MDa,b,c, Carlos M. Campos, MDd,e, Vasim Farooq, MBChBd,
Christos V. Bourantas, MD, PhDd, Friedrich W. Mohr, MD, PhDf, Antonio Colombo, MDg,
Marie-Angèle Morel, BScd, Ted E. Feldman, MDh, David R. Holmes Jr, MDi, Michael J. Mack, MDj,
Marie-Claude Morice, MDk, A. Pieter Kappetein, MD, PhDd, Tullio Palmerini, MDl,
Gregg W. Stone, MDa,b, and Patrick W. Serruys, MD, PhDd,m,*
Incomplete revascularization is common after percutaneous coronary intervention (PCI).
Whether a “reasonable” degree of incomplete revascularization is associated with a similar
favorable long-term prognosis compared with complete revascularization remains un-
known. We sought to quantify the proportion of coronary artery disease burden treated by
PCI and evaluate its impact on outcomes using a new prognostic instrument—the Synergy
Between PCI with Taxus and Cardiac Surgery (SYNTAX) Revascularization Index (SRI).
The baseline SYNTAX score (bSS), the residual SYNTAX score, and the delta SYNTAX
score (DSS) were determined from 888 angiograms of patients enrolled in the prospective
SYNTAX trial. The SRI was then calculated for each patient using the following formula:
SRI [ (DSS/bSS]) 3 100. Outcomes were examined according to the proportion of
revascularized myocardium (SRI[ 100% [complete revascularization], 50% to <100%, and
<50%). The Youden index for the SRI was computed to identify the best cutoff for 5-year
all-cause mortality. The mean bSS was 28.4 – 11.5, and after PCI, the mean DSS was 23.8 –
10.9 and the mean residual SYNTAX score was 4.5 – 6.9. The mean SRI was 85.3 – 21.2%
and was 100% in 385 patients (43.5%), <100% to 50% in 454 patients (51.1%), and <50% in
48 patients (5.4%). Five-year adverse outcomes, including death, were inversely propor-
tional to the SRI. An SRI cutoff of <70% (present in 142 patients [16.0%] after PCI) had the
best prognostic accuracy for prediction of death and, by multivariable analysis, was an
independent predictor of 5-year mortality (hazard ratio [HR] 4.13, 95% confidence interval
[CI] 2.79 to 6.11, p <0.0001). In conclusion, the SRI is a newly described method for
quantifying the proportion of coronary artery disease burden treated by PCI. The SRI is a
useful tool in assessing the degree of revascularization after PCI, with SRI ‡70% repre-
senting a “reasonable” goal for patients with complex coronary artery disease.  2015
Elsevier Inc. All rights reserved. (Am J Cardiol 2015;116:174e186)
The Synergy Between PCI with Taxus and Cardiac
Surgery (SYNTAX) score (SS) has become a well-
established instrument to quantify the extent and
complexity of baseline coronary artery disease (CAD).1 It
has been validated in many populations and patient sub-
sets.2e5 The residual SYNTAX score (rSS) was designed6
and validated to quantify the absolute amount of un-
treated CAD after percutaneous coronary intervention
(PCI) revascularization.7,8 An rSS �8 was identified as a
level of incomplete revascularization strongly associated
with increased mortality and adverse ischemic events.6,7
Recently, the SYNTAX Revascularization Index (SRI),
representing the proportion of treated baseline CAD
(baseline SYNTAX score [bSS]; delta SYNTAX score
[DSS]), was developed as a tool to better quantify and
describe the proportion of the disease treated (SRI ¼ DSS/
bSS � 100) by PCI revascularization.9 The SRI has been
shown to be an independent predictor of 1-year mortality in
patients with noneST-elevation acute coronary syndrome
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The Netherlands; eDepartment of Interventional Cardiology, Heart Institute
(InCor), University of São Paulo Medical School, São Paulo, Brazil; fKlinik
fur Herzchirurgie, Leipzig, Germany; gColumbus Hospital/San Raffaele
Hospital, Milan, Italy; hCardiology Division, Evanston Hospital, Evanston,
Illinois; iMayo Clinic, Rochester, Minnesota; jBaylor Healthcare System,
Dallas, Texas; kInstitut Cardiovasculaire Paris Sud, Paris, France; lIstituto di
Cardiologia, Policlinico S. Orsola, University of Bologna, Bologna, Italy;
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and can be used as a “goal” to be achieved by PCI. How-
ever, external validation of this concept in a different
population and who underwent longer follow-up is lacking.
We, therefore, aimed to externally validate the SRI as a new
prognostic tool in patients who underwent PCI from the
randomized SYNTAX trial.
Figure 1. Case examples with bSS, rSS, DSS, and SRI. Baseline angiogram showing angiographic 3-vessel disease with a lesion of the proximal left anterior
descending artery (LAD) and first diagonal (A), a lesion of the left proximal circumflex (LCx) and second marginal (B), and a lesion of the posterior descending
artery (C). The baseline SYNTAX score was 21. After percutaneous revascularization of the LAD and diagonal (D) and LCx and marginal (E) (DSS of 19), the
residual SYNTAX score was 2 (F), with an SRI of w90% (19 of 21).
Coronary Artery Disease/SYNTAX Revascularization Index 175
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Table 1
Baseline and procedural characteristics according to the SYNTAX Revascularization Index
Variables
SRI ¼ 100%
(N¼386)
SRI 50% to <100%
(N¼454)
SRI <50%
(N¼48)
p Value
Age (years) 64.6�9.8 65.7�9.5 65.9�8.5 0.11
Men 280 (72.5%) 362 (79.7%) 35 (72.9%) 0.04
Diabetes mellitus 85 (22.0%) 148 (32.6%) 19 (39.6%) 0.001
Insulin-requiring diabetes 27 (7.0%) 53 (11.7%) 9 (18.8%) 0.009
Body mass index (kg/m2) 28.0�4.7 28.1�4.9 29.3�4.9 0.27
Hypertension 273 (71.5%) 341 (75.6%) 39 (81.3%) 0.20
Hyperlipidemia 300 (77.9%) 353 (78.6%) 41 (87.2%) 0.34
Current smoker 79 (20.5%) 76 (16.7%) 9 (18.8%) 0.38
Chronic obstructive pulmonary disease 34 (8.8%) 34 (7.5%) 3 (6.3%) 0.70
Peripheral vascular disease 32 (8.3%) 45 (9.9%) 5 (10.4%) 0.69
History of gastrointestinal bleeding/peptic Ulcer disease 17 (4.4%) 16 (3.5%) 3 (6.5%) 0.57
History of stroke/Transient ischemic attack 27 (7.0%) 37 (8.2%) 5 (10.4%) 0.65
Creatinine >200 mmol/L 4 (1.0%) 6 (1.3%) 0 (0.0%) 0.69
Dialysis 1 (0.3%) 2 (0.4%) 0 (0.0%) 0.83
Previous myocardial infarction 114 (29.8%) 144 (32.1%) 19 (39.6%) 0.36
Unstable angina 100 (25.9%) 146 (32.2%) 10 (20.8%) 0.06
Baseline anatomical and clinical scores
Baseline SYNTAX score 23.6�10.0 32.2�10.9 29.35�13.10 <0.001
Residual SYNTAX score 0.0�0.0 6.2�3.9 23.9�12.9 <0.001
SYNTAX Revascularization Index (%) 100.0�100.0 79.9�11.1 17.3�22.3 <0.001
Total Parsonnet Score 8.2�7.1 8.7�6.8 10.2�7.3 0.07
Logistic EuroSCORE 3.8�5.5 3.8�3.6 3.5�3.1 0.78
Left ventricular ejection fraction (%) 60.3�12.2 59.8�12.9 57.4�13.9 0.002
Procedural Characteristics
Intra-aortic Balloon Pump 11 (2.8%) 8 (1.8%) 3 (6.3%) 0.14
Bifurcation 221 (57.3%) 305 (67.2%) 28 (58.3%) 0.10
Trifurcation 28 (7.3%) 33 (7.3%) 4 (8.3%) 0.96
Ostial lesion 66 (17.3%) 61 (13.4%) 9 (18.8%) 0.25
Total occlusion 47 (12.3%) 145 (31.9%) 20 (41.7%) <0.001
Severe tortuosity 213 (55.8%) 338 (74.4%) 32 (66.7%) <0.001
Lesion length >20 mm 176 (46.1%) 292 (64.3%) 24 (50.0%) <0.001
Heavy calcification 163 (42.7%) 245 (54.0%) 28 (58.3%) 0.002
Left main lesion 164 (42.5%) 173 (38.1%) 18 (37.5%) 0.41
Left main þ 3-vessel disease 37 (9.6%) 87 (19.2%) 10 (20.8%) <0.001
3-vessel disease only 211 (54.7%) 276 (60.8%) 30 (62.5%) 0.17
Right coronary lesion 289 (74.9%) 384 (86.8%) 44 (91.7%) <0.001
Left anterior descending lesion 328 (85.0%) 421 (92.7%) 43 (89.6%) 0.001
Left circumflex lesion 300 (77.7%) 413 (91.0%) 44 (91.7%) <0.01
Procedure time (hours) 1.6�0.9 1.8�0.9 2.2�1.0 <0.001
Total number of stents 4.5�2.4 4.8�2.1 4.1�2.2 0.47
Total stent length (mm) 85.8�51.6 87.1�45.0 73.1�37.5 0.75
Data present as n (%) or mean � SD.
SRI ¼ SYNTAX Revascularization Index.
Table 2
Five-year outcomes according to the SYNTAX Revascularization Index
Variables SRI ¼ 100%
(N¼386)
SRI 50% to <100%
(N¼454)
SRI <50%
(N¼48)
p Value*
Death 33 (8.6%) 73 (16.1%) 16 (33.3%) <0.0001
Cardiac death 17 (4.3%) 51 (11.2%) 13 (26.2%) <0.0001
Myocardial infarction 27 (7.1%) 48 (10.6%) 13 (26.5%) <0.0001
Unplanned revascularization 73 (18.9%) 131 (28.9%) 30 (62.5%) <0.0001
Stent thrombosis (definite/probable) 26 (6.7%) 43 (9.4%) 11 (22.2%) <0.0001
MACCE 107 (27.7%) 192 (42.3%) 34 (69.9%) <0.0001
Values are KM rate estimate.
Data presented as n (%).
MACCE ¼ major adverse cardiac and cerebrovascular events.
* Log-rank test.
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Methods
The SYNTAX trial was a randomized, prospective,
multicenter trial investigating patients with de novo 3-vessel
CAD and/or unprotected left main CAD (isolated or associ-
ated with 1-, 2-, or 3-vessel disease).2,10 In brief, a total of
1,800 patients were recruited and randomized to PCI
(n ¼ 903) or coronary artery bypass grafting (CABG;
n ¼ 897) from 85 centers in Europe and the United States.
Exclusion criteria were limited to subjects with previous
coronary revascularization, the requirement of concomitant
cardiac surgery, or ongoing acute myocardial infarction (MI).
During the local Heart Team meeting, the interventional
Figure 2. Kaplan-Meier curves showing cumulative mortality and adverse event rates through 5 years according to SRI. The rate of death (A), cardiac death (B),
MI (C), revascularization (D), and MACCE (E) significantly increased with the degree of incomplete revascularization as assessed by the SRI.
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cardiologist and cardiac surgeon specified the number of
coronary lesions requiring treatment, their angiographic
location, and characteristics using the bSS (http://www.
syntaxscore.com). In case equivalent anatomical revascular-
ization could be achieved with both treatment strategies, were
randomized on a 1:1 basis (n ¼ 1,800) to either PCI with
TAXUS Express paclitaxel-eluting stents (Boston Scientific
Corporation, Natick, Massachusetts) or CABG. Stratification
was performed by 3 ways: by clinical site, the absence or
presence of unprotected left main disease, and by the pres-
ence or absence of medically treated diabetes mellitus
(requiring oral medications or insulin). Baseline and peri- and
post-procedural data were prospectively collected by the in-
dividual participating centers. The calculation of the bSS1
was carried out by the Heart Team before randomization
and corroborated by an independent core laboratory (Car-
dialysis BV, Rotterdam, The Netherlands) blinded to the
treatment assignment. Baseline and procedural coronary an-
giograms were centrally stored. The baseline and procedural
coronary angiograms were analyzed side by side by a panel
of 3 interventional cardiologists blinded to the clinical
outcomes.
The bSS and its components, including anatomic location
of all lesions, recorded by the core laboratory in calculation
of the original SS, were used to identify all coronary lesions
in the baseline and procedural coronary angiogram. The rSS
was calculated based on the remaining obstructive CAD
after treatment with PCI. The intraobserver variability for
calculation of the rSS (quartile partitioning), based on
reanalyzing 50 cases at a 3-month interval, indicated a high
level of agreement (k statistic 0.89, 95% confidence interval
[CI] 0.79 to 0.99, p<0.001).11,12 The DSS, representative of
the burden of disease treated by PCI, was calculated by
subtracting the rSS from the bSS.6 The SRI was calculated
with the following formula: (DSS/bSS � 100).9 Figure 1
illustrates the bSS and all its derived scores. Patients were
stratified into 3 groups (as previously described)9 and
compared: SRI ¼ 100% (complete revascularization), SRI
<100% to 50%, and SRI <50%. Adverse ischemic out-
comes between groups were compared at 5 years.
Clinical outcomes included all-cause death major adverse
cardiac and cerebrovascular events (MACCE; a composite of
all-cause death, MI, cerebrovascular accident, and all-cause
revascularization), and stent thrombosis using the Academic
Research Consortium definition.13 An independent clinical
events committee, including cardiologists, cardiac surgeons,
and a neurologist, reviewed all the primary clinical end
points.14 A separate independent clinical events committee
Figure 2. (continued).
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adjudicated the Academic Research Consortium stent throm-
bosis events.
Categorical variables are presented as numbers and
percentages and are compared with the chi-square test.
Continuous variables are expressed as mean  SD and are
compared using the Student’s t test or Wilcoxon rank-sum
test based on their distributions. Time-to-event variables
are presented as Kaplan-Meier estimates and compared us-
ing the log-rank test. Multivariable analyses were performed
to identify independent predictors of incomplete revascu-
larization (SRI <100%). Multivariable analyses were con-
ducted to identify independent predictors of 5-year
Figure 3. Kaplan-Meier curves showing cumulative mortality and adverse event rates through 5 years according to SRI cutoff of 70%. The rate of death (A),
cardiac death (B), MI (C), revascularization (D), and MACCE (E) are significantly higher with an SRI <70% compared with an SRI 70%.
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Figure 3. (continued).
Figure 4. Five-year adverse event rates between different degrees of
completeness of revascularization. Reasonable incomplete revascularization
(SRI <100% to 70%) and complete revascularization (SRI 100%) had
significantly and similarly lower mortality, cardiac mortality, and MI rates
at 5 years compared with incomplete revascularization (SRI <70%).
Unplanned revascularization proportionally increased with the degree of
incompleteness of revascularization.
Table 3
Independent predictors of 5-year mortality
Variables Hazard Ratio
[95% CI]
p
Value
SYNTAX Revascularization
Index <70%
4.13 [2.79, 6.11] <0.0001
No post-procedural antiplatelet
therapy*
64.18 [24.29, 169.54] <0.0001
Left ventricular ejection
fraction <30%
5.60 [2.43, 12.93] <0.0001
Age (per increase in
10 years)
1.45 [1.22, 1.69] <0.0001
Peripheral vascular disease 1.90 [1.18, 3.06] 0.008
SYNTAX score (per increase
in 10 points)
1.23 [1.08, 1.37] 0.002
Amiodarone therapy on
discharge
3.09 [1.10, 8.65] 0.03
History of GI bleeding or
peptic ulcer disease
2.10 [1.05, 4.20] 0.04
GI ¼ gastrointestinal.
* Neither aspirin nor thienopyridine.
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Figure 5. Kaplan-Meier curves showing cumulative mortality and MACCE through 5 years according to baseline SYNTAX score tertiles. The impact of
achieving an SRI <70% versus 70% on the 5-year rate of death stratified by bSS tertiles (A: bSS <22, B: bSS 22 to 32, and C: bSS >32) and the impact of
achieving an SRI <70% versus 70% on the 5-year rate of MACCE stratified by bSS tertiles (D: bSS <22, E: bSS 22 to 32, and F: bSS >32).
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mortality, with a Cox regression model using the forced
enter method. Previously demonstrated anatomic and
clinical variables, shown to be independent predictors of
long-term mortality in the SYNTAX trial (p <0.1),15 were
entered into the model, with no exit criteria. Area under the
curve for the SRI was computed to identify the Youden
index (best cutoff) for 5-year all-cause death.16 The Youden
index is defined for all points of a receiver operating
characteristic curve, and the maximum value of the index
was used as a criterion for selecting the optimum cut-off
point for the SRI. The index is represented graphically as
the height above the chance line. It is equivalent to the area
under the curve represented by a single operating point. All
variables were stratified according to an SRI >70% (best
cutoff). A 2-sided probability value <0.05 was considered
significant for all tests. All analyses were conducted using
SPSS, version 21.0 (IBM, Armonk, New York).
Results
In the randomized PCI cohort (n ¼ 903), the bSS was
available in 899 of 903 subjects (99.6%). The mean bSS was
28.4 � 11.5. The SRI was available in 888 of 903 subjects
(98.3%). The SRI ranged from 47.1% to 100%, with a mean
of 85.3 � 21.2. The SRI was 100% in 386 patients (43.5%),
from 50% to <100% in 454 patients (51.1%), and <50% in
48 patients (5.4%). Table 1 presents the clinical characteristics
and angiographic findings, stratified by SRI. Patients with
lower SRI had a higher prevalence of diabetes, diabetes
requiring insulin, and lower left ventricular ejection fraction.
Angiographically, patients with a lower SRI were more likely
to have more complex and extensive disease, with a more
frequent presence of chronic total occlusion (CTO), heavily
calcification, long (>20 mm) and tortuous lesions, involve-
ment of the left main with 3-vessel disease, resulting in higher
bSS and rSS, and longer procedural time. Independent pre-
dictors of incomplete revascularization (SRI<100%) included
bSS (HR 1.08, 95% CI 1.07 to 1.10, p <0.0001) and diabetes
mellitus (HR 1.82, 95% CI 1.31 to 2.54, p ¼ 0.0003).
The 5-year rates of all adverse ischemic events were
strongly associated with SRI, with the lowest rates of adverse
events in the group with complete revascularization and the
highest rates in the group with SRI<50% (Table 2, Figure 2).
Receiver operating characteristic curve analysis demon-
strated a significant association between the SRI and 5-year
all-cause mortality. An SRI cutoff of 70% had the best
Figure 6. Important subgroup analysis for 5-year all-cause mortality according to SRI <70% versus �70%. The impact of SRI <70% was consistent in all
subgroups except for the subgroups of CTO, diabetes requiring insulin, and bSS, in which significant interaction was detected. 3VD ¼ 3-vessel disease;
CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary disease; CrCl ¼ creatinine clearance; DM ¼ diabetes mellitus; LM ¼ left main;
LVEF ¼ left ventricular ejection fraction; PVD ¼ peripheral vascular disease; TO ¼ total occlusion.
Coronary Artery Disease/SYNTAX Revascularization Index 183
Chapter 4.3
312
prognostic accuracy for risk prediction of death (area under
the curve 0.68, 95% CI 0.65 to 0.71, p <0.0001). Baseline
and procedural variables associated with an SRI <70%
(occurring in 142 patients [16%]) versus an SRI �70%
(occurring in 746 patients [84.0%]) are presented in
Supplementary Table 1. Figure 3 shows the occurrence of
adverse events over time according to an SRI cutoff of 70%.
Figure 4 shows and compares 5-year adverse event rates
among SRI 100%, 70% to <100%, and <70%. By multi-
variable analysis, SRI <70% remains one of the strongest
independent predictors of 5-year mortality (Table 3).
Figure 5 shows the impact of achieving an SRI <70%
versus �70% on the 5-year rate of death and MACCE
(Figure 5) according to the bSS tertiles (<22, 22 to 32, >32)
of the study cohort. Mortality and MACCE were signifi-
cantly reduced in patients with an SRI �70% compared
with <70% at all levels of bSS (p for interaction ¼ 0.037 for
mortality and 0.01 for MACCE) with the group with the
highest bSS having the greatest absolute reduction in 5-year
mortality and MACCE with achievement of SRI �70%
compared with SRI <70%.
The higher mortality of an SRI <70% was consistent in
all subgroups examined. For patients with diabetes requiring
insulin and high bSS, the impact of an SRI <70% was
markedly higher. In patients with at least 1 CTO, the
negative impact of an SRI <70% was still relevant but less
evident (Figure 6).
Discussion
The present study validates the concept of SRI, a new
practical angiographic tool aiming to quantify the level of
“reasonable” incomplete revascularization after PCI. Drawn
from a cohort of 888 patients with multivessel disease who
underwent PCI, the main findings of the current report are as
follows: (1) the SRI was associated with all 5-year adverse
ischemic outcomes, with mortality, MI, revascularization,
stent thrombosis, and MACCE being inversely correlated
with SRI; (2) the SRI was a strong and independent
predictor of 5-year all-cause mortality; (3) achievement of
an SRI �70% was associated with similar mortality and
adverse event rates as an SRI of 100% and may be
considered a “reasonable” or acceptable result for PCI; and
(4) achieving a reasonable revascularization (SRI �70%)
was beneficial in all tertiles of bSS but especially in patients
with more complex and extensive CAD (bSS >32).
Complete revascularization has been shown to be asso-
ciated with favorable outcomes compared with incomplete
revascularization.6,7,17e21 However, complete revasculariza-
tion is not always possible. The SYNTAX and Acute
Catheterization and Urgent Intervention Triage Strategy trials
demonstrated a rate of w40% of incomplete revasculariza-
tion.6,7,20,22 Complete revascularization is not always neces-
sary,23 but no precise instrument has demonstrated what
should represent a “reasonable” level of complete (or
incomplete) revascularization.
Based on the bSS1 and the rSS,6,7 we recently developed
the SRI, an index representing the proportion of CAD
treated, and demonstrated its strong association with 1-year
mortality.9 The present report confirms and extends our
previous findings and externally validates this concept. In
the present study, SRI was associated with all adverse
ischemic events and was identified as one of the indepen-
dent predictors of 5-year all-cause mortality. This finding
underlines the central importance not only of the baseline
anatomy, while risk-stratifying patients, but also of the
potential residual “untreated” CAD after PCI.
Importantly, we identified a threshold of reasonable
incomplete revascularization (SRI �70%) at which long-
term mortality is not affected by the incompleteness of
revascularization. Even more important, the achievement of
an SRI �70% substantially improved the prognosis among
each bSS tertile, especially the highest bSS tertile (bSS
>32), with a 50% absolute reduction in 5-year mortality
(69.9% vs 11.1%) and a similarly low 5-year mortality rate
as SRI ¼ 100% (8.6%). These findings are extremely
important, and the concept of reasonable incomplete
revascularization should be integrated into the Heart Team
discussion.
There are several explanations for how achieving a
reasonable level of incomplete anatomic revascularization,
compared with absolute complete revascularization, does not
affect 5-year mortality. First, it is well accepted that medical
therapy for low-risk CAD is associated with a similar prog-
nosis to more invasive strategy.24 Second, it has been well
demonstrated from several fractional flow reserve studies that
nonfunctional or ischemic lesions could be medically treated
without affecting prognosis.25 SYNTAX investigators
classified patients anatomically/angiographically as having
3-vessel disease, whereasw35% were not when assessed by
fractional flow reserve.26 Not treating “severe” angiographic
lesions that are nonischemic will probably not affect long-
term prognosis. Recent evidence challenges the importance
of an angiographic versus ischemic-driven treatment (or a
combination of both).27 Third, bifurcation studies demon-
strated that a provisional stenting approach (leaving behind
frequently untreated side braches) has not affected long-term
prognosis. Similarly, revascularization of CTOs (not
involving a large ischemic area)28 never demonstrated
improved survival and still remains a matter of debate.29 The
positive interaction in our study between the presence of
CTO and incomplete revascularization and 5-year mortality
rate suggests that incomplete revascularization involving a
CTO negatively affects long-term mortality less than patients
with no CTO lesions. This requires confirmation in larger
study. These concepts are of central importance, especially
knowing that CTO are the subset of lesions the most
frequently associated with incomplete revascularization,6,20
and that bifurcation accounts for >15% to 20% of PCI
lesions. The findings of our report, identifying a threshold of
reasonable incomplete revascularization, offers a practical
revascularization strategy in the management of multivessel
disease without compromising long-term mortality, a strategy
that has already being partially proved and embedded in
current practices and guidelines recommendation.
Left main disease characterizes a subset of patients where
the concept of reasonable revascularization may be useful.
In case the left main stenosis has been treated, accounting
for a large proportion of the baseline risk or myocardium at
risk, the amount of residual disease (and its subsequent
treatment) may affect long-term prognosis proportionally to
the extent of the non-left main CAD. For example, when
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facing a complex distal left main involving a bifurcation
lesion with the ostial left anterior descending artery and
ostial left proximal circumflex, resulting in a baseline SS of
at least 25, the treatment or not of a mid-right coronary
artery lesion and first obtuse marginal (rSS of 4, SRI of
86%) may not jeopardize the long-term prognosis. In
contrast, the same patient with additional 3-vessel disease
may benefit from a more substantial revascularization if the
long-term prognosis is to be preserved. Aiming for a
reasonably complete revascularization, with treatment of
w70% of the CAD burden, may be a more achievable goal
in such patients and not negatively affect the prognosis. The
EXCEL (Evaluation of XIENCE Everolimus Eluting Stent
System Versus Coronary Artery Bypass Surgery for Effec-
tiveness of Left Main Revascularization) trial
(NCT01205776) may bring some meaningful answers to
this question.
The present study has some limitations that should be
acknowledged. First, this study is a retrospective post
hoc analysis, and despite being derived from a large, well-
conducted randomized trial, results and conclusions should
be seen as hypothesis generating. Second, the completeness
of revascularization definition used in the present report was
purely anatomic (angiographic), and the derivation of a
“functional SRI” would be interesting, with a “reasonable”
level of ischemia-guided revascularization being the ultimate
goal.26 The current ongoing ISCHEMIA (International Study
of Comparative Health Effectiveness With Medical and
Invasive Approaches) (NCT01471522) and EXCEL trials
(NCT01205776) could bring meaningful insight to this
important question. Third, the SRI had the inherent limita-
tions of the SS itself, including all lesions 50% diameter
stenosis and vessels 1.5 mm in diameter.1 Using a different
threshold for vessel diameter (e.g., 2 mm), lesion severity
(e.g., diameter stenosis 70%) would lead to different re-
sults, although whether the prognostic accuracy would be
greater is unknown. Finally, the prognostic value of
reasonable revascularization using the SRI should be also
validated (and compared) in the CABG arm, so its applica-
tion could be broadened.
Disclosures
Dr. Généreux has received speaker fees from Abbott
Vascular (Santa Clara, California) and Cardiovascular Sys-
tem, Inc. Ted Feldman is a consultant for and receives
research grants from Abbott, Boston Scientific (Boston,
Massachusetts), and Edwards Lifescience (Irvine, Califor-
nia). The authors have no conflicts of interest to disclose.
Supplementary Data
Supplementary data related with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.amjcard.
2015.03.056.
1. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A,
Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW,
Serruys PW. The SYNTAX score: an angiographic tool grading the
complexity of coronary artery disease. EuroIntervention 2005;1:
219e227.
2. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR,
Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van
Dyck N, Leadley K, Dawkins KD, Mohr FW. Percutaneous coronary
intervention versus coronary-artery bypass grafting for severe coronary
artery disease. N Engl J Med 2009;360:961e972.
3. Capodanno D, Capranzano P, Di Salvo ME, Caggegi A, Tomasello D,
Cincotta G, Miano M, Patane M, Tamburino C, Tolaro S, Patane L,
Calafiore AM, Tamburino C. Usefulness of SYNTAX score to select
patients with left main coronary artery disease to be treated with
coronary artery bypass graft. JACC Cardiovasc Interv 2009;2:731e738.
4. Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R,
Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Prognostic
value of the SYNTAX score in patients with acute coronary syndromes
undergoing percutaneous coronary intervention: analysis from the
ACUITY (Acute Catheterization and Urgent Intervention Triage
StrategY) trial. J Am Coll Cardiol 2011;57:2389e2397.
5. Yadav M, Palmerini T, Caixeta A, Madhavan MV, Sanidas E, Kirtane
AJ, Stone GW, Genereux P. Prediction of coronary risk by SYNTAX
and derived scores: synergy between percutaneous coronary interven-
tion with taxus and cardiac surgery. J Am Coll Cardiol 2013;62:
1219e1230.
6. Genereux P, Palmerini T, Caixeta A, Rosner G, Green P, Dressler O,
Xu K, Parise H, Mehran R, Serruys PW, Stone GW. Quantification and
impact of untreated coronary artery disease after percutaneous coronary
intervention: the residual SYNTAX (Synergy between PCI with Taxus
and Cardiac Surgery) score. J Am Coll Cardiol 2012;59:2165e2174.
7. Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T,
Feldman T, Holmes DR, Mack M, Morice MC, Stahle E, Colombo A,
de Vries T, Morel MA, Dawkins KD, Kappetein AP, Mohr FW.
Quantification of incomplete revascularization and its association with
five-year mortality in the synergy between percutaneous coronary
intervention with taxus and cardiac surgery (SYNTAX) trial validation
of the residual SYNTAX score. Circulation 2013;128:141e151.
8. Capodanno D, Chisari A, Giacoppo D, Bonura S, Lavanco V,
Capranzano P, Caggegi A, Ministeri M, Tamburino C. Objectifying the
impact of incomplete revascularization by repeat angiographic risk
assessment with the residual SYNTAX score after left main coronary
artery percutaneous coronary intervention. Catheter Cardiovasc Interv
2013;82:333e340.
9. Genereux P, Campos CM, Yadav M, Palmerini T, Caixeta A, Xu K,
Francese DP, Dangas GD, Mehran R, Leon MB, Serruys PW, Stone
GW. Reasonable incomplete revascularisation after percutaneous
coronary intervention: the SYNTAX Revascularisation Index.
EuroIntervention 2014 [Epub ahead of print].
10. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E,
Colombo A, Mack MJ, Holmes DR Jr, Morel MA, Van Dyck N, Houle
VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery
versus percutaneous coronary intervention in patients with three-vessel
disease and left main coronary disease: 5-year follow-up of the rand-
omised, clinical SYNTAX trial. Lancet 2013;381:629e638.
11. Serruys PW, Onuma Y, Garg S, Sarno G, van den Brand M, Kappetein
AP, Van Dyck N, Mack M, Holmes D, Feldman T, Morice MC,
Colombo A, Bass E, Leadley K, Dawkins KD, van Es GA, Morel MA,
Mohr FW. Assessment of the SYNTAX score in the Syntax study.
EuroIntervention 2009;5:50e56.
12. Genereux P, Palmerini T, Caixeta A, Cristea E, Mehran R, Sanchez R,
Lazar D, Jankovic I, Corral MD, Dressler O, Fahy MP, Parise H,
Lansky AJ, Stone GW. SYNTAX score reproducibility and variability
between interventional cardiologists, core laboratory technicians, and
quantitative coronary measurements. Circ Cardiovasc Interv 2011;4:
553e561.
13. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA,
Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A,
Hamon M, Krucoff MW, Serruys PW; Academic Research
Consortium. Clinical end points in coronary stent trials: a case for
standardized definitions. Circulation 2007;115:2344e2351.
14. Ong AT, Serruys PW, Mohr FW, Morice MC, Kappetein AP,
Holmes DR Jr, Mack MJ, van den Brand M, Morel MA, van Es GA,
Kleijne J, Koglin J, Russell ME. The SYNergy between percutaneous
coronary intervention with TAXus and cardiac surgery (SYNTAX)
study: design, rationale, and run-in phase. Am Heart J 2006;151:
1194e1204.
15. Farooq V, Serruys PW, Bourantas C, Vranckx P, Diletti R, Garcia
Garcia HM, Holmes DR, Kappetein AP, Mack M, Feldman T, Morice
Coronary Artery Disease/SYNTAX Revascularization Index 185
Chapter 4.3
314
MC, Colombo A, Morel MA, de Vries T, van Es GA, Steyerberg EW,
Dawkins KD, Mohr FW, James S, Stahle E. Incidence and multivari-
able correlates of long-term mortality in patients treated with surgical
or percutaneous revascularization in the synergy between percutaneous
coronary intervention with taxus and cardiac surgery (SYNTAX) trial.
Eur Heart J 2012;33:3105e3113.
16. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32e35.
17. van den Brand MJ, Rensing BJ, Morel MA, Foley DP, de Valk V,
Breeman A, Suryapranata H, Haalebos MM, Wijns W, Wellens F,
Balcon R, Magee P, Ribeiro E, Buffolo E, Unger F, Serruys PW. The
effect of completeness of revascularization on event-free survival at
one year in the ARTS trial. J Am Coll Cardiol 2002;39:559e564.
18. Hannan EL, Racz M, Holmes DR, King SB III, Walford G, Ambrose
JA, Sharma S, Katz S, Clark LT, Jones RH. Impact of completeness of
percutaneous coronary intervention revascularization on long-term
outcomes in the stent era. Circulation 2006;113:2406e2412.
19. Sarno G, Garg S, Onuma Y, Gutierrez-Chico JL, van den Brand MJ,
Rensing BJ, Morel MA, Serruys PW; ARTS-II Investigators. Impact of
completeness of revascularization on the five-year outcome in percu-
taneous coronary intervention and coronary artery bypass graft patients
(from the ARTS-II study). Am J Cardiol 2010;106:1369e1375.
20. Farooq V, Serruys PW, Garcia-Garcia HM, Zhang Y, Bourantas CV,
Holmes DR, Mack M, Feldman T, Morice MC, Stahle E, James S,
ColomboA, Diletti R, PapafaklisMI, de Vries T,MorelMA, van EsGA,
Mohr FW, Dawkins KD, Kappetein AP, Sianos G, Boersma E. The
negative impact of incomplete angiographic revascularization on clinical
outcomes and its association with total occlusions: the SYNTAX (Syn-
ergy between Percutaneous Coronary Intervention with Taxus and Car-
diac Surgery) trial. J Am Coll Cardiol 2013;61:282e294.
21. Garcia S, Sandoval Y, Roukoz H, Adabag S, Canoniero M,
Yannopoulos D, Brilakis ES. Outcomes after complete versus
incomplete revascularization of patients with multivessel coronary
artery disease: a meta-analysis of 89,883 patients enrolled in ran-
domized clinical trials and observational studies. J Am Coll Cardiol
2013;62:1421e1431.
22. Head SJ, Mack MJ, Holmes DR Jr, Mohr FW, Morice MC, Serruys
PW, Kappetein AP. Incidence, predictors and outcomes of incomplete
revascularization after percutaneous coronary intervention and coro-
nary artery bypass grafting: a subgroup analysis of 3-year SYNTAX
data. Eur J Cardiothorac Surg 2012;41:535e541.
23. Rastan AJ, Walther T, Falk V, Kempfert J, Merk D, Lehmann S,
Holzhey D, Mohr FW. Does reasonable incomplete surgical revascu-
larization affect early or long-term survival in patients with multivessel
coronary artery disease receiving left internal mammary artery bypass
to left anterior descending artery? Circulation 2009;120:S70eS77.
24. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk
WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR,
Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth
DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS;
COURAGE Trial Research Group. Optimal medical therapy with or
without PCI for stable coronary disease. N Engl J Med 2007;356:
1503e1516.
25. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth
Z, Jagic N, Mobius-Winkler S, Rioufol G, Witt N, Kala P, Mac-
Carthy P, Engstrom T, Oldroyd KG, Mavromatis K, Manoharan G,
Verlee P, Frobert O, Curzen N, Johnson JB, Juni P, Fearon WF;
FAME 2 Trial Investigators. Fractional flow reserve-guided PCI
versus medical therapy in stable coronary disease. N Engl J Med
2012;367:991e1001.
26. Nam CW, Mangiacapra F, Entjes R, Chung IS, Sels JW, Tonino PA,
De Bruyne B, Pijls NH, Fearon WF; Fame Study Investigators.
Functional SYNTAX score for risk assessment in multivessel coronary
artery disease. J Am Coll Cardiol 2011;58:1211e1218.
27. Mancini GB, Hartigan PM, Shaw LJ, Berman DS, Hayes SW, Bates
ER, Maron DJ, Teo K, Sedlis SP, Chaitman BR, Weintraub WS,
Spertus JA, Kostuk WJ, Dada M, Booth DC, Boden WE. Predicting
outcome in the COURAGE trial (Clinical Outcomes Utilizing Revas-
cularization and Aggressive Drug Evaluation): coronary anatomy
versus ischemia. JACC Cardiovasc Interv 2014;7:195e201.
28. Safley DM, House JA, Marso SP, Grantham JA, Rutherford BD.
Improvement in survival following successful percutaneous coronary
intervention of coronary chronic total occlusions: variability by target
vessel. JACC Cardiovasc Interv 2008;1:295e302.
29. George S, Cockburn J, Clayton TC, Ludman P, Cotton J, Spratt J,
Redwood S, de Belder M, de Belder A, Hill J, Hoye A, Palmer N,
Rathore S, Gershlick A, Di Mario C, Hildick-Smith D; British
Cardiovascular Intervention Society; National Institute for Cardiovas-
cular Outcomes Research. Long-term follow-up of elective chronic
total coronary occlusion angioplasty: analysis from the U.K. Central
cardiac audit database. J Am Coll Cardiol 2014;64:235e243.
186 The American Journal of Cardiology (www.ajconline.org)
Chapter 4.3


C
hapter 4.4
Chapter 4.4
Smoking is associated with adverse clinical 
outcomes in patients undergoing revascularization 
with PCI or CABG: Insights from the SYNTAX trial at 
5-year follow-up
Yao-Jun Zhang, Javaid Iqbal, David van Klaveren, Carlos M Campos, David R. Holmes, 
Arie Pieter Kappetein, Marie-Claude Morice, Adrian P Banning, Ever D Grech, 
Christos V. Bourantas, Yoshinobu Onuma, Hector M. Garcia-Garcia, Michael J. Mack, 
Antonio Colombo, Friedrich W. Mohr, Ewout W. Steyerberg, Patrick W. Serruys
J Am Coll Cardiol. 2015 Mar 24;65(11):1107-15
318
Smoking Is Associated With
Adverse Clinical Outcomes in
Patients Undergoing Revascularization
With PCI or CABG
The SYNTAX Trial at 5-Year Follow-Up
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ABSTRACT
BACKGROUND Cigarette smoking is a well-known risk factor for development of coronary artery disease (CAD).
However, some studies have suggested a “smoker’s paradox,” meaning neutral or favorable outcomes in smokers who
have developed CAD, especially myocardial infarction (MI).
OBJECTIVES The study aimed to examine the association of smoking status with clinical outcomes in the randomized
controlled SYNTAX (SYNergy Between PCI With TAXUS and Cardiac Surgery) trial at 5-year follow-up.
METHODS Detailed smoking history was collected at baseline, 6-month, 1-year, 3-year, and 5-year follow-up. The
composite endpoints included death/MI/stroke (primary endpoint) plus major adverse cardiac and cerebrovascular events
(MACCE) (combination of death/MI/stroke and target lesion revascularization) according to patient smoking status. The
comparison of 5-year clinical outcomes between the groups according to smoking status was performed with Cox
regression using smoking status at baseline or smoking as a time-dependent covariate.
RESULTS A sizeable proportion (n ¼ 322, 17.9%) of patients had changing smoking status during 5-year follow-up.
One in 5 patients with complex CAD was smoking at baseline. However, 60% stopped after revascularization while
others continued to smoke. Smokers had worse clinical outcomes due to a higher incidence of recurrent MI in both
revascularization arms. Smoking was an independent predictor of the composite endpoint of death/MI/stroke (hazard
ratio [HR]: 1.8; 95% confidence interval [CI]: 1.3 to 2.5; p ¼ 0.001) and MACCE (HR: 1.4; 95% CI: 1.1 to 1.7;
p ¼ 0.02).
CONCLUSIONS Smoking is associated with poor clinical outcomes after revascularization in patients with complex CAD.
This places further emphasis on efforts at smoking cessation to improve revascularization benefits. (SYNTAX Study:
TAXUSDrug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of NarrowedArteries; NCT00114972)
(J Am Coll Cardiol 2015;65:1107–15) © 2015 by the American College of Cardiology Foundation.
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C igarette smoking is a globally well-recognized risk factor for coronaryartery disease (CAD) (1–5). Smokers
with ischemic heart disease also have higher
incidence of death and other adverse events
(5,6). However, some studies have suggested
existence of a “smoker’s paradox,” meaning
the outcomes in smokers who have devel-
oped CAD, especially myocardial infarc-
tion (MI), may be neutral or better than
nonsmokers (7–9). It is likely that the
observed paradox is largely due to differ-
ences in the baseline characteristics of smokers and
nonsmokers in these studies (7,8), or there may be
an interaction between smoking and efficacy of anti-
platelet drugs (10,11). However, such reports can
have a negative public health impact. Indeed, more
than one-third of smokers believe that the dangers
of smoking are greatly exaggerated (12). It is, there-
fore, important to study the effect of smoking on out-
comes in patients with established CAD to better
understand the effects of smoking on outcomes.
The deleterious effects of smoking after coronary
artery bypass grafting (CABG) and percutaneous cor-
onary intervention (PCI) have been shown previously
(13–17), although other studies suggested a smoker’s
paradox in this context as well (18,19). However, the
smoking status in most of these studies is usually
taken at baseline and not collected again at regular
intervals. Conversely, smokers who learn they have
established CAD may stop smoking permanently or
intermittently. Therefore, assessing the impact of
smoking status at baseline for long-term outcomes
may be unreliable. Additionally, most studies were
performed in the era of PCI without stents or with
bare-metal stents, providing little insight into the
impact of smoking in patients undergoing revascu-
larization with drug-eluting stents. Furthermore, the
effect of smoking on clinical events in patients with
complex CAD undergoing PCI or CABG remains
undefined.
This study aimed to examine the smoking status in
patients with complex coronary artery disease under-
going PCI or CABG and its prognostic significance in
the SYNTAX (SYNergy Between PCI With TAXUS and
Cardiac Surgery) trial at the final 5-year follow-up.
METHODS
The SYNTAX trial (NCT00114972) was a prospective,
multicenter, randomized trial that compared PCI with
CABG for patients with complex CAD (left main
stem and/or 3-vessel disease) (20). Eligible patients
(n ¼ 1,800) were randomized on a 1:1 ratio to CABG
(n ¼ 897) or PCI (n ¼ 903) with TAXUS Express
paclitaxel-eluting stents (Boston Scientific Corpora-
tion, Natick, Massachusetts) and followed for 5 years.
The study complied with the Declaration of Helsinki
and was approved by the ethical review board of the
institution involved.
Smoking status was checked for all patients at
baseline, 6 months, and 1, 3, and 5 years. The study
endpoint was the impact of smoking on a composite
endpoint (death/MI/stroke) at 5-year follow-up. We
also evaluated impact of smoking on other clinical
endpoints including major cardiac and cerebrovascu-
lar events (MACCE) (combination of death/MI/stroke/
target vessel revascularization). Definitions of various
clinical endpoints (e.g., MI, stroke) in the SYNTAX
trial have been previously reported (20). All events
were adjudicated by an independent clinical event
committee comprising interventional cardiologists,
cardiac surgeons, and a neurologist (21).
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean � SD and categorical variables are
shown as counts and percentages of the total. Com-
parison of 5-year clinical outcomes between the
groups according to the smoking status was per-
formed with Cox regression using smoking status at
baseline or smoking as a time-dependent covariate.
Hazard ratios (HR) with 95% confidence intervals (CI)
are shown. Chi-square test was used to assess inter-
action p values for treatment arms. A probability
value of <0.05 was considered statistically signifi-
cant. All analyses were performed using SPSS version
21.0 (IBM Corp., Armonk, New York) and STATA
version 12.0 (Stata Corp. LP, College Station, Texas).
RESULTS
In the randomized SYNTAX trial (n ¼ 1,800), infor-
mation on smoking status was available for 1,793
(99.6%) patients. The proportion of patients smoking
at different time points is shown in Figure 1. While
20.2% patients with extensive CAD were still smoking
at baseline, a significant number stopped smoking
after revascularization (8.6% were smokers at 6
months and 8.7% at 1 year). However, after 1 year,
there was a modest increase in number of smokers,
especially in the CABG arm (10.8% were smokers in
the CABG arm vs. 8.7% in the PCI group at 5-year
follow-up). Overall, 321 (17.9%) patients had a
change in smoking status during follow-up. While
nonsmokers remained nonsmokers, current and ex-
smokers had considerable change in their smoking
status across the 5 years (Table 1).
SEE PAGE 1116
ABBR EV I A T I ON S
AND ACRONYMS
CABG = coronary artery
bypass grafting
CI = confidence interval
HR = hazard ratio
MACCE = major adverse
cardiac and cerebrovascular
event(s)
MI = myocardial infarction
PCI = percutaneous
coronary intervention
Zhang et al. J A C C V O L . 6 5 , N O . 1 1 , 2 0 1 5
SYNTAX, Smoking, and Poor Clinical Outcomes M A R C H 2 4 , 2 0 1 5 : 1 1 0 7 – 1 5
1108
Chapter 4.4
320
Comparison of baseline characteristics according to
smoking status—stratified as smokers, ex-smokers,
and nonsmokers (Online Table 1A) and smoking or
nonsmoking at baseline (Online Table 1B)—revealed
that smokers were younger and predominantly
male and had extensive CAD despite lower preva-
lence of other cardiovascular risk factors including
diabetes mellitus, hypertension, or dyslipidemia.
Conversely, smokers had more prevalent chronic
obstructive pulmonary disease (COPD), peripheral
vascular disease (PVD), and poor left ventricular
ejection fraction.
EFFECT OF SMOKING ON CLINICAL OUTCOMES.
Baseline smoking status appeared to have no impact
on death/MI/stroke and MACCE at 5-year follow-up
(Figure 2A). Analyzing the data for those smoking or
not smoking at baseline also yielded similar results
(Figure 2B). However, considering that the smoking
status changed during 5-year follow-up, the analysis
with smoking as a time-dependent variable revealed
that smoking was associated with increased risk of
death/MI/stroke (HR: 1.38; 95% CI: 1.02 to 1.86;
p ¼ 0.035) and MACCE (HR: 1.28; 95% CI: 1.01 to 1.61;
p ¼ 0.041) at 5-year follow-up (Figure 2C). In total,
1,374 patients never smoked and 98 patients always
smoked during 5-year follow-up. The patients who
always smoked had significantly higher risk of MI and
stent thrombosis/graft occlusion, but not all-cause
revascularization, compared with those who never
smoked (Online Figure 1).
The baseline smoking status (current smoker
vs. ex-smoker vs. nonsmoker) was associated with
higher risk of MI during 5-year follow-up (Online
Figure 2A). Analyzing the data for those smoking or
not smoking at baseline yielded similar results
(Online Figure 2B). The predominant effect of smok-
ing as a time-dependent covariate was on subsequent
MI (unadjusted HR: 1.86; 95% CI: 1.21 to 2.86;
p ¼ 0.005; adjusted HR: 2.08; 95% CI: 1.30 to 3.32;
p ¼ 0.002) (Figure 3, Table 2), whereas no statistically
significant effect was observed on mortality or repeat
revascularization at 5-year follow-up (Figure 3). The
interaction p values for these outcomes between
CABG and PCI arms were not significant, suggesting
smoking was associated with poor outcomes inde-
pendent of revascularization strategy (Figure 3).
On multivariable Cox regression analysis using
smoking status as a time-dependent covariate,
smoking was an independent predictor of death/MI/
stroke as well as MACCE (Table 3). Subgroup analysis
showed that smoking was an independent predictor
of poor outcomes in CABG patients (HR: 1.52; 95% CI:
1.02 to 2.25; p ¼ 0.038) as well as the PCI arm
(HR: 1.26; 95% CI: 0.90 to 1.75; p ¼ 0.177). After
adjusting for other independent predictors, baseline
smoking status also was associated with poor out-
comes (Central Illustration).
FIGURE 1 Smoking Status of Patients in the SYNTAX Trial at 5-Year Follow-Up
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The smoking status of patients stratified into smokers, ex-smokers, and nonsmokers is dis-
played for overall SYNTAX (SYNergy Between PCI With TAXUS and Cardiac Surgery) trial
patients as well as coronary artery bypass grafting (CABG) and percutaneous coronary
intervention (PCI) arms. While the proportion of nonsmokers remained constant, there were
changes inproportion of smokers andex-smokers, as nearly half of smokers stopped smoking
after the index procedure but some relapsed during follow-up. Ex-smoker was defined as a
smoker quitting more than 1 month before the index procedure or follow-up time point.
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DISCUSSION
The most important finding in this paper is that
among patients with complex CAD undergoing
revascularization with either PCI or CABG, those who
are smokers have a higher incidence of adverse out-
comes including MI than those who never smoked or
stopped smoking. This finding is seen irrespective of
the specific revascularization strategy.
The SYNTAX trial enrolled patients with complex
CAD requiring coronary revascularization. It is note-
worthy that 1 in 5 patients with extensive coronary
disease were still smoking at the time of trial enroll-
ment. These data are consistent with other studies
showing that a sizeable proportion (10% to 30%) of
patients with established CAD continue to smoke
(18,22–24). The number of smokers was halved after
coronary revascularization, suggesting that most of
the patients took the smoking cessation advice at the
time of revascularization seriously (24). The time
of revascularization, therefore, presents a good op-
portunity to reinforce smoking cessation advice and
to offer practical help.
Smoking is a modifiable risk factor, and not all
current smokers remain smokers after a coronary
event or procedure. Conversely, patients may start
smoking again at any time during follow-up. Thus,
using baseline smoking status to predict long-term
outcomes is a potentially flawed approach. We have,
therefore, used smoking status as a time-dependent
variable. Indeed, our results confirm that this
approach, not unadjusted baseline smoking status, is
able to identify the link between smoking and poor
outcomes after revascularization. Another study
looking at the effect of smoking in patients under-
going CABG has suggested that smoking status at
baseline (pre-surgery) was not associated with
adverse outcomes but smoking status at follow-up
(post-surgery) predicted poor outcomes (13).
IMPACT OF SMOKING ON OUTCOMES: NO PARADOX
EXISTS. Smoking was associated with adverse out-
comes, especially recurrent MI in our study. This was
seen after adjusting for confounding variables or us-
ing smoking as a time-dependent covariate. Smoking
is a well-established risk factor for acute MI; quitting
reduces the risk of subsequent myocardial infarctions
(25). It has also been shown in multiple studies that a
ban on smoking substantially reduces the incidence
of MI, even at the population level (26–28). Adherence
to behavioral advice, including smoking cessation,
after an acute coronary syndrome is associated with a
substantially lower risk of recurrent cardiovascular
events (29). There was no significant effect of smok-
ing on repeat revascularization, consistent with pre-
vious reports (18,30), although some studies have
reported opposing results (31). It is possible that drug-
eluting stents are associated with a lower incidence of
target lesion revascularization even in those who
continue to smoke (30). Our study did not show any
statistically significant influence of smoking on
TABLE 1 Smoking Pattern in SYNTAX Patients During 5-Year Follow-Up*
Baseline 6 Months 12 Months 36 Months 60 Months n (%)
Smoking status unchanged during follow-up 1,472 (82.1)
D D D D D 98 (5.5)
� � � � � 1,374 (76.6)
Smoking status changing during follow-up 321 (17.9)
Smoking at baseline but changing status during follow-up 265 (14.8)
D D D D � 14 (0.78)
D D D � D 4 (0.22)
D D D � � 17 (0.95)
D D � D D 2 (0.11)
D D � � D 2 (0.11)
D D � � � 13 (0.73)
D � D D D 12 (0.67)
D � D � D 2 (0.11)
D � D � � 3 (0.17)
D � � D D 16 (0.89)
D � � D � 4 (0.22)
D � � � D 11 (0.61)
D � � � � 122 (6.80)
D � 3 3 3 6 (0.33)
D D � 3 3 8 (0.45)
D � � 3 3 8 (0.45)
D D D � 3 1 (0.06)
D D � D 3 1 (0.06)
D D � � 3 3 (0.17)
D � D D 3 2 (0.11)
D � D � 3 1 (0.06)
D � � D 3 5 (0.28)
D � � � 3 8 (0.45)
Nonsmoking at baseline but changing status during follow-up 56 (3.1)
� D D D D 6 (0.33)
� D D D � 2 (0.11)
� D D � D 1 (0.06)
� D � � � 1 (0.06)
� � D D D 3 (0.17)
� � D � D 1 (0.06)
� � D � � 5 (0.28)
� � � D D 16 (0.89)
� � � D � 4 (0.22)
� � � � D 10 (0.56)
� D D D 3 1 (0.06)
� � D D 3 1 (0.06)
� � � D 3 4 (0.22)
� D 3 3 3 1 (0.06)
Values are n (%). *þ ¼ smoking; � ¼ nonsmoking; 3 ¼ the subjects who died or were lost during follow-up.
SYNTAX ¼ SYNergy Between PCI With TAXUS and Cardiac Surgery.
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FIGURE 2 Kaplan-Meier Cumulative Events for Primary Endpoint and MACCE
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(A) The baseline smoking status (current smoker vs. ex-smoker vs. nonsmoker) appeared to have no impact on death/myocardial infarction (MI)/stroke (primary
endpoint) and major adverse cardiac and cerebrovascular events (MACCE) (defined as a combination of death/MI/stroke and target lesion revascularization) at 5-year
follow-up. (B) Analyzing the data for those smoking or not smoking at baseline also yielded similar results. (C) However, using smoking status as a time-dependent
covariate at follow-up, smoking was associated with an increased risk of death/MI/stroke and MACCE at final 5-year follow-up. The hazard ratio with 95% confidence
interval was calculated for outcomes at different follow-up time points. The beneficial effect of nonsmoking, although less pronounced within the short term, was
maintained throughout 5-year follow-up.
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mortality despite a 17% higher relative risk of mor-
tality in smokers, possibly reflecting lack of adequate
power to demonstrate an effect on mortality. Other
studies with larger sample sizes have shown higher
mortality in smokers undergoing CABG or PCI (15,23).
It has also been shown that smokers demonstrate
less improvement in quality of life after coronary
revascularization (32). Therefore, it is prudent to
highlight that smoker’s paradox does not exist for
patients undergoing coronary revascularization and
that smoking cessation before such revascularization
is strongly advised to improve outcomes.
FIGURE 3 Association of Smoking Status With Clinical Outcomes at 5 Years
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This forest plot shows clinical outcomes according to smoking status (as a time-dependent covariate) in the overall SYNTAX (SYNergy Between
PCI With TAXUS and Cardiac Surgery) trial population and 2 revascularization strategies. A nonsignificant p value for interaction indicates that
the hazard ratio (HR) of smoking versus not smoking remained similar across the respective percutaneous coronary intervention (PCI) and
coronary artery bypass grafting (CABG) subgroups. CI ¼ confidence interval; GO ¼ graft occlusion; ST ¼ stent thrombosis.
TABLE 2 Adjusted Cumulative Effect of Smoking Status on MI
Follow-Up
(Months)
HR
(Smoking vs. Nonsmoking) 95% CI p Value
6 2.156 1.201–3.871 0.010
12 2.326 1.325–4.084 0.003
36 1.915 1.132–3.242 0.015
60 2.081 1.304–3.319 0.002
CI ¼ confidence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction.
TABLE 3 Independent Predictors of Outcomes Using Smoking as
Time-Dependent Covariate
Variables HR 95% CI p Value
Death/MI/stroke
Smoking 1.799 1.273–2.543 0.001
PCI vs. CABG 1.292 1.015–1.645 0.038
Age per increase in 10 years 1.548 1.345–1.781 <0.001
COPD 1.523 1.071–2.168 0.019
PVD 1.849 1.344–2.543 <0.001
LVEF <30% 2.029 1.022–4.031 0.043
Amiodarone therapy on discharge 2.970 1.451–6.079 0.003
MACCE
Smoking 1.354 1.052–1.743 0.019
PCI vs. CABG 1.451 1.220–1.726 <0.001
Age per increase in 10 years 1.162 1.060–1.273 0.001
COPD 1.311 0.997–1.724 0.052
PVD 1.673 1.306–2.142 <0.001
Diabetes 1.324 1.102–1.589 0.003
LVEF <30% 1.853 1.084–3.167 0.024
SYNTAX score per point 1.009 1.001–1.017 0.027
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; COPD ¼ chronic
obstructive pulmonary disease; LVEF ¼ left ventricular ejection fraction; MACCE ¼
major adverse cardiac and cerebrovascular event(s); PCI ¼ percutaneous coronary
intervention; PVD ¼ peripheral vascular disease; SYNTAX ¼ SYNergy Between PCI
With TAXUS and Cardiac Surgery; other abbreviations as in Table 2.
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CENTRAL ILLUSTRATION Smoking Associated With Poor Clinical Outcomes: Adjusted Kaplan-Meier Cumulative Events for
Primary Endpoint and MACCE
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Zhang, Y-J. et al. J Am Coll Cardiol. 2015; 65(11):1107–15.
(A) After adjusting for confounding variables, baseline smoking status (current smoker vs. ex-smoker vs. nonsmoker) appeared to have no impact onmajor adverse cardiac
and cerebrovascular events (MACCE) (defined as a combination of death/myocardial infarction [MI]/stroke and target lesion revascularization), but current smokers had
significantly higher rate of death/MI/stroke (the primary endpoint) at 5-year follow-up. (B) Analyzing the data for those smoking or not smoking at baseline yielded
similar results. (C) Using smoking status as a time-dependent covariate at follow-up after adjusting baseline characteristics, nonsmoking significantly lowered the risk of
death/MI/stroke and MACCE at final 5-year follow-up. Hazard ratios with 95% confidence intervals were calculated for outcomes at different follow-up time points.
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CLINICAL IMPLICATIONS. Smoking is associated
with poor outcomes after coronary revascularization
with PCI or CABG. This message needs to be dissem-
inated to patients, primary and secondary care phy-
sicians, and the general population. It is important
to inquire about smoking status at each clinical
encounter, and appropriate advice should be offered
to help patients stop smoking. Dedicated smoking
cessation programs may help patients achieve
smoking cessation (33). However, these patients
remain at risk of relapse. Patients who had bypass
surgery are more prone to return to smoking than
those who had an MI (34). Primary care and
community-based physicians and nurses may play an
important role improving smoking cessation rates.
STUDY STRENGTHS AND LIMITATIONS. The main
strength of our study is that smoking status was
checked at serial time points in this all-comers clin-
ical trial in patients with complex CAD. However, this
is a post-hoc analysis and has limitations inherent to
any such analysis. The smoking status presented here
is self-reported; there was no biochemical testing
(e.g., cotinine measurement) or cross validation of
smoking status. Number of cigarettes smoked by
current or ex-smokers was not recorded. However, it
could be argued that for cardiovascular outcomes,
including MI and stroke, smoking status is more
important than actual number of cigarettes smoked;
in the CADILLAC (Controlled Abciximab and Device
Investigation to Lower Late Angioplasty Complica-
tions) trial, 1-year mortality rates were similar among
those smoking less than a half pack per day, half to 1
pack per day, or more than 1 pack per day (19).
Smoking may have an acute effect on platelets and
endothelial function, leading to arterial thrombosis
and MI (35,36).
Another limitation is that the smoking status was
collected at pre-defined intervals, and exact date of
change was not available. For example, if a patient was
smoking at 1 year and not smoking at 3 years, we
considered the patient a smoker at 1 year and ex-
smoker at 3 years, although the patient could have
stopped smoking at any time between 1 and 3 years.
However, we also performed a sensitivity analysis in a
completely opposite manner with the assumption that
patient stopped smoking just after the last visit (data
not shown), and the results remained unchanged.
Finally, the association does not confer a cause-
effect relationship. It is plausible that those who
continue to smoke may have additional lifestyle
risk factors (e.g., lack of exercise, unhealthy diet)
that could be contributing to the adverse outcomes
observed.
CONCLUSIONS
Baseline smoking status may not provide adequate
information to predict the longer-term effects of
smoking on clinical outcomes due to changes in
smoking pattern during follow-up. Smoking is
associated with adverse clinical outcomes, espe-
cially MI, after revascularization for complex CAD.
Abstinence from smoking may improve the out-
comes achieved with coronary revascularization,
and all patients undergoing PCI or CABG should
be encouraged to stop smoking indefinitely
before revascularization. Smoking cessation pro-
grams may help improve the benefits achieved with
revascularization.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Cigarette smoking is an established risk factor for
development of coronary artery disease, and studies
suggesting that smokers with coronary disease might
enjoy paradoxically better outcomes than nonsmokers
have not sufficiently considered baseline differences
in clinical risk factors or changes in smoking status
over time. After PCI or CABG, smokers with complex
coronary disease face a higher incidence of myocardial
infarction, and abstinence from smoking improves
outcomes.
COMPETENCY IN PATIENT CARE: All patients
undergoing PCI or CABG should be encouraged to
completely and permanently stop smoking.
TRANSLATIONAL OUTLOOK: Additional work is
needed to develop more effective and well-tolerated
methods to facilitate cessation and sustained absti-
nence from cigarette smoking.
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AbSTRACT
Background: Optimal control of dyslipidaemia improves clinical outcomes in patients with 
coronary artery disease but remains challenging to achieve. This study analyses the management 
of dyslipidaemia in patients enrolled in the ABSORB II clinical trial and investigates the risk 
factors associated with not achieving the ESC recommended cholesterol levels.
Methods: The ABSORB II trial (n=501) aimed to adhere with the 2007 ESC guidelines on 
cardiovascular disease prevention, which recommended achieving low density lipoprotein 
cholesterol (LDL-C) level of less than 2 mmol/L. A number of measures including serial lipid 
monitoring, central laboratory analysis, regular communication and optimization of lipid-lowering 
therapy were employed to achieve lipid control. Medication status was checked for all patients 
at baseline, 1-, 6- and 12-month follow-up.
Results: 98% patients received a lipid-lowering drug throughout the 1-year follow-up. At 
baseline, 33% patients were on simvastatin, 41% on atorvastatin and 12% on rosuvastatin. 
During 1-year follow-up, use of atorvastatin and rosuvastatin increased to 48% and 17% 
respectively. The addition of ezetimibe also increased from 4% to 6%. Only 33% patients had 
LDL-C level within the target range at baseline. There was a significant drop in LDL-C levels during 
1-year; nevertheless a significant proportion of patients (55% at 6-months and 58% at 1-year) 
remained above the target LDL-C level. The lipid profile at 1-year was: mean total cholesterol 
4.24±0.91 mmol/L, LDL 2.21±0.73 mmol/L, high density lipoprotein 1.36±0.37 mmol/L and 
triglycerides 1.48±1.09 mmol/L. Factors associated with not achieving target LDL levels included 
higher baseline LDL, prior history of myocardial infarction and lack of statin therapy.
Conclusions: Achieving guideline recommended cholesterol targets remains challenging. 
Identifying high risk patients for closer monitoring, specialist treatment and measures that 
improve patient compliance are warranted.
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InTRoDUCTIon
Low density lipoprotein cholesterol (LDL-C) 
is a risk factor for the development and 
progression of coronary artery disease1. As 
dyslipidaemia is a modifiable risk factor, 
evidence-based use of lipid-lowering therapy 
is recommended for primary prevention in 
high risk patients and secondary prevention 
in all patients with established coronary 
artery disease2-5. A recent meta-analysis from 
Cholesterol Treatment Trialists’ Collaboration 
(CTT) with >170,000 patients from several tri-
als confirmed the dose-dependent reduction 
in cardiovascular disease with LDL-C6. Every 
1.0 mmol/L (~40 mg/dL) reduction in LDL-C 
has been associated with 22% reduction in 
cardiovascular morbidity and mortality6.
Patients undergoing coronary revascu-
larization remain at a high risk for adverse 
cardiovascular events as the progression of 
atherosclerosis continues after the revascu-
larization procedure7. Therefore, all patients 
after coronary revascularisation, especially 
those with percutaneous coronary interven-
tion (PCI), should continue optimal medical 
therapy including appropriate lipid lowering 
medication8. Guidelines on the manage-
ment of dyslipidaemias from the European 
Society of Cardiology (ESC) and European 
Atherosclerosis Society consider established 
cardiovascular disease as a very high risk 
group9, 10. ESC guidelines 2011 recommend 
that in patients with a very high cardiovascular 
risk, the target of treatment is to achieve LDL-C 
levels <1.8 mmol/L (less than <70 mg/dL) and/
or more than 50% relative reduction in LDL-C 
when the target level cannot be reached 9. 
However, it remains challenging to achieve 
these target levels in clinical practice, which 
are more stringent than the ESC guidelines of 
2007 (Target LDL-C levels <2.0 mmol /L or 80 
mg/dL). The use of optimal medical therapy 
for secondary prevention remains low after 
revascularisation11-15. Moreover, the best lipid 
lowering strategy to reduce cardiovascular risk 
remains debatable9, 16-18 .
ABSORB-II is a multicentre randomised, 
controlled, clinical trial comparing the second-
generation Absorb bioresorbable vascular 
scaffold (BVS) with XIENCE-V everolimus-
eluting metallic stent. The clinical protocol of 
ABSORB-II clearly documents the importance 
of- and strategies to- improve lipid profile. The 
data on lipid profile as well as details of lipid-
lowering therapy were recorded at baseline, 
1-month, 6-month and 12-month follow-up. 
We aimed to analyse the management of dys-
lipidaemia in the ABSORB-II trial, with a view to 
identifying the risk factors associated with not 
achieving the ESC recommended LDL-C levels.
MeTHoDS
ABSORB II trial: The design of the ABSORB 
II trial (ClinicalTrials.gov ID: NCT01425281) 
has been described previously19, 20. In brief, 
it is a randomised, active-controlled, single-
blinded, multicentre clinical trial comparing 
the second-generation Absorb BVS with the 
XIENCE everolimus-eluting metallic stent, 
(both Abbott Vascular, Santa Clara, CA)20.
Management of dyslipidaemia in ABSORB 
II: The ABSORB II trial aimed to adhere with 
the 2007 ESC guidelines on cardiovascular 
disease prevention in clinical practice10. These 
guidelines recommended achieving a LDL-C 
level of less than 2 mmol/L (approximately 80 
mg/dL). A number of measures, as summarised 
in Table 1, were employed to achieve guideline 
recommended lipid targets.
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Demographic and clinical characteristics of 
all patients were recorded at baseline. Blood 
samples were taken for all patients at baseline, 
1-month, 6-month and 12-month. All samples 
were analysed at an independent core labora-
tory (ICON Plc, Dublin Ireland). Lipid profile 
(including total cholesterol, LDL-C calculated, 
high density lipoprotein cholesterol [HDL-C], 
and Triglycerides [TG]) were checked. The 
Friedewald formula (LDL-C=Total Cholesterol-
[HDL-C+TG/2.20] in mmol/L) was used for 
calculation of LDL-C concentration 21. If plasma 
TG levels were above 4.52 mmol/L (400 mg/
dL), the measured LDL-C concentration was 
then reported. Medication status for statin or 
other lipid-lowering drug was checked for all 
patients at baseline, 1-month, 6-month and 
12-month follow-up.
Statistical Analysis: Continuous variables 
are expressed as mean ± standard deviation 
and compared using t-test. Categorical vari-
ables are shown as counts and percentages of 
the total and were compared using Chi-square 
test. A multivariate logistic regression model 
was used to identify factors independently as-
sociated with not achieving target LDL levels. 
All statistical analyses were performed with 
SAS 9.3 (SAS Institute Inc. Cary, NC, USA).
ReSUlTS
Study participants: Between November, 2011, 
and June, 2013, 501 patients from 46 sites 
in Europe and New Zealand, were enrolled in 
the ABSORB II trial. Out of these 501 patients 
at baseline, 500 patients, 496 patients and 
493 patients have completed the 1-month, 
6-month and 12-month follow-up respec-
tively19. Overall demographics and clinical 
characteristics of the patients are shown in 
Table 2. Information on lipid profile at baseline, 
1-month, 6-month and 1-year follow-up was 
available for 448 (89%), 435 (87%), 451 
(91%) and 448 (91%) patients respectively.
Table 1: Measures to achieve target LDL-Cholesterol levels in the ABSORB-II trial
Global communication
Regular newsletter and investigator meetings to emphasize the 
importance of well controlled lDl-C and the level of compliance to eSC 
guidelines in the AbSoRb-II trial
Regular lipids monitoring The lipid profile was regularly monitored during enrolment and follow-up.
Independent analysis Central laboratory (ICON Plc, Dublin Ireland)
Central review Available results from laboratory were checked and reviewed within a week 
to check if a patient was on target for LDL-C according to the 2007 ESC 
guidelines (2.0 mmol/L, 80 mg/dL).
Communication with sites For patient not on-target LDL-C levels, a letter was sent to the site 
investigator to review the lipid profile of the patient and check/adjust the 
treatment strategy for dyslipidaemia.
6-month review For every patient with LDL-cholesterol > 2.0 mmol/L (80 mg/dL) at 6 month 
a ranking of this value compared to all the patients in ABSORB II was sent to 
the site with recommendations to address dyslipidaemia.
Treatment recommendations Practical approach to reach LDL-cholesterol goal as described in the ESC 
2007 Guidelines* was emphasised regularly via the newsletters and 
meetings with trial investigators.
LDL-C low density lipoprotein cholesterol, ESC European Society of Cardiology. * European guidelines on cardiovascu-
lar disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:E1-40
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Lipid lowering therapy: A large major-
ity of the patients received a lipid-lowering 
medication through the 1-year follow-up. 
Table 3 shows the lipid lowering drug usage 
at various follow-up time points. At baseline 
32.5% (n=163) of the patients were receiv-
ing simvastatin whilst 40.5% (n=203) and 
12.0% (n=60) were receiving atorvastatin 
or rosuvastatin respectively. Through the 
1-year follow-up, use of simvastatin reduced 
Table 2. Overall Baseline Patients’ Characteristics
Age (mean ± SD) 61.3 ± 10.0
Male (%) 76.8
Body Mass Index (kg/m2) (mean ± SD) 28.0 ± 4.0
Current tobacco use (%) 23.0
Hypertension (history or needing medication, %) 69.9
Dyslipidaemia (history or needing medication, %) 76.8
Diabetes (%) 24.0
Diabetes mellitus treated with insulin (% of Diabetes patients) 30.0
Family history of premature coronary artery disease (%) 38.2
Previous myocardial infarction (%) 28.3
Recent myocardial infarction with normalised enzyme (%) 2.8
Stable angina (%) 64.1
Unstable angina (%) 21.0
Silent ischaemia (%) 12.2
Table 3. Patients taking various lipid lowering drugs through 1-year
Drug1
baseline2
N=501
1-month3
N=500
6-month3
n=496
12-month3
n=493
Atorvastatin, n (%) 203 (40.5%) 218 (43.6%) 230 (46.4%) 236 (47.9%)
Dose (mg) ±SD 43.4±22.2 44.7±23.0 44.4±22.7 43.4±22.1 
Simvastatin, n (%) 163 (32.5%) 159 (31.8%) 138 (27.8%) 126 (25.6%)
Dose±SD 33.4±9.6 33.4±9.6 33.7±9.6 33.1±9.9 
Pravastatin, n (%) 15 (3%) 17 (3.4%) 15 (3.0%) 16 (3.2%)
Dose (mg) ±SD 26.0±18.0 26.5±17.3 26.4±18.6 27.3±18.3 
Rosuvastatin, n (%) 60 (12.0%) 75 (15.0%) 79 (15.9%) 84 (17.0%)
Dose (mg) ±SD 14.7±12.3 14.7±11.2 14.5±11.2 15.6±11.9 
Ezetimibe, n (%) 21 (4.2%) 24 (4.8%) 32 (6.5%) 35 (7.1%)
Ezetimibe in combination 18 (3.6%) 20 (4.0) 25 (5.0%) 28 (5.7%) 
Dose4 (mg) ±SD 10.8±2.9 10.8±2.8 10.6±2.4 10.2±2.5 
Polyunsaturated fatty acids, n (%) 11 (2.2%) 14 (2.8%) 14 (2.8%) 10 (2.0%)
Other statin, n (%) 4 (0.8%) 4 (0.8%) 3 (0.6%) 2 (0.4%)
Other Lipid Lowering Drug, n (%) 11 (2.2%) 12 (2.4%) 12 (2.4%) 12 (2.4%)
None 53 (10.6%) 22 (4.4%) 19 (3.8%) 19 (3.9%)
1Some of the medications may be combined
2Medication started before index procedure or at index procedure date
3Medication present at least up until the visit (do not include medication started at the follow-up)
4Mean dose of Ezetimibe used in combination
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to 25.6%, whilst usage of more potent drugs, 
atorvastatin and rosuvastatin, increased to 
47.9% and 17.0% respectively. The use of 
ezetimibe, as a monotherapy or in combination 
with a statin, increased from 4.2% at baseline 
to 7.1% at 1-year follow-up.
Lipid profile at baseline and follow-up: The 
mean levels for various cholesterol fractions 
at baseline were: total cholesterol 4.18±1.12 
mmol/L, LDL-C 2.49±0.97 mmol/L, HDL-C 
1.17±0.33 mmol/L and TG 1.18±0.94 mmol/L. 
The temporal trend in different fraction of lipid 
profile is shown in Figure 1. Using baseline as 
reference, LDL-C was significantly lower at 
all follow-up time points. However, the mean 
difference decreased progressively after 
1-month follow-up (from -0.34 [95% CI -0.44 
to -0.24] at 1-month to -0.28 mmol/L [-0.39 
to -0.16] at 1-year follow-up). Conversely, TG 
significantly increased after the procedure at 
all the time points and was, on average, 0.30 
(95% Confidence Interval [CI] 0.19 to 0.41) 
mmol/L higher at 1-year follow-up (P<0.01). 
HDL-C increased progressively from baseline, 
being 0.19 (95% CI 0.16 to 0.22) mmol/L at 
1-year follow-up (P<0.01). The total choles-
terol, therefore, remained unchanged during 
the 1-year follow-up. The lipid profile at 1-year 
was: total cholesterol 4.24±0.91 mmol/L, LDL 
2.21±0.73 mmol/L, high density lipoprotein 
figure 1: Average lipid profile at baseline and during the follow-up in the ABSORB-II trial
HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, TG triglycerides, SD standard de-
viation
Chapter 4.5
335
C
hapter 4.5
1.36±0.37 mmol/L and triglycerides 1.48±1.09 
mmol/L.
At baseline, only 33% patients had a LDL-C 
level within the target range of <2 mmol/L 
(Figure 2). As per the ABSORB-II protocol, this 
triggered a direct communication to the inves-
tigators to modify the therapeutic strategy for 
dyslipidaemia management or communicate 
with patients’ general practitioner. Following 
this recommendation, 47% patients were 
within target range at 1-month follow-up. 
However, a significant proportion of patients 
(53.1% at 1-month, 55.2% at 6-monht and 
58.3% at 1-year) remained above the target 
for LDL-C level. If the more stringent target 
level of 1.8 mmol/L was used, as specified in 
the ESC 2011 guidelines, then only 24-32% 
patients were within the optimal LDL-C range 
(Figure 2). However, there was a trend toward 
improvement over-time with an increase in 
the number of patients on moderate-high 
intensity statin therapy (as defined by 2013 
the American College of Cardiology/American 
Heart Association Guideline on the Treatment 
of Blood Cholesterol to Reduce Atherosclerotic 
Cardiovascular Risk in Adults)16 and propor-
tion of those achieving target LDL-C levels 
(Figure 3).
Risk factors associated with not-achieving 
target LDL levels: Clinical characteristics of 
patients on-target vs off-target for LDL-C 
levels of <2 mmol/L are shown in Table 4. It 
appears that patients with low body mass 
index (BMI), higher cholesterol levels at 
baseline, untreated hypertension and family 
history of premature coronary artery disease 
figure 2: Proportion of patients achieving LDL-cholesterol targets in the ABSORB-II trial
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figure 3. Effects of statin regimen on LDL-C levels. Patients on statin therapy with fasting LDL-C at 
baseline and 1-year is shown according to the 2007 and 2011 ESC guidelines. Subjects were classified 
in High- Moderate- and Low-Intensity Statin Therapy according to the 2013 American College of Cardi-
ology/American Heart Association Guideline.
Table 4: Comparison of patients achieving versus not achieving LDL-Cholesterol targets at 1-year
Target
on Target 
N=187
Off-Target 
n=261 Difference(95% CI) P
Age 61.8 ± 9.8 61.2 ± 9.9 0.6 [-1.3, 2.4] 0.540
Male 78% (146/187) 77% (200/261) 1.4% [-6.6%, 9.1%] 0.719
BMI 28.39 ± 4.24 27.70 ± 3.68 0.68 [-0.07, 1.44] 0.076
Baseline Total Cholesterol 3.87 ± 1.11 4.40 ± 1.04 -0.54 [-0.75, -0.32] <0.001
Baseline LDL-C 2.18 ± 0.96 2.68 ± 0.90 -0.50 [-0.69, -0.31] <0.001
Baseline HDL-C 1.13 ± 0.33 1.20 ± 0.34 -0.07 [-0.14, -0.01] 0.031
Baseline TG 1.29 ± 1.30 1.15 ± 0.68 0.13 [-0.09, 0.35] 0.232
On lipid lowering agents 69% (129/187) 73% (191/261) -4.2% [-12.8%, 4.2%] 0.332
Smoking
Non-smokers 37% (69/187) 38% (98/261) -0.6% [-9.6%, 8.4%] 0.889
Ex-smokers 43% (80/187) 41% (106/261) 2.2% [-7.0%, 11.4%] 0.646
Smokers 20% (38/187) 22% (57/261) -1.5% [-9.0%, 6.3%] 0.698
Hypertension
No 32% (60/187) 30% (79/261) 1.8% [-6.7%, 10.6%] 0.682
Treated 66% (123/187) 64% (168/261) 1.4% [-7.6%, 10.2%] 0.758
Untreated 2% (4/187) 5% (14/261) -3.2% [-6.9%, 0.7%] 0.087
Diabetes mellitus 28% (53/187) 20% (51/261) 8.8% [0.9%, 16.9%] 0.030
Family history of premature CAD32% (54/171) 43% (102/239) -11.1% [-20.2%,1.6%] 0.023
Prior MI 25% (47/186) 31% (79/259) -5.2% [-13.4%, 3.3%] 0.227
Prior PCI 33% (61/187) 35% (92/261) -2.6% [-11.3%, 6.3%] 0.563
Prior CABG 2% (4/187) 2% (6/261) -0.2% [-3.1%, 3.3%] 1.000
BMI body mass index, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TG tri-
glycerides, CAD coronary artery disease, MI myocardial infraction, PCI percutaneous coronary intervention, CABG coro-
nary artery bypass grafting
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were more likely to be off-target. On multiple 
regression analysis, higher baseline LDL-C, 
prior myocardial infarction and lack of statin 
therapy were independent predictors of not 
achieving the target levels.
DISCUSSIon
The main findings of the present study can 
be summarized as follows: (1) the vigorous 
effort to achieve guidelines recommended 
lipid targets in the ABSORB II trial resulted 
in an extremely high lipid-lowering therapy 
prescription; (2) nevertheless a sizable propor-
tion of the patients (58.3%) failed to achieve 
ESC guidelines recommended target levels of 
LDL-C.
Atherosclerosis progression remains a po-
tential enemy at the longer-term follow-up of 
coronary revascularization22, 23. Lipid lowering 
agents have been shown to improve clinical 
outcomes and are recommended as secondary 
prevention therapy in patients with clinically 
evident coronary artery disease, including 
patients who have undergone CABG or PCI5, 
24-27. Intensive lipid-lowering therapy can 
cause regression of atherosclerotic plaques28 
and reduction in future cardiovascular 
events29. However, adherence to lipid lower-
ing therapy remains low in clinical practice. 
A large international observational registry 
(REACH) of 37,154 patients with established 
atherosclerotic disease showed that only 
68% of patients were taking statins30. Only 
two-thirds of patients in the SYNTAX trial were 
taking a lipid-lowering drug, despite the fact 
that they had complex and extensive coronary 
disease31. Similar results were seen in patients 
undergoing CABG in the PREVENT-IV trial32. 
Conversely, in the present study almost all 
patients were on a lipid lowering therapy high-
lighting the success of the educational and 
motivational tools employed in the ABSORB-II 
trial to manage dyslipidaemia, despite it being 
a head-to-head trial of two different types of 
coronary devices.
In spite of taking lipid lowering therapy 
and achieving a significant reduction in LDL-C 
levels, only 41.7% achieved the LDL-C goals at 
1-year follow-up. If we use the stringent rec-
ommendations set by the 2011 ESC Guidelines 
(LDL-C <1.8 mmol/L)9, the proportion of pa-
tients achieving the target would be even less 
(43.08% at 1-month, 40.18% at 6-month and 
37.50% at 1-year). These data are consistent 
with other studies suggesting that it remains 
challenging to achieve guideline based levels 
in clinical practice33-35. In another recent study 
of 366 patients with acute myocardial infarc-
tion, one-third of patients had LDL-C levels 
above 2.5 mmol/L at 6-month follow-up36. It 
is important to try to understand why patients 
could not achieve guideline recommended 
levels. A sizable proportion of patients in 
our study were receiving moderate and high 
intensity statins and yet did not achieve target 
LDL-C; therefore, inadequate prescription 
and doses are unlikely to be responsible for 
these sub-optimal results. It is plausible that 
patients were not adherent to their medical 
therapy37. The importance of lipid lowering 
should be emphasised to patients at each 
clinical encounter to improve compliance38. 
Combining the statin with other cardiovascular 
drugs in a single tablet (polypill) may also im-
prove adherence39. It is also possible that the 
currently used drugs are not potent enough to 
achieve the desired results without the danger 
of actual/perceived side effects. In this regard, 
the new inhibitors of proprotein convertase 
subtilisin-kexin type 9 (PCSK9) were well tol-
Chapter 4.5
338
erated in short-term trials and have produced 
an additional 50–60% decrease in the LDL-C. 
However information about the long-term 
safety of these drugs, and their efficacy in pre-
venting cardiovascular events is not known40. 
Finally, it is also worth mentioning that these 
targets are rather arbitrary and not directly 
tested in any randomised clinical trials. Indeed 
some authorities have suggested to abolish 
these target LDL-C levels altogether16-18 .
It is also important to identify patient 
populations at high risk of not achieving the 
target to allow closer monitoring and intensive 
therapy. Patients with diabetes mellitus are 
generally considered to have a poor metabolic 
profile; however, these patients were more 
likely to achieve target levels in this study. This 
may be due to the fact that these patients are 
more likely to be closely followed and have 
their medication optimised. Patients with a 
family history of premature coronary disease 
were unlikely to achieve target levels possibly 
due to an element of familial dyslipidaemia 
requiring specialist intervention or simply a 
marker of unhealthy life style. There was an 
unexpected finding of rising TG levels over the 
1-year follow-up period. Statins are expected 
to reduce TG levels. We did find a few outliers 
(data not shown) which may have skewed the 
results. However, it is also well-known that 
reliable and reproducible TG measurements 
can be challenging due to variability in levels 
and effect of comorbidities including diabetic 
control. Finally, TG distribution is markedly 
skewed, which often necessitates categorical 
definitions or log transformations41.
Interventions to improve the use of optimal 
medical therapy including lipid lowering agents 
in high-risk subgroups may be beneficial42-44. 
Educating patients and health care providers 
in the community is of paramount importance. 
In the state funded health systems, adopting 
reimbursement based on results may help to 
achieve targets (for example blood pressure, 
HbA1c and LDL-C levels. This approach has 
been successfully implemented in the United 
Kingdom. In the private/insurance funding 
systems, prescription of potent generic agents 
(for example, atorvastatin) may be more help-
ful to balance treatment costs and benefits45. 
Local preventive cardiology programmes 
adapted to individual countries can be very 
helpful46. In the Unites States, programmes, 
such as the Get With The Guidelines and the 
Guidelines Applied in Practice initiatives, 
may help to improve statin prescription and 
patients’ compliance42-44.
Study limitations
The main strength of our study is the quality 
of serial data on lipid profile and medication, 
despite this being a trial of coronary stents/
scaffolds. However, this is a post-hoc analysis 
and has limitations inherent to any such 
analysis. Adherence to medical therapy was as-
sessed by patients self-reporting, without any 
external validation. Nevertheless, patient self-
report has been shown to be a good method to 
assess adherence in clinical practice47.
ConClUSIonS
A physician-oriented motivational and 
educational approach to control LDL-C 
levels resulted in a very high percentage of 
patients receiving lipid-lowering agents but 
with the majority not reaching the guidelines 
recommended LDL-C levels. Identifying high 
risk patients for closer monitoring, specialist 
treatment and measures that improve patient 
compliance are warranted.
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ABSTRACT
Bioresorbable vascular scaffolds (BRS) represent a novel approach to provide transient vessel support to drug-
delivery capability without the long-term limitations of metallic drug-eluting stents (DES). The technology has the
potential to overcome many of the safety concerns associated with metallic DES and possibly even convey further
clinical benefit. In particular, the BRS are designed to provide short-term lumen support, and after being completely
bioresorbed, eliminate the permanent caging typical of metallic DES. However, this technology has required new
imaging modalities and methodologies for its assessment because the design, degradation rate, loss of mechanical
property, and drug deliverability may affect its safety and efficacy. We provide an overview of all existing methods
for assessing bioresorbable devices, from noninvasive to invasive, from light to sound based, and from morphological
to functional parameters. (J Am Coll Cardiol Img 2014;7:1130–48) © 2014 by the American College of Cardiology
Foundation.
T he clinical introduction of bioresorbable scaf-folds (BRS) resulted in a revolutionarychange in the application of local coronary
therapies. These devices have the unique ability to
provide a temporary scaffold that is necessary to
maintain the patency of the vessel after intervention,
releasing antiproliferative drugs. The BRS then grad-
ually degrade, liberating the vessel from its cage
and permitting the restoration of vascular physiology
and integrity (1,2).
Percutaneous coronary intervention with BRS has
potential advantages over the current use of metallic
stents because after resorption, there should be no
trigger for thrombosis, thereby reducing stent/scaf-
fold thrombosis. The lack of foreign material may also
reduce the requirements for long-term dual anti-
platelet therapy and its correlated bleeding
complications. The absence of a rigid metallic cage
can facilitate restoration of the vessel vasomotor
tone, adaptive shear stress, late luminal enlargement,
and late expansive remodeling. In the long term, BRS
may allow a percutaneous/surgical revascularization
of the treated segment or pharmacologically induced
plaque regression, whereas traditional stents often
preclude this option. For clinical follow-up, BRS
enable noninvasive evaluation by multislice coronary
tomography (MSCT), enabling visualization of the
vascular lumen in the treated segment without the
blooming effect observed with metallic stents.
Over the last 10 years, considerable effort has
been put forth to develop new fully bioresorbable
devices. BRS technology has gradually matured, and
there are numerous devices available for preclinical
or clinical evaluation (Table 1). However, this
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technology has required new imaging modalities and
methodology for the assessment of BRS because
their design, degradation rate, loss of mechanical
properties, coating, and drug deliverability may
affect safety and efficacy (Table 2). This review de-
scribes the imaging methods for BRS, compares BRS
with metallic stents, and describes the clinical rele-
vance of BRS.
INVASIVE QUANTITATIVE
CORONARY ANGIOGRAPHY
Invasive quantitative coronary angiography (QCA)
remains one of the most commonly used methods for
the assessment of lumen parameters for BRS. Coro-
nary restenosis is influenced by both acute gain pro-
vided by the intervention and the subsequent late
lumen loss (Figure 1). Considering the variety of BRS
under development, clear understanding of the cor-
onary restenotic mechanics is needed.
In each patient, the treated segment (in-scaffold)
and the peri-scaffold segments (defined by a length of
5 mm proximal and distal to the scaffold edge—in-
segment) should be analyzed by QCA in paired
matched angiographic views after the procedure and
at follow-up. Because these devices are radiolucent,
the only visible structures for QCA analysis are the
metallic markers at the proximal and distal
ends of the device (Figure 2).
The following QCA parameters are computed:
minimal luminal diameter (MLD), reference
vessel diameter obtained by an interpolated
method, late loss, and binary restenosis.
LATE LOSS AND/OR LATE LUMINAL GAIN.
Late loss and/or late luminal gain are defined
as the difference between MLD at post-
procedure minus MLD at follow-up. For
lumen diameter reduction, this will be a
positive number; for late increase in lumen
size, this will be a negative number. Figure 1
summarizes the lumen size changes of cur-
rent BRS tested in clinical scenarios. Please
note the unique effect of all BRS, which is the
late increase in lumen size (late gain). This
luminal gain starts when BRS start to lose
their mechanical integrity (Table 3).
ACUTE RECOIL. For acute recoil assessment, 2 spe-
cific views are analyzed. One is an image of complete
expansion of the last balloon (either the device
delivery balloon or the post-dilation balloon) at the
highest pressure. The other is a cine frame immedi-
ately after the last balloon deflation and the subse-
quent nitrate injection. These 2 images should be
analyzed in the same angiographic projection selected
to minimize foreshortening.
SEE PAGE 1149
TABLE 1 Bioresorbable Scaffolds: Materials and Current Development
Company Product Material Development Pre-Clinical Clinical Post-Clinical
Abbott Laboratories Absorb PLLA/PDLLA ✔ ✔ ✔ ✔
Elixir DESolve PLLA/PDLLA ✔ ✔ ✔ ✔
Meril MeRes PLLA ✔ ✔ ✔
Amaranth Medical FORTITUDE PLLA ✔ ✔ ✔
ART/Terumo ART18Z PDLLA ✔ ✔ ✔
Biotronik DREAMS Magnesium þ PLLA ✔ ✔ ✔
Huaan XINSORB PLA/PCL/PGA ✔ ✔ ✔
Kyoto Medical IGAKI-TAMAI PLLA ✔ ✔ ✔
Xenogenics Ideal BioStent Polyanhydride
(ASA/adipic acid anhydride)
✔ ✔ ✔
Arterius ReBioStent Bioresorbable polymer ✔ ✔
Cardionovum ReNATURAL Metal ✔ ✔
Medtronic Mg Spiral Magnesium ✔ ✔
OrbusNeich On-AVS PLLA/PDLA/TMC/eCAP ✔ ✔
Reva Fantom Tyrosine polycarbonate ✔ ✔
S3V Avatar Not available ✔ ✔
Zorion Medical ZMED Magnesium þ polymer ✔ ✔
LifeTech Lifetech Iron Stent Iron ✔ ✔
Boston Scientific BSC BRS Magnesium ✔ ✔
Sahajanand Sahajanand BRS PLLA? ✔
ASA ¼ salicylic acid; BRS ¼ bioresorbable scaffolds; PCL ¼ polycaprolactone; PDLA ¼ poly-D-lactide; PDLLA ¼ poly(L-lactide-co-D,L-lactide); PGA ¼ polyglycolic acid;
PLA ¼ poly(lactic acid); PLLA ¼ poly-L-lactide; TMC ¼ trimethylene carbonate.
AB BR E V I A T I O N S
AND ACRONYM S
BRS = bioresorbable scaffolds
FF = fibrofatty
FFR = fractional flow reserve
ISA = incomplete scaffold
apposition
IVUS = intravascular
ultrasound
MLD = minimal lumen diameter
MPS = metallic platform stents
MSCT = multislice coronary
tomography
OCT = optical coherence
tomography
QCA = quantitative coronary
angiography
VH = virtual histology
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Acute stent/scaffold recoil is calculated as follows.
� When a stent/scaffold delivery balloon was used
for stent/scaffold expansion, acute absolute
stent/scaffold recoil is defined as the difference
between the mean diameter of the stent/scaffold
delivery balloon at the highest pressure at
implantation of stent/scaffold (X) and mean
luminal diameter of stented/scaffolded seg-
ment after implantation (Y). Absolute acute
stent/scaffold recoil is calculated as X � Y,
whereas relative acute stent/scaffold recoil is
defined as (X � Y)/X and is expressed as a
percentage.
� When a post-dilation balloon was used in the
procedure, acute absolute recoil is defined as
the difference between the mean diameter of
the post-dilation balloon at the highest pressure
in the post-dilated segment (X0) and mean
luminal diameter after post-dilation (Y0). Relative
acute recoil is defined as (X0 � Y0)/X0 and is
expressed as a percentage.
The same methodology was used throughout the
ABSORB Cohort A and Cohort B trials. The absolute
acute recoil in Absorb BVS 1.1 (Abbott Laboratories,
Abbott Park, Illinois) was 0.19 � 0.18 mm (6.7 � 6.4%),
which was not statistically different than that in BVS
1.0 (0.20 � 0.21 mm; 6.9 � 7.0%) or the metallic
everolimus-eluting stent (0.13 � 0.21 mm; 4.3 � 7.1%).
In multivariable models of the 3 pooled populations,
the balloon/artery ratio was an independent predictor
of acute recoil, whereas the type of device (scaffold or
stent) was not (3). The DESolve Nx BRS (Elixir Medi-
cal, Sunnyvale, California) and the ART stent (ART,
Noisy le Roi, France) have acute recoils of 6.4 � 4.6%
(4) and 4.0% (data on file, ART), respectively.
CONFORMABILITY. Coronary geometry changes after
stenting might result in wall shear stress changes and
adverse events. These changes in 3-dimensional (3D)
vessel geometry are associated with decreased and
increased shear stress zones close to the stent edges.
These changes were found to be related to the
asymmetrical patterns of in-stent restenosis (5). An-
giographically, the geometric changes can be assessed
by measuring the curvature and angulation. “Curva-
ture” is defined as the infinitesimal rate of change in
the tangent vector at each point of the center line.
This measurement has a reciprocal relationship with
the radius of the perfect circle defined by the curve
at each point. The curvature value is calculated as
1/radius of the circle in cm�1 (6). “Angulation” is
defined as the angle in degrees that the tip of an
intracoronary guidewire would need to reach the
distal part of a coronary bend (Figure 3) (6).
For the Absorb scaffold, from post-implantation to
follow-up, curvature increased by 8.4% (p < 0.01)
with BRS and decreased 1.9% (p ¼ 0.54) with the
metallic platform stents (MPS) (p ¼ 0.01). Angulation
increased 11.3% with BRS (p < 0.01) and 3.8% with
MPS (p ¼ 0.01); p < 0.01. From pre-implantation to
follow-up, the artery curvature decreased 3.4% with
BRS (p ¼ 0.05) and the artery angulation decreased
3.9% (p ¼ 0.16), whereas MPS presented with 26.1%
decrease in curvature (p < 0.01) and 26.9% decrease
in angulation (p < 0.01) (both p < 0.01 for the com-
parison between BRS and MPS) (7). For drug-eluting
absorbable magnesium scaffolds (DREAMS), the
vessel curvature decreased 40.5% post-implantation
(p < 0.01), but the difference between baseline and
12-month follow-up was reduced to 7.4% (p ¼ 0.03)
(8). This means that the BRS tended to restore the
coronary configuration and systolodiastolic move-
ments to those seen before implantation, whereas the
coronary geometry remained similar to that seen after
implantation with MPS.
VASOMOTION. Vasomotor testing, using nitroglyc-
erin, methylergometrine (endothelium-independent
vasoconstrictor), and acetylcholine (Ach) (endothe-
lium-dependent vasoactive agent), can be performed
at various time points.
Vasomotion of the scaffolded segment following
intraluminal administration of Ach suggests that:
1) the scaffolding function of the struts has com-
pletely disappeared and the so-called scaffolded
segment can now exhibit vasomotion; 2) the endo-
thelial lining (coverage) is coalescent; 3) the ciliary
function of the endothelial cell is functional; and
TABLE 2 Mechanical Properties and Degradation Rate
of Different Material Candidates for Bioresorbable
Coronary Scaffolds
Material
Tensile
Strength, MPa
Elongation,
%
Degradation
Time
Poly(L-lactide) 60–70 2–6 24 months*
Poly(DL-lactide) 45–55 2–6 12–16 months*
Poly(glycolide) 90–110 1–2 6–12 months*
50/50 DL-lactide/
glycolide
40–50 1–4 1–2 months*
82/18 L-lactide/
glycolide
60–70 2–6 12–18 months*
70/30L-lactide/ε-aprolactone 18–22 >100 12–24 months*
Pure Fe 200 40 0.19 mm/year
Fe-35Mn alloy 430 30 0.44 mm/year
WE43 alloy 280 2 1.35 mm/year
*Degradation time depends on geometry (44,45).
MPa ¼ megapascals.
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4) the biochemical process through which nitric
oxide is released properly works. A positive Ach test
with vasodilation of the scaffold is indirect proof that
the endothelium is functional (9).
Mean lumen diameters in the scaffolded proximal
and distal segments are measured by QCA after a
baseline infusion of saline and subselective intra-
coronary administration of Ach, infused through a
microcatheter at increasing doses up to a maximum
of 10�6 M. In particular, a 2-min selective infusion of
Ach (10�8, 10�7, and 10�6 mol/l) is administrated
with a washout period of at least 5 min between
each dose (10). Nitrate (200 mg) is administrated
following Ach. Vasoconstriction to Ach is defined as
a 3% change in the mean lumen diameter, beyond
the variability of the method of analysis, after infu-
sion of the maximal dose of Ach (10�6 M), as previ-
ously shown.
In the Absorb scaffold, patients at 24 months (n ¼
8) exhibited, on average, a significant increase in
the mean lumen diameter after Ach administration
compared with patients at 12 months [þ6.16 (�1.07,
þ13.14) vs. �6.41% (�11.74, �1.17); p ¼ 0.006] (11).
The timing of restored vasomotion after BRS is also
a surrogate for loss of structural integrity of the de-
vice and an indication when the vessel may respond
to normal and exercise-induced changes in coronary
blood flow and pressure. For the Absorb scaffold, the
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FIGURE 1 Angiographic Findings and Parameters for Bioresorbable Scaffold Assessment
(A) Time-related late lumen loss of bioresorbable vascular scaffolds (BRS) in clinical trials. (B) Angiographic parameters for bioresorbable scaffold
assessment. Immediately after scaffold implantation, there is an important luminal increase (acute gain); at follow-up, there could be either a reduction in
lumen size in comparison with the luminal size after implantation (late loss) or a further increase in lumen size (late gain). The latter is a unique angiographic
finding following the use of BRS.
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time seems to be 12 months; for the DREAMS scaffold,
the time seems to be 6 months (8).
NONINVASIVE QCA BY MSCT
Unlike any other metallic prosthesis, polymeric BRS
allow in-scaffold assessment of the coronary lumen
because the struts are radiolucent; the exception is
BRS made of tyrosine polycarbonate and iron,
which are radiopaque. Similarly to coronary angi-
ography, the only recognizable structures are the
metallic markers at both ends of the devices
(Figure 4). BRS technologies use radiopaque
markers that are made of platinum, gold, or
tantalum. These materials should not interfere with
angiographic assessments.
LATE LOSS/LATE LUMINAL GAIN. As mentioned
previously, MSCT provides QCA-like parameters, and
the same definitions are used.
CONFORMABILITY. In MSCT, the center line of the
vessels can be precisely determined and both curva-
ture and angulation can be easily computed
(Figure 5). We compute the radius of the circum-
scribed circle through 3 sequential center-line co-
ordinates. The curvature at Pi is defined as the
inverse of the radius of the circumscribed circle
around the 3 coordinates (Pa, Pi, and Pb), where Pa
and Pb are equally distant from Pi over a 4-mm
moving window at 0.1-mm intervals along the coro-
nary center line (12). Different than the curvature
measured in a fixed 2D projection in angiography, this
curvature assessment in MSCT can be performed in a
3D reconstructed image.
NONINVASIVE FRACTIONAL FLOW RESERVE.
Computational fluid dynamics, as applied to MSCT
images, is a novel method that enables prediction of
blood flow and pressure fields in coronary arteries
and calculation of lesion-specific fractional flow
reserve (FFR) (13–15). The FFR is computed from
commonly acquired MSCT scans (FFRCT) without any
modification of MSCT protocols, additional image
acquisition, or administration of medications.
The FFRCT technology is based on 3 key princi-
ples. The first is that coronary supply meets
myocardial demand at rest (total resting coronary
flow is relative to ventricular mass). The second is
that resistance of the microcirculation at rest is
inversely but not linearly proportional to the size of
the feeding vessel. The third principle is that
microcirculation reacts predictably to maximal hy-
peremic conditions in patients with normal coro-
nary flow. On the basis of these principles, a
lumped parameter model representing the resis-
tance to flow during simulated hyperemia is applied
to each coronary branch of the segmented MSCT
model. The FFRCT is modeled for conditions of
adenosine-induced hyperemia; an FFRCT #0.80 is
considered diagnostic of lesion-specific ischemia
(Figures 6A and 6B) (16).
GRAY-SCALE INTRAVASCULAR
ULTRASOUND
Treated coronary vessels are examined after the
procedure and at follow-up with intravascular ultra-
sound (IVUS) catheters. The scaffolded segment and
its 5-mm distal and proximal segments are also
examined. The vessel area, scaffold area, lumen area,
intrascaffold neointimal area, and luminal area ste-
nosis are measured with a computer-based contour
detection program.
PERCENTAGE OF LUMEN AREA STENOSIS. The per-
centage of lumen area stenosis is calculated as
FIGURE 2 Absorb BRS
The metallic markers are mounted at the proximal and distal ends of the Absorb BRS
(Cohort B device, revision 1.1) (A, yellow arrow). These markers can be seen in cine
angiography, which represents the overlapping of 2 BRS (B, black arrow and double
arrow). In the cross-sectional images of intravascular ultrasound and optical coherence
tomography, the metallic markers can be identified as high echogenic and high light-
intensity structures accompanied by backward shadows, respectively (B, white arrows).
Abbreviation as in Figure 1.
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TABLE 3 Definitions and Formulas of Parameters for Assessment of BRS
Parameter Imaging Modality Formula Definition and Notes
Late loss/late luminal gain Angiography (QCA)/MSCT MLD (post-procedure) – MLD (follow-up) For a lumen diameter reduction, this will be a positive number; for a late
increase in lumen size, this will be a negative number
Acute recoil Angiography (QCA)/MSCT 1. Without post-dilation: mean diameter
(delivery balloon at the highest pressure)
� mean luminal diameter (after
implantation)
2. With post-dilation: mean diameter (post-
dilation balloon at the highest pressure) �
mean luminal diameter (after post-dilation)
Two specific views need to be analyzed: one is an image of complete
expansion of the last balloon (either the device delivery balloon or
the post-dilation balloon) at the highest pressure and the other is a
cine frame immediately after the last balloon deflation and
subsequent nitrate injection; these 2 images are analyzed in the
same angiographic projection selected to minimize foreshortening
Curvature Angiography (QCA)/MSCT 1/r (cm�1) Defined as the infinitesimal rate of change in the tangent vector at each
point of the center line; this measurement has a reciprocal
relationship with the radius of the perfect circle defined by the
curve at each point
Angulation Angiography (QCA)/MSCT Defined as the angle in degrees that the tip of an intracoronary
guidewire would need to reach the distal part of a coronary bend
Vasomotion Angiography (QCA) 1. Vasoconstriction: D mean lumen diameter
(post-pre) #�3%
2. Vasodilation: D mean lumen diameter
(post-pre) $3%
Vasoconstriction/vasodilation are defined as at least 3% change in the
mean lumen diameter after infusion of the maximal dose of Ach/
nitrates, respectively
Noninvasive fractional flow
reserve (FFRCT)
MSCT Computed by a dedicated program; FFRCT was modeled after conditions
of adenosine-induced hyperemia; FFRCT #0.80 is considered
diagnostic of lesion-specific ischemia
Lumen area stenosis Gray-scale IVUS/OCT ([Mean lumen area – minimum lumen area]/
mean lumen area) � 100
Eccentricity index Gray-scale IVUS/OCT Minimum scaffold diameter/maximum
scaffold diameter in a frame
The average of all eccentricity indexes of each frame within a scaffolded
segment is calculated
Symmetry index Gray-scale IVUS/OCT (Minimum scaffold diameter � maximum
scaffold diameter)/maximum scaffold
diameter within a scaffolded segment
The maximum and the minimum stent/scaffold diameters in this
calculation are possibly located in 2 different frames over the length
of the device implanted
Neointima hyperplasia area Gray-scale IVUS Scaffold area – lumen area Applicable in frames where all struts are apposed
Percentage area
obstruction
Gray-scale IVUS Neointima hyperplasia area/scaffold area � 100
Late recoil Gray-scale IVUS/OCT Scaffold area at post-procedure – scaffold
area at follow-up
Incomplete apposition/late
incomplete apposition
Gray-scale IVUS/OCT Defined as 1 or more scaffold struts separated from the vessel wall;
acquired late incomplete apposition is defined as incomplete
apposition at follow-up that is not present after the procedure
Compositional area Virtual histology Necrotic core, dense calcium, fibrofatty, and fibrous areas are analyzed;
polymeric struts are usually recognized as dense calcium
Compositional area iMap Fibrotic, lipidic, necrotic, and calcified tissues are analyzed
Compositional area IB-IVUS Lipid, fibrous, dense fibrous, and calcified tissues are analyzed
Strain value Palpography Radiofrequency data obtained at different pressure levels are compared
to determine local tissue deformation; strain value is normalized to
a pressure difference of 2.5 mm Hg per frame, which allows the
construction of a “strain” image in which hard (low strain/
compliance) and soft (high strain/compliance) values range
between 0% and 2%
Scaffold area OCT At baseline, the scaffold area is measured by joining the middle point of
the black core abluminal side of the apposed struts or the abluminal
edge of the frame borders of malapposed struts; at follow-up, the
back (abluminal) side of the central black core has been used to
delimit the scaffold area
Blood flow area OCT (Scaffold area þ ISA area) – (intraluminal
strut areas þ prolapse area þ intraluminal
defect)
Neointimal hyperplasia
area
OCT 1. When all struts are apposed: scaffold area –
(lumen area þ black box area)
2. When malapposed struts: (scaffold area þ ISA
area þ malapposed strut with surrounding
tissues) – (lumen area þ strut area)
Note the difference in methodology versus that of gray-scale IVUS
Thickness of tissue
coverage
OCT Distance between the abluminal site of the
strut and the lumen – strut thickness
Ach ¼ acetylcholine; ISA ¼ incomplete stent apposition; IB ¼ integrated backscattered; IVUS ¼ intravascular ultrasound; MLD ¼ minimal lumen diameter; MSCT ¼ multislice coronary tomography;
OCT ¼ optical coherence tomography; QCA ¼ quantitative coronary angiography; other abbreviation as in Table 1.
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100 times the mean lumen cross-sectional area
minus the minimal lumen area divided by the mean
lumen cross-sectional area within the scaffolded
segment.
ECCENTRICITY AND SYMMETRY. The eccentricity
and symmetry, easily detectable by IVUS, have
previously been demonstrated to be related to either
favorable or adverse clinical outcomes (17,18). With
the transition from a metallic stent to a polymeric
bioresorbable platform, re-evaluation of these geo-
metric parameters is required at short- and long-term
follow-ups.
FIGURE 3 Curvature and Angulation Analyses
Curvature (A) and angulation (B) analyses are shown before deployment (A1 and B1) and after deployment (A2 and B2). Curvature is estimated as 1/radius
(0.203 mm1 in A1 and 0.148 mm1 in A2). Angulation is defined by the tangents of the center lines (6). BVS tends to allow restoration of the coronary
geometry and systo-diastolic movements of the coronary arteries similar to that seen before implantation (C1 to C3). Modified with permission from Gomez-
Lara et al. (7).
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FIGURE 4 Multislice Coronary Tomography
Multislice coronary tomography (MSCT) shows the radio-opaque markers visible in the scaffolded vessel (A). The radio-opaque markers appear
much larger (arrows) than the actual size because of an artefact (i.e., blooming effect) due to partial volume averaging which is typical of highly
radio-opaque objects that are imaged by MSCT (B). (C) shows a comparison of lumen assessment by MSCT for a bioresorbable scaffold (green
arrows), an overlap scaffold-metallic stent (yellow arrow), and a metallic stent (red arrow).
FIGURE 5 Curvature
(A) Method to calculate vessel curvature. A window size of the vessel diameter was moved down along the center-line path incrementally to
identify 3 adjacent points on the center-line path for the curvature calculation. In MSCT, curvature is computed as the inverse of the radius of a
circumscribed circle over a 4-mm moving window at 0.1-mm intervals along the left anterior descending artery center line (B). Modified with
permission from Choi et al. (12).
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Eccentricity index is defined as the ratio of the
minimum and maximum diameters in each frame;
thereafter, the average of all eccentricity indexes
is calculated. Symmetry index is calculated as
(maximum stent/scaffold diameter in a single frame 
minimum stent/scaffold diameter in a single frame)
divided by the maximum stent/scaffold diameter.
Note that the maximum and minimum stent/scaffold
diameters in this calculation are possibly located in
2 different frames over the length of the device
implanted (Figure 7).
NEOINTIMA HYPERPLASIA. Assessment of the neo-
intima hyperplasia by IVUS is in principle similar to
the methodology used for metallic devices. Neo-
intimal hyperplasia area is defined as scaffold area
minus lumen area if all struts are apposed. Percentage
volume obstruction is defined as neointima hyper-
plasia volume divided by scaffold volume.
LATE RECOIL. Although “late recoil” has been used
frequently in interventional cardiology to describe
the constrictive remodeling of the external elastic
membrane area, here it relates more specifically to
the area reduction of the scaffolded segment, a phe-
nomenon not previously observed in metallic stents.
Attributed to the early alteration of the mechanical
integrity of the scaffold, this phenomenon can be
controlled by polymer processing.
Late absolute stent recoil is defined as stent area at
post-procedure (X)  stent area at follow-up (Y). Late
percent stent recoil was defined as (X  Y)/X  100.
The assessment of late recoil helped to clarify
the reasons for the suboptimal performance of the
FIGURE 6 Principles of Fractional Flow Reserve
Standard coronary computed tomography angiography data are obtained. (A) Five-year results following an Absorb implantation are shown.
Arrowheads indicate the 2 metallic markers in the left anterior descending artery. Noncalcified plaque results in 62% area stenosis. (B) A
quantitative 3-dimensional anatomic model is generated. (C) A physiological model of the coronary microcirculation is derived from patient-
specific data with 3 main principles: 1) resting coronary flow proportional to myocardial mass; 2) microvascular resistance inversely proportional
to vessel size; and 3) microvascular resistance reduced to simulate maximal hyperemia. (D) Physical laws of fluid dynamics are applied to
compute coronary blood flow. (E) Fractional flow reserve (FFRCT) is calculated throughout the coronary arteries. (F) From the proximal to the
distal edge of the scaffold, the FFRCT decreases from 0.88 to 0.80. Modified with permission from Onuma et al. (46), Norgaard et al. (47), and
Nieman et al. (48).
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first-generation magnesium scaffold. For the AMS-1
(Biotronik, Bülach, Switzerland), this parameter was
responsible for 42% of luminal obstruction due to its
rapid scaffold degradation and led to its design
modification (19,20).
Late absolute and percent recoil of the Absorb BVS
1.0 was 0.65  1.71 mm2 (95% confidence interval:
0.49 to 0.80 mm2) and 7.60  23.3% (95% confidence
interval: 5.52% to 9.68%) (21). With the newer itera-
tion of the device, BVS 1.1, the mean scaffold
area increased from baseline to 3 years by IVUS
(6.3 to 7.1 mm2) and by optical coherence tomography
(OCT) (7.8 to 8.6 mm2) (22). Similarly, the DESolve Nx
BRS showed an increase in mean scaffold area by
IVUS (5.4 to 5.6 mm2) and OCT (6.6 to 6.8 mm2) (4).
INCOMPLETE APPOSITION. Incomplete apposition is
defined as 1 or more scaffold struts separated from
the vessel wall; acquired late incomplete apposition is
defined as incomplete apposition at follow-up that is
not present after the procedure.
With BVS 1.1 at baseline, 4 patients showed
incomplete stent apposition (ISA). One ISA persisted
at follow-up, and 3 ISAs resolved. At 6 months’
follow-up, 3 patients developed a late acquired ISA
(23). In the other group followed up to 1 year, at
baseline, there were 5 patients with ISA and at
follow-up there were only 4 (24). At 2 years, incom-
plete apposition by IVUS was only observed in 2 pa-
tients. At 3 years, 3 patients presented late acquired
malapposition (22). The DESolve Nx BRS resulted
in only 1 patient with malapposition at 6 months by
OCT (4).
EDGE EFFECTS. The edge effect was first introduced
in the era of endovascular brachytherapy using
radioactive stents of various activity levels to
describe tissue proliferation at the nonirradiated
proximal and distal edges and resulted in the failure
of this invasive treatment. The advent of first- and
second-generation drug-eluting stents (DES) reduced
in-stent restenosis to approximately 5% to 10%
depending on the lesion subset and type of DES.
When in-segment restenosis (stent and 5-mm prox-
imal and distal margins) occurred, it was most
commonly focal and located at the proximal edge.
Minimum and maximum
diameters through the
gravitational center
of the lumen
Center of the lumen
Cross sections of the device with the
minimum and maximum diameters (D)
through the gravitational center of the lumen,
showing different eccentricity indices
3.1 mm
1.9 mm
3.1 mm
2.5 mm
2.7 mm
2.7 mm
Intracoronary device Vessel wall
Eccentricity Index = = = 0.92
Min D per frame
Max D per frame
2.5
2.7
Symmetry Index = = = 0.13
[max D – min D]
Max D
[3.1 – 2.7]
3.1
FIGURE 7 Relationship Between the Symmetry and Eccentricity Indexes of an Intracoronary Device
Minimum and maximum diameters over the length of the device are shown. Two cross-sections with different eccentricity indexes are also
shown. Modified with permission from Brugaletta et al. (49).
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The ABSORB Cohort B trial enrolled 101 patients
and was divided into B1 (n ¼ 45) and B2 (n ¼ 56)
subgroups. The adjacent (5-mm) proximal and distal
vessel segments to the implanted Absorb BVS were
investigated at either 6 months (B1) or 1 year (B2) with
intravascular ultrasound-virtual histology (IVUS-VH)
imaging.
At the 5-mm proximal edge, the only significant
change was modest constrictive remodeling at
6 months (change in vessel cross-sectional area:
�1.80% [�3.18%; 1.30%]; p < 0.05), with a tendency
to regress at 1 year (change in vessel cross-sectional
area: �1.53% [�7.74%; 2.48%]; p ¼ 0.06). The rela-
tive changes in the fibrotic and fibrofatty (FF) tissue
areas at this segment were not statistically significant
at either time point. At the 5-mm distal edge, a
significant increase in the FF tissue areas of
43.32% (�19.90%; 244.28%; p < 0.05) 1 year post-
implantation was evident. Changes were also
observed in dense calcium areas, which need to be
interpreted with caution. The polymeric struts are
detected as “pseudo” dense calcium structures with
the IVUS-VH imaging modality, and the edges of the
polymeric scaffold are not sharply demarcated
because the vessel surrounding the imaging device
are affected by the “to and fro” motion of the cardiac
contraction, causing a longitudinal displacement of
the IVUS catheter relative to the arterial wall (25).
VIRTUAL HISTOLOGY
Ultrasound backscattered signals are acquired using
either a 20-MHz (electronic) or 45-MHz (mechanical)
IVUS catheter. Backscattering of radiofrequency sig-
nals provides information on vessel wall tissue
composition. Four tissue components (necrotic core
[red], dense calcium [white], fibrous, [green], and FF
[light green]) are identified with autoregressive clas-
sification systems and expressed as percentages per
cross-section (necrotic core, dense calcium, FF, and
fibrous) (26). In each cross-section, polymeric scaffold
struts are detected as areas of apparent dense calcium
and necrotic core resulting from the strong back-
scattering properties of the polymer. We use the
change in quantitative analyses of these areas be-
tween implantation and follow-up as a surrogate
assessment of the chemical and structural alterations
of the polymeric struts (Figure 8). The recent an-
alysis of the ABSORB Cohort B study showed that the
mean dense calcium areas were 29.84 mm2 (post-
implantation), 28.16 mm2 (6 months), 24.25 mm2
(1 year), 27.74 mm2 (2 years), and 21.52 mm2 (3-year
FIGURE 8 Comparison Between Imaging Techniques in Detecting the Degradation Parameters in Matched Frames
After implantation, the polymeric struts are seen as open boxes in optical coherence tomography (OCT), whereas they are white structures in
gray-scale intravascular ultrasound (IVUS) (at 4 and 7 to 8 o’clock). The color-coded virtual histology (VH) image depicts them in white (dense
calcium), whereas echogenicity shows them in green (hyperechogenic). Note that at follow-up, OCT shows all struts integrated (covered with
tissue) into the vessel wall. Gray-scale IVUS shows that the strut at 4 o’clock is less apparent, whereas the corresponding ones in VH and
echogenicity are also not detected. These latter observations reflect some biodegradation.
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follow-up). The average necrotic core areas, at the
same aforementioned time points, were 31.31 mm2,
30.11 mm2, 30 mm2, 31.67 mm2, and 26.49 mm2,
respectively. The sharp decrease in dense calcium
and necrotic core areas between 24 and 36 months
may also reflect the end of the inflammatory process,
with regression of the plaque behind the struts (22).
In addition, the other critical observation with
IVUS between the 6-month and 2-year follow-ups was
a late luminal enlargement (10.9%) with significant
plaque media reduction (12.7%) and without signifi-
cant change in the vessel wall area (27). It is still
unknown whether this “plaque media regression” on
IVUS is a true atherosclerotic regression, with change
in vessel wall composition and plaque morphology
(from thin-cap atheroma to thick-cap atheroma) or a
pseudo-regression due to bioresorption of the poly-
meric struts. True atherosclerotic regression could
only be hypothesized based on animal and in vitro
experiments showing that mammalian target of
rapamycin can trigger a complex chain of biological
reactions that lead finally to activation of genes
related to autophagy of macrophages. Systemic
application of everolimus decreased atherosclerotic
plaque formation in low-density lipoprotein receptor
knockout mice (28).
IMAP
Ultrasound backscattered signals are acquired using
a 40-MHz mechanically rotating IVUS catheter. iMap
is another radiofrequency-based processing method
for coronary plaque tissue characterization (29). iMap
uses a pattern recognition algorithm on the spectra
that were obtained from a fast Fourier transformation
and a histology-derived database (29). The color code
for tissue types is different than that for IVUS-VH.
iMap depicts fibrotic (light green), lipidic (yellow),
necrotic (pink), and calcified (blue) tissues, whereas
IVUS-VH depicts fibrous (green), FF (yellow-green),
necrotic core (red), and dense calcium (white) tis-
sues (30). Although iMap has been validated for
characterization of stents/scaffolds, we have
observed that it detects polymeric struts as calcified
tissue (Figure 9); however, it misses some of the
polymeric struts, which makes this technology not
suitable to serially follow the absorption process of
these polymeric scaffolds.
INTEGRATED BACKSCATTERED IVUS
Ultrasound backscattered signals are acquired using
a 40-MHz mechanically rotating IVUS catheter.
Integrated backscattered values for each tissue
component were calculated as an average power
using a fast Fourier transformation, measured in
decibels, of the frequency component of the back-
scattered signal from a small volume of tissue. With
predefined ranges of integrated backscattered values,
each plaque component is characterized as lipid
(blue), fibrous (green), dense fibrous (yellow), or
calcified (red) tissue (Figure 9) (31,32).
PALPOGRAPHY
Percutaneous implantation of metallic prostheses has
been used to alleviate flow-limiting lesions by over-
stretching the plaque and the underlying vessel wall.
From a mechanical perspective, this treatment may
locally stiffen the artery, reducing its compliance and
creating a mismatch in compliance with respect to the
segments contiguous to the implanted device (5).
This mismatch may eventually provoke flow distur-
bances and wall shear stress alterations, with subse-
quent blood stasis. The wall shear stress distribution
in a stented artery has been reported as a determinant
factor for cellular growth and thrombus formation.
The Absorb everolimus-eluting BVS theoretically has
many advantages compared with rigid metallic
stents. In particular, because the scaffold is made
completely of polylactide, it does not have the
same stiffness as metal, thereby having the potential
to overcome in part the problems related to local
stiffening of the artery and compliance mismatch
associated with MPS. In addition, the mismatch in
compliance after scaffold implantation may poten-
tially disappear in the long term once the scaffold is
completely bioresorbed.
IVUS palpography is a technique that allows for
the assessment of local mechanical tissue properties.
The underlying principle is that at defined pressure,
differences in soft-tissue (e.g., lipid-rich) compo-
nents deform more than hard-tissue components
(e.g., fibrous calcified) (33). In coronary arteries, the
tissue of interest is the vessel wall, whereas the
blood pressure, with its physiological changes during
the heart cycle, is used as the excitation force.
Radiofrequency data obtained at different pressure
levels are compared to determine local tissue
deformation. The strain value is normalized to a
pressure difference of 2.5 mm Hg per frame; this
allows the construction of a “strain” image in which
hard (low strain/compliance) and soft (high strain/
compliance) values range between 0% and 2%. In
post-mortem coronary arteries, the sensitivity and
specificity of palpography to detect high strain
values have previously been reported as 88% and
89%, respectively (34).
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Local strain is calculated from the gated radio-
frequency traces using cross-correlation analyses,
displayed and color-coded from blue (for 0% strain)
to yellow (for 2% strain) via red, as previously
described.
Strain values were assigned a Rotterdam classifi-
cation (ROC) score ranging from I to IV (ROC I 0 to
0.5%; ROC II 0.6% to <0.9%; ROC III 0.9% to 1.2%;
and ROC IV >1.2%). A region was defined as a
high-strain spot when it had high strain (ROC III to IV)
that spanned an arc of at least 12 at the surface of a
plaque (identified on the IVUS recording) adjacent to
low-strain regions (<0.5%), as previously reported
(33). The highest value of strain in the cross-section
was taken as the strain level of the spot. The
compliance of each segment is calculated per
segment (proximal edge, scaffold segment, and distal
edge) and defined as the mean of the maximum strain
values per cross-section in ROC I/II/III/IV spots,
expressed as ROC/mm.
ECHOGENICITY
Echogenicity uses the gray-scale IVUS data to
further evaluate the distribution of the gray values
within a specific coronary segment. The mean
gray value of the adventitia is used to classify
tissue components as either hypoechogenic or
FIGURE 9 Newly Implanted Polymeric Scaffold
The newly implanted appearance of a polymeric scaffold in gray-scale IVUS (A) and color-coded iMap (B). Solid arrows point at polymeric struts
characterized as calcium, whereas dotted arrows in gray-scale IVUS (B) are pointing at polymeric struts, which are not characterized as calcium
by iMap (B). (C) Gray-scale IVUS image of a polymeric scaffold inside a phantom. (D) Corresponding color-coded integrated backscattered
IVUS. The polymeric struts are classified as calcium (red). Abbreviation as in Figure 8.
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hyperechogenic (Figure 8). The adventitia sur-
rounding the coronary artery is defined as a layer
extending from 0.2 to 0.5 mm outside the external
elastic membrane. To avoid artifacts, tissue within
acoustic shadowed areas is excluded and very high
gray-level pixels are identified as upper tissue. After
the tissue identification process, the relative frac-
tion of hypoechogenic versus hyperechogenic tissue
volumes is calculated for the entire scaffolded
segment. The software calculates the echogenicity
as a volume and percentage for each scaffolded
segment (setting hypoechogenicity and hyper-
echogenicity to 100%). The percent differential
echogenicity was calculated for each scaffolded
coronary segment, as follows (35,36).
%DifferentialEchogenicity ¼
ð%Hyper6M�%HyperPreÞ�ð%HyperPost�%HyperPreÞ
ð%HyperPost�%HyperPreÞ
,100%
Echogenicity parameters have been shown to be
able to detect temporal changes in the gray-level in-
tensities for Absorb and DREAMS, being putatively
correlated to scaffold degradation over time (8,35).
OPTICAL COHERENCE TOMOGRAPHY
The BVS presents important differences with respect
to metallic stents when imaged by OCT. The optically
translucent polymeric struts appear as black central
cores framed by light-scattering borders that do not
shadow the vessel wall and allow complete imaging
of the strut thickness. The main quantitative mea-
surements (strut core area, strut area, lumen area,
scaffold area, ISA area, and neointimal area) require
different analysis rules than the metallic stents
(Figure 10).
Qualitatively, the diagnosis of acute strut fracture
resulting from balloon overdilation or late structural
strut discontinuity can be established if 2 struts
overhang each other in the same angular sector of the
lumen perimeter, with or without malapposition, or if
isolated struts are located more or less at the center of
the vessel without obvious connection to other sur-
rounding struts in 2D OCT. For confirmation of the
diagnosis, it is helpful to perform 3D OCT recon-
struction of the disrupted strut. A case description of
strut fracture is shown in Figure 11.
At baseline, the strut area is imaged as a central
black core and a light-scattering frame border. How-
ever, at follow-up, embedding, coverage, and thick-
ening of the frame borders, with apparent reduction
of the central core, render the analysis of the struts
more complex. At this time point, the strut (core) area
is defined only by its black core because the light-
scattering frame is no longer distinguishable from
surrounding tissue. At follow-up, the strut area starts
to gain some tissue filling that can be seen as “white
core” (Figure 12).
The lumen and scaffold contours are obtained with
a semiautomated detection algorithm available in
many offline software packages, and additional
manual corrections are performed if necessary. At
baseline, because the polymeric struts are trans-
lucent, the vessel wall lumen area can be imaged
and delineated at the back (abluminal) side of the
struts. At follow-up, the luminal area is drawn by
FIGURE 10 Newly Implanted BRS
(A)Metallic stent approach: lumen area 10.16 mm2; stent area 7.84 mm2 (incomplete stent
apposition [ISA] 2.32 mm2). (B) BRS approach: lumen area 10.16 mm2; stent area 9.58 mm2
(ISA 0.58 mm2). (C) Additional analysis: strut area 0.61 mm2; blood flow area (lumen area –
strut area) 9.55 mm2. (D) Follow-up. The strut (core) area is defined only by its black core
because the light-scattering frame is no longer distinguishable from surrounding tissue.
Abbreviation as in Figure 1.
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semiautomatic detection, following the endoluminal
contour of the neointima between and on top of the
apposed struts. For malapposed struts, the endolu-
minal contour of the vessel wall behind the malap-
posed struts is used.
At baseline, the scaffold area is measured by
joining the middle point of the black core abluminal
side of the apposed struts or the abluminal edge of
the frame borders of malapposed struts. The scaffold
area is identical to the lumen area in the absence of
ISA and prolapse. At follow-up, the back (abluminal)
side of the central black core is used to delimit the
scaffold area. Three different situations deserve spe-
cial consideration. First, incomplete strut apposition
is defined as a clear separation between the back
(abluminal) side of the strut and the vessel wall. For
FIGURE 11 Bioresorbable Scaffold Discontinuity
A 59-year-old man with treated hypercholesterolemia as his only cardiovascular risk factor was admitted to the hospital with stable angina. The coronary
angiogram revealed a stenotic lesion in the mid left anterior descending coronary artery. As protocol mandated, pre-dilation was performed with a single
inflation of a 2.5  12 mm Voyager balloon (Abbott Laboratories, Abbott Park, Illinois) at 10 atm, followed by implantation of a 3.0  18.0 mm bioresorbable
everolimus-eluting scaffold at 10 atm. A post-dilation was performed with a 3.25  15.0 mm Voyager balloon at 20 atm (expected balloon diameter
3.41 mm). The patient continued to be asymptomatic up to 6 months when he visited the hospital for a re-catheterization because he was enrolled in a
clinical study. By a 2-dimensional (cross-sectional) OCT image, an extreme malapposition of 1 strut was observed (B, yellow arrow). In a 3-dimensional OCT
reconstruction, the overhanging strut was clearly identified in its whole trajectory (C and D, yellow arrow). This patient was left untreated due to lack of
ischemic symptoms. Abbreviation as in Figure 8.
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malapposed struts, incomplete strut apposition area
is delineated by the abluminal side of the frame
border of the malapposed strut (covered or uncov-
ered) and the endoluminal contour of the vessel wall.
Second, in prolapse protruding between struts into
the lumen at baseline, the prolapse area can be esti-
mated between the prolapsed contour (lumen con-
tour) and the scaffold area. Third, an intraluminal
defect free from the vessel wall (e.g., thrombus) is
also quantified as an area. According to these find-
ings, the flow area is defined as (scaffold area þ ISA
area) � (intraluminal strut areas þ prolapse area þ
intraluminal defect).
Neointimal hyperplasia area is defined as (scaffold
area � [lumen area þ black box area]) if all struts are
apposed (Figure 10D), whereas it is calculated as
([scaffold area þ ISA area þ malapposed strut with
surrounding tissues] – [Lumen area þ strut area]) for
malapposed struts.
The thickness of the coverage is measured in every
strut between the abluminal site of the strut core and
the lumen. Because the strut thickness is 150 mm, the
strut is considered covered whenever the thickness of
the coverage is above this threshold value. This
method may slightly underestimate the thickness of
the coverage because it does not take into account
FIGURE 12 Optical Coherence Tomography Light Intensity Analysis
Corresponding OCT cross-sections (red asterisks indicate distal metallic markers) at 1 and 3 years. The strut next to the marker (asterisk) was
analyzed by light reflectivity. At 3 years, the strut core was partially filled by a white nucleus exhibiting high light reflectivity. Tracings at the
bottom showed graphically the light reflectivity along the scan line of incident light (red). The vertical green dotted lines correspond to the
adluminal and abluminal boundaries of the black core either empty or partially occupied by white nucleus. Histological image (Movat staining,
20�) of porcine coronary artery 36 months after implantation of Absorb scaffold shows provisional matrix (glycoconjugates) in purple, filling
the void previously occupied by the polymeric strut. A cellularized (black dot) area with connective tissue (green) is located at the center of the
strut void and is connected by a peduncle to the subintima. Multiple layers of smooth muscle cells are overlying the strut voids. OCT images of
the histological structures in a porcine model are very similar to those observed in humans. The light intensity was analyzed using open-source
software (ImageJ, National Institutes of Health, Bethesda, Maryland). Modified with permission from Serruys et al. (22).
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changes in the size of the strut core over time.
Consequently, the percentage of uncovered struts
may be slightly overestimated.
This OCT Healing Score is a weighted index that
combines the following parameters (37):
1. Presence of intrastent structure (ISS) is assigned a
weight of “4.”
2. Presence of both malapposed and uncovered struts
(%MU) is assigned a weight of “3.”
3. Presence of uncovered struts alone (%U) is
assigned a weight of “2.”
4. Presence of malapposition alone (%M) is assigned a
weight of “1.”
Neointimal Healing Score ¼
ðISS� 4Þ þ ð%MU� 3Þ þ ð%U� 2Þ þ ð%M� 1Þ
LESSONS FROM OCT FOR BRS RESORPTION. OCT
may not be sensitive enough to assess the resorption
process of the polymer, but it provides critical infor-
mation on the integration of the polymer into the
vessel wall. At the beginning, the absence of strut
footprints on OCT was interpreted as a sign of com-
plete bioresorption, but now we know that the pre-
served box appearance with optical translucency is
compatible with complete polymer dissolution (38).
The DESolve Nx BRS showed significant reduction in
the number of struts with the black box appearance at
6 months (4).
TWO-DIMENSIONAL VERSUS 3-DIMENSIONAL OCT.
Three-dimensional OCT provides much more useful
information at bifurcations and overlapping segments
than 2D OCT. Indeed, 3D OCT enables a detailed
assessment of both the longitudinal and cross-
sectional relationship between the jailed side
branches orifice and the overhanging struts (39). Se-
rial 3D OCT also provides information about anatomic
modifications such as the presence of neointimal
bridges, which usually appear as an extension of the
pre-existing carina. From the quantitative point of
view, using 3D OCT reconstructed models, one can
assess the changes over time in the number of com-
partments and their geometric areas.
Three-dimensional OCT offers a unique opportu-
nity to observe the modifications of the shape of the
struts after side branch dilation.
In the overlapping regions, 2D OCT helps to iden-
tify single or stacked struts (inner vs. outer) and
stacked strut clusters (Figure 2). Lumen area is drawn
in nonoverlapping segments, and the following con-
siderations should be made for the scaffold area: it is
drawn from the abluminal side of the black core area
of the outermost strut or stacked strut cluster (where
all of the struts appose the vessel endothelium)
apposing the vessel wall. Where there does not
appear to be any apposition of a single strut or
stacked strut cluster to the vessel endothelium, the
contour of the scaffold area continues to follow the
outermost (most abluminal) scaffold strut or stacked
strut cluster. Three-dimensional OCT of overlapping
regions also helps us to assess the type of over-
lapping: interdigitating struts versus complete over-
lap (40,41).
AGREEMENT OF QCA, IVUS, AND OCT
FOR ASSESSMENT OF BRS
For scaffold length measurement, QCA has shown a
typical systematic bias: variable underestimation of
length but consistent underestimation of the same
magnitude at the index procedure and at follow-up,
eventually due to the effect of foreshortening. OCT
is the most accurate technique for measuring scaffold
length, whereas solid-state IVUS presents a random
error, mostly due to lack of smooth and continuous
pullback; therefore, volumetric analysis is not reli-
able. There is poor agreement for minimal lumen area
estimation between all of the imaging modalities
studied, including IVUS-OCT; hence, their values are
not interchangeable (42).
IVUS, due to its limited resolution, is unable to
detect incomplete malapposition and struts at side
branches compared with OCT. IVUS also has poor
reproducibility for the assessment of these 2 vari-
ables, whereas OCT has excellent assessment (43).
CONCLUSIONS
The upcoming bioresorbable era requires new imag-
ing modalities, parameters, and methodologies for
the longitudinal assessment of BRS. One of the man-
ifested characteristics of BRS is bioresorption of the
polymeric struts into the arterial wall. Although
proper validation with VH, echogenicity, and pal-
pography to evaluate this phenomenon has been
lacking, other observations with OCT and histology
have demonstrated convincing results. We intro-
duced a detailed description of the parameters
and methodologies for the assessment of BRS that
should be needed in the future longitudinal studies.
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Abstract The objective of the study is to validate intravas-
cular quantitative echogenicity as a surrogate for molecular
weight assessment of poly-l-lactide-acid (PLLA) bioresorb-
able scaffold (Absorb BVS, Abbott Vascular, Santa Clara,
California).We analyzed at 9 time points (from1- to 42-month
follow-up) a population of 40 pigs that received 97 Absorb
scaffolds. The treated regions were analyzed by echogenicity
using adventitia as reference, and were categorized as more
(hyperechogenic or upperechogenic) or less bright (hypoe-
chogenic) than the reference. The volumes of echogenicity
categories were correlated with the measurements of molec-
ularweight (Mw)bygel permeationchromatography.Scaffold
struts appeared as high echogenic structures. The quantifica-
tion of grey level intensity in the scaffold-vessel compartment
had strong correlation with the scaffold Mw: hyperechoge-
nicity (correlation coefficient = 0.75; P\0.01), upperech-
ogenicity (correlation coefficient = 0.63; P\ 0.01) and
hyper ? upperechogenicity (correlation coefficient = 0.78;
P\0.01). In the linear regression, the R2 for high echoge-
nicity andMwwas0.57 for the combinationofhyper andupper
echogenicity. IVUS high intensity grey level quantification is
correlated to Absorb BVS residual molecular weight and can
be used as a surrogate for the monitoring of the degradation of
semi-crystalline polymers scaffolds.
Keywords Absorb  Bioresorbable vascular scaffold 
Degradation  Echogenicity  IVUS  Porcine
Abbreviations
IVUS Intravascular ultrasound
BRS Bioresorbable scaffolds
PLLA Poly-l-lactide-acid
PDLLA Poly-D, L-lactide
Mw Molecular weight
Absorb
BVS
Poly-l-lactide-acid everolimus eluting
bioresorbable scaffold
CAD Coronary artery disease
Impact on daily practice
Changes in bioresorbable vascular scaffolds (BRS), design
and compositions may affect their degradation and loss of
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biomechanical characteristics (with the risk of late recoil)
and may be associated with a second wave of arterial wall
inflammation. Therefore, studying the BRS degradation is
crucial to fully understand this technology. The present
work validates echogenicity as a surrogate for polylactide
scaffold degradation.
Introduction
Bioresorbable vascular scaffolds (BRS) are a novel
approach to the interventional treatment of coronary
artery disease (CAD), providing short-term vascular
scaffolding combined with drug-delivery capability. They
may offer potential advantages compared to metallic
drug-eluting stents (e.g. adaptive remodeling, restoration
of vasomotion and late luminal enlargement). The so
called 4th revolution in coronary artery disease revas-
cularization steered extensive scientific research in BRS
developments [1–3].
It has been shown that the designs and materials of BRS
platforms—either metallic or polymeric—influence the
resorption process [3–5]. Considering the variety of pos-
sible platforms, it is necessary to establish tools capable of
monitoring the degradation process and its correlated
mechanical characteristics.
Intravascular ultrasound-derived parameters have shown
to be useful to assess the BRS resorption of metallic and
polymeric scaffolds in humans [6–8]. One of the most
studied intravascular ultrasound (IVUS) techniques to
evaluate the resorption process is called differential ech-
ogenicity [8, 9]. This method consists in an automated and
quantitative three-dimensional analysis of coronary tissue
components scored for echogenicity using as reference the
mean level of the adventitia brightness [9] where scaffold
struts appear as bright hyperechogenic structures. In clin-
ical studies, a continuous decrease of echogenicity over
time has been shown in regions treated with BRS, being
putatively correlated to BRS degradation [7, 8]. However,
in serial human assessments, changes in the adventitia and
plaque-media compartment of the treated regions during
the follow-up period could possibly affect these interpre-
tations [10–14].
The objectives of the current study were: (1) to describe
a novel method of echogenicity for tissue analysis; (2) to
evaluate its reproducibility; and (3) to assess its aptitude to
assess the BRS degradation process through a direct cor-
relation with the molecular weight (Mw) in a preclinical
model using a drug-eluting poly-l-lactide-acid (PLLA) bi-
oresorbable scaffold (Absorb BVS, Abbott Vascular, Santa
Clara, California).
Methods
Study devices
The device used in the present preclinical study is the same
used in Cohort B of the ABSORB clinical trial [15, 16].
Absorb is a balloon-expandable BRS that consists of a
polymer backbone of Poly (L-lactide) (PLLA) coated with
a thin layer of a 1:1 mixture of Poly-D, L-lactide (PDLLA)
polymer with the antiproliferative drug everolimus to form
an amorphous drug-eluting coating matrix containing
100 lg of everolimus/cm2 of scaffold [17].
Experimental model
For validation purposes, we analyzed non-atherosclerotic
Yorkshire-Landrace swine which had been implanted with
Absorb BVS via femoral access according to published
procedures [18]. Absorb sizes were matched to the vessel
size at a target balloon-to-artery ratio of 1.0–1.1 (10 %
overstretch). Each animal received a single Absorb
(3.0 9 18 mm for 1-, 3-, and 6-month and 3.0x12 mm for
12- to 42-month) in 2 or 3 main coronary arteries. Forty
pigs (98 arteries) underwent IVUS acquisition and were
then euthanized at 1-month (n = 12 scaffolds), 3-(n = 12),
6-(n = 14), 12-(n = 12), 18-(n = 12), 24-(n = 12),
30-(n = 8), 36-(n = 8) or 42-months (n = 8). Each scaf-
fold had quantification of polymer degradation by gel
permeation chromatography (GPC). Experimental studies
received protocol approval from the institutional animal
care and use committee and were conducted in accordance
with American Heart Association guidelines for pre-clini-
cal research and the Guide for the Care and Use of Labo-
ratory Animals (National Institutes of Health 2010).
Gel permeation chromatography (GPC)
A previously reported GPC method, with a slightly modi-
fied sample extraction/purification process, was employed
to investigate the degradation of polymer over time by
evaluating the number-average molecular weight (Mn) of
polymer in the Absorb [19]. In the present method, the
extraction and purification of the polymer was repeated up
to five times until the polymer was fully extracted from the
tissue (i.e., the polymer signal in the last extract below the
quantitation limit of 0.3 mg/mL). The samples were ana-
lyzed prior at 1-, 3-, 6-, 12-, 18-, 24-, 30-, 36- and
42-months after implantation.
IVUS acquisition and analysis
All IVUS runs were acquired with 40 MHz mechanical
systems, using Galaxy V2.02 (Boston Scientific, MA,
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USA) at 1-, 3-, 6- and 12-month follow-ups and iLab at
18-, 24-, 30-, 36- and 42-month (Boston Scientific, MA,
USA). We used motorized pullback of 0.5 mm/s with a
frame rate of 30 frames/second. The regions of interest
were restrict to the scaffolded areas, identified by the first
and the last cross-sectional IVUS frame in which scaffold
struts could be identified and/or where the proximal or
distal metallic markers could be identified. Vessel, scaffold
and lumen contours were delimited every 0.5 mm blind to
molecular weight results. We analysed four compartments
by IVUS: the luminal, scaffold, vessel and the neointimal
volume (vessel volume-lumen volume). The scaffold was
delineated semiautomatically at the luminal leading edge
of the struts and the lumen was delineated at the inner
detectable tissue (Fig. 1).
To evaluate inter-observer reproducibility, 2 readers
(C.C. and Y.I.) independently analyzed 30 segments ran-
domly selected from the total number of the investigated
segments. To determine intra-observer reproducibility, one
reader (C.C.) analyzed these segments twice, with the
second reading occurring 3 months later. The inter- and
intra-observer reproducibility were good according to the
conventional norms [20] (hyperechogenicity inter-observer
interclass correlation coefficient [ICC] = 0.80, intra-
observer ICC = 0.95; hypoechogenicity: inter-observer
ICC = 0.78, intra-observer ICC = 0.97; upperechogenici-
ty: inter-observer ICC = 0.92, intra-observer ICC = 0.97)
(Supplementary material).
Automatic quantitative echogenicity analysis
The principle of echogenicity has been previously descri-
bed elsewhere [9, 21, 22]. Echogenicity aims to classify the
vessel wall components located between the luminal
boundary and the external elastic membrane (EEM) into
categories based on their grey-level intensity in B-mode
IVUS images rather than based on radiofrequency ultra-
sound signal analysis [23–26] (Fig. 1). Here we quantified
5 tissue types: hypoechogenic, hyperechogenic, calcified,
upperechogenic and unknown.
Comparison with the adventitia allows for normaliza-
tion with respect to transducer variability, gain settings
and across populations [21]. However, in the analysis of
atherosclerotic tissue, the adventitia can be partially
obscured or darkened as a result of the guide-wire
shadowing or the presence of dense tissue (e.g. calcium)
which reduces the average grey-level values of the
adventitia. Therefore, these parts need to be excluded
from the reference adventitial area. To determine the
reference adventitia area in each frame, the full adven-
titial area located just outside the EEM is first deter-
mined based on a minimum (0.01 mm) and maximum
(0.21 mm) distance from the EEM contour (Fig. 1). To
remove the low echogenic parts of the adventitia an
adaptive threshold value for the entire adventitia area is
determined based on Otsu’s method [27]. Otsu’s method
is a classic automatic non-parametric threshold selection
method which maximizes the between-class variance.
Next, the adventitial area is divided into 2-degree wide
sectors. If more than half of the pixels inside of a sector
is below the adaptive threshold, the sector is excluded
from the reference adventitia area. Finally, the histo-
grams of the reference adventitial areas of the individual
frames are combined into a global adventitia grey-level
intensity histogram and the median value is computed as
a threshold. Cross-section pixels with an intensity lower
than the median value are classified as hypoechogenic,
pixels with an intensity higher than the median value
threshold are classified as hyperechogenic.
Calcified plaque is typically identified in B-mode
IVUS images as a highly echogenic area creating an
acoustic shadow [21]. To determine the high-intensity
grey-level threshold for highly echogenic components we
use the adaptive threshold selection method described in
[28]. First Otsu’s method is applied to the entire grey-
level histogram of an image resulting in an optimal
threshold value. In the next 2 iterations, Otsu’s method is
applied to the histogram of all intensities above the
threshold found in the previous step. Next, we apply an
in-house developed acoustic shadow detection algorithm.
Highly echogenic areas with a grey-level intensity higher
than the high-intensity threshold but without acoustic
shadow behind them are classified as upperechogenic,
while highly echogenic areas with acoustic shadow are
classified as calcified and the shadow itself is classified
as unknown. The entire method has been implemented
and tested in QCU-CMS-Research v4.69 (research ver-
sion of QIvus, developed by the Leiden University
Medical Center) [29].
Data analysis
Continuous variables are presented as mean ± SD or
medians (interquartile range). The ANOVA test was used
to compare continuous variables. As we had different
scaffold lengths we normalized all measurements by the
mean length for all pigs as described previously [30].
This adjusts for differing segment lengths across animals,
thereby providing equal weighting of each individual in
the calculation of echogenicity volumes. The residual
scaffold molecular weight by GPC was compared to the
echogenicity findings and the correlation coefficient was
used as a measure of the degree of relationship (Pear-
son’s correlation coefficient). A linear regression was
used to evaluate if hyper and/or upperechogenicity were
able to predict the residual molecular weight. A
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Fig. 1 Differential
echogenicity methodology.
a The first step was to determine
the lumen-scaffold and scaffold-
vessel compartments by
defining the vessel, lumen and
luminal scaffold contours in
every 0.5 mm. After guidewire
masking, the software identifies
the adventitia as a ring between
0.01 and 0.21 mm outside
vessel contours. b However, if
the software uses as reference
the whole layer around the
vessel contour, it will include
low intensity structures (e.g.,
pericardium, side branches, low
attenuated tissues, etc.) resulting
in a histogram with a non-
normal distribution (right
panel). c The present software
detects automatically high
signal adventitia as reference,
excluding low intensity
structures (arrow heads). The
right panel shows that the
combination of high signal
adventitia in all frames obtains a
bell shaped normally distributed
histogram. The yellow line
represents the referential
adventitial median value. d The
color legend of each
echogenicity classification is
provided. As we used a non-
atherosclerotic porcine model
there was no calcification and
unknown tissue. Nevertheless,
the present software is able to
detect theses tissues
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hierarchical cluster analysis using Ward’s method
(Squared Euclidean distance) was applied for
hyper ? upperechogenicity and hypoechogenicity vol-
umes. The differences were regarded significant when
P\ 0.05 (two-tailed). SPSS version 21.0 (SPSS Inc.,
Chicago, Illinois) was used for all statistical analyses.
Results
The main grey scale IVUS volumetric findings are shown
in Fig. 2 and the comparisons between each group are
given in the supplementary material (Tables 2-5). The
mean scaffold length was 16.5 mm. Compared with
1-month follow-up, the vessel, scaffold and lumen volumes
had a trend to be larger after 18-month follow-up. These
three aforementioned volumes were significantly larger at
36- and 42-month. Additionally, the neointima had the
biggest volume at 1-month follow-up, being similar among
groups thereafter (Fig. 3).
Differential echogenicity and molecular weight
Table 1 summarizes the main findings on differential
echogenicity and mean Mw at each time point. The highest
total hypoechogenicity volume was found at 1-month fol-
low-up, the time point with also the highest neointimal
hyperplasia as aforementioned. The lumen-scaffold com-
partment had an increase in hyper ? upperechogenic vol-
umes up to 12-month and subsequently a decrease until
42-month. Using the as reference the 1-month group, the
hyper ? upperechogenic decreased significantly in the
scaffold vessel compartment after 12 months (supplemen-
tary material).
The GPC results indicated a continuous decrease in
molecular weight over time. The rate of reduction was
slower during the first 6-months of scaffold implantation
followed by a more rapid decline thereafter, being fully
resorbed 36-months after implantation (Fig. 2).
To validate the scaffold degradation by echogenicity we
took into consideration the hyper- and upperechogenicity in
Fig. 2 Grey Scale intravascular ultrasound volumetric findings at different time points. a Vessel volume; b Lumen Volume; c Scaffold Volume
and d Neointimal Volume. Values are median and interquartile range
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Table 1, the earlier IVUS were more likely to present higher
grey-level intensity (hyper ? upperechogenicity). The scaf-
fold-vessel hyperechogenicity (Pearson correlation coeffi-
cient = 0.75; P\ 0.01), upperechogenicity (Pearson
correlation coefficient = 0.63; P\ 0.01) and hyper ? up-
perechogenicity (Pearson correlation coefficient = 0.78;
P\ 0.01) had strong correlation with the scaffold molecular
weight. As shown in Fig. 4, in linear regression, the best
correlation found in linear regression model for molecular
weight was scaffold-vessel hyper ? upperechogenicity (R
squared = 0.57; P\ 0.01); i.e., all grey-level intensity
higher than median adventitia in the scaffold-vessel com-
partment should be considered for monitoring the degrada-
tion process of this semi-crystalline polymers scaffold. Post-
Hoc comparisons between each group are given in the sup-
plementary material (Tables 6-8).
Additionally, a cluster analysis was run for scaffold-
vessel hyper ? upperechogenicity and hypoechogenicity.
It produced five clusters, among which the variables were
significantly different in the main (Fig. 5). The comparison
among clusters of hyper ? upperechogenicity showed a
clear positive association scaffold-vessel hyper ? upper-
echogenicity and molecular weight (Fig. 5).
Fig. 3 IVUS echogenicity
analysis at 1- (a), 18- (b) and
42-month (c). The high
echogenic (including
hyper = light green and
upper = light blue) parameters
decrease over time. d Gel
permeation chromatography
(GPC) for the assessment of
degradation of Absorb showing
the in vivo degradation of
polymer of Absorb over time
Int J Cardiovasc Imaging
123
Chapter 5.2
378
T
a
b
le
1
D
if
fe
re
n
ti
al
ec
h
o
g
en
ic
it
y
fi
n
d
in
g
s
an
d
p
o
ly
m
er
m
o
le
cu
la
r
w
ei
g
h
t
b
y
g
el
p
er
m
ea
ti
o
n
ch
ro
m
at
o
g
ra
p
h
y
1
M
o
n
th
(n
=
1
2
)
3
M
o
n
th
s
(n
=
1
2
)
6
M
o
n
th
s
(n
=
1
4
)
1
2
M
o
n
th
s
(n
=
1
2
)
1
8
M
o
n
th
s
(n
=
1
2
)
2
4
M
o
n
th
s
(n
=
1
2
)
3
0
M
o
n
th
s
(n
=
8
)
3
6
M
o
n
th
s
(n
=
8
)
4
2
M
o
n
th
s
(n
=
8
)
P
v
al
u
e
fo
r
o
v
er
al
l
co
m
p
ar
is
o
n
T
o
ta
l
h
y
p
o
ec
h
o
g
en
ic
it
y
V
o
lu
m
e
(m
m
3
)
4
9
.3
±
6
.9
3
4
.7
±
6
.8
3
1
.4
±
5
.5
2
8
.7
±
4
.5
3
3
.3
±
6
.2
4
2
.2
±
8
2
8
.4
±
7
3
8
.6
±
1
2
.2
3
7
.6
±
1
4
.3
\
0
.0
1
%
T
o
ta
l
h
y
p
o
ec
h
o
g
en
ic
it
y
7
9
.4
±
4
.9
6
8
.3
±
7
.8
7
0
.3
±
6
.5
7
1
.6
±
6
.7
8
0
.5
±
5
.0
8
6
.8
±
5
.4
7
8
.1
±
6
.1
8
9
.7
±
4
.3
9
2
.0
±
3
.4
\
0
.0
1
T
o
ta
l
h
y
p
er
ec
h
o
g
en
ic
it
y
v
o
lu
m
e
(m
m
3
)
8
.5
±
2
.7
8
.7
±
4
6
.6
±
1
6
.5
±
2
.8
4
.8
±
1
3
.9
±
1
.5
4
.3
±
1
.3
2
.8
±
1
.2
2
.2
±
1
.1
\
0
.0
1
%
T
o
ta
l
H
y
p
er
ec
h
o
g
en
ic
it
y
1
3
.6
±
3
.6
1
7
.2
±
7
.0
1
5
.5
±
2
.7
1
6
.1
±
6
.1
1
1
.8
±
2
.4
8
.0
±
2
.6
1
2
.0
±
2
.9
6
.7
±
2
.5
5
.3
±
1
.9
\
0
.0
1
T
o
ta
l
u
p
p
er
ec
h
o
g
en
ic
it
y
v
o
lu
m
e
(m
m
3
)
6
.3
±
3
.5
1
3
.7
±
5
1
2
.9
±
3
.6
1
4
.1
±
7
.1
9
.5
±
5
.5
6
.1
±
3
.6
1
1
.3
±
4
.3
3
.9
±
2
.1
2
.9
±
1
.9
\
0
.0
1
%
T
o
ta
l
u
p
p
er
ec
h
o
g
en
ic
it
y
7
.0
±
3
.9
1
4
.5
±
5
.5
1
4
.1
±
5
.3
1
2
.3
±
5
.3
7
.7
±
4
.0
5
.2
±
2
.9
9
.9
±
3
.4
3
.7
±
1
.9
2
.8
±
1
.6
\
0
.0
1
T
o
ta
l
h
y
p
er
an
d
u
p
p
er
ec
h
o
g
en
ic
it
y
v
o
lu
m
es
(m
m
3
)
1
4
.9
±
4
.5
2
2
.4
±
5
.2
1
9
.6
±
4
.4
2
0
.6
±
6
.8
1
4
.4
±
6
.1
1
0
±
4
.9
1
5
.6
±
5
.3
6
.7
±
3
.1
6
5
.1
±
3
\
0
.0
1
%
T
o
ta
l
h
y
p
er
an
d
u
p
p
er
ec
h
o
g
en
ic
it
y
2
0
.6
±
4
.9
3
1
.7
±
7
.8
2
9
.7
±
6
.5
2
8
.4
±
6
.7
1
9
.5
±
5
.1
1
3
.2
±
5
.4
2
1
.9
±
6
.1
1
0
.3
±
4
.3
8
.1
±
3
.4
\
0
.0
1
L
u
m
en
-s
ca
ff
o
ld
h
y
p
o
ec
h
o
g
en
ic
it
y
V
o
lu
m
e
(m
m
3
)
1
3
.6
±
5
.5
1
3
.4
±
4
.3
7
.7
±
7
.5
3
.9
±
1
.9
6
.7
±
2
.5
7
.8
±
4
.1
2
.9
±
2
0
±
0
.1
0
±
0
.1
\
0
.0
1
%
L
u
m
en
-s
ca
ff
o
ld
h
y
p
o
ec
h
o
g
en
ic
it
y
9
1
.9
±
4
.3
8
8
.8
±
4
.5
8
8
.4
±
4
.1
8
0
.5
±
1
1
.6
8
9
.3
±
3
.7
9
2
.3
±
2
.9
8
6
.1
±
4
.5
2
2
.0
±
4
1
.3
4
4
.5
±
4
8
.3
\
0
.0
1
L
u
m
en
-s
ca
ff
o
ld
h
y
p
er
ec
h
o
g
en
ic
it
y
v
o
lu
m
e
(m
m
3
)
1
.2
5
±
0
.9
1
.5
±
0
.8
1
.2
±
1
.8
0
.8
±
0
.5
0
.4
±
0
.2
0
.3
±
0
.2
0
.3
±
0
.2
0
0
\
0
.0
1
%
L
u
m
en
-s
ca
ff
o
ld
h
y
p
er
ec
h
o
g
en
ic
it
y
8
.1
±
4
.4
1
0
.7
±
4
.7
1
1
.0
±
3
.8
1
9
.0
±
1
1
.6
6
.5
±
3
.0
4
.0
±
2
.0
9
.9
±
3
.5
1
.8
±
5
.0
3
.7
±
8
.7
\
0
.0
1
L
u
m
en
-s
ca
ff
o
ld
u
p
p
er
ec
h
o
g
en
ic
it
y
v
o
lu
m
e
(m
m
3
)
1
.9
±
1
.3
6
.6
±
2
.8
6
.6
±
2
.8
9
.3
±
5
.1
6
.6
±
3
.9
3
.8
±
2
.2
7
.7
±
3
.2
2
2
.4
±
1
.4
1
.8
±
1
.3
\
0
.0
1
%
L
u
m
en
-s
ca
ff
o
ld
u
p
p
er
ec
h
o
g
en
ic
it
y
0
.1
±
0
.1
0
.5
±
0
.7
0
.5
±
0
.7
0
.4
±
0
.5
4
.2
±
0
.9
3
.1
±
1
.2
4
.0
±
1
.7
1
.2
±
3
.4
1
.8
±
5
1
\
0
.0
1
L
u
m
en
-s
ca
ff
o
ld
h
y
p
er
an
d
u
p
p
er
ec
h
o
g
en
ic
it
y
V
o
lu
m
es
(m
m
3
)
3
.2
±
1
.5
8
.1
±
3
.1
7
.9
±
2
.6
1
0
.1
±
5
.4
7
.1
±
4
4
.1
±
2
.4
8
±
3
.3
2
.4
±
1
.4
1
.8
±
1
.3
\
0
.0
1
%
L
u
m
en
-s
ca
ff
o
ld
h
y
p
er
an
d
u
p
p
er
ec
h
o
g
en
ic
it
y
8
.1
±
4
.3
1
1
.2
±
4
.5
1
1
.6
±
4
.1
1
9
.5
±
1
1
.6
1
0
.7
±
3
7
7
.1
±
2
.9
1
3
.9
±
4
.5
3
.0
±
8
.4
5
.5
±
1
0
.3
\
0
.0
1
S
ca
ff
o
ld
-v
es
se
l
h
y
p
o
ec
h
o
g
en
ic
it
y
v
o
lu
m
e
(m
m
3
)
3
5
.7
±
4
2
1
.3
±
5
.1
2
3
.8
±
9
.3
2
4
.9
±
4
.6
2
6
.6
±
4
.9
3
4
.4
±
7
.9
2
5
.5
±
7
.9
3
8
.5
±
1
2
.2
3
7
.7
±
1
4
.3
\
0
.0
1
%
S
ca
ff
o
ld
-v
es
se
l
h
y
p
o
ec
h
o
g
en
ic
it
y
7
5
.5
±
6
.0
5
9
.6
±
8
.6
6
6
.9
±
8
.3
7
0
.1
±
6
.9
7
8
.4
±
6
.2
8
5
.3
±
6
.3
7
7
.0
±
6
.3
8
9
.7
±
4
.3
9
1
.9
±
3
.4
\
0
.0
1
S
ca
ff
o
ld
-v
es
se
l
h
y
p
er
ec
h
o
g
en
ic
it
y
v
o
lu
m
e
(m
m
3
)
7
.3
±
2
7
.2
±
4
.2
5
.4
±
2
.3
5
.7
±
2
.5
4
.4
±
0
.9
3
.5
±
1
.3
4
±
1
.4
2
.8
±
1
.1
2
.2
±
1
.2
\
0
.0
1
%
S
ca
ff
o
ld
-v
es
se
l
h
y
p
er
ec
h
o
g
en
ic
it
y
1
5
.4
±
4
.1
1
9
.5
±
7
.3
1
6
.3
±
2
.9
1
5
.9
±
5
.7
1
3
.1
±
2
.8
8
.9
±
3
.0
1
2
.3
±
3
.0
6
.7
±
2
.5
5
.3
±
1
.9
\
0
.0
1
S
ca
ff
o
ld
-v
es
se
l
u
p
p
er
ec
h
o
g
en
ic
it
y
v
o
lu
m
e
(m
m
3
)
4
.4
±
2
.6
7
.1
±
2
.5
6
.3
±
1
.8
4
.8
±
2
.1
2
.9
±
1
.7
2
.3
±
1
.4
3
.5
±
1
.5
1
.5
±
0
.8
1
.1
±
0
.8
\
0
.0
1
%
S
ca
ff
o
ld
-v
es
se
l
u
p
p
er
ec
h
o
g
en
ic
it
y
9
.2
±
5
.3
2
0
.8
±
8
.3
1
6
.7
±
6
.7
1
4
.4
±
6
.4
8
.5
±
4
.9
5
.8
±
3
.5
1
0
.7
±
3
.7
3
.7
±
1
.9
2
.8
±
1
.6
\
0
.0
1
Int J Cardiovasc Imaging
123
Chapter 5.2
379
C
hapter 5.2
Discussion
In the present study, using IVUS grey scale derived
parameters we attempted to assess the degradation process
of the Absorb poly-L-lactide bioresorbable everolimus-
eluting scaffold at multiple time points in a porcine model.
The major findings of this study can be summarized as
follows: (1) hyperechogenic and upperechogenic thresh-
olds had strong and positive correlations with the scaffold
molecular weight assessment; (2) the combination of hyper
and upperechogenicity could be used as a surrogate for the
chromatographic assessment of scaffold molecular weight
and (3) echogenicity demonstrated good inter- and intra-
observer reproducibility (Supplementary Material).
The present manuscript describes a new software
designed to assess the differential echogenicity and, for the
first time, ascertained the correlation between IVUS grey
scale intensities and quantitative assessment of Mw by
GPC. The first novelty is that it was not necessary to use
ECG gating and therefore, it is not needed a dedicated
IVUS console or post-processing correction. The robust-
ness of this method and the aforementioned good repro-
ducibility demonstrate, for the first time, good correlation
of echogenicity with the degradation of the scaffold with-
out being mandatory correction for motion artifacts [30].
Image resolution can be defined as the capability of
making distinguishable the individual parts of an object.
Therefore, the use of 40 MHz IVUS catheter in the present
study has potential to be more precise to detect scaffold
degradation than the previous methodology with the
20 MHz ultrasound [7, 31]. Ultrasound at a center fre-
quency of 10 MHz has demonstrated to detect decline in
the acoustic impedance of PLA when molecular weight
varied from 60 to 24 kDa, but further decrease in molecular
weight to 15 kDa did not result in discernible change [32].
In the present study, working with the higher resolution of
the 40 MHz IVUS catheter, we were able to detect acoustic
differences in 150 m thick samples degrading from *100
to\4 kDa.
The use of ultrasound to monitor the degradation
process of polymers has been initially proposed with a
wave pulse-echo method in an in vitro essay [31]. Wu
succeeded to monitor by ultrasound the degradation
process of three biodegradable polymers: poly(glycolic
acid) (PGA), poly(L-lactic acid) (PLLA) and 50:50
poly(D, L-lactide-co-glycolide) (PDLLG) [33]. Another
IVUS based approach to detect the resorption process in
human is virtual histology [6]. The spectral analysis of
the raw backscattered ultrasound misrepresents polymeric
struts as dense calcium (DC) and necrotic core (NC). As
these parameters are shown to decrease over time after
implantation, they have been correlated putatively with
resorption [6, 16, 34, 35].T
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Fig. 4 Linear regressions between molecular weight and echogenicity derived parameters in the scaffold-vessel compartment
Fig. 5 A hierarchical cluster analysis labeled by animal was run for
scaffold-vessel hyper ? upperechogenicity and hypoechogenicity.
Cluster 2 and 3 had similar hyper ? upperechogenicity but statisti-
cally significant greater hypoechogenicity volumes in the cluster 2.
Cluster 3 and 5 had similar hypoechogenicity but markedly higher
hyper ? upperechogenicity volumes in cluster 5. There was a clear
positive association between scaffold-vessel hyper ? upperechoge-
nicity and molecular weight. The sample sizes are number of
scaffolds included in each pig cluster. The values are mean ± stan-
dard deviation and the errors bars are 95 % confidence interval
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Previously, echogenicity has been used to assess paired
serial acoustic properties of coronary plaques in BRS-
treated segments in the clinical setting [7, 8, 35]. It has
been shown that these segments had an increase in hy-
perechogenic tissue after implantation which decreased
over time [7, 8, 35]. The aforementioned methodology
succeeds to document the progressive decrease of high
intensity grey level tissues in both metallic and polymeric
BRS [8, 35].
However, until now, the link between echogenicity and
the degradation process has been hypothetically assumed.
The pending question was whether temporal plaque chan-
ges could interfere with the multistage degradation of the
polymer and confound the echogenicity analysis. It has
been shown that coronary atherosclerosis is a dynamic
phenomenon and numerous factors can influence the ath-
erosclerotic changes as detected by IVUS-derived param-
eters. For instance, statin treatment may reduce the
percentage lipid volume index over time [13] and may
increase the calcified plaque component [11]. Additionally,
there is a significant decrease in NC (16 %) and DC (30 %)
content in coronary plaque located behind the struts of the
everolimus-eluting bioresorbable vascular scaffold [36].
All the above-mentioned confounding factors might influ-
ence the acoustic properties in the lumen-vessel compart-
ment and hinder the clinical relevance of echogenicity for
BRS degradation assessment.
As we have used a porcine non-atherosclerotic model,
we did not have the confounding presence of coronary
artery disease, thus enabling the evaluation of Poly-L-
Lactide’s echogenic characteristics over time. Hyperecho-
genic, upperechogenenic and hyper ? upperechogenic
tissues had strong and positive correlations between ech-
ogenicity and the degradation process. Echogenicity is
determined by the difference in acoustic impedance
between two mediums, which is proportional to density and
acoustic velocity. The acoustic velocity is proportional to
the square root of the stiffness (bulk and shear moduli).
Many factors impact the stiffness of PLA, including
molecular weight, polydispersity, crystallinity, orientation
of crystalline microstructure, and other environmental
conditions [37]. As a result, one would expect to change
the impedance of PLA as it degrades and molecular weight
to have a generalized relationship to this decline.
Qualitatively, the correlation was however not perfectly
linear. For instance, at 1-month the combination hyper ?
upper tended (without statistical significance; Table 6, sup-
plementary material), in average, to be lower than at
3-months whereas the molecular weight had a continuous
decrease in the same period. From the ultrasonic point of
view, the significantly higher neointimal hyperplasia (Fig. 2)
at 1-month might have affected the ultrasound penetration
and therefore the echogenicity interpretation. Additionally,
the scaffold-vessel hyper ? upperechogenicity at
30-months was numerically comparable to that at 18-month.
However, the degradation process may be influenced by
individual biological factors and it has to be emphasized that
these assessments were not serial. However, we showed a
consistent individual positive correlation between the
molecular weight and echogenicity (Figs. 4 and 5).
Limitations
Arteries used for molecular weight assessment could not be
evaluated histologically. Therefore, changes in the
observed echogenicity (both lumen-scaffold and scaffold-
vessel) could not be related to the histologic changes over
time [19, 38]. As this study has been performed in a non-
atherosclerotic model, it should be acknowledged that the
rate of degradation has not been confirmed in atheroscle-
rotic coronary arteries. However, as the degradation of
PLLA is a hydrolytically driven and not enzymatically
driven process, it is expected that the rates would be largely
equivalent.
We could not test the reproducibility of the echogenicity
IVUS findings in the two different consoles. However as we
worked at the same ultrasound frequency (40 MHz) and the
tissue classifications were normalized by the individual
adventitia grey scale intensity we could show a robust cor-
relation between scaffold degradation and high echogenic
parameters. It has been shown that the comparison with the
adventitia allows for normalization with respect to trans-
ducer variability, gain settings and across populations [21].
The changes in vessel, lumen, scaffold and neointima
volumes over time are in line with the serial IVUS findings
in the pre-clinical model and clinical setting showing
progressive increase in vessel, lumen area and scaffold area
[16, 18, 39, 40]. However, in the porcine model the somatic
growth can influence our findings [39]. As we do not have
the IVUS at baseline we could not normalize these geo-
metrical changes for the increase in the reference vessel
size. Nevertheless, this information has been described in
the literature and are beyond the main scope of the current
manuscript.
Conclusion
IVUS high intensity grey level quantification is correlated
to Absorb scaffold residual molecular weight assessment.
Echogenicity is a reproducible technique which could be
considered as a surrogate assessment of polylactide
molecular weight decrease as assessed by chromatography
and allows for monitoring of the degradation of semi-
crystalline polymeric scaffolds.
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KEY POINTS
 The analysis of bioresorbable scaffolds (BRSs) by optical coherence tomography (OCT)
requires a dedicated methodology, as the polymeric scaffold has a distinct appearance
and undergoes dynamic structural changes with time, unlike metallic stents.
 The high resolution of OCT allows for the detailed assessment of scaffold implantation,
rupture, discontinuity, and strut integration.
 OCT does not provide reliable information on the extent of scaffold degradation, as it cannot
differentiate between polylactide polymer and the provisional matrix of proteoglycan formed
by connective tissue.
 Three-dimensional OCT reconstruction can aid in the evaluation of BRS in special scenarios
such as overlapping scaffold segments and bifurcations.
INTRODUCTION
BRSs represent a novel approach in the
treatment of coronary artery disease. They
support the vessel transiently to maintain
patency after intervention, deliver antiprolifera-
tive drug to the vessel wall, and then gradually
degrade.1,2 BRS technology has matured, and
there are numerous devices that are commer-
cially available outside the United States or are
undergoing preclinical or clinical evaluation
(Fig. 1). BRS has required new imaging modal-
ities, methodologies, and strategies, because
scaffold design, degradation rate, loss of
mechanical properties (Table 1), coating, and
drug deliverability may affect BRS safety and
efficacy.3,4 OCT has played a central role in un-
derstanding the short and long term BRS perfor-
mance, OCT provides more detailed and precise
morphologic information about BRS than does
intravascular ultrasonography (IVUS) because of
its higher resolution.5,6 This review summarizes
the methodology and clinical application of
OCT in the assessment of BRS, in particular for
the commercially available Absorb Bioresorbable
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Fig. 1. Optical coherence tomography images of different bioresorbable vascular scaffolds. Absorb BVS 1.1
(Abbott Vascular, Santa Clara, CA, USA); Fortitude (Amaranth Medical, Mountain View, CA, USA); DESolve BRS
(Elixir, Sunnyvale, CA, USA); DREAMS 1.0 absorbable metallic scaffold (Biotronik, Berlin, Germany); Ideal II BioStent
(Xenogenics, Philadelphia, PA, USA); Igaki-Tamai scaffold (Kyoto Medical Planning Co, Kyoto, Japan); On-AVS
(Orbus Neich, Wanchai, Hong Kong); REVA (REVA Medical Inc, San Diego, CA, USA). An OCT image for Igaki-
Tamai was not available at baseline.
Table 1
Mechanical properties and degradation rate of different material candidates for bioresorbable
coronary scaffolds
Material Tensile Strength (MPa) Elongation (%) Degradation Time
Poly(L-lactide) 60–70 2–6 24 moa
Poly(DL-lactide) 45–55 2–6 12–16 moa
Poly(glycolide) 90–110 1–2 6–12 moa
50/50 DL-lactide/glycolide 40–50 1–4 1–2 moa
82/18 L-lactide/glycolide 60–70 2–6 12–18 moa
70/30 L-lactide/ε-aprolactone 18–22 >100 12–24 moa
Pure Fe 200 40 0.19 mm/y
Fe-35 Mn alloy 430 30 0.44 mm/y
WE43 alloy 280 2 1.35 mm/y
a Degradation time depends on geometry.
Data from Moravej M, Mantovani D. Biodegradable metals for cardiovascular stent application: interests and new oppor-
tunities. Int J Mol Sci 2011;12:4250–70; and van Alst M, Eenink MJ, Kruft MA, et al. ABC’s of bioabsorption: application of
lactide based polymers in fully resorbable cardiovascular stents. EuroIntervention 2009;5(Suppl F):F23–7.
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Vascular Scaffold (BVS) (Abbot Vascular, Santa
Clara, CA, USA), as this device had the most
extensive short- and long-term follow-up data.
RATIONALE FOR THE NEED FOR A
DEDICATED ANALYSIS METHODOLOGY
FOR THE OPTICAL COHERENCE
TOMOGRAPHIC ASSESSMENT OF
BIORESORBABLE SCAFFOLDS
The OCT appearance of polymeric scaffolds
differs significantly from that of metallic scaffolds
and stents (Fig. 2A). The appearance of magne-
sium scaffolds immediately after implantation is
similar to that of a permanent metallic stent, that
is, a bright strut with well-delimited borders
with a shadow behind (see Fig. 2A). In
contradistinction, polymeric struts are optically
translucent and appear as a black central core
framed by light-scattering borders that do not
shadow the vessel wall, and therefore the
complete thickness of the scaffold strut can be
visualized (see Fig. 2B). The main quantitative
measurements for scaffold evaluation by OCT
include strut core area, strut area, lumen area,
scaffold area, incomplete strut apposition (ISA)
area, andneointimal area. Becausepolymeric scaf-
folds scatter light differently and have different
OCT characteristics than metallic stents/scaffolds
(see Fig. 2B, C), these measurements must be ac-
quired using different image analysis rules.
OPTICAL COHERENCE TOMOGRAPHIC
EVALUATION OF BIORESORBABLE
SCAFFOLDS AT TIME OF IMPLANTATION
Several OCT parameters can be collected at the
time of short-term implantation of the BRS;
these are summarized in Table 2. Key quantifica-
tions include the lumen and scaffold areas, the
magnitude of ISA, lumen prolapse, and flow
area. The high resolution provided by OCT
also allows the operator to visualize the quality
of scaffold implantation and the potential
complications related to it. Important analyses
include assessments of short-term strut fracture,
edge dissection, eccentricity, and symmetry.
Contours
At baseline, the lumen and scaffold contours are
obtained with a semiautomated detection
algorithm available in numerous off-line software
packages. These contours can be corrected
manually if necessary.
Lumen and Scaffold Areas
Because the polymeric struts are translucent, the
vessel lumen border can be visualized and the
vessel lumen area delineated along the external
(abluminal) side of the struts. The scaffold area
is measured by joining the internal middle points
of the abluminal side of the black cores of the
apposed struts or the abluminal edge of the
frame borders of malapposed struts. In the
absence of ISA and plaque prolapse, the scaffold
area is identical to the lumen area (see Fig. 2C).
Incomplete Strut Apposition
ISA is defined by a clear separation between the
abluminal side of the strut and the vessel wall.
ISA area is delineated by the abluminal side of
the frame border of the malapposed struts and
the endoluminal contour of the lumen.
Lumen Prolapse
Several different parameters can be collected in
the case of lumen or plaque prolapse protruding
between the struts into the lumen. The prolapse
area can be estimated by the planimetered
difference between the prolapsed contour (ie,
lumen contour) and the scaffold area. An intralu-
minal defect that is separated from the vessel wall
(eg, thrombus) can also be quantified as an area.
Flow Area
Flow area takes into account ISA, plaque pro-
lapse, and intraluminal defects. It is defined as
the difference between the sum of the scaffold
and ISA areas and the sum of the areas of intra-
luminal struts, prolapse, and intraluminal defect
(ie, flow area 5 [scaffold area 1 ISA area] 
[intraluminal strut areas 1 prolapse area 1 intra-
luminal defect area]).
Short-term Strut Fracture
The diagnosis of short-term strut fracture due
to balloon overdilation can be established if
2 struts overhang each other within the same
angular sector of the lumen perimeter (Fig. 3).
This complication may be observed with or
without concomitant strut malapposition. How-
ever, if isolated struts are located more or less
at the center of the vessel without an obvious
connection with other surrounding struts, strut
fracture may also be present. It is helpful to
perform 3-dimensional reconstruction of the
OCT dataset to confirm the diagnosis.
Edge Dissection
Edge dissection is defined by OCT as the disrup-
tion of the endoluminal vessel surface at the
proximal and distal edges of the BRS (Fig. 4).7
In the ABSORB Cohort B trial, 24% of patients
had proximal and 42% had distal edge dissec-
tion flaps postprocedure.8 On follow-up, prox-
imal and distal edge dissection flaps seem to
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This complication may be observed with or
without concomitant strut malapposition. How-
ever, if isolated struts are located more or less
at the center of the vessel without an obvious
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fracture may also be present. It is helpful to
perform 3-dimensional reconstruction of the
OCT dataset to confirm the diagnosis.
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Fig. 2. (A) Representative optical
coherence tomographic image of
the drug-eluting absorbable metal
scaffold DREAMS (Biotronik, Bu¨lach,
Switzerland) immediately after im-
plantation looks like a permanent
metallic stent (left). Absorb BVS has
optically translucent struts and ap-
pears as a black central core framed
by light-scattering borders that do
not shadow the vessel wall and allow
complete imaging of the strut
thickness (right). (B) Methodology
for the assessment of incomplete
scaffold apposition (ISA) with the
drug-eluting absorbable metal scaf-
fold DREAMS. (C) Newly implanted
bioresorbable scaffold. Differences
in the methodology of OCT assess-
ment between metallic stents and
BVS are illustrated. Panel 1. Metallic
stent approach. Note that with
metallic scaffold/stent analysis, de-
vice area is calculated by planimetry
of the endoluminal border of the
struts. Lumen area, 10.16 mm2; stent
area, 7.84 mm2, ISA, 2.32 mm2.
Panel 2. BVS approach. Lumen
area, 10.16 mm2; stent area,
9.58 mm2; ISA, 0.58 mm2. Panel 3.
Additional BVS analyses. Strut area,
0.61 mm2; blood flow area (lumen
area  strut area), 9.55 mm2. Panel
4. Follow-up OCT imaging of BVS.
Strut area is defined only by its black
core, because the light-scattering
frame is no longer distinguishable
from the surrounding tissue. Neoin-
timal area is defined by (scaffold
area  lumen area  strut area).
([C] Adapted from Garcia-Garcia
HM, Serruys PW, Campos CM,
et al. Assessing bioresorbable coro-
nary devices: methods and parame-
ters. JACC Cardiovasc Imaging
2014;7:1130–48.)
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Table 2
Definitions and formulas for the quantification of OCT parameters for the assessment of BRSs
Parameter Formula Definition and Notes
Eccentricity index Minimum scaffold
diameter/maximum
scaffold diameter in a frame
The average of all eccentricity
indices of each frame within
scaffolded segment is
calculated
Symmetry index (Minimum scaffold diameter 
maximum scaffold diameter)/
maximum scaffold diameter
within a scaffolded segment
The maximum and the
minimum stent/scaffold
diameters in this calculation
were possibly located in 2
different frames along the
length of the device
implanted
Scaffold area At baseline, the scaffold area is
measured by joining the
middle points of the
abluminal sides of the black
cores of the apposed struts
or the abluminal edge of the
frame borders of
malapposed struts. At
follow-up, the abluminal side
of the central black core is
used to delimit the scaffold
area
Blood flow area (Scaffold area 1 ISA area) 
(intraluminal strut areas 1
prolapse area 1 intraluminal
defect area)
Neointimal hyperplasia area i. In case of all struts apposed
Scaffold area  [lumen area 1
black box area]
ii. In case of malapposed struts
[Scaffold area 1 ISA area 1
malapposed strut with
surrounding tissues] 
[lumen area 1 strut area]
Note the difference of
methodology with that of
gray-scale IVUS
Thickness of tissue coverage Distance between the
abluminal site of the strut
and the lumen  strut
thickness
Since the strut thickness is
150 mm (ABSORB), the strut
was considered as covered
whenever the thickness of
the coverage was more than
this threshold value. This
method may slightly
underestimate the thickness
of the coverage because it
does not take into account
changes in the size of the
strut core over time
Adapted from Garcia-Garcia HM, Serruys PW, Campos CM, et al. Assessing bioresorbable coronary devices: methods and
parameters. JACC Cardiovasc Imaging 2014;7:1130–48.
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have resolved. In serial OCT analysis of BRSs,
postprocedural proximal edge dissection was
noted in 21% of cases and distal edge dissection
in 38% of cases, compared with 2% and 5% at
6 months, respectively. At 1 year, an edge
dissection was present in only 2% (proximal)
and none were observed at 2- and 3-year
follow-up. No scaffold thrombosis was reported
in this trial.8 Therefore, although edge dissection
by OCT is often detected, most of these dissec-
tions healed within 6 months without any clinical
sequelae. However, the small sample size of this
study limits any definitive conclusion with
respect to the effect of residual edge dissection
on clinical outcomes.
Eccentricity and Symmetry
The eccentricity and symmetry of implanted
BRSs are easily assessed by OCT (see Table 2).
These parameters have been shown to be asso-
ciated with clinical outcomes after metallic
stents.9,10 With the clinical adoption of various
Fig. 3. Representative OCT image
of scaffold fracture and disconti-
nuity. (A) Scaffold fracture. During
the index procedure after postdila-
tation of an Absorb BVS, OCT
cross-sectional image shows scaffold
fracture (blue arrow, left). The strut
luminal and abluminal surfaces are
no longer orientated perpendicular
to the light source. OCT cross-
sectional image 1 month later shows
extensive strut disarray (dotted blue
arrow, right). (B) Scaffold disconti-
nuity. OCT acquisition 6 months
after Absorb BVS implantation. In
the 2-dimensional (cross-sectional)
OCT image, extreme malapposition
of 1 strut is seen (panel B2, yellow
arrow). In the 3-dimensional recon-
struction, the overhanging strut is
clearly identified in its whole
trajectory (panel B3, B4; yellow
arrow). Further intervention was
deferred because of lack of ischemic
symptoms. ([A] Adapted from
Ormiston JA, De Vroey F, Serruys
PW, et al. Bioresorbable polymeric
vascular scaffolds: a cautionary tale.
Circ Cardiovasc Interv 2011;4:535–
8; and [B] From Garcia-Garcia HM,
Serruys PW, Campos CM, et al.
Assessing bioresorbable coronary
devices: methods and parameters.
JACC Cardiovasc Imaging
2014;7:1130–48.)
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bioresorbable devices, the reevaluation of the
clinical effect of these geometric parameters is
required at short- and long-term follow-up. The
eccentricity ratio is defined as the ratio of the
minimum and maximum diameters of the scaf-
fold in each frame. The eccentricity index is ob-
tained by calculating the average of all
eccentricity ratios along the length of the scaf-
fold.3 The symmetry index is derived from the
maximum scaffold diameter and minimum scaf-
fold diameter along the length of the BRS, which
may be located within different frames. It is
calculated as the difference between the
maximum scaffold diameter and the minimum
scaffold diameter, divided by the maximum scaf-
fold diameter.3 It must be emphasized that the
maximum and the minimum scaffold diameters
in this calculation may be located in 2 different
frames along the length of the implanted device
(Fig. 5).
Bioresorbable Scaffold Versus Drug-Eluting
Stent at Time of Implantation
BRSs have distinct mechanical properties
compared with metallic stents that could influ-
ence the aforementioned OCT parameters.
Mattesini and colleagues11 compared the final,
postimplantation results of the Absorb BVS and
second-generation drug-eluting stents (DESs)
using OCT. A total of 50 complex coronary
lesions (class B2/C by the American College
of Cardiology/American Heart Association
definition) treated with a BVS undergoing a final
OCT examination were compared with an equal
Fig. 4. Representative imaging of a dissection at the distal edge of Absorb BVS. (A) Longitudinal view of a distal
dissection. (B) Three-dimensional reconstruction of OCT pullback showing luminal disruption at distal edge of the
scaffold (double white arrow). (C, D) Three-dimensional reconstruction at 6-month and 2-year follow-up, respec-
tively, demonstrating that the dissection has healed. (E) No distal edge dissection is visible from the angiograms
postprocedure (yellow arrow). (F) OCT cross-sectional images immediately after implantation show that a dissec-
tion extends into the media. (G) OCT image at 6-month follow-up demonstrates an increase in lumen area at
that region without visible dissection. (H) At 2-year follow-up, the lumen area has decreased with detected calcific
tissue. Asterisk, side branch. (From Zhang YJ, Iqbal J, Nakatani S, et al. ABSORB Cohort B Study Investigators. Scaf-
fold and edge vascular response following implantation of everolimus-eluting bioresorbable vascular scaffold: a
3 year serial optical coherence tomography study. JACC Cardiovasc Interv 2014;7(12):1361–9.)
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number of matched lesions treated with
second-generation DESs. In the BRS group,
there was more extensive lesion preparation
(eg, significantly greater balloon diameter:refer-
ence vessel diameter ratio and higher inflation
predilation pressure) and significantly higher
postdilatation pressure used. Final OCT exami-
nation demonstrated a trend toward greater tis-
sue prolapse area (P 5 .08) and a significantly
higher rate of proximal edge ISA (P 5 .04) in
the BVS group. There was no significant differ-
ence in the overall ISA, mean lumen area, and
eccentricity index between the 2 groups. There
were 2 cases of strut fractures in the lesions
treated with BVS, whereas none was observed
with DES.11
OPTICAL COHERENCE TOMOGRAPHIC
EVALUATION OF BIORESORBABLE
SCAFFOLD OVER LONG-TERM
FOLLOW-UP
Because BRSs are designed to degrade with time
after implantation, the structural characteristics
of the scaffold are dynamic and can be well visu-
alized by OCT imaging. Key parameters that may
Fig. 5. Definition of the symmetry and eccentricity indices according to OCT. Minimum and maximum diameters
along the length of the device are shown. Two cross-sections with different eccentricity indices are also shown.
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be assessed during ongoing follow-up include
the presence of any scaffold discontinuity, scaf-
fold eccentricity, strut coverage, and neointimal
hyperplasia.
Scaffold Discontinuity
OCT may detect scaffold discontinuity during
the process of resorption. The assessment of
scaffold discontinuity is the same as that of scaf-
fold fracture after short-term BRS implantation,
that is, discontinuity is present if 2 struts over-
hang each other in the same angular sector of
the lumen perimeter, with or without malapposi-
tion, or if isolated struts are located near the
center of the vessel lumen without obvious
connection with other surrounding struts in the
2-dimensional image. Three-dimensional OCT
reconstruction is helpful to better understand
scaffold discontinuity (see Fig. 3B).
Eccentricity
As the scaffold degrades, its biomechanical
properties are altered, and therefore, eccen-
tricity may change with time and should be
assessed for new BRSs. In a small series of 8 pa-
tients with 5-year follow-up after Absorb BVS im-
plantation, eccentricity decreased with time (see
Fig. 5, Table 2).12
Strut Coverage and Neointimal Hyperplasia
The analysis of strut coverage is complex, as it
must take into account the embedding and
thickening of the frame borders, along with a
reduction of the strut central core. The strut
area is defined only by its black core, because
the light-scattering frame is no longer distin-
guishable from the surrounding tissue and the
tissue begins to fill the strut area, a phenomenon
that can be identified by irregular, high-intensity
areas. At follow-up, the luminal area follows the
endoluminal contour of the neointima between
and on top of the apposed struts; this can be
traced by semiautomatic detection. In the case
of malapposed struts, the endoluminal contour
of the vessel wall behind the malapposed struts
should be used to define the luminal border. The
abluminal side of the central black core is used
to delimit the scaffold area. If all struts are
apposed, neointimal hyperplasia area is calcu-
lated as the difference between the scaffold
area and the sum of the lumen and black box
areas (ie, scaffold area  [lumen area 1 black
box area]). In the setting of malapposed struts,
neointimal hyperplasia area is calculated by sub-
tracting the sum of the lumen and strut areas
from the sum of the scaffold area, ISA area,
and the area of malapposed struts and
surrounding tissues (ie, [scaffold area 1 ISA
area 1 malapposed strut with surrounding tis-
sues]  [lumen area 1 strut area]) (see Fig. 2C,
Table 2).
SERIAL OPTICAL COHERENCE
TOMOGRAPHIC OBSERVATIONS IN
SCAFFOLDED SEGMENTS
The OCT results of Absorb BVS Cohorts B1 and
B2 have been reported up to 3-year follow-up.
The findings of these OCT analyses are illus-
trated in Fig. 6. There was an initial decrease
Fig. 6. Optical coherence tomography (OCT) findings
in ABSORB Cohort B trial. OCT was performed post-
procedure, at 6, 12, 24, and 36 months. The different
parameters are color coded. , Scaffold area in cohort
B1; , scaffold area in cohort B2; , mean lumen area
in cohort B1; , mean lumen area in cohort B2; , min-
imum scaffold area in cohort B1; , Minimum scaffold
area in cohort B2; , minimum lumen area in cohort B1;
, minimum lumen area in cohort B2; , neointimal
area in cohort B1; , neointimal area in cohort B2.
(Adapted from Serruys PW, Onuma Y, Garcia-Garcia
HM, et al. Dynamics of vessel wall changes following
the implantation of the absorb everolimus-eluting bio-
resorbable vascular scaffold: a multi-imaging modality
study at 6, 12, 24 and 36 months. EuroIntervention
2014;9(11):1271–84.)
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in the minimal and mean lumen area that stabi-
lized over the longer term. Although there was
an increase in neointima between 1 and 3 years,
it was compensated by the parallel increase in
the mean and minimum scaffold area, thereby
maintaining the lumen area unchanged. A total
of 98% percent of struts were covered, and
3 of the 13 scaffolds had malapposed struts
with an average malapposition area of
0.60 mm2.13 Serial OCT evaluation of edge
and scaffold vascular responses of the Absorb
BVS showed less lumen loss at the edges than
lumen loss within the scaffold.8 Neointimal
coverage of the Absorb BVS seems to be driven
by shear stress patterns of the blood flow
(Fig. 7).
Serial OCT examinations have demonstrated
that Absorb BVS may potentially passivate
vulnerable plaques (Fig. 8).14 In one such study,
46 patients treated with Absorb BVS and 20 pa-
tients treated with bare metal stents (Svelte
coronary Integrated Delivery System, a balloon-
expandable, cobalt-chromium, thin-strut fixed
wire stent) had thin-capped fibroatheromas
(TCFAs) identified within the device implantation
regions and in the adjacent native coronary seg-
ments. At 6- to 12-month follow-up, only 8% of
the TCFAs detected at baseline were still pre-
sent within the Absorb BVS compared with
27% within the bare metal stent implantation
segments (P 5 .231). A total of 60% of the
TCFAs in native segments did not change their
phenotype at follow-up. The more aggressive
neointimal response to the bare metal stent
resulted in a greater reduction in luminal dimen-
sions compared with the Absorb BVS. The loss of
the scaffold’s structural integrity allowed the
device to expand and accommodate the tissue
that developed and recapped the underlying
high-risk plaques.14
The serial changes in atherosclerotic plaques
after BRS implantation can be quantified by
OCT. In ex vivo validation studies, highly
attenuating regions (attenuation coefficient
mt �8 mm�1) seen on OCT have been associated
with the presence of necrotic core or macro-
phages. Conversely, attenuation coefficient less
than 6 mm�1 was associated with healthy
vessels, calcified plaque, or intimal thick-
ening.15,16 In a small series of 8 patients with
5-year follow-up after Absorb BVS implantation,
OCT demonstrated a low-attenuating layer
covering the treated atherosclerotic plaques
(Fig. 9). In 1 patient, a TCFA was observed at
Fig. 7. (A–C) Distribution of the endothelial shear stress (ESS) and neointimal thickness (NT) in a scaffolded
segment. The dashed lines in the reconstructed segment in (A) and (B) indicate the location of the optical coher-
ence tomographic images in 1 and 2. 10 0 and 20 0 show the ESS distribution across the circumference of the vessel
wall; the neointimal thickness is portrayed in a semitransparent manner. As shown in i, ii, and iii, the ESS is low in the
between-strut areas and high on top of the struts. The neointimal tissue appears to be increased in segments with
low ESS and reduced in segments with high ESS values. The blood flow streamlines are shown with velocity color
coding (right), whereas the ESS distribution along the baseline luminal surface is portrayed according to the color-
coded map (left). The neointimal thickness at 1-year follow-up is shown in a semitransparent fashion. Low ESS and
recirculation zones are noted in the interstrut areas, whereas ESS values are high on top of the struts. The ESS dis-
tribution seems to affect neointimal formation, because there is increased neointimal tissue in the regions between
the struts and minimal neointimal tissue over the struts. (D) Three-dimensional reconstruction of coronary anatomy
from the baseline coronary angiographic and OCT data and blood flow simulation, with the local ESS being por-
trayed in a color-coded map (blue indicates low ESS and red, high ESS). The distribution of the ESS in the scaf-
folded segment is illustrated at the top right side of the panel, whereas below there is an electron microscopic
image acquired 14 days after Absorb BVS implantation in an animal model showing the rugged luminal surface.
(D1, D2) Baseline ESS distribution around the circumference of the vessel wall in 2 OCT cross-sectional images.
Normal to high ESS noted over a fibroatheroma with a cap thickness of 90 mm in D1, whereas in D2, the ESS is
low over the vessel wall and normal over the struts. The asterisk in both images indicates a side branch. At
follow-up, the ESS values are normalized in the scaffolded segment and seem to be increased when compared
with baseline (E). The magnified view demonstrates the thin layer of neointima that has developed and is portrayed
with light gray. High ESS was noted over the fibroatheroma detected at baseline, but the neointimal tissue has
sealed the plaque (E1). The low ESS estimated at baseline across the circumference of the vessel wall in D2 is
normalized at follow-up (E2). ([A–C] Adapted from Bourantas CV, Papafaklis MI, Kotsia A, et al. Effect of the endo-
thelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold im-
plantation: an optical coherence tomography study. JACC Cardiovasc Interv 2014;7:315–24; and [D, E] From
Bourantas CV, Papafaklis MI, Garcia-Garcia HM, et al. Short- and long-term implications of a bioresorbable vascular
scaffold implantation on the local endothelial shear stress patterns. JACC Cardiovasc Interv 2014;7:100–1.)
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the distal scaffold segment with cap disruption
and small thrombus.16 Qualitatively, comparison
with prior follow-up OCT examinations did not
demonstrate any evidence for the accumulation
of de novo adluminal necrotic core within the
scaffolded segments.16 Conversely, patients
treated with metallic DESs seemed to develop
neoatherosclerosis within the neointima (see
Fig. 9).16 Given the small sample size, and the
observation of a different tissue response in 1 pa-
tient, these findings require confirmation in
larger studies.
OPTICAL COHERENCE TOMOGRAPHY
AND SCAFFOLD DEGRADATION
OCT may not be sensitive enough to assess the
extent of polymer degradation. The absence of
strut footprints on OCT was at first interpreted
as a sign of complete bioresorption; however,
it was subsequently shown that OCT cannot
differentiate the polylactide of the polymer
from the provisional matrix of proteoglycan
formed by connective tissue.13,17 Thus, polymer
may no longer be present in the black core areas
Fig. 8. (A) OCT images acquired from a matched site at baseline, 6 months, and 5 years after Absorb BVS implan-
tation. The amount of tissue overlying the calcific deposition increased from baseline to 6 months because of neo-
intimal response to scaffold implantation. At 5 years, the scaffold struts and neointima have merged into a thick
layer of tissue covering the underlying plaque. Arrowheads indicate scaffold struts. GW indicates guidewire artifact.
(B) Histologic findings 10 years after Igaki-Tamai bioresorbable scaffold implantation at the left anterior descending
coronary artery. The spaces previously occupied by PLLA scaffold struts disappeared. Elastica van Gieson staining
shows thick intima. This thick intima consisted of smooth muscle cells and fibrotic tissues without almost no inflam-
matory cells. ([A] Adapted from Karanasos A, Simsek C, Gnanadesigan M, et al. OCT assessment of the long-term
vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol
2014;64(22):2343–56.)
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Fig. 9. (A) Example of attenuation
analysis. Tissue attenuation proper-
ties within adluminal and abluminal
contour are measured in all frames
and displayed on a color scale
(blue represents low-attenuation
regions, whereas red and yellow
represent high-attenuation re-
gions). For intimal thickness less
than 200 mm, as in the 6-o’clock
to 7-o’clock position, analysis is
not performed because of lack of
a sufficient imaging window. (B,
C) Spread-out maps demon-
strating attenuation coefficient in
predefined depths from the vessel
surface (100, 200, and 400 mm).
In (B) there is a low-attenuating
layer of 200 mm separating the un-
derlying plaque (starting at
w400 mm) from the lumen. In (C),
this layer was absent, and attenu-
ating areas were close to the
lumen. (D) Potential paradigm shift
in the treatment of atherosclerosis
with Absorb BVS. After metal stent
implantation, struts are preserved
and the neointimal area clearly
delineated between stent and
lumen contour even at long-term
follow-up. There is a possible
development of neoatherosclerosis
within the neointima. Conversely,
bioresorbable scaffolds in long-
term follow-up of the neointimal
boundaries are unclear after degra-
dation (dotted line), and the intima
resembles native plaque, defined
as neoplaque. The signal-rich layer
is the layer that separates the un-
derlying plaque components from
the lumen. (Adapted from Karana-
sos A, Simsek C, Gnanadesigan
M, et al. OCT assessment of the
long-term vascular healing
response 5 years after everolimus-
eluting bioresorbable vascular scaf-
fold. J Am Coll Cardiol
2014;64(22):2343–56.)
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seen on OCT. OCT does provide information
regarding scaffold integration, that is, when
the scaffold struts start to have cellular areas
with connective tissue (Fig. 10).13,17
OVERLAPPING SEGMENTS,
BIFURCATIONS, AND 2-DIMENSIONAL
VERSUS 3-DIMENSIONAL OPTICAL
COHERENCE TOMOGRAPHY
Three-dimensional OCT provides much more
useful information at bifurcations and
overlapping segments than does 2-dimensional
OCT. In overlapping regions, 2-dimensional
OCT helps to identify single or stacked struts (in-
ner vs outer) and stacked strut clusters (Fig. 11).
Lumen area should be calculated similarly to
nonoverlapping segments. Scaffold area at over-
lapping segments should be calculated by
planimetry from the backside (ie, abluminal
side) of the black core area of the outermost
strut or stacked strut cluster (at the point of all
the struts apposing the vessel endothelium)
apposing the vessel wall. Where there does not
Fig. 10. Comparison of serial OCT and histologic findings in a porcine model. OCT cross sections were matched
according to the presence of distal metallic markers (red asterisks) at 1 and 3 years. One of the matched struts next
to the marker (asterisk) was analyzed by light reflectivity.21 At 3 years, the strut core that was initially black became
partially filled by a nucleus exhibiting high light reflectivity. Tracings at the bottom showed graphically the light
reflectivity along the scan line of incident light (red). The vertical green dotted lines correspond to the adluminal
and abluminal boundaries of the black core either empty or partially occupied by white nucleus. Histologic picture
(Movat staining) of porcine coronary artery 36 months after implantation of Absorb scaffold showed provisional
matrix (glycoconjugates) in purple, filling the void previously occupied by the polymeric strut. A cellularized (black
dots) area with connective tissue (green staining) is located at the center of the strut void and is connected to the
subintima. Multilayers of smooth muscle cells are overlying the strut voids. OCT images of the histologic structures
in a porcine model are similar to those observed in human. (Adapted from Serruys PW, Onuma Y, Garcia-Garcia
HM, et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bio-
resorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention
2014;9(11):1271–84.)
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appear to be any apposition of a single strut or
stacked strut cluster to the vessel endothelium,
the contour of the scaffold area continues to
follow the outermost (most abluminal) scaffold
strut or stacked strut cluster. Three-
dimensional OCT of overlapping regions helps
define the type of overlapping, interdigitating
struts versus complete overlap.18
Within bifurcations, 3-dimensional OCT
enables a detailed assessment of both the longi-
tudinal and cross-sectional relationship between
the jailed side branch orifice and the over-
hanging struts.19 Modifications of the shape of
the struts after side branch dilatation can
be observed with 3-dimensional OCT. Serial
3-dimensional OCT provides information
regarding the evolution of the bifurcation
anatomy after scaffold implantation, such as
the presence of neointimal bridges, which usu-
ally appear as an extension of the preexisting
carina. From a quantitative point of view,
3-dimensional OCT reconstruction can be used
to assess the changes over time in the number
of compartments and their geometric areas
(Fig. 12).
AGREEMENT AND REPRODUCIBILITY OF
OPTICAL COHERENCE TOMOGRAPHY FOR
THE ASSESSMENT OF BIORESORBABLE
SCAFFOLDS
OCT has excellent reproducibility for the assess-
ment of incomplete malapposition and struts at
side branches.20 OCT is the most accurate
technique for measuring scaffold length. There
is a moderate agreement with IVUS in the mea-
surement of in-scaffold minimum lumen area
assessment at the same coronary segment, and
therefore their values should not be used
interchangeably.5
Fig. 11. In the cross-sectional images of optical coherence tomography, the metallic markers can be identified
as high-echogenic and high–light intensity structures accompanied with backward shadows (asterisks). The
3-dimensional OCT reconstruction helps to understand the overlapping region. (From Garcia-Garcia HM, Serruys
PW, Campos CM, et al. Assessing bioresorbable coronary devices: methods and parameters. JACC Cardiovasc
Imaging 2014;7:1130–48.)
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Fig. 12. Three-dimensional OCT side branch classification. (A) Classification based on the relative location with the
side-branch ostium. Four different types could be identified: proximal, distal, proximal and distal, or crossing.
Dotted lines indicate side-branch ostia; arrowheads indicate tissue bridge. (B) Upper panel shows the bio-
resorbable vascular scaffold (BVS) with polymeric struts. Yellow circles represent the orifice of the side branch
(SB). A nonjailed SB is defined as the complete absence of struts across the orifice (1a) or BVS struts located
over the orifice without compartmentalization (1b). Lower panel shows jailed SB orifices are separated into various
compartments. Types of SB jailing are expressed in alphabetical letters given according to resemblance of the strut
structure across the orifice. ([A] From Karanasos A, Simsek C, Gnanadesigan M, et al. OCT assessment of the long-
term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol
2014;64(22):2343–56; and [B] Adapted from Okamura T, Onuma Y, Garcia-Garcia HM, et al. 3-Dimensional optical
coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for
classification. JACC Cardiovasc Interv 2010;3:836–44.)
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SUMMARY
OCT is a valuable tool for BRS assessment
because of its high resolution. It provides detailed
and reproducible information regarding the
interaction between the device and lumen sur-
face. A dedicatedmethodology for OCT analysis,
different from that for metallic stents, is required
for the short- and long-term assessment of BRS.
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Background: Coronary plaque sizemodification, by either local (device) or systemic treatments, has been the tar-
get for many years.
Methods: From ABSORB Cohort A (Absorb BVS 1.0), ABSORB Cohort B (Absorb BVS 1.1), SPIRIT FIRST (Multi-Link
Vision vs. Xience V) & SPIRIT II (Xience V vs. Taxus), we calculated the total plaque area (vesselminus lumen area
– thus it comprises both compartments – the plaque behind struts and the neointima.) changes by IVUS.
Results:A total of 313 patientswere included. Comparison-at-6-month follow-up: All devices induced an increase
in the total plaque area. The largest increase occurredwith Vision and Taxus stents as compared to other devices
[Absorb BVS (1.0 and 1.1) and Xience V], (p = 0.0002). Comparison-at-2-year follow-up: Absorb BVS 1.1 had a
larger increase from post procedure in total plaque compared to Absorb BVS 1.0, Xience V and Taxus (p =
0.0499). However, in Absorb BVS 1.1 total plaque showed a reduction of 2.2% from 1 to 3 years. Specifically,
the total plaque in the sequential cohorts of Absorb BVS 1.1 increased 16.2% from baseline to 2 years (Cohort
B1) while at 3 years this increase is only 5% compared to baseline (Cohort B2).
Conclusions: Local devices affect coronary plaque size differently and it depends on the platform (metallic vs.
polymeric) and onwhether it is a bare— or drug eluting stent. Coronary scaffolds appear to be a promising alter-
native to metallic stents since they allow plaque regression at long-term follow-up.
© 2014 Elsevier Ireland. Ltd. All rights reserved.
1. Introduction
Coronary atherosclerosis is a worldwide pandemic disease. Treat-
ment options vary according to the clinical presentation. [1] Broadly
speaking, most of patients are medically treated, and in addition some
also require percutaneous coronary intervention (PCI) or surgical treat-
ment. PCI offers different options: bare metal or drug eluting stents and
more recently everolimus eluting bioresorbable scaffolds. Medical and
stenting treatments affect uniquely coronary plaque size and its compo-
sition (IBIS 2 and APPROACH restenosis) [2,3]. Commonly, patients re-
ceive concomitantly medical treatment and PCI and therefore the
coronary vessel wall response will vary in relation to the interaction of
both treatments. At follow-up, implants will be surrounded by plaque,
behind (peri-stent) the struts and endoluminally (neointima). These
two compartments are biologically active and will be influenced differ-
ently by the presence of a complex interaction formed by the platform
(metallic/polymeric) + polymer + drug. For example, stents/scaffolds
eluting everolimus will similarly affect plaque size (i.e. by clearing
macrophages and inhibiting formation of neointima), but the net effect
will be dissimilar since theplatforms are different (metallic vs. polymer-
ic). Thus, the effects on plaque size of this complex interplay (eluted
drug/platform) can only be explored by measuring serially the size of
the coronary plaque-media and neointima compartment.
The objective of this study is therefore to assess serially the changes
in plaque size using IVUS by evaluating five different stent types (Ab-
sorb bioresorbable everolimus eluting scaffold — Absorb BVS 1.0 and
1.1; everolimus eluting metallic stent — Xience V —;bare metal stent
— Vision and paclitaxel-eluting metallic stent — Taxus)
2. Methods
2.1. Study population
For the present analysis, we screened all the patients from ABSORB Cohort A and Co-
hort B trials and from the SPIRIT First [4] and SPIRIT II trials [5] and we selected only the
patientswith available IVUS data post-stent/scaffold implantation and truly serial imaging
at different timepoints at follow-up. In total, there are 5 groups according to the implanted
device (Absorb BVS 1.0, Absorb BVS 1.1, Xience V, Taxus and Vision). The design of the
ABSORB studies has been already described. [6,7] Briefly, in the ABSORB Cohort A (n =
30) and ABSORB Cohort B trials (n= 101), patients with a diagnosis of stable or unstable
angina or silent ischemia, were enrolled. In Cohort A, all treated lesionswere single and de
novo in a native coronary artery of 3.0 mm diameter, shorter than 8 mm for the 12 mm
scaffold and shorter than 14mm for the 18mm scaffold, with a diameter stenosis greater
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than 50% and less than 100%, andwith a thrombolysis inmyocardial infarction (TIMI)flow
grade more than 1. In Cohort B, similar lesion types were treated by implantation of Ab-
sorb BVS revision 1.1 (3.0 × 18 mm).
The SPIRIT FIRST and SPIRIT II trials were planned to assess the safety and efficacy of
the everolimus eluting stent (Xience V) in patients with coronary artery disease. Both tri-
als were prospective, multicenter, single-blinded, randomized–controlled clinical investi-
gations and compared Xience V with bare metal stent (Vision — SPIRIT FIRST trial) or
paclitaxel-eluting stent (Taxus— SPIRIT II trial). These trialswere approved by ethics com-
mittee at each participating institution and each patient gave written informed consent
before inclusion.
2.2. Study devices
The Absorb BVS (Abbott Vascular, Santa Clara, California, USA) has an amorphous
poly-DL-lactide (PDLLA) coating that contains and controls the release of an anti-
proliferative drug everolimus. The scaffold body is made of semi-crystalline poly-L-
lactide (PLLA). PLA is completely degraded via hydrolysis and bioresorbed via the Krebs
cycle [6,7]. The scaffold has struts with an approximate thickness of 150 μm.
Xience V everolimus-eluting stent (Abbott Vascular, Santa Clara, California, USA) is a
cobalt chromium alloy device. The platform consists of serpentine rings connected by
links fabricated from a single piece, with a strut thickness of 81 μm; the polymer and
drug coating add a combined thickness of 7 μm.
Taxus paclitaxel-eluting stent (Boston Scientific, Natwick, Massachusetts, USA) is a
stainless stent, with a strut thickness of 132 μm; the polymer and drug coating add a com-
bined thickness of 16 μm.
Lesionswere treatedwith routine interventional techniques that includedmandatory
pre-dilatation using a balloon shorter than the study device and 0.5 mm less in diameter.
The Absorb BVS was implanted at a pressure not exceeding the rated burst pressure
(16 atm). Post-dilatation with a balloon shorter than the implanted device was allowed
at the operator's discretion, as was bailout treatment.
2.3. Intravascular ultrasound analysis
Post-procedure treated vessel segment was examined with phased array or mechan-
ical intravascular ultrasound (Eagle-eye Volcano, Rancho Cordova, California; Atlantis,
Boston Scientific, Natick, Massachusetts), using automated pullback at 0.5mm per second
after administration of 0.2 mg intracoronary nitroglycerin. IVUS analyses were performed
by an independent core laboratory (Cardialysis BV, Rotterdam, The Netherlands). A
computer-based contour detection software was used for automated 2D reconstruction
of the treated segment (CURAD Vessel Analysis, Curad B.V. Wijk bij Duurstede, The
Netherlands). The lumen, stent boundaries and external elasticmembrane (vessel bound-
aries) were detected using a minimum cost algorithm [8].
In all treated vessel segments, we assess in each analysed frame (every 1mm), lumen,
stent/scaffold, vessel and plaque areas. Total plaque area is defined as thedifference of ves-
sel minus lumen area. This includes then the stent/scaffold components (metal or poly-
mer). Plaque behind the stent is defined as the difference of the vessel minus stent area
and neointima area as the difference of stent area and lumen area. These variables were
available at all time points and for all different study devices except for Absorb BVS
1.0 at 2 years where only total plaque area was available since plaque behind stent was
not determined due to the absence of struts (scaffold was resorbed).
2.4. Statistical analysis
There are 2 main comparisons, one at 6 months (comparison-at-6-month) where the
five different devices were imaged and the other one at 2 years (comparison-at-2-year)
where all devices (except Vision) were imaged at baseline and 2 years.
Categorical variables are presented as counts and percentages and compared by
means of the Fisher's exact test. Continuous variables are presented asmeans± standard
deviation (SD). The distribution of the variables used has been tested as normal or not nor-
mal distribution by Kolmogorov–Smirnov test. Comparison between two groups has been
made by Wilcoxon signed ranked test or Kruskal Wallis test when there are more than 2
groups. A p-value b 0.05 was considered as significant.
3. Results
3.1. Baseline clinical and angiographic characteristics (Table 1)
We studied 313 patients (313 lesions) enrolled in ABSORB Cohort A
and B and in SPIRIT FIRST and II trials. Particularly, patients with avail-
able post-stent implantation IVUS analysis and at different follow-up
time pointswere included. In Table 1, the baseline characteristics are re-
ported. The range of mean age is from 62 to 64.2 years and most of pa-
tients were male. There were many more patients with previous MI in
the Xience V group (p= 0.0003) andmore patients with unstable angi-
na in the Taxus group (p= 0.012) of the SPIRIT II trial compared to the
other groups. The rest of the baseline and demographic characteristics
of the groups were comparable.
In Table 1 on the supplement online, the quantitative IVUS and cor-
onary angiography findings are described. Since the vessel and lumen
areas were significantly different post-PCI, although no the plaque
Table 1
Clinical baseline characteristics.
Absorb A Absorb B Spirit first Spirit II
BVS 1.0
(n = 30)
BVS 1.1
(n = 45)
BVS
1.1
(n = 55)
XIENCE-V
(n = 27)
Multilink vision
(n = 29)
XIENCE-V
(n = 94)
TAXUS
(n = 33)
p-Value
Age, mean ± SD 62.46 ± 8.98 64.60 ± 9.47 60.50 ± 8.10 64.21 ± 9.56 61.37 ± 9.31 62.01 ± 10.85 62.22 ± 8.86 0.427
Men, % (n) 60.0 (18) 73.3 (33) 70.9 (39) 70.4 (19) 75.9 (22) 72.3 (68) 78.8 (26) 0.782
Hypertension requiring medication, % (n) 60.0 (18) 60.0 (27) 63.0 (34) 70.4 (19) 41.4 (12) 63.8 (60) 51.5 (17) 0.307
Hyperlipidaemia requiring medication, % (n) 65.5 (19) 93.3 (42) 67.3 (37) 70.4 (19) 75.9 (22) 74.4 (67) 75.8 (25) 0.073
Smokers, % (n) 20.0 (6) 11.4 (5) 21.8 (12) 29.6 (8) 31.0 (9) 33.0 (31) 31.3 (10) 0.155
Diabetes, % (n) 3.3 (1) 13.3 (6) 20.0 (11) 11.1 (3) 10.3 (3) 25.5 (24) 25.0 (8) 0.064
Previous cardiac intervention, % (n) 20.0 (6) 28.9 (13) 16.4 (9) 18.5 (5) 6.9 (2) 19.1 (18) 9.1 (3) 0.230
Previous MI, % (n) 10.0 (3) 35.6 (16) 16.7 (9) 22.2 (6) 13.8 (4) 41.9 (39) 15.2 (5) 0.0003
Stable angina, % (n) 70.0 (21) 73.3 (33) 63.6 (35) 77.8 (21) 79.3 (23) 59.6 (56) 51.5 (17) 0.118
Unstable angina, % (n) 26.7 (8) 13.3 (6) 16.4 (9) 18.5 (5) 13.8 (4) 28.7 (27) 45.5 (15) 0.012
Silent ischaemia, % (n) 3.3 (1) 0 (0) 7.3 (4) 3.7 (1) 6.9 (2) 3.2 (3) 0 (0) 0.407
Target vessel, % (n)
Left anterior descending 46.7 (14) 37.8 (17) 47.3 (26) 48.1 (13) 44.8 (13) 48.9 (46) 63.6 (21) 0.506
Left circumflex 30.0 (9) 26.7 (12) 21.8 (12) 22.2 (6) 20.7 (6) 25.5 (24) 9.1 (3) 0.511
Right coronary artery 23.3 (7) 36.6 (16) 30.9 (17) 29.6 (8) 34.5 (10) 25.5 (24) 27.3 (9) 0.866
PCI = percutaneous coronary interventions; AMI = acute myocardial infarction.
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areas, we decided to make most of the comparisons based on the rela-
tive changes.
3.2. Intravascular Total Plaque area changes — Figs. 1 and 2 (supplement
online: Table 1)
The total plaque comprises both compartments, the plaque behind
struts and the neointima.
3.2.1. Comparison-at-6-month
All devices induced an increase in the total plaque area. The largest
increase occurred with Vision and Taxus stents as compared to other
[Absorb BVS (1.0 and 1.1) and Xience V], (p = 0.0002). Comparison-
at-2-year: Absorb BVS 1.1 had a larger increase from post procedure in
total plaque compared to Absorb BVS 1.0, Xience V and Taxus (p =
0.0499). This was due to a shrinkage in total plaque between 6 months
and 2 years in the Absorb BVS 1.0, Xience V and Taxus vs. a further in-
crease in total plaque in Absorb BVS 1.1 (p b 0.001 for the change be-
tween 6 months and 2 years). Importantly, Absorb BVS 1.1 total
plaque showed a reduction of 2.2% from 1 to 3 years. Also interesting
to note is that the total plaque in the sequential cohorts of Absorb BVS
1.1 increased by 16.2% from baseline to 2 years (cohort B1) and at
3 years this increase is of only 5% compared to baseline (cohort B2; sup-
plement online: Fig. 3).
Fig. 1. Change from baseline to 6 months in total plaque (B) areas. In green bars the post-procedure areas in mm2. In red bars, the absolute difference (also in mm2) between baseline and
6 months. The black arrows indicate the direction of the change and also the relative difference (%) is given.
Fig. 2. Serial changes in total plaque (C) areas up to 2 years. In green bars, the post-procedure areas inmm2. In red bars, the absolute difference (also inmm2) between 6 months and post-
procedure; in blue bars, the absolute difference (mm2) between 2 years and 6 months and; in yellow bars, the absolute difference (mm2) between 2 years and post-procedure. The black
arrows indicate the direction of the change and also the relative difference (%) is given.
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3.3. Intravascular Ultrasound Vessel area changes (remodelling) – (supple-
ment online: Fig. 1 and Table 1)
Comparison-at-6-month: All devices but one (Vision) induced a rela-
tive increase in the vessel area (i.e. expansive remodelling). Thus Vision
was associated with restrictive remodelling (p= 0.0018). Comparison-
at-2-year: Absorb BVS 1.1, Xience V and Taxus showed an expansive re-
modelling while Absorb BVS 1.0 showed the opposite (p= 0.0006). In-
terestingly, when looking at the changes between 6 months and
2 years, all devices except the Absorb BVS 1.1 were associated with re-
strictive remodelling. Thus, DES (with the exception of BVS 1.1) present
at 6 months important expansive remodelling followed bymild restric-
tive remodelling from 6 months to 2 years. The Vision showed at all
time points restrictive remodelling. In contrast, Absorb BVS 1.1 showed
at all time points expansive remodelling.
3.4. Intravascular Ultrasound Plaque behind struts area changes (supple-
ment online: Table 1, Fig. 2A)
All the changes observed in the vessel area were related to changes
in the plaque behind the struts in the same direction. Comparison-at-
6-month: All devices but one (Vision) induced increase in the plaque
area behind the struts. Thus Vision was associated with a decrease in
plaque size (p = 0.0009). Comparison-at-2-year: Absorb BVS 1.1 had a
larger increase in plaque behind the struts compared to Xience V and
Taxus (p = 0.0007). This was due to a shrinkage in total plaque be-
tween 6 months and 2 years in the Xience V and Taxus vs. a further in-
crease in total plaque in Absorb BVS 1.1 (p b 0.001 for the change
between 6 months and 2 years).
3.5. Intravascular Ultrasound Neointimal Area (supplement online: Table 1,
Fig. 2B)
Comparison-at-6-month: the neointimal area was significantly sup-
pressed in the drug eluting devices irrespective of the platform (i.e. me-
tallic vs. polymeric), as detected by IVUS and compared to bare metal
stent (i.e. Vision), (p b 0.0001).
When relative changes within the Absorb BVS 1.1, Xience and Taxus
groups were compared, the Taxus group showed compaction of the
neointima between 6 months and 2 years (Comparison-at-2-year), as
demonstrated by amild decrease in neointimal area of 4.5% but without
reaching statistical significance.
4. Discussion
The main findings of this report are: i. at six months, the vessel wall
experienced a change in its size that goes from a 2.4% shrinkage (i.e. re-
strictive remodelling in Vision) to a maximal 9.0% increase in size (i.e.
expansive remodelling in DES). After the first six months, all devices
(except Absorb BVS 1.1) had a decrease in their vessel wall size (i.e. re-
strictive remodelling). Thus, bare metal stents had a distinctive pattern
of remodellingwhich is restrictive at all time points.Within themetallic
DES, after the first increase, all present a regression in their vessel wall
size.While in the polymeric (bioresorbable scaffolds) DES, these chang-
es are associated with the rate of absorption (e.g. Absorb BVS 1.0 has a
faster bioresorption rate and therefore it behaves like the other metallic
DES; in contrast the Absorb BVS 1.1 has a slower bioresorption rate and
the vessel wall continues to expand for a longer period). ii. Changes in
the vessel area are associated inmagnitude and direction to the changes
in the plaque behind the struts area. iii. All devices showed first an in-
crease in total plaque size and thereafter a reduction; all devices, except
for Absorb BVS 1.0, had at follow-up a larger total plaque compared to
post-procedure.
4.1. Remodelling changes in the vessel wall after stenting or scaffolding
In pathological studies, the differential effect of the metallic
intracoronary devices (either bare or drug eluting stents) on the vessel
area has been characterised [9]. The Taxus had a significantly larger ves-
sel area than bare metal stents (Express) and a limus eluting stent (Cy-
pher). This increase in vessel area after stenting has been also described
in previous IVUS studies [10]. In the report by Aoki J et al., Taxus had a
larger increase in vessel area compared to the BMS (NIR conformer
stent) up to 6 months. Thereafter, there was a decrease in both stents
between 6 months and 2 years. These results are in line with our find-
ings: at six months, Taxus showed a 9% increase in vessel area which
was much larger to that of Absorb BVS, Xience V or Vision.
In contrast, the paclitaxel drug-eluting absorbable metal scaffold
(DREAMS) showed a vessel area reduction at 6 months and even more
between 6 months and 12 months [11]. These observations highlight
the fact that the vessel wall response varies according to the stent design
and that it is almost impossible to discern at this point whether it is the
drug, the polymer or the constituents of the back bone (metal vs. poly-
mer) which play the most determinant role in triggering these changes.
4.2. Plaque size changes in the vessel wall
All the changes observed in the vessel area are mostly related to
changes in the same direction of the plaque area changes. Ultimately,
themain goal of any intervention is tomodify the natural history of cor-
onary atherosclerosis disease, coronarymetal devices achieved that at a
short term (redistributing the plaque and scaffolding the vessel wall)
but failed to achieve that in a long term since they remain in the vessel
wall preventing the restoration of the architecture (i.e. angulation and
curvature of the vessel) and physiology (i.e. cyclic strain and shear
stress) of the coronaries.
In addition, permanent devices hinder any further reduction of the
size of the plaque by lastingly staying in the vesselwall. On the contrary,
bioresorbable scaffolds are designed to fulfil the short-term needs (scaf-
folding the coronary vessel wall while inhibiting effectively neointima
formation by eluting everolimus) and also to prevent late complications
such as stent thrombosis by their disappearance. Everolimus is a mTOR
inhibitor and its systemic application decreases atherosclerotic plaque
formation in both apolipoprotein E (ApoE−/−) and low-density
lipoprotein-receptor (LDL-R−/−) knockout mice [12]. Moreover,
everolimus has been associated with clearance of the macrophages via
autophagia and thereby making those plaques less inflamed [13].
These additional effects may further modify the native plaque where
the device was placed.
The full absorption of the Absorb BVS brings back the response to cy-
clic strain and shear stress with all the positive effects related to them.
Also important, the coronary plaquemay respond again to pharmacolog-
ical treatments. Though, the pharmacological treatment, even using the
best of the options, in the study using intravenous recombinant ApoA-I
Milano/phospholipid complexes (ETC.-216), therewas, albeit significant,
a reduction in percent atheroma volume of 1.06% [14] and in the SATURN
study patients treated with rosuvastatin showed also only a minor re-
duction in the percent atheroma volume by 1.22% after 2 years of treat-
ment [15], the combination of a temporary coronary scaffold (i.e. BVS)
plus mTOR inhibitors (i.e. everolimus) as a first strategy, followed by
an intensive statin treatment appears the best approach so far.
4.3. Limitations
“This is a post hoc analysis and therefore there are some differences
at baseline (post-PCI) in patient characteristics. In the BVS 1.0 group, pa-
tients had lower risk for conventional pro-atherogenic factors (e.g., DM,
priorMI). This is due to the fact that the BVS 1.0 was used in the first-in-
man ABSORB Cohort A trial. Likewise, a lower risk profile was also to be
observed in Xience V and Vision groups included in the SPIRIT First trial
4 H.M. García-García et al. / International Journal of Cardiology xxx (2014) xxx–xxx
Please cite this article as: García-García HM, et al, Differential impact of five coronary devices on plaque size: Insights from the ABSORB and SPIRIT
trials, Int J Cardiol (2014), http://dx.doi.org/10.1016/j.ijcard.2014.06.026
Chapter 5.4
410
(Table 1). IVUS had also distinct baseline characteristics among groups.
This is the reason why the comparisons were made based on relative
differences. IVUS is often not performed pre-TLR so that changes de-
scribed here are based on the patients who did not have events.”
5. Conclusions
Coronary plaque size is affected differently by local devices and this
modification depends on the platform (metallic vs. polymeric) and on
whether it is a bare — or drug eluting stent. Coronary scaffolds appear
to be a promising alternative to metallic stents since they allow plaque
regression.
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Abstract Background Metallic stents change perma-
nently the mechanical properties of the vessel wall. How-
ever little is known about the implications of bioresorbable
vascular scaffolds (BVS) on the vessel wall strain.Methods
Patients (n = 53) implanted with an Absorb BVS that had
palpographic evaluation at any time point [before device
implantation, immediate after treatment, at short-term
(6–12 months) or mid-term follow-up (24–36 months)]
were included in the current analysis. The palpographic
data were used to estimate the mean of the maximum strain
values and the obtained measurements were classified
using the Rotterdam classification (ROC) score and
expressed as ROC/mm. Results Scaffold implantation led
to a significant decrease of the vessel wall strain in the
treated segment [0.35 (0.20, 0.38) vs. 0.19 (0.09, 0.29);
P = 0.005] but it did not affect the proximal and distal
edge. In patients who had serial palpographic examination
the vessel wall strain continued to decrease in the scaf-
folded segment at short-term [0.20 (0.12, 0.29) vs. 0.14
(0.08, 0.20); P = 0.048] and mid-term follow-up [0.20
(0.12, 0.29) vs. 0.15 (0.10, 0.19), P = 0.024]. No changes
were noted with time in the mechanical properties of the
vessel wall at the proximal and distal edge. Conclusions
Absorb BVS implantation results in a permanent alteration
of the mechanical properties of the vessel wall in the
treated segment. Long term follow-up data are needed in
order to examine the clinical implications of these findings.
Keywords Bioresorbable vascular scaffold 
Palpography  Vessel wall strain
Introduction
Vessel wall mechanical behavior appears to be associated
with the compositional characteristics of the plaque and
predict future cardiovascular events [1–4]. Several studies
have shown that pharmaceutical or an interventional
treatment can influence the mechanical properties of the
vessel wall by altering its constituents [5–9]. Following an
endoluminal device implantation (i.e., a metallic stent or a
bioresorbable scaffold) the local vessel wall strain of the
implanted segment is reduced and this has been attributed
to the increased stiffness of the deployed device [5, 6, 9].
Recently we have reported the results of the palpo-
graphic analysis performed in segments implanted with the
updated revision of the Absorb bioresorbable vascular
scaffold (BVS) 1.1 [6]. We found that the vessel wall strain
is reduced in the scaffolded segments immediately after
device deployment but there are no further changes in the
mechanical properties of the vessel wall between post-
scaffold implantation and at short-term follow-up (i.e., at
6–12 months). The present analysis aims to investigate the
mid-term implications (i.e., at 24–36 months) of the
Absorb BVS 1.1 on the vessel wall strain.
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Methods
Included patients and study design
The ABSORB Cohort B trial (A Clinical Evaluation of the
Bioabsorbable Everolimus Eluting Coronary Stent System
the Treatment of Patients with de Novo Native Coronary
Artery Lesions) was a prospective multicenter single-arm
study designed to investigate the safety and efficacy of the
Absorb BVS 1.1 (Abbott Vascular, Santa Clara, CA, USA)
[10]. One hundred one patients were included in this study
and were divided in two groups (B1 and B2). The first
group had invasive imaging evaluation [i.e., coronary
angiography, grayscale intravascular ultrasound (IVUS),
IVUS virtual histology, palpographic and optical coherence
tomographic imaging] at baseline, 6 months and 2 years
follow-up; while the second group had the abovementioned
invasive tests at baseline, 1 year and at 3 years follow-up.
Optical coherence tomographic (OCT) examination was
optional and was not performed in all the studied patients.
The current analysis included only the patients who had a
palpographic assessment at least at one time point. The
Absorb Cohort B study was sponsored and financially
supported by Abbott Vascular.
The Absorb BVS 1.1 used in the ABSORB Cohort B
trial, is a fully bioresorbable device with dimensions
3.0 9 18 mm. The composition of the device consists of
poly-L-lactide (PLLA) that is covered by an thin layer of an
amorphous matrix of poly-D,L-lactide (PDLLA) which
contains and controls the release of the anti-proliferative
drug everolimus (concentration: 100 lg/cm2). The Absorb
BVS 1.1 has an in-phase zigzag hoops linked with bridges
design that provides the device increased radial strength
and eliminates the risk of late scaffold recoil, while the
polymer of this revision has been processed in such a way
so as to have a delayed degradation (by approximately
18 months comparing to the 1st revision).
The palpographic sub-study of the ABSORB Cohort B
trial had pre-specified hypotheses. In particular the inves-
tigators expected that the delayed degradation in Absorb
BVS 1.1 would result: either (1) in a delayed restoration of
the normal, pre-scaffold implantation, strain, or (2) it
would allow the built up of neointima tissue that would
permanently alter the mechanical properties of the vessel
wall.
IVUS acquisition and analysis
Intravascular ultrasound imaging was performed in the
treated artery using an Eagle Eye 20 MHz imaging catheter
(acquisition frame rate 30 frames/s, Volcano Corp, Rancho
Cordova, CA, USA) that was withdrawn with the use of an
automated pull-back device at a speed of 0.5 mm/s. During
IVUS examination the electrocardiogram and the aortic
pressure were recorded.
The radiofrequency IVUS imaging data were acquired
using a custom designworkstation andwere transferred to an
independent clinical research organization (Cardialysis,
Rotterdam, the Netherlands) for offline analysis. For each
studied artery the IVUS images portraying the 5 mm prox-
imal, the scaffolded, and the 5 mm distal segment were
analyzed. The local strain was estimated from the radiofre-
quency IVUS data using cross correlation analysis according
to a previously described methodology [11]. The measured
strain values were displayed in spread-out vessel plots using
a color coded map with the blue indicating low strain values
and the red/yellow a high strain (range 0–2 %) [11].
The strain values were classified according to the Rotter-
dam classification (ROC) score to four classes (ROC I:
0–0.5 %, ROC II: 0.6–\0.9 %, ROC III: 0.9–\1.2 % and
ROCIV:[1.2 %).Across sectionwas considered tohavehigh
strain when the measured strain was classified as ROC III–IV
in anarc of[12. For eachcross section thehighest strain value
was recorded and considered as the strain of this section. The
mean of themaximumstrain valuesmeasured in each segment
was determined and used to characterize the strain of the
segment. Results are presented as ROC/mm (Fig. 1).
Statistics
Continuous variables depending on their distribution are
presented as mean ± standard deviation or as median with
25th and 75th percentiles, as indicated in the tables. Cate-
gorical variables are presented as absolute values and per-
centages. Because of the small number of patients who had
palpographic evaluation at different time points we merged
the data from Cohort B1 and B2 and present our results at 4
time points: at baseline pre-scaffold implantation, immedi-
ately after scaffold implantation, at short-term (6–12 months),
and at mid-term follow-up (24–36 months). Comparison
between the two cohortswas done by t test andChi square test,
or Fisher’s exact test when Cochran’s rule is not met.
Changes in the strain values between two different time
points were evaluated by means of paired Wilcoxon singed
rank test. A P value \0.05 (two-tailed) was considered
statistically significant. Data analysis was performed using
the SAS statistical computer package (SAS 9.2, SAS
Institute Inc., Cary, NC, USA).
Results
Studied population
Fifty-three from the 101 patients who were enrolled in the
Absorb Cohort B study had palpographic evaluation at
478 Int J Cardiovasc Imaging (2014) 30:477–484
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least at one time point and included in this analysis. The
baseline characteristics of the studied population are shown
in Table 1. The patients that were enrolled in the Absorb
Cohort B1 group did not smoke and were more likely to
suffer from hypercholesterolemia and be admitted with
stable angina symptoms comparing to the subjects included
in the Absorb Cohort B2 group but otherwise there were
not significant differences in the baseline demographics
and angiographic characteristics between the two groups.
Palpographic evaluation
Only 14 patients had palpographic evaluation before scaf-
fold implantation, 44 patients had this investigation
immediate after device deployment, 41 at short-term, and
36 at mid-term follow-up. Twenty patients had serial pal-
pographic examination at the three time points (i.e., at
baseline immediate after scaffold deployment, at short-
term and mid-term follow-up).
For the entire study population (n = 53 patients) the strain
values did not change immediate after scaffold deployment
at the proximal and distal edge (Table 2). On the other hand
in the treated segment the strain decreased significantly after
device deployment. The vessel wall strain estimated at the
proximal edge at the two follow-up time points was not
different from the vessel wall strain before scaffold
deployment (P = 0.814 for the short-term follow-up and
P = 0.162 for the mid-term follow-up). However, when we
compared the follow-up values at the proximal edge with the
strain measured immediately after scaffold deployment we
found statistical significant differences (Table 2). At the
distal edge the strain values did not change with time.
The strain values in the scaffolded segment at the two
follow-up time points were considerably lower comparing
to baseline before device implantation (P = 0.002 for the
short-term and P = 0.001 for the mid-term follow-up) but
they were not different from these measured immediately
after scaffold deployment.
When we included in our analysis only the segments
(n = 20 patients) that had serial palpographic examination
(i.e., at baseline immediate after device deployment, at short-
term, and at mid-term follow-up) we found that the strain of
the proximal edge and distal edge did not change with time
(Table 3; Fig. 2). On the other hand in the scaffolded seg-
ment the strain values were significantly decreased at short-
and mid-term follow-up comparing to baseline.
Discussion
In this study we examined for the first time the implications
of the second revision Absorb BVS on the mechanical
Fig. 1 Snapshot showing the palpographic evaluation of a lesion
before scaffold implantation. Panel A shows a longitudinal IVUS
cross-section of the studied segment while panel B a spread out plot of
the measured vessel wall strain (the blue color indicates low strain
and the red/yellow high strain values). An IVUS cross section with the
estimated strain at the superficial plaque shown in color coding is
portrayed in panel C. Panel D shows the electrocardiogram, the
measured strain, and the blood pressure changes during the cardiac
circle throughout the pull-back of the catheter, whereas panel
E displays the strain values measured in the cross-section shown in
panel C. High strain was noted at 1 and 6 o’clock
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properties of the vessel wall. We found that in contrast to
the first generation which has a transient effect on vessel
wall strain, the updated revision Absorb BVS 1.1 causes a
permanent decrease of the strain values at the treated
segment without affecting the mechanical properties of the
proximal and distal edge [5, 6].
The reduction of the vessel wall strain noted immedi-
ately after Absorb BVS 1.0 or after Absorb BVS 1.1
deployment has been attributed to the shielding effect of
the device, and to fact that the foreign material is likely to
interfere with the palpographic estimations due to the
artifactual acoustic properties of the struts [5, 6, 12]. In the
first revision Absorb BVS the change in the strain values at
the treated vessel was temporary as at 6 months and
24 months follow-up the measured strain was increased
and approached the strain estimated before device
Table 1 Baseline demographics, angiographic characteristics and medications of the studied population
Patients’ demographics Absorb Cohort B Absorb Cohort B1 Absorb Cohort B2 P
N = 53 N = 20 N = 33
Age (years) 61.28 ± 8.41 63.84 ± 8.87 59.72 ± 7.85 0.096
Male 71.7 % (38/53) 75.0 % (15/20) 69.7 % (23/33) 0.678
Hypertension 67.3 % (35/52) 60.0 % (12/20) 71.9 % (23/32) 0.374
Hypercholesterolemia 83.0 % (44/53) 100.0 % (20/20) 72.7 % (24/33) 0.010
Diabetes 18.9 % (10/53) 15.0 % (3/20) 21.2 % (7/33) 0.725
Current smoking 15.1 % (8/53) 0.0 % (0/20) 24.2 % (8/33) 0.019
Prior PCI 22.6 % (12/53) 25.0 % (5/20) 21.2 % (7/33) 0.748
Stable angina 73.6 % (39/53) 90.0 % (18/20) 63.6 % (21/33) 0.035
Unstable angina 9.4 % (5/53) 5.0 % (1/20) 12.1 % (4/33) 0.639
Silent ischemia 1.9 % (1/53) 0.0 % (0/20) 3.0 % (1/33) 1.000
Treated vessel
Left anterior descending 47.2 % (25/53) 45.0 % (9/20) 48.5 % (16/33) 0.805
Left circumflex 24.5 % (13/53) 25.0 % (5/20) 24.2 % (8/33) 1.000
Right coronary artery 28.3 % (15/53) 30.0 % (6/20) 27.3 % (9/33) 0.831
QCA analysis pre-treatment
RVD (mm) 2.61 ± 0.34 2.60 ± 0.44 2.61 ± 0.28 0.949
MLD (mm) 1.04 ± 0.27 0.99 ± 0.31 1.07 ± 0.23 0.365
Diameter stenosis (%) 59.80 ± 9.96 61.25 ± 12.74 58.94 ± 7.98 0.482
Medications
b-blockers 73.6 % (39) 65.0 % (13) 78.8 % (26) 0.270
RAAS inhibitors 69.8 % (37) 65.0 % (13) 72.7 % (24) 0.443
Statins 94.3 % (50) 100.0 % (20) 90.9 % (30) 0.165
PCI percutaneous coronary intervention, QCA quantitative coronary angiography, RVD reference vessel diameter, MLD minimum luminal
diameter, RAAS renin angiotensin aldosterone system
Table 2 Strain values at the proximal edge, the scaffolded segment and the distal edge before device implantation, immediately after device
deployment, at short-term follow-up and at mid-term follow-up
Pre-scaffold
implantation (n = 14)
Post-scaffold
implantation (n = 44)
P1 Short term follow-
up (n = 41)
Mid-term follow-
up (n = 36)
P2 P3 P4
Proximal
edge
0.19 (0.13, 0.36) (12) 0.23 (0.10, 0.35) (29) 0.793 0.17 (0.12, 0.31)
(28)
0.15 (0.07, 0.20)
(19)
0.989 0.022 0.043
Scaffolded
segment
0.35 (0.20, 0.38) (14) 0.19 (0.09, 0.29) (44) 0.001 0.16 (0.12, 0.22)
(41)
0.15 (0.10, 0.20)
(36)
0.391 0.064 0.410
Distal edge 0.14 (0.08, 0.31) (9) 0.15 (0.06, 0.28) (28) 0.739 0.10 (0.04, 0.26)
(29)
0.19 (0.11, 0.26)
(25)
0.675 0.771 0.445
P1 denotes the significance of difference between the strain values estimated before and immediate after device implantation; P2 the significance
of difference between the strain values at post-scaffold implantation and at short-term follow-up; P3 the significance of difference between the
strain values at post-scaffold implantation and at mid-term follow-up; and P4 the significance of differences of the strain values at the two follow-
up time points
The number in the parenthesis at the left side of each column indicates the number of segments analyzed at each time point
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implantation [5, 6]. These findings were attributed to the
resorption process which was completed at 2 years follow-
up but also to the late recoil noted in the first revision [13,
14]. The latter argument is highlighted by the findings of
Tanimoto et al. [13] who showed that late scaffold recoil is
more intense at 6 months follow-up in the high-strain fibro-
necrotic plaques; thus it can be speculated that the late
recoil of the scaffold over these plaques may allow resto-
ration of their mechanical properties contributing to the
increased strain values noted at 6 and 24 months follow-up.
On the other hand in the second revision Absorb BVS
the polymer has been processed in such a way so as its
degradation to delay by approximately 18 months com-
paring to the first revision and the scaffold has a different
design which provides the device with a better radial
support [14]. These modifications prolong the mechanical
integrity of the scaffold resulting in a delayed restoration of
vessel vasomotion at 12 months follow-up, and eliminate
the risk of late recoil [15].
Furthermore, we have recently demonstrated that in
Absorb BVS 1.1 a thick layer of neointimal tissue develops
(mean thickness 210–220 lm at short-term follow-up) that
covers the entire circumference of the vessel shielding the
underlying plaque [16]. Histology studies in porcine
models have shown that the neointima tissue consists of
smooth muscles cells and fibrous tissue and thus the
superficial plaque is anticipated to exhibit low strain values
in a palpographic examination [2, 3, 17]. Indeed the strain
values reported in our analysis at short- and mid-term
follow-up are close to the strain measured in fibrotic pla-
ques by Korte et al. [3] using elastography in pig models. It
appears that the second revision Absorb BVS 1.1 modifies
permanent the mechanical properties of the superficial
plaque by altering its phenotype to a more stable form
(Fig. 3). Our findings indicate that in contrast to the
metallic stents, which are anticipated to have a similar
effect on the mechanical properties of the vessel wall, in
bioresorbable scaffolds minor changes in their design are
Table 3 Strain values at the proximal edge, the scaffolded segment
and the distal edge before device implantation, immediately after
device deployment, at short-term and at mid-term follow-up in
patients who had serial palpographic examination immediate after
scaffold implantation and at the two follow-up time points
Post-scaffold implantation
(n = 20)
Short term follow-up
(n = 20)
Mid-term follow-up
(n = 20)
P1 P2 P3
Proximal edge 0.25 (0.13, 0.33) (12) 0.15 (0.07, 0.23) (12) 0.16 (0.09, 0.22) (12) 0.278 0.135 0.817
Scaffolded
segment
0.20 (0.12, 0.29) (20) 0.14 (0.08, 0.20) (20) 0.15 (0.10, 0.19) (20) 0.048 0.024 0.922
Distal edge 0.11 (0.04, 0.23) (12) 0.11 (0.06, 0.31) (12) 0.20 (0.11, 0.24) (12) 0.880 0.874 0.692
P1 denotes the significance of difference between the strain values at post-scaffold implantation and at short-term follow-up; P2 the significance
of difference between the strain values at post-scaffold implantation and at mid-term follow-up; and P3 the significance of differences of the
strain values at the two follow-up time points
The number in the parenthesis at the left side of each column indicates the number of segments analyzed at each time point
Fig. 2 Changes in vessel wall
strain (ROC/mm) at the
proximal edge the scaffolded
segment and the distal edge in
patients who had serial
palpographic examination
immediately after scaffold
implantation at short-term and
mid-term follow-up. ROC
Rotterdam classification
Int J Cardiovasc Imaging (2014) 30:477–484 481
123
Chapter 5.5
419
C
hapter 5.5likely to have detrimental implications on vessel wall
strain. Thus the results of this analysis cannot be extrapo-
lated to other scaffolds even to these with a similar design
and composition.
The effect of the decreased strain on vessel wall path-
ophysiology is yet unknown. Several studies have dem-
onstrated that the ability of the vessel wall to expand as a
response to a pulsatile cyclic strain has an athero-protective
role as it stimulates eNOS gene regulation, promotes
prostacyclin synthesis and maintains the contractile phe-
notype of the smoothes muscles cells [18–20]. However,
plaques exhibiting low strain such as the pathological
intimal thickening appear stable and rarely cause future
events, while the plaques that demonstrate a high strain are
associated with increased vulnerability [1, 4, 21]. Therefore
it can be argued that the low strain estimated in stable
plaques is sufficient for the stimulation of the pulsatile
cyclic strain-dependent athero-protective mechanisms and
for triggering the necessary mechanotransduction and
pathophysiogical pathways that prevent plaque progres-
sion. In Absorb BVS this argument is supported by his-
tology studies showing that in scaffolded segments the
smooth muscles cells maintain their benign contractile
phenotype, and by clinical reports demonstrating
Fig. 3 Spread out plot of the vessel wall strain at baseline before
Absorb BVS implantation (Ai), immediate after scaffold deployment
(Bi), at short-term (Ci), and mid-term follow-up (Di). The blue color
indicates low strain values where the red/yellow a high strain. It is
apparent that the incidence of the high strain values decreased
immediate after scaffold deployment and it is even lower at short-and
mid-term follow-up. Panels Aii, Bii, Cii and Dii portray correspond-
ing IVUS cross-sections acquired at baseline before and immediate
after scaffold deployment, at short-term, and at mid-term follow-up
respectively. The position of these frames in the spread-out vessel
plots is indicated with a yellow line. High strain values are noted at
the shoulders of an echolucent plaque before scaffold implantation
(Aii), however immediate after device deployment the strain values
are low in the entire circumference of the lumen (Bii). OCT imaging
performed after scaffold deployment this time point (Biii) indicates
the presence of a lipid rich plaque (the correspondence between IVUS
and OCT is shown with an asterisk). The strain values remain low at
short- and mid-term follow-up in the IVUS cross-section (panels Cii
and Dii respectively). OCT performed at the follow-up time points
shows that neointima tissue has been developed that sealed the
underlying plaque. The mean thickness of the neointima tissue is
measured 150 lm at short-term and 220 lm at mid-term follow-up
(Supplementary figure)
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restoration of the endothelial dependent vasomotion at
1 year follow-up, suggesting a functionally normal endo-
thelium that is capable to respond to chemical and
mechanical stimuli [15, 22].
Although palpography appears unable to predict the
natural history of a high risk plaque there is robust evi-
dence to support that the mechanical properties of the
vessel wall provide useful prognostic information since
patients with high strain plaques are more likely to expe-
rience acute coronary events comparing to those with low
strain lesions [1, 4]. Furthermore, the Integrated Bio-
markers and Imaging Studies I and II have shown that an
aggressive pharmaceutical treatment reduces local strain
values, whereas the vShield Evaluated at Cardiac hospital
in Rotterdam for Investigation and Treatment of TCFA
(SECRITT) trial that implemented a self-expanding stent to
seal high risk plaques have demonstrated a significant
decrease of the strain values immediate after device
deployment [7–9]. Our results are similar to what has been
reported to metallic stents, showing that Absorb BVS 1.1
implantation changes permanently the mechanical proper-
ties of the vessel wall and stabilizes the plaque. However,
further palpographic data after the full resorption of the
BVS are needed to confirm this statement and further
research and robust data from randomized control trials are
required before advocating the use of these devices for the
invasive sealing of vulnerable, prone-to-rupture plaques
[16, 23, 24].
Limitations
A major limitation of the current study is the fact that a
considerable number of patients did not have serial pal-
pographic examination. Thus, we included all the data
that were available from each patient acknowledging the
fact that missing examinations can affect the reported
results. To confirm the findings of our initial analysis we
also performed a sub-analysis including the patients who
had truly serial examinations. Although the number of
patients in the sub-analysis was small the agreement noted
between the results of the initial analysis and the sub-
analysis with regards the scaffolded segment allows us to
report these findings with some certainty. Another limi-
tation of our analysis was the lack of a control group with
serial palpographic examination that would allow us to
compare the reported changes in the vessel wall stain in
the scaffolded segments with these in native untreated
arteries.
Unfortunately OCT was an optional examination in the
ABSORB Cohort B study and thus only very few patients
(n = 4) had serial palpographic and OCT assessment. Thus
we were unable to combine these data and examine the
association between the changes in the measured strain at
follow-up and the neointimal thickness as well as the effect
of the different plaque characteristics (i.e., composition of
the plaque, thickness of the fibrous tissue over calcific and
lipid tissue, extent of the lipid and calcific tissue, plaque
burden and eccentricity) on this relation [25, 26].
Conclusions
This study for the first time investigated the mid-term
implications of the second revision Absorb BVS on the
mechanical properties of the plaque. We found that in
contrast to the first revision where the strain values of the
treated segment change temporarily, in the second revision
the strain of the vessel wall gradually decreases with time.
Long-term clinical follow-up data and evidence from ran-
domized studies are required in order to examine the
clinical implications of these findings.
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AbSTRACT:
Introduction and objectives:
Absorb BVS has shown to decrease the total plaque areas in the treated segment. However, 
whether the plaque size modification effect occurs only in scaffolded segments or may be 
extended to other coronary segments is not known.
Methods:
Absorb Cohort A is a single-arm, prospective study, with safety and imaging endpoints in which 
30 patients underwent PCI with the first generation Absorb BVS. Noninvasive MSCT imaging 
was performed in eighteen patients at 18-month and 5-year follow-up. The present study is 
a intra-patient comparison of matched segments (normalized by the segment length) of the 
scaffolded region with non-intervened segments for: lumen volume, vessel volume, plaque 
volume, plaque burden and % Change in Plaque Atheroma Volume.
Results:
All 18 scaffold segments were analyzable. In the non-intervened, one of 72 segments 1 had 
motion artifacts and was excluded. Serial comparison showed that the scaffolded segments did 
not have a significant change in the mean plaque burden, total atheroma volume, total lumen 
volume and vessel volume between 18 months and 5 years. Conversely, the non-treated segments 
had a significant increase in plaque burden (2.7±6.5%; P<0.01) and normalized plaque volumes 
(8.0±22.8mm3, P<0.01). This resulted in a significant difference in plaque burden comparison 
between scaffolded and non-intervened segments (P=0.03).
Conclusion:
 In this small series, Absorb BVS showed potential to locally reduce the progression of 
% plaque burden on top of pharmacological treatment. Larger studies are needed to confirm 
these findings.
Keywords: Absorb, atherosclerosis, computed tomography coronary angiography, coronary 
plaque, disease progression
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InTRoDUCTIon
The clinical introduction of bioresorbable 
scaffolds (BRS) was enacted as the fourth 
revolution in interventional cardiology. 
These devices have the unique ability to pro-
vide a temporary scaffold that is necessary 
to maintain the patency of the vessel after 
intervention, and then they gradually permit 
the restoration of vascular physiology and 
integrity[1-3]. Among the potential advantages 
of BRS, the atherosclerotic plaque reduction 
and late lumen enlargement in the treated 
regions [4-6] may represent a paradigm shift 
in the treatment of coronary artery disease 
(CAD).
Pharmacological therapy has shown that, 
depending on patient clinical profile, it is 
possible to promote plaque regression [7-9]. 
Therefore, plaque regression in patients 
treated with BRS may be related not to the 
device itself but due to the effect of the 
pharmacological therapy in a vessel that is 
free from its internal cage.
The aim of the present study was to perform 
a within-patient comparison of the natural his-
tory of coronary atherosclerosis between seg-
ments treated with poly-l-lactide-acid (PLLA) 
everolimus-eluting bioresorbable scaffold 
(Absorb BVS first generation, Abbott Vascular, 
Santa Clara, California) and non-intervened 
segments in the Absorb Cohort A trial assessed 
by multislice computed tomography (MSCT).
MeTHoDS
Study Population
The design of the Absorb Cohort A trial has 
been previously described[10]. In brief, it is a 
single-arm, prospective, open-label study, 
with safety and imaging endpoints. A total of 
30 patients were enrolled at 4 participating 
sites between March and July 2006. Patients 
were older than 18 years of age with a diag-
nosis of stable, unstable, or silent ischemia. 
All treated lesions (diameter stenosis >50%) 
were single, de novo in a native coronary artery 
of 3.0 mm in diameter, suitable for the 12- or 
18-mm scaffold. Major exclusion criteria were 
patients presenting with an acute myocardial 
infarction (MI), unstable arrhythmias, or a left 
ventricular ejection fraction <30%, restenotic 
lesions, lesions located in the left main coro-
nary artery, lesions involving a side branch >2 
mm in diameter, and the presence of thrombus 
or another clinically significant stenosis in the 
target vessel. The ethics committees approved 
the protocol at the participating institutions, 
and the enrolled patients gave written 
informed consent before inclusion. Clinical 
endpoints were assessed at 30 days, 6 and 9 
months, and 1, 2, 3, 4, and 5 years. Noninvasive 
MSCT imaging studies were done at 18-month 
and 5-year follow-up.
Study device
The study device has been described else-
where[10]. Briefly, the polymeric device consists 
of a backbone of poly-L-lactide (PLLA) coated 
with poly-D,Llactide (PDLLA) that contains and 
controls the release of the antiproliferative 
drug everolimus. Absorb BVS first generation 
has a crossing profile of 1.4 mm in circum-
ferential hoops of PLLA with struts 150 µm 
thick either directly joined or linked by straight 
bridges. Both ends of the scaffold have two 
adjacent radio-opaque metal markers. The 
doses of everolimus on the Absorb BVS 1.0 
are 98 µg for a 12 mm scaffold and 153 µg for 
the 18 mm scaffold.
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MSCT angiography
 The CT scanners used were 64-slice CT 
(Brilliance 64,Philips, Best, the Netherlands; 
CVi, GE Healthcare, Milwaukee,Wisconsin), 
256-slice CT (iCT, Philips), 320-slice CT 
(Aquilion One, Toshiba, Nasu, Japan), 64-slice 
dualsource CT (Definition, Siemens AG, Forch-
heim, Germany), and 128-slice dual-source 
CT (Definition Flash,Siemens). Standard 
acquisition techniques were used, which 
included beta-blockers in patients with a fast 
heart rate, tube settings depending on patient 
size (80 to 140 kV), and axial scan protocols 
for patients with lower heart rates to reduce 
radiation doses, all at the discretion of the 
individual sites. Images were reconstructed 
using thin slices (0.5 to 0.67 mm) and medium 
smooth reconstruction filters, including 1 or 
more phases of cardiac cycle depending on 
the scan protocol.
MSCT analysis
The MSCT analysis followed a previously 
established methodology[3, 11-13]. All datasets 
were transferred to an offline workstation 
for analysis using a semi-automated plaque 
analysis software (QAngioCT Research Edition 
version 2.1, Medis medical imaging systems 
b.v., Leiden, the Netherlands). The assessment 
of the inner lumen and outer vessel volumes 
was performed following a stepwise approach. 
First, a centreline originating from the ostium 
was automatically extracted. Straightened 
multiplanar reformatted images were gener-
ated, and the lumen and vessel borders were 
detected longitudinally in 4 different vessel 
views by the software. Cross-sectional images 
of these longitudinal contours were examined 
at 0.5-mm intervals and, if necessary, adjusted 
by an experienced observer. The settings for 
window level and width were fixed at 740 HU 
and 220 HU, respectively. Gradient magnitude 
images, which display the degree of CT at-
tenuation change, were used to facilitate the 
detection of lumen and vessel wall borders.
Only the major epicardial vessels were 
considered for analysis using the modified 
17-segment American Heart Association model 
for coronary segment classification (proximal 
and mid segments of the right, left circumflex 
and left descending anterior coronary arteries) 
[14]. The scaffolded regions were delimited by 
the presence of the radiopaque markers. In 
case of overlapping metallic stents (n=3), the 
scaffolded regions were assessed up to the re-
gions without stent interference. The present 
study used as comparator for the scaffolded 
regions the intra-patient non-intervened 
native coronary vessels by assessing the first 
2 proximal segments, divided in proximal 
or distal according to stablished anatomical 
references (Figure 1) [14].
MSCT study imaging endpoints
Normalization for segment length provides 
equal weighting of each patient in the calcula-
tion of atheroma volume and also for varying 
segment length between the two scans [11, 
15]. The following IVUS-like parameters were 
calculated for the non-intervened and scaf-
folded segments after normalization:
Percent atheroma volume (PAV): [(total ves-
sel volume – total lumen volume)/total vessel 
volume] *100%
Normalized TAV (TAVnorm): [(total vessel 
volume – total lumen volume)/segment length] 
* mean segment length in the population.
Normalized Percentage change in TAV (% 
change in TAV): [(TAVnorm at 5 years – TAVnorm 
at 18 months)/TAVnorm at 18 months] * 100% 
X mean segment length in the population
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Statistical analysis
Continuous variables are presented as 
mean±SD and median (interquartile range 
[IQR]), as indicated. Categorical variables are 
presented as counts and percentages. Continu-
ous variables between the 2 different time 
points were compared by the paired samples 
t test. A p value <0.05 was considered sig-
nificant. Statistical analyses were performed 
with use of SPSS version 22.0 software (SPSS, 
Chicago, Illinois).
ReSUlTS
Patient demographic characteristics and a 
flow chart of the present study are shown in 
Table 1 and Figure 1, respectively. Of the 30 
patients enrolled in the Absorb Cohort A trial, 
18 underwent serial MSCT at 18-month and 
5-year follow-up, and were included in the 
present analysis. The mean age was 62 ± 8 
years old, 67% were male, 6% had diabetes 
mellitus and 78% had stable angina pectoris. 
The most frequently treated vessel was the 
LAD (44%) and the mean lesion length at 
baseline was 9.1 ± 3.6mm.
All scaffolds (n=18) were assessable by 
MSCT at 18-month and 5-year follow-up. 
Regarding the non-intervened segments, of 
72 possible analysable segments, 1 segment 
at 18-months was excluded due to motion 
artefacts (Figure 1). The mean scaffold length 
was 11.9±1.9mm and the mean length of the 
non-intervened segments was 22.6±11.7mm.
Matched Segment Serial Comparison. 
Between 18-month and 5-year follow-up, 
scaffolded segments did not show a significant 
change in any analysed parameters, including 
mean plaque burden, total atheroma volume, 
figure 1. Flowchart of the 5-Year Serial MSCT Study. Scaffolded segments (left panel; represented in 
green) were matched at 18-month and 5-year follow-up for serial comparison. Non-intervened seg-
ments delimited by anatomical markers (right panel; represented in blue) were matched at 18-month 
and 5-year follow-up for serial comparison. One non-intervened segment had motion artifact at 
18-months hindering the serial comparison and was excluded.
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total lumen volume and vessel volume (Table 2; 
Figure 2). Control segments had a significant 
temporal increase in atherosclerotic burden 
as determined by the mean plaque burden 
(increased in 2.7±6.5%; P=0.03) and total 
atheroma volume (increased in 8.0±22.8mm3; 
P<0.01)(Table 2; Figure 2).
Comparison of natural history of athero-
sclerosis in scaffolded vs. non-intervened 
segments. The change in percent atheroma 
volume was significantly different between 
scaffolded regions and non-intervened seg-
ments. While in the scaffolded segments the 
mean plaque burden decreased by 1.2±7.7%, 
in the non-intervened segments it increased 
by 2.7±6.5% (P=0.03) (Table 2; Figure 2). There 
was also a trend to difference in the change 
of normalized total atheroma volume (P=0.10) 
and % change in total atheroma volume 
(P=0.09) in favour of scaffolded segments 
(Table 2, Figures 2 and 3). The change in the 
vessel volume was only slightly greater in the 
non-intervened segments (P=0.72). Although 
Table 1. Baseline Clinical and Angiographic Char-
acteristics
N=18
Age, years ±SD 62.1 ± 7.8
Male gender, n(%) 12 (67)
Current tobacco use, n(%) 2 (11)
Diabetes, n(%) 1 (6)
Hypertension, n(%) 11 (61)
Hypercholesterolemia, n(%) 13 (76)
Family history of coronary artery 
disease, n(%)
13 (72)
Stable angina 14 (78)
Unstable angina, n(%) 4 (22)
Prior MI, n(%) 2 (11)
Target vessel , n(%)
RCA 4 (22) 
LAD 8 (44)
LCX 6 (33)
Lesion length, mm ± SD 9.1 ± 3.6
ACC/AHA lesion classification, n(%)
B1 9 (50) 
B2 9 (50)
MI= myocardial infarction; RCA=right coronary artery; 
LAD=left anterior descending coronary artery; LCX= left 
circumflex coronary artery
Table 2. MSCT IVUS-Like Analysis Results
Scaffold (n=18) Non-intervened (n=71)
Scaffold
Vs.
non TV
18 months 5 years Change P 
value
18 months 5 years Change P value P value for 
changes
Percent atheroma volume, %
Mean ±SD 49.3±10.5 48.1±8.7 -1.2±7.7 0.51 44.6±9.9 47.3±11.0 2.7±6.5 <0.01 0.03
% change in total atheroma volume
Median (IQR) 0.6±22.0 11.9±25.6 0.09
normalized total atheroma volume, mm3
Mean ±SD 94.2±34.6 92.6±32.2 -1.6±18.7 0.72 95.0±33.5 103.0±36.2 8.0±22.8 <0.01 0.10
normalized total lumen volume, mm3
Mean ±SD 96.1±33.6 99.8±37.0 3.7±14.4 0.28 122.2±50.8 118.8±51.7 -3.4±19.83 0.16 0.16
normalized vessel volume, mm3
Mean ±SD 190.3±54.9 192.4±57.5 2.1±16.4 0.59 217.2±69.7 221.8±67.6 4.6±29.0 0.18 0.72
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figure 2. MSCT IVUS like parameters. Scaffold segments did not show significant temporal change in 
vessel, lumen and plaque volume parameters. The non-intervened segments had an increase in the 
plaque volume (C), representing a higher percentage of the vessel area (D).
figure 3. Percentage change in the atheroma volume in the scaffolded (green) and non-intervened ves-
sels (blue). Each dot represents one segment. The observed shift to the left in scaffolded regions cor-
respond to a trend towards atherosclerosis regression compared to non-intervened vessels (P=0.09).
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the difference between groups was not sig-
nificant, the bigger increase in plaque burden 
without proportional increase in vessel vol-
ume in the non-intervened segment resulted 
in an opposite change in the lumen volume; 
while there was a lumen gain (increase of 
3.7±14.4mm3) in the scaffold segment, a lumen 
loss in non-intervened segments (decrease of 
figure 4. (A) Lumen and vessel areas of a scaffold implanted in left anterior descending coronary artery 
at 18 months (upper panel, left) and 5 years (upper panel, right). There is an increase in the lumen vol-
ume and decrease in the plaque burden (lower panel). (B) Lumen and vessel areas of the same patient 
but in the proximal right coronary artery at 18 months (upper panel, left) and 5 years (upper panel, 
right). There is an increase in the plaque burden (lower panel) and vessel volume with a slight increase 
in the lumen volume (lower panel).
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3.4±19.8 mm3; P=0.16) was observed (Table 2, 
Figure 2 and 3). An example of intra-patient 
comparison of matched segments is given in 
Figure 4.
DISCUSSIon
The main findings of the present study can be 
summarized as follows: (1) Segments treated 
with Absorb BVS 1.0 had a stabilization of the 
atherosclerotic process, without significant 
paired change in the vessel, lumen and plaque 
dimensions; (2) non-intervened coronary 
segments had a significant increase in the 
plaque volume and percent atheroma volume; 
(3) the comparison between scaffolded and 
non-intervened segments showed a significant 
benefit of the Absorb BVS scaffold in terms of 
plaque burden.
Coronary atherosclerosis has been challeng-
ing medical practice in terms of reversion of 
its chronic progressive inflammatory process 
and subsequent symptoms and events[7, 9, 11, 
16, 17]. As summarized in Table 3, therapeutic 
interventions may influence progression or 
regression of coronary artery disease. In ad-
dition, many individual factors may influence 
the coronary plaque modification such as 
diabetes, waist circumference, serum CD40L, 
baseline diastolic blood pressure, gender and 
the aptitude in improving the lipid profile and 
C-reactive protein [8, 18-20]. The present study, 
being a matched segment within-patient 
comparison, for the first time, assessed the 
long-term evolution of atherosclerosis in 
segments treated by a scaffold and non-
intervened segments. It raises the hypothesis 
that local therapy with Absorb BVS could add 
benefit to atherosclerosis regression on top 
of pharmacological therapy. Importantly, 
the atherosclerosis progression observed in 
the non-intervened segments is not at vari-
ance with previous data that used the same 
methodology[11] (Table 3) and did not result in 
coronary events [5].
The plaque burden reduction in the Absorb 
BVS–implanted coronary segments has been 
documented previously [4, 21]. The explanation 
for this finding may come from the ability of 
mTOR inhibitors to hinder atherosclerotic 
plaque formation. Rapamycin and rapalogs are 
potent inhibitors of vascular smooth muscle 
cell (SMC) proliferation. mTOR inhibitors have 
anti-macrophage properties through different 
mechanisms such as inhibition of monocyte 
Table 3. Impact of therapy on atherosclerosis in recent natural progression/regression trials
Trial
Change in PAV,%
Mean (95% CI)
% Change in TAV
Mean (95% CI) follow-up
SATURN(6) 26 months
Atorvastatin 80 mg -0.99 (−1.19 to −0.63) - 
Rosuvastatin 40mg -1.22 (−1.52 to −0.90) - 
PROSPECT (MSCT sub study)(10) –0.07 (-1.43 to 1.57) 6.7 (1.0 to 12.43) 39 months
IBIS 4(17) 13 months
Rosuvastatin 40mg -0.9 (-1.56 to -0.25) -13.1 (-22.5 to -3.8) 
Present study 42 months
Scaffolded segments -1.2 (-4.8 to 2.4) 0.65 (-9.54 to 10.84) 
Non-intervened segments segments 2.6 (1.16 to 4.2) 11.9 (5.99 to 17.91)
PAV=percent atheroma volume; TAV=total atheroma volume
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chemoattractant protein-1 (MCP-1) upregula-
tion, impaired recruitment of monocytes to 
the vessel and downregulation of de novo 
protein synthesis[22]. mTORC inhibition also 
prevents lipid accumulation in the plaque 
due to stimulation of cholesterol efflux and 
downregulation of low-density lipoprotein 
(LDL) and scavenger receptors[22]. It has been 
hypothesized that everolimus may produce a 
local autophagic response resulting in deg-
radation and/or efflux of lipids via lipophagy 
and the loss of macrophages in the plaque 
[23]. Indeed, also in animal studies, systemic 
administration of rapamycin or everolimus 
has shown to promote 7-85% plaque reduc-
tion[22, 24, 25]. However, this process is not fully 
understood since the Absorb BVS elutes 80% 
of everolimus within 30 days and the plaque 
regression in patients treated with Absorb BVS 
occurs only after 2 years[4, 21]. We hypothesize 
also that the disappearance of struts with 
consequent shrinking of connective tissue may 
result in reduction in plaque burden.
The impact of five coronary devices on 
plaque sizes by intravascular ultrasound have 
been compared previously: (Absorb bioresorb-
able everolimus eluting scaffold — Absorb 
BVS 1.0 and 1.1; everolimus eluting metallic 
stent — Xience V —;bare metal stent — Vision 
and paclitaxel-eluting metallic stent — Taxus)
[21]. At 6-month follow-up, all devices induced 
an increase in the total plaque area but Vision 
and Taxus induced larger increase as compared 
to other devices [Absorb BVS (1.0 and 1.1) and 
Xience V], (p= 0.0002). The comparison-at-2-
year follow-up showed that Absorb BVS 1.1 
had a larger increase from post procedure 
in total plaque compared to Absorb BVS 1.0, 
Xience V and Taxus (p =0.0499). However, in 
Absorb BVS 1.1 total plaque showed a reduc-
tion of 2.2% from 1 to 3 years. Taxus showed 
a 9% increase in vessel area which was much 
larger to that of Absorb BVS, Xience V or Vi-
sion. In addition, Haude et al. have shown that 
drug-eluting absorbable magnesium scaffold 
(DREAMS) showed a vessel area reduction at 6 
months and even more between 6 months and 
12 months[26]. These observations highlight 
the fact that the vessel wall response varies 
according to the device design. At this point, 
it is not possible to fully understand whether 
it is the drug, the polymer or the constituents 
of the back bone (metal vs. polymer) which 
play the most determinant role in triggering 
these changes. However, permanent devices 
hinder any further reduction of the size of the 
plaque by lastingly staying in the vessel wall. 
On the other hand, bioresorbable scaffolds 
are designed to provide temporary scaffolding 
the coronary vessel wall, inhibit effectively 
neointima formation (by eluting everolimus) 
and also prevent late complications such as 
stent thrombosis by their disappearance.
In addition to the plaque burden reduction, 
it has been hypothesized that Absorb BVS 
may seal the thin-cap fibroatheromas (TCFA), 
which are lipid core plaques covered by a thin 
fibrous cap (<65 µm) [27]. An optical coherence 
tomography study has shown that 1-year after 
Absorb BVS implantation there is formation of 
symmetric neo-tissue with a mean thickness 
of 220  µm[27]. As the device is completely 
degradeted, this may therefore favour the use 
of a bioresorbable device for the treatment of 
TCFA. Furthermore, pre-clinical studies have 
demonstrated that the main component of the 
neointima following Absorb BVS implantation 
is fibrous tissue, whereas fibrin and granu-
lomatous cells are infrequent at long-term 
follow-up[28].
Finally, the present manuscript documents 
the longest non-invasive assessment after 
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Absorb BVS implantation and demonstrates 
the feasibility of MSCT on following patients 
with bioresorbable polymeric devices and 
quantifying the atherosclerotic burden in all 
coronary tree.
limitations
The present study is a retrospective analysis 
that assessed patients in a first-in-humans 
trial including patients with low clinical and 
anatomical complexity. Our results should be 
considered as hypothesis generating given 
the small sample size herewith described, not 
permitting a definitive statement that Absorb 
BVS should be used as a standard therapy for 
plaque regression. Additionally, progression/
regression studies have shown that that the 
larger the PAV at baseline, the higher the 
chance of regression. This fact may have 
potential to influence the more pronounced 
regression at scaffolded segments. The ongo-
ing Multicentre Prospective Natural History 
Study Using Multimodality Imaging in Patients 
With Acute Coronary Syndromes (PROSPECT 
ABSORB trial, ClinicalTrials.gov Identifier: 
NCT02171065) will examine whether the 
treatment of lesions with plaque burden ≥70% 
with the Absorb BVS plus optimal medical 
therapy safely increases the minimal lumen 
diameter at 2 years compared with optimal 
medical treatment alone and may add further 
evidence in this regard.
ConClUSIon:
In this small series, Absorb BVS showed 
potential to locally reduce the progression of 
% plaque burden on top of pharmacological 
treatment. Larger studies are needed to con-
firm these findings.
Role of funding source. The Absorb Cohort A 
trial was sponsored by Abbott Vascular (Santa 
Clara, California).
Conflicts of interest: Susan Veldhof is full-
time employee of Abbott Vascular, Diegem, 
Belgium. The others authors have no conflict of 
interest and did not receive grants or financial 
support from industry or from any other source 
to prepare this manuscript.
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SUMMARY
In coronary artery disease (CAD), patients and 
plaque’s characteristics have been scrutinized 
to understand how risk factors relate to the 
hazard of subsequent cardiovascular events. 
The rationale for local plaque assessment 
is based on the fact that the atherosclerotic 
plaque represents the pathological substrate 
for the occurrence of ischemic cardiovascular 
events. However, the coronary atheroscle-
rotic disease burden is not the only factor 
that affect patients’ prognosis. Patients with 
complex coronary artery disease, clinical 
factors beyond plaque are components of 
the final outcome and affects the decision-
making proccess of coronary revascularization. 
Moreover, the coronary revascularization still 
does not represents the cure for CAD requiring 
adequate risk assesment, secondary preven-
tion and development of therapeutics that are 
able to modify the natural history of coronary 
atherosclerosis. This thesis offers significant 
insights into these, and provides important 
data regarding CAD risk management.
IMAGInG MeTHoDS foR ASSeSSInG 
CARDIoVASCUlAR RISK
In chapter 1.1, we described the current 
histopathological definitions and state-of-
the-art imaging techniques for identication 
of vulnerable coronary plaques. One of most 
widely used methods for in vivo identification 
of vulnerable plaques is Virtual Histology In-
travascular Ultrasound (VH-IVUS). We describe 
in chapter 1.2 the algorithm for VH IVUS using 
the 45-MHz rotational IVUS catheter and the 
associated ex vivo validation in comparison to 
the gold standard histology.
In recent years, coronary Ctangiography (CCTA) 
has become a widely adopted technique, not 
only due to its high diagnostic accuracy, but 
also to the fact that CCTA provides a non-
invasice evaluation of the total (obstructive 
and non-obstructive) coronary atherosclerotic 
burden. More recently, this technique has be-
come mature, with a large body of evidence 
addressing its prognostic validation. In addi-
tion, CT angiography has moved from the field 
of ‘imagers’ and clinicians and entered the 
interventional cardiology arena. In chapter 1.3 
we describe CCTA accuracy, prognostic value 
and its hability and limitations in assessing 
plaque characteristics.
The presence of coronary plaques with 
complex morphologic features in coronary 
angiography is the angiographic hallmark 
of unstable coronary syndromes. In chapter 
1.4 we assessed coronary plaque features by 
angiography in patients with acute coronary 
syndrome after noncardiac surgery, patients 
in the emergency room with spontaneous 
acute coronary syndromes, and patients with 
stable coronary artery disease. In chapter 1.5 
we assessed the distribution of angiographic 
thrombus-containing lesions in an all-comer 
population admitted with a heterogeneous 
clinical presentation (stable, ustable angina, or 
an acute coronary syndrome) and its long-term 
prognostic implications.
Optical coherence tomography (OCT) is an 
intravascular light-based imaging method with 
a near-histological resolution of 10-20 µm. 
Currently, OCT is the only technology available 
in the clinical setting that provides spatial 
resolution sufficient to assess fibrous cap 
thickness accurately (FCT). Coronary lesions 
precursors of acute events remain elusive, 
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since they undergo continuous changes and 
their temporal changes are not very well 
characterized. In natural history studies, 
optical frequency domain imaging (OFDI) has 
been used only to assess fibroatheromas as 
a two-dimensional structure and sometimes 
in a single frame fashion. In chapter 1.6 we 
described the changes of coronary fibroath-
eromas over a 6-month follow-up period, 
describing the serial volumetric modifications 
of the FC as determined by OCT.
InTeRPlAY beTWeen CoRonARY 
ATHeRoSCleRoSIS AnD ClInICAl 
PRofIle
Individual risk factors and coronary plaque 
characteristics have been correlated in 
medical literature. However, the clinical and 
health outcomes measures assessed by the 
Seattle Angina Questionnaire (SAQ) have 
never been correlated with the characteristics 
of obstructive plaque determined by intra-
vascular ultrasound (IVUS). In chapter 2.1 we 
discussed the impact of gender on progres-
sion/regression of coronary atherosclerosis as 
assessed by intravascular ultrasound. Chapter 
2.2 described the largest ever description of 
pre-treatment intravascular ultrasound (IVUS 
grey scale and backscatter tissue data) findings 
according to patient demographics and health 
outcome measures as assessed by the Seattle 
Angina Questionnaire (SAQ). We showed that 
clinical characteristics still were able to dif-
ferentiate the manifestation of obstructive 
coronary artery disease . Additionally, nega-
tive remodelling was associated with worse 
angina frequency by the SAQ. Patient reported 
physical limitation and angina stability were, 
respectively, associated with necrotic core size 
and plaque burden.
Coronary angiography still is the gold standard 
method for decision making in coronary artery 
disease. Interventional cardiologists and sur-
geons in the SYNTAX (SYNergy Between PCI 
With TAXUS and Cardiac Surgery) trial originally 
used the SYNTAX score (SS) to extract objective 
information from the coronary angiogram on 
the technical challenges posed by coronary 
anatomy to percutaneous coronary interven-
tion (PCI) and to facilitate discussions made 
by the Heart Team. Subsequently, it became 
apparent that the SS had a prognostic value 
to predict short- and long-term outcomes. In 
chapter 2.3 we demonstrated that the SYNTAX 
score assessment by clinicians had consider-
able difference when compared with an expe-
rienced corelab. However, the combination of 
clinical factors with the SYNTAX score (referred 
to as the SYNTAX-II score) reduced the vari-
ability, retaining its predictive performance.
Among patients’ clinical characteristics, 
diabetes mellitus has an important role in 
the development of coronary artery disease 
and has been associated with a subsequent 
increase rate of death. Moreover, about a 
quarter of patients treated with coronary 
revascularization are diabetics. In chapter 
2.4 we investigated whether stent thrombosis 
rate is different between diabetic patients 
and their counterparts in one of the largest 
randomized stent trials that was powered for 
stent thrombosis.
RISK STRATIfICATIon In CoMPleX 
CoRonARY ARTeRY DISeASe
 In a non-emergency setting, an accurate risk 
estimation of patients with complex coronary 
Summary
445
Sum
m
ary
artery disease (CAD) is fundamental to deter-
mine if the patient should be treated either 
by percutaneous coronary intervention (PCI) 
or coronary artery bypass surgery (CABG). 
Currently, international guidelines recom-
mend a multidisciplinary approach referred 
to as the Heart Team for this decision-making 
proccess. Aiming to help the Heart Team to 
decide between CABG and PCI in patients 
with complex CAD, the SYNTAX Score II (SSII) 
combines 2 anatomic and 6 clinical factors 
and predicts long-term mortality of patients 
treated by either CABG or PCI. The SSII was 
developed in the all-comers, randomized 
population of the SYNTAX trial, where selec-
tion bias were minimal. The SSII also suggests 
a revascularization strategy (CABG or PCI) 
depending on the difference of estimated 
mortalities. The SSII recommends CABG if the 
difference in the predicted mortality risk is in 
favor of CABG with 95% confidence. The SSII 
recommends PCI if the difference in mortality 
risk predictions is in favor of PCI with 95% 
confidence. Conversely, the SSII recommends 
PCI or CABG if mortality risk predictions are 
within the 95% confidence interval of the dif-
ference in mortality risk predictions. In chapter 
3.1 we assessed the applicability of the SSII 
recommendations in conjunction with the 
Heart Team decision-making process regarding 
the revascularization strategy in patients with 
3-vessel coronary artery disease (CAD). The 
SYNTAX score II showed to be a suitable tool 
for guiding treatment decisions of patients 
with 3-vessel coronary artery disease being 
endorsed by the Heart Team in the vast major-
ity (85.4%) of the patients. In chapters 3.2 and 
3.3 we explored the validity of the SYNTAX 
score II theoretical treatment recommendation 
in the long-term prognosis. We found that pa-
tients who the SYNTAX score II recomendation 
was CABG but were treated by PCI had worse 
prognosis when compared with patients that 
had equipoised risk between CABG and PCI or 
when PCI was recommended. These findings 
were not always related to the anatomical 
SYNTAX score alone.
Previously, SSII was predominantly vali-
dated in Western patients. In chapter 3.2 we 
validated the SSII in a Japanese population of 
complex coronary artery disease. Japanese 
have unique epidemiological characteristics. 
Japan has the longest life expectancy at birth 
worldwide and a substantially lower propor-
tion of mortality from cardiovascular diseases, 
compared with Western countries. We showed 
a robust prognostic accuracy of the SSII, both 
in CABG and in PCI patient groups. Compared 
with the anatomical SS alone, the SSII was 
more accurate in stratifying patients for late 
mortality in a real-world complex coronary 
artery disease population.
We continued to study the SYNTAX score 
II and in chapter 3.5 explored its cost-effec-
tiveness perspective in the SYNTAX trial. We 
found that in patients for whom the SYNTAX 
Score II favoured PCI based on lower predicted 
4 year mortality, PCI was also economically 
dominant, whereas in those patients for whom 
the SYNTAX Score II favoured surgery, CABG 
was highly economically attractive.
The relevance of an unprotected left main 
coronary artery (ULMCA) stenosis was first 
described more than 100 years ago. James 
Herrick reported the story of a 55-year-old 
male who died in cardiogenic shock after a 
period of 52 hours. The autopsy found an 
extensive necrosis of the left ventricle as-
sociated with total occlusion of the left main 
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coronary artery by a thrombus overlying an 
area of atherosclerotic narrowing. The expla-
nation for this massive necrosis is the large 
area of myocardium at risk in patients with 
ULMCA. It has been shown that, in a usual right 
dominant coronary anatomy, the left coronary 
artery supplies approximately 84% of the 
flow to the left ventricle. In chapter 3.6 we 
described the rational, designs, similarities 
and contrasts of two large scale randomized 
trials of PCI versus CABG for ULMCA disease 
(EXCEL and Noble trials). In addition, in chapter 
3.7 we, for the first time, proposed a prospec-
tive validation of the SYNTAX score II in the 
EXCEL trial. Based on the SYNTAX Score II, we 
predicted a 77.9% chance of a lower 4-year 
mortality in the PCI arm of the EXCEL trial, with 
a 40% chance that this will achieve statistical 
significance in favour of PCI.
PoST-ReVASCUlARIZATIon RISK 
ASSeSSMenT AnD MAnAGeMenT
Coronary artery disease is, predominantly, a 
chronic and progressive disease. Therefore, 
patient’s risk will not cease after coronary 
revascularization. In chapter 4 we studied the 
post-revascularization risk assessment. One 
of the main factors of long-term survival of 
these patients is the completeness of coronary 
revascularization. In chapter 4.1 we discussed 
the impact of the residual (rSS) SYNTAX score 
for ULMCA revascularization. The rSS was de-
signed and validated to quantify the absolute 
amount of untreated CAD after percutaneous 
coronary intervention (PCI) revascularization. 
An rSS>8 was identified as a level of incom-
plete revascularization was associated with 
increased mortality and adverse ischemic 
events.
We continued to study the degre of coro-
nary revascularization and in chapter 4.2 we 
proposed the SYNTAX Revascularization Index 
(SRI), representing the proportion of treated 
baseline CAD (baseline SYNTAX score [bSS]; 
delta SYNTAX score [DSS]), to better quantify 
and describe the proportion of the disease 
treated (SRI= DSS/ bSS 100) by PCI revascu-
larization. In chapter 4.3 we demonstrated 
that the SRI to be an independent predictor 
of 1-year mortality in patients with noneST-
elevation acute coronary syndrome and low 
anatomical complexity. In chapter 4.4 we 
validated the SRI in the population with com-
plex CAD of the SYNTAX trial, with SRI>70% 
representing a “reasonable” goal for patients 
with complex coronary artery disease.
Reducing risk factors after coronary revas-
cularization has also a major role for patient 
survival. Cigarette smoking is a well-known 
risk factor for development of coronary artery 
disease. However, some studies have suggest-
ed a “smoker’s paradox,” meaning neutral or 
favorable outcomes in smokers who have de-
veloped CAD, especially myocardial infarction. 
In chapter 4.4 we examined the association of 
smoking status with clinical outcomes in the 
randomized controlled SYNTAX trial at 5-year 
follow-up. Smoking was associated with poor 
clinical outcomes after revascularization in 
patients with complex CAD. This placed further 
emphasis on efforts at smoking cessation to 
improve revascularization benefits.
Optimal control of dyslipidaemia improves 
clinical outcomes in patients with coronary 
artery disease. In chapter 4.5 we and inves-
tigated the risk factors associated with not 
achieving the European Society of Cardiology 
recommended cholesterol levels. There was a 
significant drop in LDL-C levels during 1-year; 
nevertheless a significant proportion of pa-
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tients (55% at 6-months and 58% at 1-year) 
remained above the target LDL-C level. We 
found that factors associated with not achiev-
ing target LDL levels included higher baseline 
LDL, prior history of myocardial infarction and 
lack of statin therapy.
Impact of Bioresorbable Scaffolds 
in the natural history of coronary 
atherosclerosis
The cardiovascular science community has 
pursued the quest to modify the natural 
history of coronary atherosclerosis. The clini-
cal introduction of bioresorbable scaffolds 
(BRS) resulted in a revolutionary change in 
the application of local coronary therapies. 
These devices have the unique ability to 
provide a temporary scaffold that is neces-
sary to maintain the patency of the vessel 
after intervention, releasing antiproliferative 
drugs. Due to the polymeric composition, 
bioresorbable vascular scaffolds (BVS) have 
unique characteristics when imaged. In chap-
ter 5.1 we described the imaging methods for 
BRS, compared BRS with metallic stents, and 
describes the clinical relevance of BRS.
Changes in bioresorbable vascular scaffolds 
(BRS), design and compositions may affect 
their degradation and loss of biomechanical 
characteristics (with the risk of late recoil) 
and may be associated with a second wave of 
arterial wall inflammation. Therefore, studying 
the BRS degradation is crucial to fully under-
stand this technology. Chapter 5.2 validated 
echogenicity (an automated and quantitative 
analysis of coronary tissue components scored 
for grey level intensity using as reference the 
mean level of the adventitia brightness) as a 
surrogate for polylactide scaffold degradation.
OCT has played a central role in understand-
ing the short and long term BRS performance, 
since provides more detailed and precise 
morphologic information about BRS than does 
intravascular ultrasonography. In chapter 5.3 
we reviewed the the acute and long-terms 
methodology and clinical application of OCT 
in the assessment of BRS.
Coronary plaque size modification, by either 
local (device) or systemic treatments, has been 
the target for many years. Commonly, patients 
receive concomitantly medical treatment and 
PCI and therefore the coronary vessel wall 
response will vary in relation to the interaction 
of both treatments. At follow-up, implants will 
be surrounded by plaque, behind (peri-stent) 
the struts and endoluminally (neointima). 
These two compartments are biologically ac-
tive and will be influenced differently by the 
presence of a complex interaction formed by 
the platform (metallic/polymeric) + polymer 
+ drug. For example, stents/scaffolds eluting 
everolimus will similarly affect plaque size 
(i.e. by clearing macrophages and inhibiting 
formation of neointima), but the net effect will 
be dissimilar since the platforms are different 
(metallic vs. polymeric). Thus, the effects on 
plaque size of this complex interplay (eluted 
drug/platform) can only be explored by 
measuring serially the size of the coronary 
plaque-media and neointima compartment. In 
chapter 5.4 we show that local devices affect 
coronary plaque size differently and it depends 
on the platform (metallic vs. polymeric) and on 
whether it is a bare— or drug eluting stent. 
Specifically, the total plaque in the sequential 
cohorts of Absorb BVS 1.1 increased 16.2% 
from baseline to 2 years while at 3 years this 
increase is only 5% compared to baseline.
Vessel wall mechanical behavior appears 
to be associated with the compositional char-
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acteristics of the plaque and predict future 
cardiovascular events. Patients with high 
strain plaques are more likely to experience 
acute coronary events comparing to those with 
low strain lesions. Several studies have shown 
that pharmaceutical or an interventional treat-
ment can influence the mechanical properties 
of the vessel wall by altering its constituents. 
In chapter 5.5 we found that after Absorb BVS 
1.1 implantation the strain of the vessel wall 
gradually decreased with time.
Among the potential advantages of biore-
sorbable scaffolds, the atherosclerotic plaque 
reduction and late lumen enlargement in the 
treated regions may represent a paradigm shift 
in the treatment of coronary artery disease. 
However, pharmacological therapy has also 
shown that, depending on patient clinical 
profile, it is possible to promote plaque regres-
sion. Therefore, plaque regression in patients 
treated with bioresorbable scaffolds may be 
related not to the device itself but due to the 
effect of the pharmacological therapy in a ves-
sel that is free from its internal cage. In chapter 
5.6 we performed an intra-patient multi-slice 
computed tomography comparison of matched 
segments (normalized by the segment length) 
of the scaffolded region with non-intervened 
segments for: lumen volume, vessel volume, 
plaque volume, plaque burden and % change 
in plaque atheroma volume. Serial comparison 
showed that the scaffolded segments did not 
have a significant change in the mean plaque 
burden, total atheroma volume, total lumen 
volume and vessel volume between 18 months 
and 5 years. Conversely, the non-treated seg-
ments had a significant increase in plaque 
burden (2.7 ± 6.5%; P<.01) and normalized 
plaque volumes (8.0 ± 22.8 mm3, P<.01). This 
resulted in a significant difference in plaque 
burden comparison between scaffolded and 
non-intervened segments (P=.03).
ConClUSIonS
This thesis comprehensively reflects the many 
considerations related to the risk stratifica-
tion for coronary artery disease, as well as 
the futures perspectives for interventional 
cardiology. I believe this thesis is of value as 
it has particularly:
• offered a comprehensive guide of imag-
ing modalities for identifying high-risk 
characteristics of coronary artery disease;
• provided important insights into the 
interplay of clinical and anatomical 
considerations for patients prognosis and 
their impacts on decision making;
• proposed for the first time an unbiased 
prospective validation of a risk score;
• assessed the needs and challenges of 
patient management post coronary revas-
cularization;
• presented new data on the impact of 
bioresorbable scaffolds for modification 
of coronary atherosclerosis
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Bij coronaire hartziekten (CHZ) is gedetailleerd 
onderzoek gedaan naar patiënt- en plaquek-
enmerken om inzicht te krijgen in de relatie 
tussen risicofactoren en de kans op cardio-
vasculaire voorvallen. De belangrijkste reden 
voor lokale beoordeling van plaque berust 
op het feit dat de atherosclerotische plaque 
het pathologische substraat vormt voor het 
optreden van cardiovasculaire ischemische 
voorvallen. De ernst van coronaire hartzieken 
is echter niet de enige factor die van invloed is 
op de prognose van de patiënt. Bij patiënten 
met complexe coronaire hartziekten zijn, 
naast plaque, ook andere klinische factoren 
onderdeel van de definitieve resultaten en dit 
heeft gevolgen voor het besluitvormingspro-
ces bij coronaire revascularisatie. Bovendien is 
coronaire revascularisatie nog steeds niet de 
juiste behandeling voor CHZ en zijn adequate 
risicobeoordeling, secundaire preventie en 
ontwikkeling van behandelingen vereist 
om het natuurlijke beloop van coronaire 
atherosclerose te kunnen beïnvloeden. In dit 
proefschrift worden waardevolle inzichten 
gegeven in deze onderwerpen en belangrijke 
gegevens verstrekt over risicobeheer bij CHZ.
BEELDVORMENDE METHODEN 
VOOR BEOORDELING VAN 
CARDIOVASCULAIRE RISICO’S
In hoofdstuk 1.1 gaven we een beschrijving 
van de huidige histopathologische definities 
en de allernieuwste beeldvormende tech-
nieken voor het opsporen van kwetsbare 
coronaire plaques. Eén van de meest gebruikte 
methoden voor in-vivo identificatie van 
kwetsbare plaques is Virtual Histology Intra-
vascular Ultrasound (VH-IVUS). In hoofdstuk 
1.2 beschreven we het algoritme voor VH-IVUS 
met behulp van de 45-MHz roterende IVUS-
katheter en de bijbehorende ex-vivo validatie 
in vergelijking met de gouden standaard voor 
histologie.
De laatste jaren is coronaire CT-angiografie 
(CCTA) een veelvuldig toegepaste techniek, 
niet alleen vanwege de hoge diagnostische 
nauwkeurigheid, maar ook vanwege het feit 
dat CCTA de mogelijkheid biedt tot een niet-
invasieve beoordeling van de totale ernst van 
(obstructieve en niet-obstructieve) coronaire 
atherosclerose. Meer recentelijk heeft deze 
techniek een volwassen stadium bereikt en 
bestaat er een grote hoeveelheid bewijsma-
teriaal voor de prognostische validiteit ervan. 
Bovendien heeft CT-angiografie zich verplaatst 
van het terrein van de ‘beeldvormers’ en de 
clinici naar de arena van de interventionele 
cardiologie. In hoofdstuk 1.3 beschreven we 
de nauwkeurigheid, de prognostische waarde, 
en het nut en de beperkingen van CCTA bij de 
beoordeling van plaque-eigenschappen.
Bij coronaire angiografie is de aanwezigheid 
van coronaire plaques met complexe mor-
fologische kenmerken hèt angiografische 
kenmerk voor instabiele coronaire syndromen. 
In hoofdstuk 1.4 beoordeelden we met behulp 
van angiografie de kenmerken van coronaire 
plaques bij patiënten met een acuut coronair 
syndroom na niet-cardiale chirurgie, patiënten 
op de afdeling voor spoedeisende hulp met 
een spontaan acuut coronair syndroom en pa-
tiënten met stabiele coronaire hartziekten. In 
hoofdstuk 1.5 beoordeelden we de verdeling 
van angiografische laesies met trombus over 
een totale populatie die is opgenomen met 
heterogene klinische manifestatie (stabiele, 
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instabiele angina pectoris, of een acuut coro-
nair syndroom) en de bijbehorende implicaties 
voor de langetermijnprognose.
Optische Coherentie Tomografie (OCT) is een 
intravasculaire, op licht gebaseerde beeldvor-
mende methode met een bijna-histologische 
resolutie van 10-20 µm. OCT is momenteel de 
enige beschikbare technologie in de klinische 
setting die voldoende ruimtelijke resolutie 
biedt voor een nauwkeurige beoordeling van 
de dikte van de fibreuze kap. Het blijft moeilijk 
coronaire laesies op te sporen die de voorbo-
des zijn van acute voorvallen, aangezien deze 
voortdurend veranderingen ondergaan en 
hun veranderingen in de loop van de tijd niet 
zeer goed zijn getypeerd. In studies naar het 
natuurlijke beloop is alleen gebruikgemaakt 
van Optical Frequency Domain Imaging (OFDI) 
voor de beoordeling van fibroatheromen als 
een tweedimensionale structuur en soms 
als single-frame methode. In hoofdstuk 1.6 
beschreven we de veranderingen van coro-
naire fibroatheromen gedurende een follow-
upperiode van 6 maanden. Hierbij werden de 
seriële volumetrische veranderingen van de 
fibreuze kap beschreven die met behulp van 
OCT zijn gemeten.
WISSELWERKING TUSSEN CORONAIRE ATHERO-
SCLEROSE EN KLINISCH PROFIEL
Er is gedetailleerd onderzoek gedaan naar 
patiënt- en plaquekenmerken om inzicht te 
krijgen in de relatie tussen risicofactoren 
en de kans op cardiovasculaire voorvallen. 
De klinische en gezondheidsgerelateerde 
uitkomstmaten die werden beoordeeld met 
behulp van de Seattle Angina Questionnaire 
(SAQ), zijn echter nooit gecorreleerd met de 
kenmerken van obstructieve plaque die wordt 
vastgesteld met behulp van intravasculaire 
echografie (IVUS). In hoofdstuk 2.1 bespraken 
we de invloed van geslacht op de progressie/
regressie van coronaire atherosclerose bij 
beoordeling met behulp van intravasculaire 
echografie. In hoofdstuk 2.2 werd ingegaan 
op de meest uitgebreide beschrijving ooit 
van bevindingen vóór behandeling met intra-
vasculaire echografie (IVUS-weefselbeelden 
bestaande uit grijsschaal en achterwaartse 
verstrooiing) aan de hand van patiëntgegevens 
en gezondheidsgerelateerde uitkomstmaten 
die werden bepaald met behulp van de Seattle 
Angina Questionnaire (SAQ). We lieten zien dat 
de manifestatie van obstructieve coronaire 
hartziekten nog steeds kon worden gedifferen-
tieerd met behulp van klinische kenmerken. 
Bovendien werd negatieve remodellering in 
verband gebracht met een hogere frequentie 
van angina pectoris door de SAQ. Door de pati-
ent genoemde fysieke beperking en stabiliteit 
van angina pectoris werden respectievelijk 
in verband gebracht met de grootte van de 
necrotische kern en de ernst van de plaque.
Coronaire angiografie geldt nog steeds 
als gouden-standaardmethode voor de 
besluitvorming bij coronaire hartziekten. 
Interventiecardiologen en chirurgen in de 
SYNTAX (SYNergy Between PCI With TAXUS 
and Cardiac Surgery)-studie gebruikten de 
SYNTAX-score (SS) aanvankelijk om uit het 
coronaire angiogram objectieve gegevens te 
extraheren over de technische uitdagingen die 
de coronaire anatomie stelt aan percutane co-
ronaire interventie (PCI) en om discussies van 
het ’hartteam’ te ondersteunen. Vervolgens 
werd duidelijk dat de SS een prognostische 
waarde had bij het voorspellen van korte- en 
langetermijnresultaten. In hoofdstuk 2.3 
lieten we zien dat de beoordeling aan de 
hand van de SYNTAX-score door clinici een 
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aanzienlijk verschil opleverde wanneer we 
deze vergeleken met de beoordeling door een 
ervaren kernlaboratorium. De combinatie van 
klinische factoren met de SYNTAX-score (aan-
geduid als de SYNTAX-II-score) verminderde 
de variabiliteit echter, zodat de voorspellende 
waarde ervan behouden bleef.
Bij de klinische patiëntkenmerken speelt 
diabetes mellitus een belangrijke rol bij de 
ontwikkeling van coronaire hartziekten en 
is deze aandoening in verband gebracht met 
een stijging van het sterftecijfer. Bovendien is 
ongeveer één vierde van de patiënten die een 
coronaire revascularisatie hebben ondergaan 
diabeet. In hoofdstuk 2.4 onderzochten we 
of er een verschil bestaat in het aantal geval-
len van stenttrombose tussen diabetische 
en niet-diabetische patiënten in een van de 
grootste gerandomiseerde stentstudies die 
naar stenttrombose werden gedaan.
RISICOSTRATIFICATIE BIJ COMPLEXE CORO-
NAIRE HARTZIEKTEN
In een niet-spoedeisende situatie is een 
nauwkeurige risico-inschatting bij patiënten 
met complexe coronaire hartziekten (CHZ) es-
sentieel om te bepalen of de patiënt moet wor-
den behandeld met een percutane coronaire 
interventie (PCI) of coronaire bypasschirurgie 
(CABG). Momenteel wordt in de internationale 
richtlijnen voor dit besluitvormingsproces een 
multidisciplinaire aanpak aanbevolen die 
wordt aangeduid als het ’hartteam’. De SYN-
TAX-II-score (SSII) is bedoeld om het hartteam 
te helpen beslissen tussen CABG en PCI bij 
patiënten met complexe CHZ. De score is een 
combinatie van 2 anatomische en 6 klinische 
factoren en voorspelt de langetermijnsterfte 
bij patiënten die zijn behandeld met CABG of 
PCI. De SSII werd ontwikkeld in de gerandomi-
seerde, totale populatie van de SYNTAX-studie, 
waarbij de selectievertekeningen minimaal 
waren. De SSII heeft ook suggestieve waarde 
voor een revascularisatiestrategie (CABG of 
PCI) die afhankelijk is van het verschil tussen 
de geschatte sterftecijfers. De SSII beveelt 
CABG aan als het verschil in het voorspelde 
overlijdensrisico gunstig uitvalt voor CABG 
met een betrouwbaarheidsinterval van 95%. 
De SSII beveelt PCI aan als het verschil in de 
voorspelling van het overlijdensrisico gunstig 
uitvalt voor PCI met een betrouwbaarheidsin-
terval van 95%. Omgekeerd beveelt de SSII 
PCI of CABG aan als de voorspellingen van 
het overlijdensrisico binnen het betrouwbaar-
heidsinterval van 95% liggen van het verschil 
tussen de voorspellingen van het overlijdens-
risico. In hoofdstuk 3.1 beoordeelden we de 
toepasbaarheid van de SSII-aanbevelingen in 
combinatie met het besluitvormingsproces 
van het hartteam over de revascularisatiestra-
tegie bij patiënten met coronaire hartziekten 
(CHZ) van 3 vaten. De SYNTAX-II-score bleek 
een geschikt hulpmiddel als richtlijn bij be-
handelingsbeslissingen voor patiënten met 
coronaire hartziekten in 3 vaten, en werd voor 
de overgrote meerderheid (85,4%) van de 
patiënten onderschreven door het hartteam. 
In hoofdstuk 3.2 en 3.3 onderzochten we 
de validiteit van de theoretische behande-
lingsaanbeveling uit de SYNTAX-II-score voor 
de langetermijnprognose. We stelden vast 
dat patiënten bij wie de SYNTAX-II-score de 
aanbeveling CABG opleverde, maar die werden 
behandeld met PCI, een slechtere prognose 
hadden dan patiënten met een even zwaar 
wegend risico bij CABG als bij PCI, of wanneer 
de aanbeveling PCI luidde. Deze bevindingen 
hingen niet altijd samen met enkel de anato-
mische SYNTAX-score.
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Voorheen werd de SSII overwegend gevali-
deerd bij Westerse patiënten. In hoofdstuk 
3.2 valideerden we de SSII in een Japanse po-
pulatie met complexe coronaire hartziekten. 
Japanners hebben unieke epidemiologische 
kenmerken. Japan heeft wereldwijd de hoogte 
levensverwachting bij de geboorte en een 
aanzienlijk lager sterftepercentage door 
cardiovasculaire aandoeningen dan Westerse 
landen. We toonden de sterke prognostische 
nauwkeurigheid van de SSII aan, zowel in 
de CABG- als in de PCI-patiëntengroep. In 
vergelijking met alleen de anatomische SS 
was de SSII nauwkeuriger bij de stratificatie 
van patiënten voor late mortaliteit in een 
werkelijke populatie met complexe coronaire 
hartziekten.
We gingen verder met de studie van de 
SYNTAX-II-score en in hoofdstuk 3.5 onder-
zochten we het kosten-batenperspectief in 
de SYNTAX-studie. We stelden vast dat bij 
patiënten bij wie de SYNTAX-II-score wees in 
de richting van PCI op basis van een lagere 
voorspelde mortaliteit na 4 jaar, PCI ook in 
economisch opzicht prevaleerde, terwijl bij 
patiënten bij wie de SYNTAX-II-score wees in 
de richting van een operatie, CABG in hoge 
mate economisch aantrekkelijk bleek.
De relevantie van een onbeschermde stenose 
van de linker hoofdkransslagader (ULMCA: 
unprotected left main coronary artery) werd 
meer dan 100 jaar geleden voor het eerst 
beschreven. James Herrick beschreef het 
verhaal van een 55 jaar oude man die overleed 
tijdens een cardiogene shock na een periode 
van 52 uur. Bij autopsie werd een uitgebreide 
necrose van het linker ventrikel aangetroffen 
in combinatie met totale occlusie van de linker 
hoofdkransslagader door een trombus die een 
gebied met atherosclerotische vernauwing 
afsloot. De verklaring voor deze omvangrijke 
necrose is het grote gebied van het myocard 
dat risico loopt bij patiënten met een ULMCA. 
Er is aangetoond dat bij een normale, rechts-
dominante coronaire anatomie de linker krans-
slagader ongeveer 84% van de bloedstroom 
naar het linker ventrikel verzorgt. In hoofdstuk 
3.6 beschreven we de belangrijkste redenen, 
opzet, punten van overeenkomst en verschil 
van twee grootschalige gerandomiseerde 
studies naar PCI versus CABG bij ULMCA (EX-
CEL- en Noble-studie). Bovendien deden we 
in hoofdstuk 3.7 voor de eerste keer een 
voorstel voor een prospectieve validatie van 
de SYNTAX-II-score in de EXCEL-studie. Op 
basis van de SYNTAX-II-score voorspelden we 
dat er 77,9% kans bestond dat de mortaliteit 
na 4 jaar lager was in de PCI-arm van de EXCEL-
studie, met een kans van 40% dat dit leidt tot 
statistische significantie ten gunste van PCI.
RISICOBEOORDELING EN -BEHEER NA REVAS-
CULARISATIE
Coronaire hartziekten zijn, hoofdzakelijk, 
chronische en progressieve aandoeningen. 
Daarom is het risico voor de patiënt niet ten 
einde na een coronaire revascularisatie. In 
hoofdstuk 4 bestudeerden we het risicobeheer 
na revascularisatie. Eén van de belangrijkste 
factoren voor overleving op langere termijn 
van deze patiënten is de volledigheid van 
coronaire revascularisatie. In hoofdstuk 4.1 
bespraken we de invloed van de residuele (rSS) 
SYNTAX-score bij ULMCA-revascularisatie. 
De rSS werd ontworpen en gevalideerd voor 
het kwantificeren van het absolute aantal 
onbehandelde CHZ na revascularisatie via een 
percutane coronaire interventie (PCI). rSS>8 
werd aangemerkt als een niveau voor een 
onvolledige revascularisatie, welke in verband 
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werd gebracht met een verhoogde mortaliteit 
en ischemische bijwerkingen.
We gingen verder met het bestuderen van 
de mate van coronaire revascularisatie en in 
hoofdstuk 4.2 deden we een voorstel voor de 
SYNTAX Revascularization Index (SRI). Deze 
geeft de verhouding weer van behandelde 
CHZ in de beginfase (SYNTAX-score beginfase 
[bSS]; delta SYNTAX-score [DSS]) en biedt de 
mogelijkheid om de hoeveelheid behandelde 
ziektegevallen (SRI= DSS/bSS 100) met behulp 
van PCI-revascularisatie beter te kwantificeren 
en te beschrijven. In hoofdstuk 4.3 toonden we 
aan dat de SRI een onafhankelijke voorspel-
lende factor is voor de mortaliteit na 1 jaar 
bij patiënten met acute coronaire hartaan-
doeningen zonder ST-verhoging en geringe 
anatomische complexiteit. In hoofdstuk 4.4 
valideerden we de SRI in de populatie met 
complexe CHZ van de SYNTAX-studie, waarbij 
SRI>70% overeenkwam met een “redelijke” 
doelstelling voor patiënten met complexe 
coronaire hartziekten.
Verder speelt ook vermindering van de risico-
factoren na een coronaire revascularisatie een 
grote rol bij de overlevingskans van patiënten . 
Roken is een welbekende risicofactor voor het 
ontstaan van coronaire hartziekten. In som-
mige studies bestond echter het vermoeden 
van een ‘rokersparadox’. Dit hield in dat bij 
rokers met CHZ, en met name myocardinfarct, 
de resultaten neutraal of gunstig waren. In 
hoofdstuk 4.4 bestudeerden we de combinatie 
van de rookstatus en de klinische resultaten 
in de gerandomiseerde, gecontroleerde 
SYNTAX-studie na een follow-upperiode van 
5 jaar. Roken werd in verband gebracht met 
slechte klinische resultaten na revascularisatie 
bij patiënten met complexe CHZ. Dit onder-
streepte nog eens het belang van pogingen 
om te stoppen met roken om de voordelen 
van de revascularisatie te verhogen.
Optimale behandeling van dyslipidemie 
verbetert de klinische resultaten bij patiën-
ten met coronaire hartziekten. In hoofdstuk 
4.5 onderzochten we welke risicofactoren 
er bestaan wanneer de door de Europese 
Vereniging voor Cardiologie aanbevolen 
cholesterolniveaus niet worden gehaald. Er 
bestond een significante daling van de LDL-
C-niveaus gedurende 1 jaar; een significant 
gedeelte van de patiënten (55% na 6 maanden 
en 58% na 1 jaar) bleef echter boven de LDL-
C-streefwaarde. We stelden vast dat o.a. de 
volgende factoren samenhingen met het niet 
bereiken van de LDL-streefwaarden: hogere 
LDL-niveau in de beginfase, voorgeschiedenis 
van myocardinfarct en ontbrekende/ontoerei-
kende statinebehandeling.
Het effect van bioresorbeerbare scaffolds 
op het natuurlijke beloop van coronaire 
atherosclerose
In de cardiovasculaire wetenschap werd 
altijd gezocht naar een manier om het na-
tuurlijke beloop van coronaire atherosclerose 
te beïnvloeden. De klinische introductie van 
bioresorbeerbare scaffolds (BRS) leidde tot 
een revolutionaire verandering in de toepas-
sing van lokale behandeling van coronaire 
aandoeningen. Deze hulpmiddelen bezitten 
het unieke vermogen om te voorzien in een 
tijdelijke structuur die nodig is om de doorgan-
kelijkheid van het bloedvat na een interventie 
te handhaven, terwijl ze een antiproliferatief 
middel afgeven. Vanwege hun polymere 
samenstelling hebben bioresorbeerbare vas-
culaire scaffolds (BVS) unieke eigenschappen 
bij beeldvormend onderzoek. In hoofdstuk 5.1 
beschreven we de beeldvormende methoden 
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voor BRS, vergeleken we BRS met metalen 
stents en beschreven we de klinische rele-
vantie van BRS.
Wijzigingen aan het ontwerp en de samen-
stellingen van bioresorbeerbare vasculaire 
scaffolds (BRS) kunnen van invloed zijn op 
hun afbreekbaarheid, de biomechanische 
eigenschappen aantasten (met het risico op 
late recoil) en mogelijk in verband worden 
gebracht met een tweede ontstekingsgolf van 
de slagaderwand. Daarom is het cruciaal dat 
de afbreekbaarheid van BRS wordt bestudeerd 
om deze technologie volledig te begrijpen. In 
hoofdstuk 5.2 werd de echogeniciteit gevali-
deerd (een geautomatiseerde en kwantitatieve 
analyse van coronaire weefselcomponenten; 
hierbij wordt de intensiteit van de grijsschaal 
gescoord en wordt als referentie het gemid-
delde helderheidsniveau van de adventitia 
gebruikt) als vervanging voor de afbreekbaar-
heid van polylactide scaffolds.
OCT heeft een centrale rol gespeeld bij het 
verwerven van inzicht in de BRS-prestaties 
op kortere en langere termijn, aangezien deze 
methode meer gedetailleerde en nauwkeurige 
morfologische informatie oplevert over BRS 
dan intravasculaire echografie. In hoofdstuk 
5.3 hebben we gekeken naar de acute en 
langetermijnmethodologie, en de klinische 
toepassing van OCT bij de beoordeling van 
BRS.
Al vele jaren richt men zich op beïnvloeding 
van de omvang van coronaire plaques, ofwel 
via lokale (instrumentele) ofwel via syste-
mische behandeling. Gewoonlijk worden 
patiënten gelijktijdig behandeld met medi-
catie en PCI. Daarom zal de respons van de 
coronaire vaatwand variëren overeenkomstig 
de wisselwerking tussen beide behandelingen. 
Bij de follow-up zullen de implantaten zijn 
omgeven door plaque, namelijk achter de 
stentstruts (’peri-stent’) en endoluminaal 
(neo-intima). Deze twee compartimenten zijn 
biologisch actief en zullen op verschillende 
wijze worden beïnvloed door de aanwezig-
heid van een complexe wisselwerking die 
ontstaat door het platform (metaal/poly-
meer) + polymeer + geneesmiddel. Zo zullen 
everolimus-eluerende stents/scaffolds op 
vergelijkbare wijze invloed uitoefenen op 
de plaque-omvang (d.w.z. door verwijdering 
van macrofagen en remming van de vorming 
van neo-intima). Het netto effect zal echter 
ongelijk zijn omdat de platformen verschillend 
zijn (metaal versus polymeer). Daarom kunnen 
de effecten die deze complexe wisselwerking 
(geëlueerd geneesmiddel/platform) heeft op 
de plaque-omvang alleen worden onderzocht 
door seriële meting van de omvang van het 
media- en neo-intimacompartiment van de 
coronaire plaque. In hoofdstuk 5.4 laten we 
zien dat lokale hulpmiddelen een andere 
uitwerking op de omvang van de coronaire 
plaque hebben en dat dit afhankelijk is van het 
platform (metaal versus polymeer), en van het 
feit of er een kale of medicijn-eluerende stent 
wordt gebruikt. Met name de totale plaque-
omvang nam in de sequentiële cohorten van 
Absorb BVS 1.1 toe met 16,2% 2 jaar vanaf de 
baseline, terwijl deze stijging na 3 jaar vanaf 
de baseline nog maar 5% bedroeg.
Het mechanisch gedrag van de vaatwand lijkt 
samen te hangen met de samenstellingsken-
merken van de plaque en een voorspellende 
factor te zijn voor latere cardiovasculaire 
voorvallen. Patiënten met plaques met een 
hoge vervorming krijgen waarschijnlijk eerder 
te maken met acute coronaire voorvallen dan 
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patiënten met laesies met lage vervorming. In 
verschillende studies is aangetoond dat een 
medicinale of interventionele behandeling de 
mechanische eigenschappen van de vaatwand 
kan beïnvloeden door verandering van de 
componenten. In hoofdstuk 5.5 stelden we 
vast dat na implantatie van Absorb BVS 1.1 de 
vervorming van de vaatwand na verloop van 
tijd geleidelijk aan afnam.
Enkele van de mogelijke voordelen van 
bioresorbeerbare scaffolds, namelijk vermin-
dering van atherosclerotische plaque en late 
lumenvergroting in de behandelde gebieden, 
vormen mogelijk de aanleiding tot verschui-
vingen in het behandelingsparadigma voor 
coronaire hartziekten. Bij farmacologische 
behandeling is echter ook aangetoond dat 
het, afhankelijk van het klinische profiel van 
de patiënt, mogelijk is plaqueregressie te 
bevorderen. Daarom hangt plaqueregressie 
bij patiënten die zijn behandeld met bioresor-
beerbare scaffolds mogelijk niet samen met dit 
hulpmiddel zelf, maar is dit het gevolg van het 
effect van de farmacologische behandeling op 
een vat dat is bevrijd van zijn interne ’kooi’. 
In hoofdstuk 5.6 hebben we een intra-patiënt 
multislice-computer-tomografie vergelijking 
gemaakt tussen matchende segmenten 
(genormaliseerd door de segmentlengte) 
van de scaffold-regio’s en niet-behandelde 
segmenten voor: lumenvolume, vaatvolume, 
plaquevolume, plaque-ernst en veranderings-
percentage in het volume van de atheroscle-
rotische plaque. Bij seriële vergelijking bleek 
dat de met scaffolds behandelde segmenten 
in de periode tussen 18 maanden en 5 jaar 
geen significante veranderingen vertoonden 
van de gemiddelde plaque-ernst, het totale 
atheroomvolume, het totale lumenvolume en 
het vaatvolume. Omgekeerd vertoonden de 
niet-behandelde segmenten een significante 
toename van de plaque-ernst (2,7 ± 6,5%; 
P<0,01) en genormaliseerde plaquevolumes 
(8,0 ± 22,8 mm3, P<0,01). Dit resulteerde in 
een significant verschil in plaque-ernst bij 
vergelijking tussen met scaffolds behandelde 
en niet-behandelde segmenten (P=0,03).
ConClUSIeS
In dit proefschrift worden uitgebreid de 
talloze overwegingen weergegeven die 
samenhangen met de risicostratificatie voor 
coronaire hartziekten, evenals de toekomst-
perspectieven voor interventionele cardio-
logie. Ik ben van mening dat dit proefschrift 
waardevol is, met name vanwege de volgende 
redenen:
• Het biedt een uitgebreide richtlijn voor 
de beeldvormende modaliteiten bij de bepa-
ling van hoge risicofactoren voor coronaire 
hartziekten;
• Het verschaft belangrijke inzichten in 
de wisselwerking tussen klinische en anato-
mische overwegingen bij de prognose van 
patiënten en de gevolgen van beide op de 
besluitvorming;
• Het biedt als eerste een onvertekende 
prospectieve validatie van een risicoscore;
• Het beoordeelt de behoeften en de proble-
men van patiëntbehandeling na een coronaire 
revascularisatie;
• Het presenteert nieuwe gegevens over het 
effect van bioresorbeerbare scaffolds voor 
beïnvloeding van coronaire atherosclerose.
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